82_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
1_CD
Presentation_NOMZ
of_PIN
the_DT
financial_JJ
statements_NOMZ
Additional_JJ
information_NOMZ
in_PIN
accordance_NN
with_PIN
the_DT
requirements_NOMZ
of_PIN
US_FPP1
generally_RB
accepted_VBD [PRIV]
accounting_GER
principles_NN
US_FPP1
GAAP_NN
is_VPRT [PASS]
included_VBN
Description_NOMZ
of_PIN
business_NOMZ
in_PIN
the_DT
Notes_NN
to_PIN
the_DT
Financial_NN
statements_NOMZ
._.
In_PIN
Note_NN
37_CD
a_DT
statement_NOMZ
of_PIN
GlaxoSmithKline_NN
is_VPRT [BEMA]
a_DT
major_JJ
global_JJ
healthcare_NN
group_NN
which_WDT [WHSUB]
is_VPRT
differences_NN
,_,
and_ANDC
a_DT
reconciliation_NOMZ
of_PIN
net_JJ
income_NN
and_PHC
shareholders_NN
engaged_VBN [WZPAST]
in_PIN
the_DT
creation_NOMZ
and_PHC
discovery_NN
,_,
development_NOMZ
,_,
manufacture_NN
equity_NOMZ
,_,
between_PIN
UK_NN
and_PHC
US_FPP1
GAAP_NN
are_VPRT [PASS]
provided_VBN
,_,
and_ANDC
the_DT
principal_NN
and_PHC
marketing_GER
of_PIN
pharmaceutical_JJ
products_NN
including_VBG [WZPRES]
vaccines_NN
,_,
Financial_NN
statements_NOMZ
are_VPRT [PASS]
presented_VBN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
over-the-counter_JJ
OTC_NN
medicines_NN
and_CC
health-related_JJ
consumer_NN
and_CC
in_PIN
a_DT
US_FPP1
GAAP_NN
format_NN
._.
GlaxoSmithKlines_NN
principal_JJ
pharmaceutical_JJ
products_NN
include_VPRT
medicines_NN
in_PIN
the_DT
following_VBG
therapeutic_JJ
areas_NN
:_:
Merger_NN
of_PIN
Glaxo_NN
Wellcome_NN
plc_NN
and_PHC
SmithKline_NN
Beecham_NN
plc_NN
central_JJ
nervous_JJ
system_NN
,_,
respiratory_JJ
,_,
anti-virals_NN
,_,
anti-bacterials_NN
,_,
GlaxoSmithKline_NN
plc_NN
acquired_VBD
Glaxo_NN
Wellcome_NN
plc_NN
and_PHC
SmithKline_NN
metabolic_JJ
and_PHC
gastro-intestinal_JJ
,_,
vaccines_NN
,_,
oncology_NN
and_PHC
emesis_NN
,_,
Beecham_NN
plc_NN
by_PIN
way_NN
of_PIN
a_DT
scheme_NN
of_PIN
arrangement_NOMZ
for_PIN
the_DT
merger_NN
of_PIN
cardiovascular_JJ
and_CC
arthritis_NN
._.
the_DT
two_CD
companies_NN
which_WDT [WHSUB]
became_VBD
effective_JJ
on_PIN
27th_JJ
December_NN
2000_CD
._.
Financial_JJ
period_NN
Under_IN
UK_NN
GAAP_NN
the_DT
Financial_NN
statements_NOMZ
of_PIN
GlaxoSmithKline_NN
plc_NN
These_DEMO
Financial_NN
statements_NOMZ
cover_VPRT
the_DT
financial_JJ
year_NN
from_PIN
are_VPRT [PASS]
prepared_VBN
as_IN
a_DT
merger_NN
of_PIN
Glaxo_NN
Wellcome_NN
plc_NN
and_PHC
SmithKline_NN
1st_CD
January_NN
to_TO
31st_VB
December_NN
2002_CD
,_,
with_PIN
comparative_JJ
gures_NN
for_PIN
Beecham_NN
plc._NN
._.
The_DT
comparative_JJ
gures_NN
for_PIN
the_DT
year_NN
to_PIN
the_DT
financial_JJ
years_NN
from_PIN
1st_CD
January_NN
to_TO
31st_VB
December_NN
2001_CD
and_CC
31st_CD
December_NN
2000_CD
therefore_CONJ
include_VPRT
the_DT
results_NN
of_PIN
Glaxo_NN
1st_CD
January_NN
to_TO
31st_VB
December_NN
2000_CD
._.
Wellcome_NN
plc_NN
and_PHC
SmithKline_NN
Beecham_NN
plc._NN
._.
Under_IN
US_FPP1
GAAP_NN
the_DT
Financial_NN
statements_NOMZ
of_PIN
GlaxoSmithKline_NN
plc_NN
Composition_NOMZ
of_PIN
the_DT
Group_NN
are_VPRT [BEMA]
prepared_PRED
as_IN
an_DT
acquisition_NOMZ
of_PIN
SmithKline_NN
Beecham_NN
plc_NN
by_PIN
A_DT
list_NN
of_PIN
the_DT
subsidiary_NN
and_CC
associated_VBN
undertakings_GER
which_WDT [WHOBJ]
,_,
in_PIN
the_DT
Glaxo_NN
Wellcome_NN
plc_NN
at_PIN
27th_JJ
December_NN
2000_CD
._.
Accordingly_RB
the_DT
opinion_NN
of_PIN
the_DT
Directors_NN
,_,
principally_RB
affected_VBD
the_DT
amount_NN
of_PIN
profit_NN
results_NN
of_PIN
SmithKline_NN
Beecham_NN
for_PIN
all_QUAN
periods_NN
prior_RB
to_PIN
that_DEMO
date_NN
are_VPRT
or_CC
the_DT
net_JJ
assets_NN
of_PIN
the_DT
Group_NN
is_VPRT [PASS]
given_VBN
in_PIN
Principal_NN
Group_NN
not_XX0
consolidated_JJ
._.
Presentation_NOMZ
of_PIN
statement_NOMZ
of_PIN
profit_NN
and_PHC
loss_NN
Composition_NOMZ
of_PIN
financial_JJ
statements_NOMZ
A_DT
columnar_NN
presentation_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
adopted_VBN
in_PIN
the_DT
statement_NOMZ
of_PIN
The_DT
consolidated_JJ
financial_JJ
statements_NOMZ
are_VPRT [PASS]
drawn_VBN
up_RP
in_PIN
accordance_NN
profit_NN
and_PHC
loss_NN
in_PIN
order_NN
to_TO
illustrate_VB
underlying_VBG
business_NOMZ
performance_NN
with_PIN
UK_NN
generally_RB
accepted_VBD [PRIV]
accounting_GER
principles_NN
UK_NN
GAAP_NN
and_CC
as_IN
this_DEMP
is_VPRT [BEMA]
the_DT
primary_JJ
measure_NN
used_VBN [WZPAST]
by_PIN
management_NOMZ
._.
For_PIN
this_DEMO
with_PIN
UK_NN
accounting_GER
presentation_NOMZ
._.
purpose_NN
certain_JJ
items_NN
are_VPRT [BEMA]
identied_JJ
separately_RB
and_CC
are_VPRT [PASS]
excluded_VBN
The_DT
Financial_NN
statements_NOMZ
comprise_VPRT
:_:
from_PIN
business_NOMZ
performance_NN
._.
These_DEMP
comprise_VPRT
:_:
merger_NN
and_PHC
integration_NOMZ
items_NN
,_,
including_VBG
product_NN
divestments_NOMZ
:_:
costs_NN
relating_VBG [WZPRES]
to_TO
previously_TIME
Consolidated_NN
statement_NOMZ
of_PIN
profit_NN
and_PHC
loss_NN
announced_VBD [PUBV]
manufacturing_GER
and_CC
other_JJ
restructuring_GER
,_,
and_ANDC
the_DT
effect_NN
Consolidated_NN
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
of_PIN
disposals_NN
of_PIN
subsidiaries_NN
._.
Consolidated_NN
statement_NOMZ
of_PIN
cash_NN
ow_NN
Consolidated_NN
balance_NN
sheet_NN
Trading_GER
profit_NN
reects_VPRT
sales_NN
less_RB
:_:
cost_NN
of_PIN
sales_NN
,_,
comprising_VBG
costs_NN
Reconciliation_NOMZ
of_PIN
movements_NOMZ
in_PIN
equity_NOMZ
shareholders_NN
funds_NN
of_PIN
manufacture_NN
and_CC
external_JJ
royalties_NN
:_:
selling_GER
,_,
general_JJ
and_CC
Company_NN
balance_NN
sheet_NN
administrative_JJ
expenditure_NN
,_,
comprising_VBG [PRESP]
the_DT
costs_NN
of_PIN
selling_GER
,_,
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
._.
distribution_NOMZ
and_CC
medical_JJ
support_NN
of_PIN
currently_RB
marketed_VBN
products_NN
and_CC
the_DT
costs_NN
of_PIN
administration_NOMZ
:_:
and_ANDC
the_DT
costs_NN
of_PIN
research_NN
and_CC
As_IN
permitted_VBN
by_PIN
Section_NOMZ
230_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
,_,
the_DT
development_NOMZ
to_TO
create_VB
future_JJ
products_NN
for_PIN
sale_NN
._.
profit_NN
and_PHC
loss_NN
account_NN
of_PIN
the_DT
company_NN
is_VPRT [PASS]
not_XX0
presented_VBN
._.
The_DT
consolidated_JJ
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
Accounting_GER
convention_NOMZ
includes_VPRT
:_:
The_DT
Financial_NN
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
using_VBG
the_DT
historical_JJ
cost_NN
convention_NOMZ
._.
the_DT
realized_VBN [PRIV]
profit_NN
attributable_JJ
to_PIN
shareholders_NN
as_IN
reected_VBN
in_PIN
the_DT
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
Accounting_GER
standards_NN
the_DT
unrealised_JJ
gain_NN
or_CC
loss_NN
in_PIN
the_DT
value_NN
of_PIN
the_DT
Groups_NN
overseas_PLACE
The_DT
Financial_NN
statements_NOMZ
comply_VPRT
with_PIN
all_QUAN
applicable_JJ
UK_NN
accounting_GER
net_JJ
assets_NN
,_,
less_JJ
related_JJ
foreign_JJ
currency_NN
borrowings_GER
,_,
attributable_JJ
standards_NN
._.
to_PIN
currency_NN
movements_NOMZ
over_IN
the_DT
period_NN
._.
The_DT
reconciliation_NOMZ
of_PIN
movements_NOMZ
in_PIN
equity_NOMZ
shareholders_NN
funds_NN
Accounting_GER
principles_NN
and_PHC
policies_NN
comprises_VPRT
the_DT
items_NN
contributing_VBG [WZPRES]
to_PIN
the_DT
increase_NN
or_CC
decrease_NN
over_IN
The_DT
preparation_NOMZ
of_PIN
Financial_NN
statements_NOMZ
in_PIN
conformity_NOMZ
with_PIN
generally_RB
the_DT
period_NN
in_PIN
shareholders_NN
funds_NN
._.
Such_JJ
items_NN
include_VPRT
:_:
accepted_VBN [PRIV]
accounting_GER
principles_NN
requires_VPRT [SUAV]
management_NOMZ
to_TO
make_VB
estimates_NN
and_PHC
assumptions_NOMZ
that_TSUB
affect_VPRT
the_DT
reported_VBN [PUBV]
amounts_NN
of_PIN
the_DT
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
for_PIN
the_DT
period_NN
assets_NN
and_PHC
liabilities_NOMZ
and_PHC
disclosure_NN
of_PIN
contingent_JJ
assets_NN
and_PHC
dividends_NN
paid_VBN
and_PHC
proposed_VBN [SUAV]
liabilities_NOMZ
at_PIN
the_DT
date_NN
of_PIN
the_DT
Financial_NN
statements_NOMZ
and_CC
the_DT
reported_VBN [PUBV]
the_DT
proceeds_NN
of_PIN
shares_NN
issued_VBN [WZPAST]
during_PIN
the_DT
period_NN
amounts_NN
of_PIN
revenues_NN
and_PHC
expenses_NN
during_PIN
the_DT
reporting_GER
period_NN
._.
the_DT
cost_NN
of_PIN
shares_NN
purchased_VBN [WZPAST]
for_PIN
cancellation_NOMZ
under_IN
the_DT
Actual_JJ
results_NN
could_POMD
differ_VB
from_PIN
those_DEMO
estimates_NN
._.
share_NN
buy-back_NN
program_NN
changes_NN
to_PIN
goodwill_NN
,_,
arising_VBG [PRESP]
on_PIN
acquisitions_NOMZ
prior_RB
to_PIN
The_DT
Financial_NN
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
1st_CD
January_NN
1998_CD
,_,
which_WDT [SERE]
has_VPRT [PEAS]
been_VBN [PASS]
set_VBN
directly_RB
against_PIN
reserves_NN
._.
the_DT
companys_NN
accounting_VBG [WZPRES]
policies_NN
approved_VBN [WZPAST]
by_PIN
the_DT
Board_NN
and_CC
described_VBN
in_PIN
Note_NN
2_CD
._.
The_DT
company_NN
has_VPRT [PEAS]
implemented_VBN
one_CD
new_JJ
Financial_NN
Reporting_GER
Standard_NN
in_PIN
2002_CD
as_IN
described_VBN
in_PIN
Note_NN
3_CD
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
83_CD
2_CD
Accounting_GER
policies_NN
Foreign_JJ
currency_NN
transactions_NOMZ
Foreign_JJ
currency_NN
transactions_NOMZ
by_PIN
Group_NN
companies_NN
are_VPRT [PASS]
booked_VBN
Consolidation_NOMZ
in_PIN
local_JJ
currency_NN
at_PIN
the_DT
exchange_NN
rate_NN
ruling_NN
on_PIN
the_DT
date_NN
of_PIN
The_DT
consolidated_JJ
Financial_NN
statements_NOMZ
include_VPRT
:_:
transaction_NOMZ
,_,
or_CC
at_PIN
the_DT
forward_JJ
rate_NN
if_COND
hedged_VBN
by_PIN
a_DT
forward_RB
the_DT
assets_NN
and_PHC
liabilities_NOMZ
,_,
and_ANDC
the_DT
results_NN
and_PHC
cash_NN
ow_NN
,_,
of_PIN
the_DT
exchange_NN
contract_NN
._.
Foreign_JJ
currency_NN
assets_NN
and_PHC
liabilities_NOMZ
are_VPRT
company_NN
and_CC
its_PIT
subsidiary_NN
undertakings_GER
,_,
including_VBG
Employee_NN
translated_VBN [WZPAST]
into_PIN
local_JJ
currency_NN
at_PIN
rates_NN
of_PIN
exchange_NN
ruling_NN
at_PIN
the_DT
Share_NN
Ownership_NN
Trusts_VPRT
ESOTs_NN
balance_NN
sheet_NN
date_NN
,_,
or_CC
at_PIN
the_DT
forward_JJ
rate_NN
._.
Exchange_NN
differences_NN
the_DT
Groups_NN
share_NN
of_PIN
the_DT
net_JJ
assets_NN
and_PHC
results_NN
of_PIN
joint_JJ
ventures_NN
are_VPRT [PASS]
included_VBN
in_PIN
trading_GER
profit_NN
._.
Revenue_NN
The_DT
Financial_NN
statements_NOMZ
of_PIN
undertakings_GER
consolidated_VBN [WZPAST]
are_VPRT [PASS]
made_VBN
Revenue_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
when_RB
goods_NN
up_IN
to_PIN
31st_CD
December_NN
._.
or_CC
services_NN
are_VPRT [PASS]
supplied_VBN
to_PIN
external_JJ
customers_NN
against_PIN
orders_NN
Undertakings_GER
in_PIN
which_WDT [PIRE]
the_DT
Group_NN
has_VPRT
a_DT
material_NN
interest_NN
are_VPRT [PASS]
received_VBN
._.
Turnover_NN
represents_VPRT
the_DT
net_JJ
invoice_NN
value_NN
,_,
after_IN
the_DT
accounted_VBN
for_PIN
as_IN
subsidiaries_NN
where_RB
the_DT
Group_NN
exercises_VPRT
dominant_JJ
deduction_NOMZ
of_PIN
discounts_NN
given_VBN [WZPAST]
at_PIN
the_DT
point_NN
of_PIN
sale_NN
,_,
of_PIN
products_NN
inuence_NN
,_,
as_IN
joint_JJ
ventures_NN
where_RB
the_DT
Group_NN
exercises_VPRT
joint_JJ
control_NN
despatched_VBD
to_TO
,_,
or_CC
available_JJ
for_PIN
collection_NOMZ
by_PIN [STPR]
,_,
customers_NN
,_,
less_JJ
and_CC
as_IN
associates_NN
where_RB
the_DT
Group_NN
can_POMD
exercise_VB
significant_JJ
accruals_NN
for_PIN
estimated_JJ
future_JJ
rebates_NN
and_PHC
returns_NN
._.
ESOTs_NN
are_VPRT [PASS]
accounted_VBN
for_PIN
as_IN
subsidiaries_NN
on_PIN
the_DT
grounds_NN
and_CC
other_JJ
sales_NN
taxes_NN
are_VPRT [PASS]
excluded_VBN
from_PIN
revenue_NN
._.
that_THVC
the_DT
Group_NN
has_VPRT
fide_NN
facto_JJ
control_NN
._.
Expenditure_NN
Interests_NN
acquired_VBN [WZPAST]
in_PIN
undertakings_GER
are_VPRT [PASS]
consolidated_VBN
from_PIN
the_DT
Expenditure_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
respect_NN
of_PIN
goods_NN
and_PHC
services_NN
received_VBN
effective_JJ
date_NN
of_PIN
acquisition_NOMZ
and_PHC
interests_NN
sold_VBN [WZPAST]
are_VPRT [PASS]
consolidated_VBN
when_RB
supplied_VBN
in_PIN
accordance_NN
with_PIN
contractual_JJ
terms_NN
._.
Provision_NN
is_VPRT [BEMA]
up_RB
to_PIN
the_DT
date_NN
of_PIN
disposal_NN
._.
made_VBN
when_RB
an_DT
obligation_NOMZ
exists_VPRT
for_PIN
a_DT
future_JJ
liability_NOMZ
in_PIN
respect_NN
of_PIN
a_DT
Transactions_NOMZ
and_PHC
balances_NN
between_PIN
subsidiary_NN
undertakings_GER
are_VPRT [BEMA]
past_JJ
event_NN
and_ANDC
where_RB
the_DT
amount_NN
of_PIN
the_DT
obligation_NOMZ
can_POMD
be_VB [SPAU] [PASS]
reliably_RB
eliminated_VBN
:_:
no_SYNE
profit_NN
is_VPRT [PASS]
taken_VBN
on_PIN
sales_NN
between_PIN
subsidiary_NN
estimated_VBN [PRIV]
._.
Advertising_GER
expenditure_NN
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
undertakings_GER
or_CC
sales_NN
to_PIN
joint_JJ
ventures_NN
and_CC
associated_VBN
undertakings_GER
account_VPRT
as_IN
incurred_VBN
._.
Shipment_NOMZ
costs_NN
on_PIN
inter-company_JJ
transfers_NN
are_VPRT
until_IN
the_DT
products_NN
are_VPRT [PASS]
sold_VBN
to_PIN
customers_NN
outside_PLACE
the_DT
Group_NN
._.
charged_VBN [PASTP]
to_PIN
cost_NN
of_PIN
sales_NN
:_:
distribution_NOMZ
costs_NN
on_PIN
sales_NN
to_PIN
customers_NN
are_VPRT [PASS]
included_VBN
in_PIN
selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenditure_NN
._.
Goodwill_NN
arising_VBG [WZPRES]
on_PIN
the_DT
acquisition_NOMZ
of_PIN
interests_NN
in_PIN
subsidiary_NN
Restructuring_GER
costs_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
respect_NN
of_PIN
the_DT
direct_JJ
undertakings_GER
,_,
joint_JJ
ventures_NN
and_CC
associated_VBN
undertakings_GER
,_,
expenditures_NN
of_PIN
a_DT
business_NOMZ
reorganisation_NOMZ
where_RB
the_DT
plans_NN
are_VPRT
representing_VBG
the_DT
excess_NN
of_PIN
the_DT
purchase_NN
consideration_NOMZ
over_IN
the_DT
sufciently_RB
detailed_JJ
and_CC
well_RB
advanced_VBD
,_,
and_ANDC
where_RB
appropriate_JJ
Groups_NN
share_NN
of_PIN
the_DT
separable_JJ
net_JJ
assets_NN
acquired_VBN
,_,
is_VPRT [PASS]
capitalized_VBN
communication_NOMZ
to_PIN
those_DEMP
affected_VBN
has_VPRT [PEAS]
been_VBN [PASS]
undertaken_VBN
at_PIN
the_DT
as_IN
a_DT
separate_JJ
item_NN
in_PIN
the_DT
case_NN
of_PIN
subsidiary_NN
undertakings_GER
and_CC
as_IN
balance_NN
sheet_NN
date_NN
._.
part_NN
of_PIN
the_DT
cost_NN
of_PIN
investment_NOMZ
in_PIN
the_DT
case_NN
of_PIN
joint_JJ
ventures_NN
and_CC
associated_VBN
undertakings_GER
._.
Goodwill_NN
is_VPRT [PASS]
denominated_VBN
in_PIN
the_DT
currency_NN
Research_NN
and_PHC
development_NOMZ
in_PIN
which_WDT [PIRE]
the_DT
acquisition_NOMZ
is_VPRT [PASS]
made_VBN
and_PHC
nanced_VBN
._.
In_PIN
the_DT
case_NN
of_PIN
Research_NN
and_PHC
development_NOMZ
expenditure_NN
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
acquisitions_NOMZ
prior_RB
to_PIN
1998_CD
,_,
goodwill_NN
was_VBD [PASS]
written_VBN [PUBV]
off_PIN
against_PIN
and_CC
loss_NN
account_NN
in_PIN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
it_PIT
is_VPRT [PASS]
incurred_VBN
._.
Tangible_JJ
reserves_NN
:_:
on_PIN
a_DT
subsequent_JJ
disposal_NN
of_PIN
assets_NN
from_PIN
such_JJ
acquisitions_NOMZ
,_,
xed_VBD
assets_NN
used_VBN [WZPAST]
for_PIN
research_NN
and_PHC
development_NOMZ
are_VPRT [PASS]
depreciated_VBN
in_PIN
any_QUAN
related_JJ
goodwill_NN
is_VPRT [PASS]
removed_VBN
from_PIN
consolidated_JJ
reserves_NN
and_PHC
accordance_NN
with_PIN
the_DT
Groups_NN
policy_NN
._.
charged_VBN [PASTP]
to_PIN
the_DT
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
._.
The_DT
Groups_NN
interests_NN
in_PIN
its_PIT
joint_JJ
ventures_NN
are_VPRT [PASS]
accounted_VBN
for_PIN
using_VBG
Environmental_JJ
expenditure_NN
the_DT
gross_JJ
equity_NOMZ
method_NN
._.
The_DT
Groups_NN
interests_NN
in_PIN
its_PIT
associated_VBN
Environmental_NN
expenditure_NN
related_VBN
to_TO
existing_VBG
conditions_NOMZ
resulting_VBG [WZPRES]
undertakings_GER
are_VPRT [PASS]
accounted_VBN
for_PIN
using_VBG
the_DT
equity_NOMZ
method_NN
._.
from_PIN
past_JJ
or_CC
current_JJ
operations_NOMZ
and_CC
from_PIN
which_WDT [PIRE]
no_SYNE
current_JJ
or_CC
future_JJ
benefit_NN
is_VPRT [BEMA]
discernible_PRED
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
Deferred_VBN
taxation_NOMZ
relief_NN
on_PIN
unrealised_JJ
intra-Group_JJ
profit_NN
is_VPRT
account_NN
._.
The_DT
Group_NN
determines_VPRT [SUAV] [PRIV]
its_PIT
liability_NOMZ
on_PIN
a_DT
site-by-site_JJ
basis_NN
accounted_VBD
for_PIN
only_DWNT
to_PIN
the_DT
extent_NN
that_TOBJ
it_PIT
is_VPRT [PASS]
considered_VBN [PRIV]
recoverable_JJ
._.
and_ANDC
records_NN
a_DT
liability_NOMZ
at_PIN
the_DT
time_NN
when_RB
it_PIT
is_VPRT [BEMA]
probable_PRED
and_CC
can_POMD
be_VB
Assets_NN
and_PHC
liabilities_NOMZ
of_PIN
overseas_PLACE
subsidiary_NN
and_CC
associated_VBN
reasonably_RB
estimated_VBN [PRIV]
._.
This_DEMO
liability_NOMZ
includes_VPRT
the_DT
Groups_NN
own_VPRT
portion_NOMZ
undertakings_GER
and_CC
joint_JJ
ventures_NN
including_VBG [WZPRES]
related_JJ
goodwill_NN
,_,
are_VPRT [BEMA]
of_PIN
the_DT
costs_NN
and_CC
also_RB
a_DT
portion_NOMZ
of_PIN
other_JJ
potentially_RB
responsible_JJ
translated_VBN
into_PIN
sterling_GER
at_PIN
rates_NN
of_PIN
exchange_NN
ruling_NN
at_PIN
the_DT
balance_NN
parties_NN
costs_NN
when_RB
it_PIT
is_VPRT [BEMA]
probable_PRED
that_THAC
they_TPP3
will_PRMD
not_XX0
be_VB [BEMA]
able_PRED
to_TO
satisfy_VB
sheet_NN
date_NN
._.
The_DT
results_NN
and_PHC
cash_NN
ows_NN
of_PIN
overseas_PLACE
subsidiary_NN
and_CC
their_TPP3
respective_JJ
shares_NN
of_PIN
the_DT
clean-up_JJ
obligation_NOMZ
._.
When_RB
recoveries_NN
associated_VBN
undertakings_GER
and_CC
joint_JJ
ventures_NN
are_VPRT [PASS]
translated_VBN
into_PIN
of_PIN
reimbursements_NOMZ
are_VPRT [BEMA]
virtually_RB
certain_PRED
they_TPP3
are_VPRT [PASS]
recorded_VBN
as_IN
assets_NN
._.
sterling_GER
using_VBG [WZPRES]
average_JJ
rates_NN
of_PIN
exchange_NN
._.
Exchange_NN
adjustments_NOMZ
arising_VBG [WZPRES]
when_RB
the_DT
opening_GER
net_JJ
assets_NN
and_CC
the_DT
profits_NN
for_PIN
the_DT
year_NN
Legal_NN
and_CC
other_JJ
disputes_NN
retained_VBN [WZPAST]
by_PIN
overseas_PLACE
subsidiary_NN
and_CC
associated_VBN
undertakings_GER
and_PHC
Provision_NN
is_VPRT [PASS]
made_VBN
for_PIN
the_DT
anticipated_JJ
settlement_NOMZ
costs_NN
and_CC
legal_JJ
and_PHC
joint_JJ
ventures_NN
are_VPRT [PASS]
translated_VBN
into_PIN
sterling_GER
,_,
less_JJ
exchange_NN
differences_NN
other_JJ
expenses_NN
associated_VBN [WZPAST]
with_PIN
claims_NN
received_VBN
and_CC
legal_JJ
and_PHC
other_JJ
arising_VBG
on_PIN
related_VBN
foreign_JJ
currency_NN
borrowings_GER
,_,
are_VPRT [PASS]
taken_VBN
directly_RB
disputes_NN
against_PIN
the_DT
Group_NN
where_RB
a_DT
reasonable_JJ
estimate_NN
can_POMD
be_VB [BEMA]
to_PIN
reserves_NN
and_CC
reported_VBN [PUBV]
in_PIN
the_DT
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
made_VBN
of_PIN
the_DT
likely_JJ
outcome_NN
of_PIN
the_DT
dispute_NN
._.
No_SYNE
provision_NN
is_VPRT [PASS]
made_VBN
for_PIN
gains_NN
and_PHC
losses_NN
._.
unasserted_JJ
claims_NN
or_CC
where_RB
an_DT
obligation_NOMZ
exists_VPRT
under_IN
a_DT
dispute_NN
but_CC
it_PIT
is_VPRT [BEMA]
not_XX0
possible_PRED
to_TO
make_VB
a_DT
reasonable_JJ
estimate_NN
._.
Costs_NN
associated_VBN [WZPAST]
In_PIN
translating_VBG
into_PIN
sterling_GER
,_,
assets_NN
,_,
liabilities_NOMZ
,_,
results_NN
and_PHC
cash_NN
ows_NN
with_PIN
claims_NN
made_VBN [WZPAST]
by_PIN
the_DT
Group_NN
against_PIN
third_JJ
parties_NN
are_VPRT [PASS]
charged_VBN
to_PIN
of_PIN
overseas_PLACE
subsidiary_NN
and_CC
associated_VBN
undertakings_GER
and_CC
joint_JJ
ventures_NN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
as_IN
they_TPP3
are_VPRT [PASS]
incurred_VBN
._.
reported_VBN [PUBV] [PASTP]
in_PIN
currencies_NN
of_PIN
hyper-inationary_JJ
economies_NN
,_,
adjustments_NOMZ
are_VPRT [PASS]
made_VBN
to_TO
reect_VB
current_JJ
price_NN
levels_NN
._.
Any_QUAN
loss_NN
on_PIN
net_JJ
monetary_JJ
assets_NN
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
._.
84_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
2_CD
Accounting_GER
policies_NN
continued_VBD
Tangible_JJ
xed_JJ
assets_NN
Tangible_JJ
xed_VBD
assets_NN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
cost_NN
less_JJ
provisions_NN
for_PIN
Pensions_NN
and_CC
post-retirement_JJ
benets_NN
depreciation_NOMZ
or_CC
impairment_NOMZ
._.
The_DT
costs_NN
of_PIN
acquiring_VBG
and_PHC
developing_VBG
The_DT
cost_NN
of_PIN
providing_VBG
pensions_NN
and_CC
other_JJ
employee_NN
post-retirement_JJ
computer_NN
software_NN
for_PIN
internal_JJ
use_NN
and_PHC
internet_NN
sites_NN
for_PIN
external_JJ
benets_NN
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
on_PIN
a_DT
use_NN
are_VPRT [PASS]
capitalized_VBN
as_IN
a_DT
tangible_JJ
xed_JJ
asset_NN
where_RB
the_DT
software_NN
or_CC
systematic_JJ
and_PHC
rational_JJ
basis_NN
,_,
based_VBN [PASTP]
on_PIN
actuarial_JJ
assumptions_NOMZ
,_,
over_IN
site_NN
supports_VPRT
a_DT
significant_JJ
business_NOMZ
system_NN
and_CC
the_DT
expenditure_NN
the_DT
period_NN
during_PIN
which_WDT [PIRE]
benefit_NN
is_VPRT [PASS]
derived_VBN
from_PIN
employees_NN
services_NN
._.
leads_NN
to_PIN
the_DT
creation_NOMZ
of_PIN
a_DT
durable_JJ
asset_NN
._.
Any_QUAN
difference_NN
between_PIN
this_DEMO
charge_NN
and_CC
the_DT
contributions_NOMZ
paid_VBN [WZPAST]
is_VPRT [PASS]
included_VBN
as_IN
an_DT
asset_NN
or_CC
liability_NOMZ
in_PIN
the_DT
consolidated_JJ
balance_NN
sheet_NN
._.
Depreciation_NOMZ
is_VPRT [PASS]
calculated_VBN [PRIV]
to_TO
write_VB [PUBV]
off_PIN
the_DT
cost_NN
of_PIN
tangible_JJ
xed_JJ
assets_NN
,_,
excluding_VBG
freehold_JJ
land_NN
,_,
in_PIN
equal_JJ
annual_JJ
instalments_NOMZ
over_IN
Employee_NN
share_NN
plans_VPRT
their_TPP3
expected_VBN [PRIV]
useful_JJ
lives_NN
._.
The_DT
normal_JJ
expected_VBN [PRIV]
useful_JJ
lives_NN
of_PIN
the_DT
Incentives_NN
in_PIN
the_DT
form_NN
of_PIN
shares_NN
are_VPRT [PASS]
provided_VBN
to_PIN
employees_NN
under_IN
major_JJ
categories_NN
of_PIN
tangible_JJ
xed_JJ
assets_NN
are_VPRT [PASS]
reviewed_VBN
annually_RB
share_NN
option_NOMZ
and_PHC
share_NN
award_NN
schemes_NN
._.
In_PIN
respect_NN
of_PIN
award_NN
and_CC
are_VPRT
:_:
schemes_NN
and_CC
certain_JJ
share_NN
option_NOMZ
grants_NN
,_,
the_DT
company_NN
provides_VPRT
Freehold_NN
buildings_GER
20_CD
to_PIN
50_CD
years_NN
finance_NN
to_PIN
ESOTs_NN
to_TO
purchase_VB
company_NN
shares_NN
on_PIN
the_DT
open_JJ
market_NN
Leasehold_NN
land_NN
and_CC
The_DT
shorter_JJ
of_PIN
lease_NN
term_NN
and_CC
50_CD
to_TO
meet_VB
the_DT
companys_NN
obligation_NOMZ
to_TO
provide_VB
shares_NN
when_RB
buildings_GER
years_NN
employees_NN
exercise_VPRT
their_TPP3
option_NOMZ
or_CC
award_NN
:_:
any_QUAN
excess_NN
of_PIN
the_DT
Plant_NN
and_PHC
machinery_NN
10_CD
to_PIN
20_CD
years_NN
purchase_NN
price_NN
of_PIN
the_DT
shares_NN
above_PLACE
the_DT
exercise_NN
price_NN
of_PIN
the_DT
options_NOMZ
Fixtures_NN
and_PHC
equipment_NOMZ
3_CD
to_PIN
10_CD
years_NN
and_PHC
awards_NN
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
over_IN
the_DT
ERP_NN
systems_NN
software_NN
7_CD
years_NN
periods_NN
of_PIN
service_NN
in_PIN
respect_NN
of_PIN
which_WDT [PIRE]
the_DT
options_NOMZ
and_PHC
awards_NN
are_VPRT [BEMA]
Other_JJ
computer_NN
software_NN
3_CD
to_PIN
5_CD
years_NN
granted_VBN [SUAV]
._.
In_PIN
respect_NN
of_PIN
other_JJ
share_NN
option_NOMZ
grants_NN
,_,
share_NN
options_NOMZ
when_RB
exercised_VBN
are_VPRT [PASS]
accounted_VBN
for_PIN
as_IN
share_NN
issues_NN
at_PIN
exercise_NN
price_NN
._.
ERP_NN
systems_NN
software_NN
generally_RB
involves_VPRT
significant_JJ
customisation_NOMZ
Additional_JJ
employer_NN
costs_NN
in_PIN
respect_NN
of_PIN
options_NOMZ
and_PHC
awards_NN
are_VPRT [BEMA]
prior_RB
to_PIN
implementation_NOMZ
and_CC
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
have_VB
a_DT
useful_JJ
economic_JJ
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
over_IN
the_DT
periods_NN
of_PIN
service_NN
._.
life_NN
of_PIN
seven_CD
years_NN
,_,
rather_CONJ
than_PIN
the_DT
maximum_JJ
five_CD
years_NN
of_PIN
other_JJ
Costs_NN
of_PIN
running_VBG
the_DT
ESOTs_NN
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
computer_NN
software_NN
._.
Shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
ESOTs_NN
are_VPRT [PASS]
accounted_VBN
for_PIN
as_IN
xed_JJ
asset_NN
On_PIN
disposal_NN
of_PIN
a_DT
tangible_JJ
xed_JJ
asset_NN
,_,
the_DT
cost_NN
and_CC
related_JJ
investments_NOMZ
held_VBN [PRIV] [WZPAST]
at_PIN
cost_NN
less_JJ
a_DT
provision_NN
to_TO
recognize_VB [PRIV] [THATD]
any_QUAN
shortfall_NN
accumulated_VBN
depreciation_NOMZ
are_VPRT [PASS]
removed_VBN
from_PIN
the_DT
financial_JJ
in_PIN
the_DT
proceeds_NN
receivable_NN
from_PIN
employees_NN
on_PIN
exercise_NN
unless_COND
there_EX
statements_NOMZ
and_CC
the_DT
net_JJ
amount_NN
,_,
less_JJ
any_QUAN
proceeds_NN
,_,
is_VPRT [PASS]
taken_VBN
to_TO
is_VPRT [PASS]
deemed_VBN [PRIV]
to_TO
be_VB [BEMA]
a_DT
permanent_JJ
impairment_NOMZ
in_PIN
value_NN
._.
the_DT
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
._.
Goodwill_NN
Leases_NN
Goodwill_NN
is_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
cost_NN
less_JJ
a_DT
provision_NN
for_PIN
amortisation_NOMZ
._.
Leasing_GER
agreements_NOMZ
which_WDT [WHSUB]
transfer_VPRT
to_PIN
the_DT
Group_NN
substantially_RB
all_QUAN
Amortisation_NOMZ
is_VPRT [PASS]
calculated_VBN [PRIV]
to_TO
write_VB [PUBV]
off_PIN
the_DT
cost_NN
in_PIN
equal_JJ
annual_JJ
the_DT
benets_NN
and_PHC
risks_NN
of_PIN
ownership_NN
of_PIN
an_DT
asset_NN
are_VPRT [PASS]
treated_VBN
as_IN
instalments_NOMZ
over_IN
its_PIT
expected_VBN [PRIV]
useful_JJ
life_NN
._.
The_DT
useful_JJ
life_NN
is_VPRT
not_XX0
finance_VB
leases_NN
,_,
as_IN
if_COND
the_DT
asset_NN
had_VBD [PEAS]
been_VBN [PASS]
purchased_VBN
outright_RB
._.
The_DT
normally_RB
expected_VBN [PRIV]
to_TO
exceed_VB
20_CD
years_NN
._.
assets_NN
are_VPRT [PASS]
included_VBN
in_PIN
tangible_JJ
xed_JJ
assets_NN
and_CC
the_DT
capital_NN
element_NOMZ
of_PIN
the_DT
leasing_GER
commitments_NOMZ
is_VPRT [PASS]
shown_VBN [PRIV]
as_IN
obligations_NOMZ
under_IN
finance_NN
Intangible_NN
xed_VBD
assets_NN
leases_NN
._.
Assets_NN
held_VBN [PRIV]
under_IN
finance_NN
leases_NN
are_VPRT [PASS]
depreciated_VBN
over_IN
the_DT
Intangible_JJ
assets_NN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
cost_NN
less_JJ
a_DT
provision_NN
for_PIN
amortisation_NOMZ
._.
shorter_JJ
of_PIN
the_DT
lease_NN
terms_NN
and_CC
the_DT
useful_JJ
lives_NN
of_PIN
the_DT
assets_NN
._.
The_DT
Acquired_VBN
licences_NN
,_,
patents_NN
,_,
know-how_NN
and_PHC
marketing_GER
rights_NN
are_VPRT
interest_NN
element_NOMZ
of_PIN
the_DT
lease_NN
rental_NN
is_VPRT [PASS]
charged_VBN
against_PIN
profit_NN
._.
amortised_VBN
over_IN
their_TPP3
estimated_VBN [PRIV]
useful_JJ
lives_NN
in_PIN
equal_JJ
instalments_NOMZ
,_,
All_QUAN
other_JJ
leases_NN
are_VPRT
operating_VBG
leases_NN
and_CC
the_DT
annual_JJ
rentals_NN
are_VPRT
but_CC
no_SYNE
longer_JJ
than_PIN
15_CD
years_NN
._.
Items_NN
capitalized_VBN [WZPAST]
are_VPRT [PASS]
restricted_VBN
to_TO
charged_VBN
against_PIN
profit_NN
on_PIN
a_DT
straight-line_JJ
basis_NN
over_IN
the_DT
lease_NN
term_NN
._.
those_DEMP
related_VBN
to_PIN
specic_JJ
compounds_NN
or_CC
products_NN
which_WDT [WHSUB]
are_VPRT
being_VBG [PASS]
developed_VBN
for_PIN
commercial_JJ
applications_NOMZ
._.
The_DT
estimated_VBN [PRIV]
useful_JJ
lives_NN
Impairment_NOMZ
of_PIN
xed_JJ
assets_NN
for_PIN
determining_VBG [SUAV] [PRIV]
the_DT
amortisation_NOMZ
charge_NN
are_VPRT [PASS]
reviewed_VBN
annually_RB
,_,
The_DT
carrying_VBG
values_NN
of_PIN
xed_JJ
assets_NN
are_VPRT [PASS]
reviewed_VBN
for_PIN
impairment_NOMZ
and_CC
take_VB
into_PIN
account_NN
the_DT
estimated_VBN [PRIV]
time_NN
it_PIT
takes_VPRT
to_TO
bring_VB
the_DT
when_RB
there_EX
is_VPRT
an_DT
indication_NOMZ
that_TOBJ
the_DT
assets_NN
might_POMD
be_VB [PASS]
impaired_VBN
._.
compounds_NN
or_CC
products_NN
to_PIN
market_NN
as_IN
marketable_JJ
products_NN
._.
Any_QUAN
provision_NN
for_PIN
impairment_NOMZ
is_VPRT [PASS]
charged_VBN
against_PIN
profit_NN
in_PIN
the_DT
year_NN
Any_QUAN
development_NOMZ
costs_NN
which_WDT [WHSUB]
are_VPRT [BYPA]
incurred_VBN
by_PIN
the_DT
Group_NN
and_CC
concerned_JJ
._.
First_JJ
year_NN
impairment_NOMZ
reviews_NN
are_VPRT [PASS]
conducted_VBN
for_PIN
are_VPRT [PASS]
associated_VBN
with_PIN
an_DT
acquired_VBN
licence_NN
,_,
patent_NN
,_,
know-how_NN
acquired_VBD
goodwill_NN
and_CC
intangible_JJ
assets_NN
._.
Certain_JJ
intangibles_NN
are_VPRT
or_CC
marketing_GER
rights_NN
are_VPRT [PASS]
written_VBN [PUBV]
off_PIN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
considered_VBN [PRIV]
to_TO
have_VB
an_DT
indefinite_JJ
life_NN
and_CC
are_VPRT
therefore_CONJ
not_XX0
when_RB
incurred_VBN
._.
Such_JJ
intangibles_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
annual_JJ
impairment_NOMZ
tests_NN
._.
Impairment_NOMZ
is_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
reference_NN
to_PIN
the_DT
higher_JJ
of_PIN
net_JJ
Brands_NN
are_VPRT [PASS]
valued_VBN
independently_RB
as_IN
part_NN
of_PIN
the_DT
fair_JJ
value_NN
of_PIN
realisable_JJ
value_NN
and_PHC
value_NN
in_PIN
use_NN
,_,
which_WDT [SERE]
is_VPRT [BYPA]
measured_VBN
by_PIN
reference_NN
businesses_NOMZ
acquired_VBN [WZPAST]
from_PIN
third_JJ
parties_NN
where_RB
the_DT
brand_NN
has_VPRT
a_DT
value_NN
to_PIN
discounted_JJ
future_JJ
cash_NN
ows_NN
._.
The_DT
value_NN
of_PIN
shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
which_WDT
is_VPRT [BEMA]
substantial_PRED
and_PHC
long-term_PRED
and_ANDC
where_RB
the_DT
brands_NN
can_POMD
be_VB
ESOTs_NN
is_VPRT [PASS]
reviewed_VBN
quarterly_JJ
to_TO
determine_VB [SUAV] [PRIV]
if_COND
there_EX
is_VPRT
any_QUAN
permanent_JJ
sold_VBN
separately_RB
from_PIN
the_DT
rest_NN
of_PIN
the_DT
businesses_NOMZ
acquired_VBN
._.
are_VPRT [PASS]
amortised_VBN
over_IN
the_DT
estimated_VBN [PRIV]
useful_JJ
lives_NN
but_CC
no_SYNE
longer_JJ
than_PIN
20_CD
years_NN
,_,
except_PIN
where_RB
the_DT
end_NN
of_PIN
the_DT
useful_JJ
economic_JJ
life_NN
of_PIN
the_DT
Investments_NOMZ
in_PIN
joint_JJ
ventures_NN
and_PHC
associates_NN
brand_NN
can_POMD
not_XX0
be_VB [PASS]
foreseen_VBN
._.
Investments_NOMZ
in_PIN
joint_JJ
ventures_NN
and_CC
associated_VBN
undertakings_GER
are_VPRT [BEMA]
Prior_RB
to_PIN
1998_CD
,_,
acquired_VBN
minor_JJ
brands_NN
and_CC
similar_JJ
intangibles_NN
were_VBD [PASS]
carried_VBN
in_PIN
the_DT
consolidated_JJ
balance_NN
sheet_NN
at_PIN
the_DT
Groups_NN
share_VPRT
eliminated_VBN
in_PIN
the_DT
Group_NN
balance_NN
sheet_NN
against_PIN
reserves_NN
in_PIN
the_DT
year_NN
of_PIN
their_TPP3
net_JJ
assets_NN
at_PIN
date_NN
of_PIN
acquisition_NOMZ
and_CC
of_PIN
their_TPP3
postof_JJ
acquisition_NOMZ
._.
acquisition_NOMZ
retained_VBD
profits_NN
or_CC
losses_NN
together_RB
with_PIN
any_QUAN
goodwill_NN
arising_VBG [WZPRES]
on_PIN
the_DT
acquisition_NOMZ
,_,
net_NN
of_PIN
amortisation_NOMZ
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
85_CD
2_CD
Accounting_GER
policies_NN
continued_VBD
Debt_NN
instruments_NOMZ
Debt_NN
instruments_NOMZ
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
amount_NN
of_PIN
net_JJ
proceeds_NN
Stocks_NN
adjusted_VBN
to_TO
amortise_VB
the_DT
issue_NN
cost_NN
of_PIN
debt_NN
evenly_RB
over_IN
the_DT
term_NN
Stocks_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
financial_JJ
statements_NOMZ
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
of_PIN
the_DT
debt_NN
._.
including_VBG
manufacturing_GER
overheads_NN
,_,
where_RB
appropriate_JJ
and_PHC
net_JJ
realisable_JJ
value_NN
._.
Cost_NN
is_VPRT [SPAU] [PASS]
generally_RB
determined_VBN [SUAV] [PRIV]
on_PIN
a_DT
first_JJ
in_PIN [STPR]
,_,
first_RB
out_PIN
3_CD
New_JJ
accounting_GER
policies_NN
and_CC
future_JJ
requirements_NOMZ
basis_NN
._.
The_DT
Group_NN
has_VPRT [PEAS]
implemented_VBN
Financial_NN
Reporting_GER
Standard_NN
19_CD
Taxation_NOMZ
Deferred_NN
Tax_NN
in_PIN
2002_CD
which_WDT
requires_VPRT [SUAV]
deferred_VBN
tax_NN
to_TO
be_VB [PASS]
accounted_VBN
The_DT
Group_NN
accounts_NN
for_PIN
taxation_NOMZ
which_WDT [WHSUB]
is_VPRT [PASS]
deferred_VBN
or_CC
accelerated_VBN
for_PIN
on_PIN
a_DT
full_JJ
provision_NN
basis_NN
,_,
rather_CONJ
than_PIN
a_DT
partial_JJ
provision_NN
basis_NN
as_IN
by_PIN
reason_NN
of_PIN
timing_NN
differences_NN
which_WDT [WHSUB]
have_VPRT [PEAS]
originated_VBN
but_CC
not_XX0
before_RB
._.
Comparative_JJ
information_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
as_RB
necessary_JJ
._.
reversed_VBN [PASTP]
by_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Deferred_JJ
tax_NN
assets_NN
are_VPRT [BEMA]
only_DWNT
The_DT
effect_NN
in_PIN
2001_CD
is_VPRT
to_TO
increase_VB
the_DT
business_NOMZ
performance_NN
tax_NN
recognized_VBN [PRIV] [WZPAST]
to_PIN
the_DT
extent_NN
that_TOBJ
they_TPP3
are_VPRT [PASS]
considered_VBN [PRIV]
recoverable_JJ
charge_NN
by_PIN
8_CD
million_CD
2000_CD
43_CD
million_CD
and_CC
the_DT
overall_JJ
tax_NN
charge_NN
against_PIN
future_JJ
taxable_JJ
profits_NN
._.
Deferred_JJ
tax_NN
on_PIN
the_DT
retained_VBN
earnings_GER
by_PIN
6_CD
million_CD
2000_CD
48_CD
million_CD
._.
The_DT
net_JJ
deferred_VBN
tax_NN
asset_NN
at_PIN
of_PIN
overseas_PLACE
subsidiaries_NN
is_VPRT [SPAU] [PASS]
only_DWNT
provided_VBN
when_RB
there_EX
is_VPRT
a_DT
binding_JJ
31st_CD
December_NN
2001_CD
has_VPRT [PEAS]
been_VBN [BYPA]
reduced_VBN
by_PIN
127_CD
million_CD
._.
commitment_NOMZ
to_TO
distribute_VB
past_JJ
earnings_GER
in_PIN
future_NN
periods_NN
._.
In_PIN
June_NN
2002_CD
,_,
the_DT
Council_NN
of_PIN
the_DT
European_NN
Union_NN
adopted_VBD
a_DT
Deferred_JJ
tax_NN
is_VPRT [PASS]
measured_VBN
at_PIN
the_DT
average_JJ
tax_NN
rates_NN
that_TSUB
are_VPRT [PASS]
expected_VBN [PRIV] [THATD]
Regulation_NOMZ
requiring_VBG [SUAV] [WZPRES]
listed_VBN
companies_NN
in_PIN
its_PIT
Member_NN
States_NN
to_TO
to_TO
apply_VB
in_PIN
the_DT
periods_NN
in_PIN
which_WDT [PIRE]
the_DT
timing_NN
differences_NN
are_VPRT [PASS]
expected_VBN [PRIV]
prepare_VPRT
their_TPP3
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
accordance_NN
with_PIN
to_TO
reverse_VB
._.
Deferred_JJ
tax_NN
liabilities_NOMZ
and_PHC
assets_NN
are_VPRT [PASS]
not_XX0
discounted_VBN
._.
The_DT
Group_NN
has_VPRT [PEAS]
initiated_VBN
a_DT
project_NN
to_TO
plan_VB
for_PIN
and_CC
implement_VB
the_DT
conversion_NN
from_PIN
Current_JJ
asset_NN
investments_NOMZ
UK_NN
GAAP_NN
to_PIN
International_NN
Financial_NN
Reporting_GER
Standards_NN
IFRSs_NN
._.
Current_JJ
asset_NN
investments_NOMZ
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
and_CC
net_JJ
The_DT
first_JJ
Annual_JJ
Report_NN
prepared_VBN
under_IN
IFRSs_NN
will_PRMD
be_VB
that_DEMO
for_PIN
the_DT
realisable_JJ
value_NN
._.
The_DT
first_JJ
financial_JJ
results_NN
announcement_NOMZ
prepared_VBN [WZPAST]
in_PIN
accordance_NN
with_PIN
IFRSs_NN
will_PRMD
be_VB
that_DEMO
for_PIN
In_PIN
the_DT
case_NN
of_PIN
securities_NOMZ
acquired_VBN [WZPAST]
at_PIN
a_DT
significant_JJ
premium_NN
or_CC
the_DT
first_JJ
quarter_NN
of_PIN
2005_CD
._.
discount_NN
to_PIN
maturity_NOMZ
value_NN
,_,
and_ANDC
intended_VBN [SUAV]
to_TO
be_VB [PASS]
held_VBN [PRIV]
to_PIN
redemption_NOMZ
,_,
cost_NN
is_VPRT [PASS]
adjusted_VBN
to_TO
amortise_VB
the_DT
premium_NN
or_CC
discount_NN
over_IN
the_DT
life_NN
4_CD
Exchange_NN
rates_NN
to_PIN
maturity_NOMZ
of_PIN
the_DT
security_NOMZ
._.
Floating_VBG
rate_NN
bonds_NN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
cost_NN
._.
Interest_NN
income_NN
is_VPRT [PASS]
taken_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
on_PIN
a_DT
The_DT
Group_NN
uses_VPRT
the_DT
average_NN
of_PIN
exchange_NN
rates_NN
prevailing_VBG [WZPRES]
during_PIN
receivable_JJ
basis_NN
._.
the_DT
period_NN
to_TO
translate_VB
the_DT
results_NN
and_PHC
cash_NN
ows_NN
of_PIN
overseas_PLACE
Group_NN
subsidiary_NN
,_,
joint_JJ
venture_NN
and_CC
associated_VBN
undertakings_GER
into_PIN
sterling_JJ
Equity_NOMZ
investments_NOMZ
are_VPRT [PASS]
included_VBN
as_IN
current_JJ
assets_NN
when_RB
regarded_VBN
and_CC
period_NN
end_NN
rates_NN
to_TO
translate_VB
the_DT
net_JJ
assets_NN
of_PIN
those_DEMO
as_IN
available_JJ
for_PIN
sale_NN
._.
The_DT
currencies_NN
which_WDT
most_EMPH
inuence_JJ
these_DEMO
translations_NOMZ
,_,
and_ANDC
the_DT
relevant_JJ
exchange_NN
rates_NN
,_,
were_VBD
:_:
Derivative_JJ
financial_JJ
instruments_NOMZ
The_DT
Group_NN
does_VPRT
not_XX0
hold_VB [PRIV]
or_CC
issue_VB
derivative_JJ
financial_JJ
instruments_NOMZ
2002 2001 2000_CD
for_PIN
trading_GER
purposes_NN
._.
Average_JJ
rates_NN
:_:
Derivative_JJ
financial_JJ
instruments_NOMZ
are_VPRT [PASS]
used_VBN
to_TO
manage_VB
exposure_NN
to_TO
US$_$
1.50_CD
1.44_CD
1.52_CD
market_NN
risks_NN
from_PIN
treasury_NN
operations_NOMZ
._.
The_DT
principal_JJ
derivative_JJ
Euro_NN
1.59_CD
1.61_CD
1.64_CD
instruments_NOMZ
are_VPRT
currency_NN
swaps_NN
,_,
forward_RB
exchange_NN
contracts_NN
and_PHC
Yen_NN
188.00_CD
175.00_CD
163.46_CD
Period_NN
end_NN
rates_NN
:_:
interest_NN
rate_NN
swaps_NN
._.
The_DT
derivative_JJ
contracts_NN
are_VPRT [PASS]
treated_VBN
from_PIN
US$_$
1.61_CD
1.45_CD
1.49_CD
inception_NOMZ
as_IN
an_DT
economic_JJ
hedge_NN
of_PIN
the_DT
underlying_VBG
financial_JJ
Euro_NN
1.54_CD
1.64_CD
1.61_CD
instrument_NOMZ
,_,
with_PIN
matching_JJ
accounting_GER
treatment_NOMZ
and_PHC
cash_NN
ows_NN
._.
Yen_NN
192.00_CD
190.00_CD
171.00_CD
The_DT
derivative_JJ
contracts_NN
have_VPRT
high_JJ
correlation_NOMZ
with_PIN
the_DT
specic_JJ
financial_JJ
instrument_NOMZ
being_VBG [WZPRES] [PASS]
hedged_VBN
both_DT
at_PIN
inception_NOMZ
and_CC
throughout_PIN
the_DT
hedge_JJ
period_NN
._.
Derivative_JJ
instruments_NOMZ
no_RB
longer_RB
5_CD
Merger_NN
of_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
designated_VBN
as_IN
hedges_NN
are_VPRT [PASS]
restated_VBN
at_PIN
market_NN
value_NN
and_CC
any_QUAN
future_JJ
The_DT
combination_NOMZ
of_PIN
Glaxo_NN
Wellcome_NN
plc_NN
and_PHC
SmithKline_NN
Beecham_NN
plc_NN
changes_NN
in_PIN
value_NN
are_VPRT [PASS]
taken_VBN
directly_RB
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
was_VBD [PASS]
treated_VBN
as_IN
a_DT
merger_NN
at_PIN
27th_JJ
December_NN
2000_CD
under_IN
UK_NN
GAAP_NN
._.
Currency_NN
swaps_NN
and_CC
forward_RB
exchange_NN
contracts_NN
used_VBN
to_TO
x_SYM
the_DT
Under_IN
merger_NN
accounting_GER
,_,
the_DT
shares_NN
issued_VBN [WZPAST]
by_PIN
GlaxoSmithKline_NN
plc_NN
value_NN
of_PIN
the_DT
related_JJ
asset_NN
or_CC
liability_NOMZ
in_PIN
the_DT
contract_NN
currency_NN
and_CC
to_TO
acquire_VB
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
were_VBD [PASS]
accounted_VBN
at_PIN
the_DT
contract_NN
rate_NN
are_VPRT [PASS]
accrued_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
for_PIN
at_PIN
par_NN
and_CC
no_SYNE
share_NN
premium_NN
arose_VBD
:_:
the_DT
shares_NN
acquired_VBN [WZPAST]
by_PIN
over_IN
the_DT
life_NN
of_PIN
the_DT
contract_NN
._.
Gains_NN
and_PHC
losses_NN
on_PIN
foreign_JJ
exchange_NN
GlaxoSmithKline_NN
in_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
were_VBD [PASS]
contracts_NN
designated_VBN
as_IN
hedges_NN
of_PIN
forecast_NN
foreign_JJ
exchange_NN
similarly_CONJ
accounted_VBD
for_PIN
at_PIN
the_DT
nominal_JJ
value_NN
of_PIN
the_DT
shares_NN
issued_VBN
._.
transactions_NOMZ
are_VPRT [PASS]
deferred_VBN
and_PHC
included_VBN
in_PIN
the_DT
measurement_NOMZ
of_PIN
the_DT
In_PIN
the_DT
consolidated_JJ
Financial_NN
statements_NOMZ
of_PIN
GlaxoSmithKline_NN
,_,
the_DT
related_VBN
foreign_JJ
currency_NN
transactions_NOMZ
in_PIN
the_DT
period_NN
they_TPP3
occur_VPRT
._.
results_NN
and_CC
net_JJ
assets_NN
of_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
Gains_NN
and_PHC
losses_NN
on_PIN
balance_NN
sheet_NN
hedges_NN
are_VPRT [PASS]
accrued_VBN
and_PHC
are_VPRT [PASS]
were_VBD [PASS]
combined_VBN
,_,
at_PIN
their_TPP3
book_NN
amounts_NN
,_,
subject_JJ
to_TO
alignment_VB
taken_VBN
directly_RB
to_PIN
reserves_NN
,_,
except_PIN
that_DEMO
forward_JJ
premium_NN
discounts_NN
adjustments_NOMZ
._.
are_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
interest_NN
over_IN
the_DT
life_NN
of_PIN
the_DT
contracts_NN
._.
In_PIN
view_NN
of_PIN
the_DT
proximity_NOMZ
of_PIN
the_DT
merger_NN
date_NN
to_PIN
the_DT
financial_JJ
year_NN
end_NN
Interest_NN
differentials_NN
under_IN
interest_NN
swap_NN
agreements_NOMZ
are_VPRT [PASS]
recognized_VBN [PRIV]
date_NN
,_,
and_ANDC
the_DT
relative_JJ
insignicance_NN
of_PIN
any_QUAN
business_NOMZ
activity_NOMZ
between_PIN
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
by_PIN
adjustment_NOMZ
of_PIN
interest_NN
expense_NN
27th_JJ
December_NN
2000_CD
and_CC
31st_CD
December_NN
2000_CD
,_,
the_DT
accounting_GER
over_IN
the_DT
life_NN
of_PIN
the_DT
agreement_NOMZ
._.
date_NN
of_PIN
the_DT
merger_NN
was_VBD [BEMA]
for_PIN
practical_JJ
purposes_NN
taken_VBN
as_IN
31st_CD
December_NN
2000_CD
._.
The_DT
whole_NN
of_PIN
the_DT
profit_NN
for_PIN
the_DT
financial_JJ
year_NN
2000_CD
of_PIN
each_QUAN
of_PIN
Glaxo_NN
Wellcome_NN
plc_NN
and_PHC
SmithKline_NN
Beecham_NN
plc_NN
was_VBD [PASS]
deemed_VBN [PRIV]
to_TO
relate_VB
to_PIN
the_DT
period_NN
prior_RB
to_PIN
the_DT
merger_NN
date_NN
._.
86_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
6_CD
Segment_NOMZ
information_NOMZ
An_DT
analysis_NN
of_PIN
turnover_NN
,_,
profit_NN
before_IN
taxation_NOMZ
,_,
total_JJ
assets_NN
,_,
net_JJ
assets_NN
and_CC
tangible_JJ
xed_JJ
assets_NN
by_PIN
business_NOMZ
and_CC
geographical_JJ
sector_NN
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
._.
The_DT
business_NOMZ
sectors_NN
consist_VPRT
of_PIN
Pharmaceuticals_NN
prescription_NOMZ
pharmaceuticals_NN
and_PHC
vaccines_NN
and_PHC
Consumer_NN
Healthcare_NN
oral_JJ
care_NN
,_,
OTC_NN
medicines_NN
and_CC
nutritional_JJ
healthcare_NN
._.
The_DT
geographical_JJ
sectors_NN
reect_VPRT
the_DT
Groups_NN
most_EMPH
significant_JJ
regional_JJ
markets_NN
and_CC
are_VPRT [BEMA]
consistent_PRED
with_PIN
the_DT
Groups_NN
regional_JJ
market_NN
management_NOMZ
reporting_VBG [PUBV] [WZPRES]
structure_NN
._.
Business_NOMZ
sector_NN
data_NN
includes_VPRT
an_DT
allocation_NOMZ
of_PIN
corporate_JJ
costs_NN
to_PIN
the_DT
sector_NN
._.
There_EX
are_VPRT
no_SYNE
sales_NN
between_PIN
business_NOMZ
sectors_NN
._.
The_DT
Groups_NN
activities_NOMZ
are_VPRT [PASS]
organised_VBN
on_PIN
a_DT
global_JJ
basis_NN
._.
The_DT
geographical_JJ
sector_NN
gures_NN
are_VPRT [SPAU] [BYPA]
therefore_CONJ
inuenced_VBN
by_PIN
the_DT
location_NOMZ
of_PIN
the_DT
Groups_NN
operating_VBG [WZPRES]
resources_NN
,_,
in_CONJ
particular_NULL
manufacturing_GER
and_PHC
research_NN
,_,
and_ANDC
by_PIN
variations_NOMZ
over_IN
time_NN
in_PIN
intra-Group_JJ
trading_GER
and_PHC
funding_GER
arrangements_NOMZ
._.
2001 2000 2002_CD
restated_VBN
restated_VBN
Turnover_NN
by_PIN
business_NOMZ
sector_NN
m_NN
m_FW
m_FW
Pharmaceuticals_NN
17,995_CD
17,205_CD
15,429_CD
Consumer_NN
Healthcare_NN
3,217_CD
3,284_CD
2,650_CD
External_NN
turnover_NN
21,212_CD
20,489_CD
18,079_CD
profit_NN
before_IN
tax_NN
by_PIN
business_NOMZ
sector_NN
Pharmaceuticals_NN
5,068_CD
4,302_CD
4,316_CD
Consumer_NN
Healthcare_NN
483 432 413_CD
Operating_GER
profit_NN
5,551_CD
4,734_CD
4,729_CD
Share_NN
of_PIN
profits_NN
losses_NN
of_PIN
joint_JJ
ventures_NN
and_CC
associated_VBN
undertakings_GER
75_CD
71_CD
57_CD
profit_NN
on_PIN
disposal_NN
of_PIN
interest_NN
in_PIN
associate_JJ
96_CD
144_CD
profit_NN
on_PIN
disposal_NN
of_PIN
businesses_NOMZ
10_CD
Product_NN
divestments_VPRT
11_CD
296_CD
1,402_CD
Merger_NN
transaction_NOMZ
costs_NN
121_CD
Net_JJ
interest_NN
payable_JJ
141_CD
88_CD
182_CD
profit_NN
before_IN
taxation_NOMZ
5,506_CD
4,517_CD
6,029_CD
profit_NN
before_IN
taxation_NOMZ
5,506_CD
4,517_CD
6,029_CD
Taxation_NOMZ
1,461_CD
1,333_CD
1,747_CD
Minority_NOMZ
interests_NN
110_CD
97_CD
120_CD
Preference_NN
share_NN
dividends_NN
20_CD
34_CD
56_CD
Earnings_GER
3,915_CD
3,053_CD
4,106_CD
Total_JJ
assets_NN
by_PIN
business_NOMZ
sector_NN
Pharmaceuticals_NN
18,608_CD
18,495_CD
Consumer_NN
Healthcare_NN
3,719_CD
3,848_CD
Total_JJ
assets_NN
22,327_CD
22,343_CD
Net_JJ
assets_NN
by_PIN
business_NOMZ
sector_NN
Pharmaceuticals_NN
5,720_CD
6,573_CD
Consumer_NN
Healthcare_NN
1,668_CD
1,679_CD
Net_JJ
assets_NN
7,388_CD
8,252_CD
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
87_CD
6_CD
Segment_NOMZ
information_NOMZ
continued_VBD
2001 2000 2002_CD
restated_VBN
restated_VBN
Turnover_NN
by_PIN
location_NOMZ
of_PIN
subsidiary_NN
undertaking_GER
m_NN
m_FW
m_FW
USA_NN
11,096_CD
10,517_CD
8,850_CD
Europe_NN
10,423_CD
10,704_CD
9,970_CD
International_NN
6,824_CD
7,540_CD
5,112_CD
Gross_NN
turnover_NN
28,343_CD
28,761_CD
23,932_CD
USA_NN
168 327 297_CD
Europe_NN
3,873_CD
4,372_CD
4,294_CD
International_NN
3,090_CD
3,573_CD
1,262_CD
Inter-segment_NOMZ
turnover_NN
7,131_CD
8,272_CD
5,853_CD
USA_NN
10,928_CD
10,190_CD
8,553_CD
Europe_NN
6,550_CD
6,332_CD
5,676_CD
International_NN
3,734_CD
3,967_CD
3,850_CD
External_NN
turnover_NN
21,212_CD
20,489_CD
18,079_CD
Turnover_NN
by_PIN
location_NOMZ
of_PIN
customer_NN
USA_NN
10,807_CD
10,087_CD
8,554_CD
Europe_NN
6,064_CD
5,855_CD
5,264_CD
International_NN
4,341_CD
4,547_CD
4,261_CD
External_NN
turnover_NN
21,212_CD
20,489_CD
18,079_CD
profit_NN
before_IN
tax_NN
by_PIN
location_NOMZ
of_PIN
subsidiary_NN
undertaking_GER
USA_NN
2,117_CD
934_CD
1,190_CD
Europe_NN
2,490_CD
2,580_CD
2,586_CD
International_NN
944_CD
1,220_CD
953_CD
Operating_GER
profit_NN
5,551_CD
4,734_CD
4,729_CD
Share_NN
of_PIN
profits_NN
losses_NN
of_PIN
joint_JJ
ventures_NN
and_CC
associated_VBN
undertakings_GER
75_CD
71_CD
57_CD
profit_NN
on_PIN
disposal_NN
of_PIN
interest_NN
in_PIN
associate_JJ
96_CD
144_CD
profit_NN
on_PIN
disposal_NN
of_PIN
businesses_NOMZ
10_CD
Product_NN
divestments_VPRT
11_CD
296_CD
1,402_CD
Merger_NN
transaction_NOMZ
costs_NN
121_CD
Net_JJ
interest_NN
payable_JJ
141_CD
88_CD
182_CD
profit_NN
before_IN
taxation_NOMZ
5,506_CD
4,517_CD
6,029_CD
profit_NN
before_IN
taxation_NOMZ
5,506_CD
4,517_CD
6,029_CD
Taxation_NOMZ
1,461_CD
1,333_CD
1,747_CD
Minority_NOMZ
interests_NN
110_CD
97_CD
120_CD
Preference_NN
share_NN
dividends_NN
20_CD
34_CD
56_CD
Earnings_GER
3,915_CD
3,053_CD
4,106_CD
Total_JJ
assets_NN
by_PIN
location_NOMZ
of_PIN
subsidiary_NN
undertaking_GER
USA_NN
4,455_CD
5,454_CD
Europe_NN
12,614_CD
10,831_CD
International_NN
2,950_CD
3,927_CD
Total_JJ
operating_VBG
assets_NN
20,019_CD
20,212_CD
Cash_NN
at_PIN
bank_NN
and_CC
liquid_JJ
investments_NOMZ
2,308_CD
2,131_CD
Total_JJ
assets_NN
22,327_CD
22,343_CD
Net_JJ
assets_NN
by_PIN
location_NOMZ
of_PIN
subsidiary_NN
undertaking_GER
USA_NN
376_CD
1,232_CD
Europe_NN
7,298_CD
6,524_CD
International_NN
2,049_CD
2,597_CD
Net_NN
operating_VBG [WZPRES]
assets_NN
9,723_CD
10,353_CD
Net_JJ
debt_NN
2,335_CD
2,101_CD
Net_JJ
assets_NN
7,388_CD
8,252_CD
88_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
6_CD
Segment_NOMZ
information_NOMZ
continued_VBD
2002_CD
2001_CD
Plant_NN
,_,
Land_NN
and_PHC
equipment_NOMZ
Computer_NN
Assets_NN
in_PIN
buildings_GER
and_PHC
vehicles_NN
software_NN
construction_NOMZ
Total_JJ
Total_JJ
Tangible_JJ
xed_JJ
assets_NN
by_PIN
location_NOMZ
of_PIN
subsidiary_NN
undertaking_GER
m_NN
m_FW
m_FW
m_FW
m_FW
m_FW
USA_NN
680_CD
379_CD
31_CD
322_CD
1,412_CD
1,536_CD
Europe_NN
1,700_CD
1,833_CD
118_CD
553_CD
4,204_CD
4,138_CD
International_NN
524_CD
370_CD
11_CD
128_CD
1,033_CD
1,171_CD
Total_JJ
2,904_CD
2,582_CD
160_CD
1,003_CD
6,649_CD
6,845_CD
UK_NN
segment_NOMZ
Information_NOMZ
is_VPRT [PASS]
given_VBN
separately_RB
in_PIN
respect_NN
of_PIN
the_DT
UK_NN
,_,
which_WDT [SERE]
,_,
although_CONC
included_VBN
in_PIN
the_DT
Groups_NN
Europe_NN
market_NN
region_NN
,_,
is_VPRT [PASS]
considered_VBN [PRIV]
the_DT
Groups_NN
home_NN
segment_NOMZ
for_PIN
the_DT
purposes_NN
of_PIN
segmental_JJ
reporting_GER
._.
2001_CD
2002_CD
restated_VBN
2000_CD
m_FW
m_FW
m_FW
Turnover_NN
by_PIN
location_NOMZ
of_PIN
customer_NN
1,366_CD
1,328_CD
1,151_CD
Gross_NN
turnover_NN
4,945_CD
5,388_CD
3,306_CD
Inter-segment_NOMZ
turnover_NN
3,230_CD
3,753_CD
1,798_CD
Turnover_NN
by_PIN
location_NOMZ
of_PIN
subsidiary_NN
1,715_CD
1,635_CD
1,508_CD
Operating_GER
profit_NN
1,276_CD
1,772_CD
1,665_CD
Total_JJ
assets_NN
8,846_CD
7,274_CD
Net_NN
operating_VBG [WZPRES]
assets_NN
4,910_CD
4,514_CD
7_CD
Merger_NN
items_NN
,_,
restructuring_VBG
costs_NN
and_CC
divested_JJ
businesses_NOMZ
Manufacturing_GER
and_CC
other_JJ
restructuring_GER
costs_NN
were_VBD [BYPA]
incurred_VBN
by_PIN
GlaxoSmithKline_NN
during_PIN
2002_CD
and_CC
2001_CD
in_PIN
implementation_NOMZ
of_PIN
previously_TIME
announced_VBN [PUBV]
plans_NN
for_PIN
restructuring_GER
of_PIN
manufacturing_GER
and_CC
other_JJ
activities_NOMZ
._.
These_DEMO
costs_NN
were_VBD [SPAU] [BYPA]
also_RB
incurred_VBN
by_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
in_PIN
2000_CD
._.
Merger_NN
integration_NOMZ
costs_NN
relate_VPRT
to_PIN
the_DT
integration_NOMZ
of_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
into_PIN
a_DT
unied_JJ
GlaxoSmithKline_NN
business_NOMZ
._.
These_DEMO
costs_NN
include_VPRT
consultancy_NN
fees_NN
in_PIN
respect_NN
of_PIN
integration_NOMZ
planning_GER
,_,
severance_NN
costs_NN
,_,
asset_NN
write-offs_NN
,_,
costs_NN
related_VBN [WZPAST]
to_PIN
the_DT
early_TIME
vesting_GER
or_CC
lapse_NN
of_PIN
performance_NN
conditions_NOMZ
on_PIN
share_NN
options_NOMZ
and_PHC
share_NN
incentive_NN
awards_NN
and_PHC
costs_NN
of_PIN
the_DT
program_NN
to_TO
encourage_VB
staff_NN
to_TO
convert_VB
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
share_NN
options_NOMZ
into_PIN
GlaxoSmithKline_NN
share_NN
options_NOMZ
._.
Integration_NOMZ
costs_NN
were_VBD [PASS]
incurred_VBN
in_PIN
2002_CD
and_CC
2001_CD
relating_VBG
to_PIN
the_DT
integration_NOMZ
of_PIN
the_DT
Block_NN
Drug_NN
businesses_NOMZ
._.
These_DEMO
costs_NN
include_VPRT
professional_JJ
fees_NN
,_,
severance_NN
costs_NN
and_PHC
asset_NN
write-offs_NN
._.
Product_NN
divestment_NOMZ
income_NN
arising_VBG [WZPRES]
in_PIN
2002_CD
related_VBN
to_PIN
the_DT
nalisation_NOMZ
of_PIN
the_DT
disposals_NN
of_PIN
Famvir_NN
,_,
Kytril_NN
and_CC
other_JJ
products_NN
required_VBN [SUAV] [WZPAST]
in_PIN
2000_CD
in_PIN
order_NN
to_TO
obtain_VB
regulatory_JJ
approval_NN
for_PIN
the_DT
merger_NN
._.
Merger_NN
transaction_NOMZ
costs_NN
were_VBD [PASS]
incurred_VBN
in_PIN
2000_CD
in_PIN
order_NN
to_TO
effect_VB
the_DT
merger_NN
._.
These_DEMO
costs_NN
comprise_VPRT
the_DT
fees_NN
and_PHC
expenses_NN
incurred_VBN [WZPAST]
in_PIN
preparing_VBG
and_PHC
implementing_VBG
the_DT
scheme_NN
of_PIN
arrangement_NOMZ
for_PIN
the_DT
merger_NN
._.
The_DT
disposal_NN
of_PIN
businesses_NOMZ
in_PIN
2002_CD
related_VBN
to_PIN
the_DT
nalisation_NOMZ
of_PIN
the_DT
disposals_NN
of_PIN
Clinical_JJ
Laboratories_NN
and_PHC
Healthcare_NN
Services_NN
in_PIN
1999_CD
._.
The_DT
disposal_NN
of_PIN
businesses_NOMZ
in_PIN
2001_CD
primarily_RB
arose_VBD
on_PIN
the_DT
sale_NN
of_PIN
Affymax_NN
._.
It_PIT
included_VBD
a_DT
299_CD
million_CD
write_VB [PUBV]
off_PIN
of_PIN
goodwill_NN
which_WDT [WHSUB]
was_VBD [SPAU] [PASS]
previously_TIME
eliminated_VBN
against_PIN
Group_NN
reserves_NN
._.
The_DT
disposal_NN
of_PIN
businesses_NOMZ
in_PIN
2000_CD
relates_VPRT
to_PIN
the_DT
disposal_NN
of_PIN
Healthcare_NN
Services_NN
in_PIN
1999_CD
._.
Restructuring_GER
costs_NN
were_VBD [PASS]
incurred_VBN
in_PIN
Healthcare_NN
Services_NN
before_IN
its_PIT
disposal_NN
._.
The_DT
share_NN
of_PIN
associate_NN
in_PIN
2000_CD
related_VBN
to_TO
restructuring_VBG
costs_NN
incurred_VBN [WZPAST]
by_PIN
Quest_NN
Diagnostics_NN
._.
RestrucDisposal_NN
of_PIN
Merger_NN
turing_VBG [WZPRES]
Block_NN
Drug_NN
subsidiaries_NN
Total_JJ
2002_CD
m_FW
m_FW
m_FW
m_FW
m_FW
Manufacturing_GER
and_CC
other_JJ
restructuring_GER
121_CD
121_CD
Merger_NN
integration_NOMZ
costs_NN
851_CD
851_CD
Block_NN
Drug_NN
integration_NOMZ
costs_NN
60_CD
60_CD
Effect_NN
on_PIN
operating_GER
profit_NN
851_CD
121_CD
60_CD
1,032_CD
Product_NN
divestments_VPRT
11_CD
11_CD
profit_NN
on_PIN
disposal_NN
of_PIN
businesses_NOMZ
10_CD
10_CD
Effect_NN
on_PIN
profit_NN
before_IN
tax_NN
840_CD
121_CD
60_CD
10_CD
1,011_CD
Effect_NN
on_PIN
taxation_NOMZ
operating_GER
items_NN
266_CD
Effect_NN
on_PIN
taxation_NOMZ
non-operating_JJ
items_NN
33_CD
Effect_NN
on_PIN
taxation_NOMZ
299_CD
Effect_NN
on_PIN
earnings_GER
712_CD
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
89_CD
7_CD
Merger_NN
items_NN
,_,
restructuring_VBG
costs_NN
and_CC
divested_JJ
businesses_NOMZ
continued_VBD
RestrucDisposal_NN
of_PIN
Total_NN
Merger_NN
turing_VBG [WZPRES]
Block_NN
Drug_NN
subsidiaries_NN
restated_VBN
2001_CD
m_FW
m_FW
m_FW
m_FW
m_FW
Manufacturing_GER
and_CC
other_JJ
restructuring_GER
162_CD
162_CD
Merger_NN
integration_NOMZ
costs_NN
1,069_CD
1,069_CD
Block_NN
Drug_NN
integration_NOMZ
costs_NN
125_CD
125_CD
Effect_NN
on_PIN
operating_GER
profit_NN
1,069_CD
162_CD
125_CD
1,356_CD
Loss_NN
on_PIN
disposal_NN
of_PIN
businesses_NOMZ
296_CD
296_CD
Effect_NN
on_PIN
profit_NN
before_IN
tax_NN
1,069_CD
162 125 296_CD
1,652_CD
Effect_NN
on_PIN
taxation_NOMZ
operating_GER
items_NN
355_CD
Effect_NN
on_PIN
taxation_NOMZ
non-operating_JJ
items_NN
33_CD
Effect_NN
on_PIN
taxation_NOMZ
322_CD
Effect_NN
on_PIN
earnings_GER
1,330_CD
RestrucDisposal_NN
of_PIN
Total_NN
Merger_NN
turing_VBG [WZPRES]
Associate_NN
subsidiaries_NN
restated_VBN
2000_CD
m_FW
m_FW
m_FW
m_FW
m_FW
Manufacturing_GER
and_CC
other_JJ
restructuring_GER
171_CD
171_CD
Merger_NN
integration_NOMZ
costs_NN
400_CD
400_CD
Effect_NN
on_PIN
operating_GER
profit_NN
400 171 571_CD
Share_NN
of_PIN
associate_JJ
8_CD
8_CD
Product_NN
divestments_NOMZ
1,416_CD
1,416_CD
Merger_NN
transaction_NOMZ
costs_NN
121_CD
121_CD
Loss_NN
on_PIN
disposal_NN
of_PIN
business_NOMZ
14_CD
14_CD
Effect_NN
on_PIN
profit_NN
before_IN
tax_NN
895_CD
171_CD
8_CD
14_CD
702_CD
Effect_NN
on_PIN
taxation_NOMZ
operating_GER
items_NN
120_CD
Effect_NN
on_PIN
taxation_NOMZ
non-operating_JJ
items_NN
370_CD
Effect_NN
on_PIN
taxation_NOMZ
250_CD
Effect_NN
on_PIN
earnings_GER
452_CD
8_CD
Other_JJ
operating_GER
income_NN
expense_NN
2002 2001 2000_CD
m_FW
m_FW
m_FW
Royalties_NN
and_CC
other_JJ
income_NN
75_CD
34_CD
43_CD
Other_JJ
operating_GER
expense_NN
209_CD
126_CD
58_CD
134_CD
92_CD
15_CD
Income_NN
from_PIN
equity_NOMZ
investments_NOMZ
and_CC
other_JJ
disposals_NN
23 129 289 111_CD
37_CD
274_CD
Royalties_NN
and_CC
other_JJ
income_NN
is_VPRT [BEMA]
principally_RB
a_DT
core_NN
of_PIN
recurring_VBG
income_NN
in_PIN
the_DT
form_NN
of_PIN
royalties_NN
from_PIN
the_DT
out-licensing_GER
of_PIN
intellectual_JJ
property_NN
._.
Other_JJ
operating_GER
expense_NN
comprises_VPRT
non-recurring_JJ
costs_NN
related_VBN [WZPAST]
to_PIN
product_NN
liability_NOMZ
and_CC
other_JJ
claims_NN
and_CC
other_JJ
costs_NN
in_PIN
respect_NN
of_PIN
product_NN
withdrawals_NN
._.
Income_NN
from_PIN
equity_NOMZ
investments_NOMZ
and_CC
other_JJ
disposals_NN
arises_VPRT
from_PIN
equity_NOMZ
investment_NOMZ
sales_NN
and_PHC
equity_NOMZ
investment_NOMZ
write-downs_NN
due_JJ
to_PIN
adverse_JJ
market_NN
conditions_NOMZ
,_,
product_NN
and_PHC
property_NN
disposals_NN
._.
90_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
9_CD
Operating_GER
profit_NN
2002 2001 2000_CD
m_FW
m_FW
m_FW [BEMA]
The_DT
following_JJ
items_NN
have_VPRT [PEAS]
been_VBN [PASS]
charged_VBN
in_PIN
operating_GER
profit_NN
:_:
Employee_NN
costs_NN
Note_VPRT [PRIV]
33_CD
4,940_CD
4,686_CD
4,487_CD
Advertising_GER
688 696 652_CD
Distribution_NOMZ
costs_NN
281 272 260_CD
Depreciation_NOMZ
of_PIN
tangible_JJ
xed_JJ
assets_NN
:_:
Owned_JJ
assets_NN
760 758 733_CD
Leased_JJ
assets_NN
4_CD
32_CD
Amortisation_NOMZ
of_PIN
goodwill_NN
12_CD
10_CD
11_CD
Amortisation_NOMZ
of_PIN
intangible_JJ
xed_JJ
assets_NN
60_CD
40_CD
27_CD
Exchange_NN
losses_NN
on_PIN
foreign_JJ
currency_NN
deposits_NN
loans_NN
3_CD
Operating_GER
lease_NN
rentals_NN
:_:
Plant_NN
and_PHC
machinery_NN
50_CD
41_CD
44_CD
Land_NN
and_PHC
buildings_GER
61_CD
70_CD
70_CD
Audit_NN
fees_NN
6.1_CD
7.2_CD
6.3_CD
Fees_NN
to_PIN
auditors_NN
for_PIN
other_JJ
work_NN
:_:
Auditors_NN
UK_NN
rm_VBD
5.2_CD
13.1_CD
9.4_CD
Auditors_NN
overseas_PLACE
rms_VPRT
9.6_CD
22.6_CD
15.3_CD
Analysis_NN
of_PIN
fees_NN
to_PIN
auditors_NN
for_PIN
other_JJ
work_NN
:_:
Non-statutory_JJ
assurance_NN
services_NN
1.8_CD
1.6_CD
Tax_NN
advisory_JJ
services_NN
4.2_CD
5.9_CD
Merger_NN
of_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
6.0_CD
14.6_CD
Other_JJ
services_NN
2.8_CD
13.6_CD
Included_VBN
within_PIN
audit_NN
fees_NN
above_PLACE
is_VPRT [BEMA]
a_DT
fee_NN
of_PIN
10,000_CD
2001_CD
10,000_CD
,_,
2000_CD
10,000_CD
relating_VBG
to_PIN
the_DT
company_NN
audit_NN
of_PIN
GlaxoSmithKline_NN
plc._NN
._.
Included_VBN [PASTP]
within_PIN
fees_NN
to_PIN
auditors_NN
for_PIN
other_JJ
work_NN
are_VPRT
amounts_NN
of_PIN
6.0_CD
million_CD
2001_CD
17.4_CD
million_CD
paid_VBN
to_PIN
the_DT
auditors_NN
management_NOMZ
consulting_GER
practice_NN
,_,
which_WDT [SERE]
was_VBD [BYPA]
sold_VBN
by_PIN
them_TPP3
in_PIN
2002_CD
._.
10_CD
Joint_NN
ventures_NN
and_CC
associated_VBN
undertakings_GER
2002 2001 2000_CD
m_FW
m_FW
m_FW
Associated_NN
undertakings_GER
:_:
Share_NN
of_PIN
profits_NN
of_PIN
Quest_NN
Diagnostics_NN
Inc._NN
94_CD
79_CD
64_CD
Share_NN
of_PIN
losses_NN
of_PIN
other_JJ
associated_VBN
undertakings_GER
1_CD
1_CD
Amortisation_NOMZ
of_PIN
goodwill_NN
6_CD
7_CD
7_CD
88_CD
71_CD
56_CD
Share_NN
of_PIN
losses_NN
profits_NN
of_PIN
joint_JJ
ventures_NN
13_CD
1_CD
75_CD
71_CD
57_CD
Share_NN
of_PIN
turnover_NN
of_PIN
joint_JJ
ventures_NN
8_CD
88_CD
Sales_NN
to_PIN
joint_JJ
ventures_NN
and_CC
associated_VBN
undertakings_GER
7_CD
11_CD
15_CD
11_CD
Net_JJ
interest_NN
payable_JJ
2002 2001 2000_CD
m_FW
m_FW
m_FW
Interest_NN
payable_JJ
On_PIN
bank_NN
loans_NN
and_PHC
overdrafts_NN
6_CD
26_CD
45_CD
On_PIN
other_JJ
loans_NN
198 169 271_CD
In_PIN
respect_NN
of_PIN
finance_NN
leases_NN
2_CD
3_CD
1_CD
206 198 317_CD
Share_NN
of_PIN
interest_NN
payable_JJ
of_PIN
associate_JJ
8_CD
19 23 214 217_CD
340_CD
Investment_NOMZ
income_NN
Interest_NN
income_NN
71 129 159_CD
Realised_VBN [PRIV]
gains_NN
2_CD
Provision_NN
for_PIN
market_NN
value_NN
adjustments_NOMZ
1_CD
73 129 158 141_CD
88_CD
182_CD
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
91_CD
12_CD
Taxation_NOMZ
2001 2000 2002_CD
restated_VBN
restated_VBN
Taxation_NOMZ
charge_NN
based_VBN [WZPAST]
on_PIN
profits_NN
for_PIN
the_DT
period_NN
m_NN
m_FW
m_FW
UK_NN
corporation_NOMZ
tax_NN
at_PIN
the_DT
UK_NN
statutory_JJ
rate_NN
479 838 928_CD
Less_RB
double_JJ
taxation_NOMZ
relief_NN
117 351 384 362_CD
487_CD
544_CD
Overseas_PLACE
taxation_NOMZ
1,036_CD
876_CD
1,242_CD
Deferred_JJ
taxation_NOMZ
29_CD
53_CD
55_CD
1,427_CD
1,310_CD
1,731_CD
Share_NN
of_PIN
taxation_NOMZ
charge_NN
of_PIN
associates_NN
34_CD
23_CD
16_CD
1,461_CD
1,333_CD
1,747_CD
2001_CD
2000_CD
Reconciliation_NOMZ
of_PIN
the_DT
current_JJ
taxation_NOMZ
rate_NN
on_PIN
Group_NN
profits_NN
2002_CD
restated_VBN
restated_VBN
%_NN
%_NN
%_NN
UK_NN
statutory_JJ
rate_NN
of_PIN
taxation_NOMZ
30.0_CD
30.0_CD
30.0_CD
Overseas_PLACE
taxes_NN
0.1_CD
1.1_CD
2.2_CD
Average_NN
Group_NN
tax_NN
rate_NN
30.1_CD
28.9_CD
32.2_CD
Effect_NN
of_PIN
special_JJ
tax_NN
status_NN
in_PIN
manufacturing_VBG
locations_NOMZ
3.9_CD
3.7_CD
3.2_CD
Share_NN
option_NOMZ
deductions_NOMZ
in_PIN
the_DT
USA_NN
0.2_CD
1.1_CD
0.8_CD
Merger_NN
and_CC
restructuring_VBG
costs_NN
0.7_CD
5.4_CD
0.2_CD
R&D_NN
credits_NN
not_XX0
previously_TIME
recognized_VBN [PRIV]
1.2_CD
0.9_CD
1.1_CD
Other_JJ
permanent_JJ
differences_NN
0.8_CD
0.4_CD
1.4_CD
Capital_NN
allowances_NN
in_PIN
excess_NN
of_PIN
depreciation_NOMZ
0.5_CD
0.2_CD
Intra-Group_NN
profit_NN
1.3_CD
1.3_CD
1.2_CD
Reversing_VBG
timing_NN
differences_NN
on_PIN
tax_NN
losses_NN
2.5_CD
0.2_CD
Other_JJ
timing_NN
differences_NN
2.3_CD
3.9_CD
2.5_CD
Prior_RB
year_NN
items_NN
2.4_CD
0.7_CD
Current_JJ
tax_NN
rate_NN
on_PIN
ordinary_JJ
activities_NOMZ
25.4_CD
30.2_CD
29.6_CD
Capital_NN
allowances_NN
in_PIN
excess_NN
of_PIN
depreciation_NOMZ
0.5_CD
0.2_CD
Intra-Group_NN
profit_NN
1.3_CD
1.3_CD
1.2_CD
Reversing_VBG
timing_NN
differences_NN
on_PIN
tax_NN
losses_NN
2.5_CD
0.2_CD
Other_JJ
timing_NN
differences_NN
2.3_CD
3.9_CD
2.5_CD
Share_NN
of_PIN
associates_NN
taxation_NOMZ
0.6_CD
0.5_CD
0.3_CD
Prior_RB
year_NN
items_NN
3.6_CD
1.5_CD
Tax_NN
rate_NN
on_PIN
ordinary_JJ
activities_NOMZ
26.5_CD
29.5_CD
29.0_CD
The_DT
Group_NN
operates_VPRT
in_PIN
countries_NN
where_RB
the_DT
tax_NN
rate_NN
differs_VPRT
to_PIN
the_DT
UK_NN
rate_NN
._.
The_DT
standard_JJ
rate_NN
of_PIN
tax_NN
for_PIN
the_DT
Group_NN
has_VPRT [PEAS]
been_VBN [BYPA]
estimated_VBN [PRIV]
by_PIN
aggregating_VBG
the_DT
local_JJ
standard_JJ
tax_NN
rates_NN
and_PHC
weighting_GER
these_DEMO
in_PIN
proportion_NOMZ
to_TO
accounting_VBG
profits_NN
._.
profits_NN
arising_VBG [WZPRES]
from_PIN
manufacturing_VBG
operations_NOMZ
in_PIN
Singapore_NN
,_,
Puerto_NN
Rico_NN
and_PHC
Ireland_NN
are_VPRT [PASS]
taxed_VBN
at_PIN
reduced_JJ
rates_NN
._.
The_DT
effect_NN
of_PIN
this_DEMO
reduction_NOMZ
in_PIN
the_DT
taxation_NOMZ
charge_NN
increased_VBD
earnings_GER
per_PIN
share_NN
by_PIN
3.6_CD
p_NN
in_PIN
2002_CD
,_,
2.7_CD
p_NN
in_PIN
2001_CD
and_CC
by_PIN
3.2_CD
p_NN
in_PIN
2000_CD
._.
The_DT
integrated_JJ
nature_NN
of_PIN
the_DT
Groups_NN
worldwide_JJ
operations_NOMZ
,_,
involving_VBG
significant_JJ
investment_NOMZ
in_PIN
research_NN
and_CC
strategic_JJ
manufacture_NN
at_PIN
a_DT
limited_JJ
number_NN
of_PIN
locations_NOMZ
,_,
with_PIN
consequential_JJ
cross-border_JJ
supply_NN
routes_NN
into_PIN
numerous_JJ
end-markets_NN
,_,
gives_VPRT
rise_NN
to_PIN
complexity_NOMZ
and_PHC
delay_NN
in_PIN
negotiations_NOMZ
with_PIN
revenue_NN
authorities_NOMZ
as_IN
to_PIN
the_DT
profits_NN
on_PIN
which_WDT [PIRE]
individual_JJ
Group_NN
companies_NN
are_VPRT [BEMA]
liable_PRED
to_PIN
tax_NN
._.
Disagreements_NOMZ
with_PIN [STPR]
,_,
and_ANDC
between_PIN [STPR]
,_,
revenue_NN
authorities_NOMZ
as_IN
to_PIN
intra-Group_JJ
transactions_NOMZ
,_,
in_CONJ
particular_NULL
the_DT
price_NN
at_PIN
which_WDT [PIRE]
goods_NN
should_NEMD
be_VB [PASS]
transferred_VBN
between_PIN
Group_NN
companies_NN
in_PIN
different_JJ
tax_NN
jurisdictions_NOMZ
,_,
can_POMD
produce_VB
conicting_VBG
claims_NN
from_PIN
revenue_NN
authorities_NOMZ
as_IN
to_PIN
the_DT
profits_NN
that_TSUB
fall_VPRT
to_TO
be_VB [PASS]
taxed_VBN
in_PIN
individual_JJ
territories_NN
._.
Resolution_NOMZ
of_PIN
such_JJ
issues_NN
is_VPRT [BEMA]
a_DT
continuing_VBG
fact-of-life_NN
for_PIN
GlaxoSmithKline_NN
._.
In_PIN
the_DT
USA_NN
,_,
for_PIN
a_DT
number_NN
of_PIN
years_NN
,_,
GlaxoSmithKline_NN
has_VPRT [PEAS]
had_VBN
significant_JJ
open_JJ
issues_NN
relating_VBG [WZPRES]
to_TO
transfer_VB
pricing_GER
._.
These_DEMO
issues_NN
affect_VPRT
all_QUAN
years_NN
from_PIN
1989_CD
to_PIN
the_DT
present_JJ
and_CC
concern_NN
a_DT
number_NN
of_PIN
products_NN
,_,
although_CONC
the_DT
most_EMPH
significant_JJ
relates_VPRT
to_PIN
the_DT
success_NN
of_PIN
Zantac_NN
,_,
in_PIN
respect_NN
of_PIN
which_WDT [PIRE]
the_DT
claims_NN
of_PIN
the_DT
US_FPP1
Internal_NN
Revenue_NN
Service_NN
IRS_NN
substantially_RB
exceed_VPRT
the_DT
Groups_NN
estimation_NOMZ
of_PIN
its_PIT
taxation_NOMZ
liabilities_NOMZ
._.
The_DT
IRS_NN
claims_NN
,_,
which_WDT [SERE]
are_VPRT [PASS]
not_XX0
completely_AMP
quantied_VBN
,_,
continue_VPRT
to_TO
be_VB [BEMA]
the_DT
subject_NN
of_PIN
discussions_NN
between_PIN
the_DT
US_FPP1
and_PHC
UK_NN
tax_NN
authorities_NOMZ
under_IN
the_DT
competent_JJ
authority_NOMZ
provisions_NN
of_PIN
the_DT
double_JJ
tax_NN
convention_NOMZ
between_PIN
the_DT
two_CD
countries_NN
._.
Within_PIN
these_DEMO
discussions_NN
there_EX
is_VPRT
a_DT
wide_JJ
variation_NOMZ
between_PIN
the_DT
views_NN
of_PIN
the_DT
US_FPP1
and_PHC
UK_NN
tax_NN
authorities_NOMZ
and_CC
,_,
exceptionally_RB
,_,
they_TPP3
may_POMD
be_VB [BEMA]
unable_PRED
to_TO
reach_VB
agreement_NOMZ
to_TO
settle_VB
the_DT
dispute_NN
._.
In_PIN
the_DT
event_NN
of_PIN
the_DT
UK_NN
and_PHC
US_FPP1
tax_NN
authorities_NOMZ
not_XX0
reaching_VBG
agreement_NOMZ
,_,
the_DT
matter_NN
may_POMD
have_VB
to_TO
be_VB [BYPA]
resolved_VBN [SUAV]
by_PIN
litigation_NOMZ
._.
GlaxoSmithKline_NN
uses_VPRT
the_DT
best_JJ
advice_NN
in_PIN
determining_VBG [SUAV] [PRIV]
its_PIT
transfer_NN
pricing_GER
methodology_NN
and_CC
in_PIN
seeking_VBG
to_TO
manage_VB
transfer_NN
pricing_GER
issues_NN
to_PIN
a_DT
satisfactory_JJ
conclusion_NN
and_CC
,_,
on_PIN
the_DT
basis_NN
of_PIN
external_JJ
professional_JJ
advice_NN
,_,
continues_VPRT
to_TO
believe_VB [PRIV]
that_THVC
it_PIT
has_VPRT [PEAS]
made_VBN
adequate_JJ
provision_NN
for_PIN
the_DT
liabilities_NOMZ
likely_JJ
to_TO
arise_VB
from_PIN
open_JJ
assessments_NOMZ
._.
92_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
12_CD
Taxation_NOMZ
continued_VBD
Except_PIN
as_IN
shown_VBN [PRIV]
in_PIN
these_DEMO
Financial_NN
statements_NOMZ
,_,
no_SYNE
provision_NN
has_VPRT [PEAS]
been_VBN [PASS]
made_VBN
for_PIN
taxation_NOMZ
which_WDT [WHSUB]
would_PRMD
arise_VB
on_PIN
the_DT
distribution_NOMZ
of_PIN
profits_NN
retained_VBN [WZPAST]
by_PIN
overseas_PLACE
subsidiary_NN
and_CC
associated_VBN
undertakings_GER
,_,
on_PIN
the_DT
grounds_NN
that_TOBJ
no_SYNE
remittance_NN
of_PIN
profit_NN
retained_VBN [WZPAST]
at_PIN
31st_CD
December_NN
2002_CD
is_VPRT [PASS]
required_VBN [SUAV]
in_PIN
such_EMPH
a_NULL
way_NN
that_TOBJ
incremental_JJ
tax_NN
will_PRMD
arise_VB
._.
At_PIN
31st_CD
December_NN
2002_CD
,_,
the_DT
Group_NN
had_VBD
corporate_JJ
tax_NN
losses_NN
of_PIN
approximately_RB
69_CD
million_CD
and_CC
capital_NN
losses_NN
estimated_VBN [PRIV]
to_TO
be_VB [BEMA]
in_PIN
excess_NN
of_PIN
9_CD
billion_CD
which_WDT
are_VPRT [PASS]
not_XX0
recognized_VBN [PRIV]
as_IN
deferred_JJ
tax_NN
assets_NN
because_CAUS
there_EX
is_VPRT
insufficient_JJ
evidence_NN
that_TOBJ
these_DEMO
losses_NN
will_PRMD
be_VB [PASS]
used_VBN
._.
Current_JJ
Deferred_NN
Deferred_NN
tax_NN
creditor_NN
tax_NN
debtor_NN
tax_NN
provision_NN
Tax_NN
balances_NN
m_VPRT
m_FW
m_FW [BEMA]
At_PIN
1st_CD
January_NN
2002_CD
as_IN
previously_TIME
reported_VBN [PUBV]
1,672_CD
871_CD
Prior_RB
year_NN
adjustment_NOMZ
426_CD
553_CD
At_PIN
1st_CD
January_NN
2002_CD
as_IN
restated_VBN
1,672_CD
1,297_CD
553_CD
Exchange_NN
adjustments_NOMZ
103_CD
79_CD
12_CD
Charge_NN
to_TO
profit_VB
and_CC
loss_NN
account_NN
1,398_CD
15_CD
14_CD
Cash_NN
paid_VBN
1,633_CD
Other_JJ
movements_NOMZ
115 170 163_CD
At_PIN
31st_CD
December_NN
2002_CD
1,449_CD
1,373_CD
742 2001 2002_CD
restated_VBN
Deferred_JJ
taxation_NOMZ
asset_NN
liability_NOMZ
m_NN [PASS]
m_NN [PASS]
Accelerated_VBD
capital_NN
allowances_NN
710_CD
691_CD
Stock_NN
valuation_NOMZ
adjustment_NOMZ
113_CD
113_CD
Intra-Group_JJ
profit_NN
487_CD
375_CD
Product_NN
and_PHC
business_NOMZ
disposals_NN
125_CD
161_CD
Pensions_NN
and_CC
other_JJ
post-retirement_JJ
benets_NN
190_CD
298_CD
Tax_NN
losses_NN
93_CD
97_CD
Legal_NN
and_CC
other_JJ
disputes_NN
124_CD
25_CD
Manufacturing_GER
restructuring_GER
52_CD
71_CD
Other_JJ
net_JJ
timing_NN
differences_NN
633 843 631 744_CD
Of_PIN
the_DT
above_PLACE
categories_NN
of_PIN
provided_VBN
deferred_VBN
taxation_NOMZ
,_,
stock_NN
valuation_NOMZ
adjustments_NOMZ
,_,
intra-Group_JJ
profit_NN
and_CC
other_JJ
timing_NN
differences_NN
are_VPRT [BEMA]
current_PRED
._.
All_QUAN
deferred_VBN
taxation_NOMZ
movements_NOMZ
arise_VPRT
from_PIN
the_DT
origination_NOMZ
and_PHC
reversal_NN
of_PIN
timing_NN
differences_NN
._.
The_DT
Group_NN
has_VPRT [PEAS]
implemented_VBN
the_DT
new_JJ
Financial_NN
Reporting_GER
Standard_NN
,_,
FRS_NN
19_CD
Deferred_NN
Tax_NN
,_,
in_PIN
2002_CD
,_,
which_WDT [SERE]
requires_VPRT [SUAV]
deferred_VBN
tax_NN
to_TO
be_VB [PASS]
accounted_VBN
for_PIN
on_PIN
a_DT
full_JJ
provision_NN
basis_NN
rather_RB
than_PIN
a_DT
partial_JJ
provision_NN
basis_NN
as_IN
before_RB
._.
For_PIN
the_DT
full_JJ
year_NN
2001_CD
the_DT
business_NOMZ
performance_NN
tax_NN
charge_NN
is_VPRT [BYPA]
increased_VBN
by_PIN
8_CD
million_CD
,_,
and_ANDC
the_DT
total_JJ
tax_NN
charge_NN
by_PIN
6_CD
million_CD
._.
The_DT
net_JJ
deferred_VBN
tax_NN
asset_NN
at_PIN
31st_CD
December_NN
2001_CD
has_VPRT [PEAS]
been_VBN [BYPA]
reduced_VBN
by_PIN
127_CD
million_CD
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
93_CD
13_CD
Earnings_GER
per_PIN
share_NN
2001 2000 2002_CD
restated_VBN
restated_VBN
p_JJ
pp_NN
Basic_JJ
earnings_GER
per_PIN
share_NN
66.2_CD
50.3_CD
67.7_CD
Adjustment_NOMZ
for_PIN
merger_NN
items_NN
,_,
restructuring_VBG
costs_NN
and_PHC
disposal_NN
of_PIN
subsidiaries_NN
:_:
Merger_NN
integration_NOMZ
and_PHC
transaction_NOMZ
costs_NN
10.8_CD
13.0_CD
6.8_CD
Product_NN
divestments_NOMZ
16.8_CD
Restructuring_GER
costs_NN
1.5_CD
2.0_CD
2.2_CD
Block_NN
Drug_NN
integration_NOMZ
costs_VPRT
0.7_CD
1.6_CD
Disposal_NN
of_PIN
businesses_NOMZ
0.9_CD
5.4_CD
0.2_CD
Associates_NN
0.1_CD
Adjusted_VBN
earnings_GER
per_PIN
share_NN
78.3_CD
72.3_CD
60.2_CD
Diluted_VBN
earnings_GER
per_PIN
share_NN
66.0_CD
49.9_CD
66.9_CD
Basic_JJ
and_PHC
adjusted_JJ
earnings_GER
per_PIN
share_NN
have_VPRT [PEAS]
been_VBN [BYPA]
calculated_VBN [PRIV]
by_PIN
dividing_VBG
the_DT
profit_NN
attributable_JJ
to_PIN
shareholders_NN
by_PIN
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
in_PIN
issue_NN
during_PIN
the_DT
period_NN
._.
The_DT
numbers_NN
used_VBN [WZPAST]
in_PIN
calculating_VBG [PRIV]
basic_JJ
and_PHC
diluted_JJ
earnings_GER
per_PIN
share_NN
are_VPRT [PASS]
reconciled_VBN
below_PLACE
._.
To_TO
illustrate_VB
business_NOMZ
performance_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
primary_JJ
performance_NN
measure_NN
used_VBN [WZPAST]
by_PIN
management_NOMZ
,_,
adjusted_VBN
earnings_GER
and_CC
adjusted_VBN
earnings_GER
per_PIN
share_NN
are_VPRT [PASS]
presented_VBN
after_IN
excluding_VBG
merger_NN
items_NN
,_,
integration_NOMZ
and_PHC
restructuring_GER
costs_NN
and_PHC
disposal_NN
of_PIN
businesses_NOMZ
._.
Management_NOMZ
believes_VPRT [PRIV]
that_THVC
exclusion_NN
of_PIN
these_DEMO
non-recurring_JJ
items_NN
provides_VPRT
a_DT
better_JJ
comparison_NN
of_PIN
business_NOMZ
performance_NN
for_PIN
the_DT
periods_NN
presented_VBN
._.
Accordingly_RB
this_DEMO
information_NOMZ
is_VPRT [PASS]
provided_VBN
as_IN
a_DT
supplement_NOMZ
to_PIN
that_DEMP
contained_VBN
in_PIN
the_DT
consolidated_JJ
statement_NOMZ
of_PIN
profit_NN
and_PHC
loss_NN
on_PIN
pages_NN
76_CD
and_CC
77_CD
prepared_JJ
in_PIN
accordance_NN
with_PIN
UK_NN
GAAP_NN
._.
Basic_JJ
and_PHC
diluted_JJ
earnings_GER
per_PIN
share_NN
include_VPRT
these_DEMO
non-recurring_JJ
items_NN
._.
Net_JJ
profit_NN
for_PIN
the_DT
period_NN
attributable_JJ
to_PIN
shareholders_NN
m_VPRT
m_FW
m_FW
Earnings_GER
basic_JJ
and_PHC
diluted_JJ
3,915_CD
3,053_CD
4,106_CD
Adjustments_NOMZ
for_PIN
merger_NN
items_NN
,_,
restructuring_VBG
costs_NN
and_PHC
disposal_NN
of_PIN
subsidiaries_NN
712_CD
1,330_CD
452_CD
Adjusted_VBN
earnings_GER
4,627_CD
4,383_CD
3,654_CD
Weighted_VBN
average_JJ
number_NN
of_PIN
shares_NN
in_PIN
issue_NN
millions_NN
millions_NN
millions_NN
Basic_JJ
and_PHC
adjusted_JJ
5,912_CD
6,064_CD
6,065_CD
Dilution_NOMZ
for_PIN
share_NN
options_NOMZ
22_CD
52_CD
69_CD
Diluted_NN
5,934_CD
6,116_CD
6,134_CD
Shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
Employee_NN
Share_NN
Ownership_NN
Trusts_NN
ESOT_NN
are_VPRT [PASS]
excluded_VBN
._.
The_DT
trustees_NN
have_VPRT [PEAS]
waived_VBN
their_TPP3
rights_NN
to_PIN
dividends_NN
on_PIN
the_DT
shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
ESOTs_NN
._.
94_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
14_CD
Dividends_NN
2002_CD
2001_CD
m_NN
m_NN
GlaxoSmithKline_NN
plc_NN
:_:
First_NN
interim_JJ
535_CD
546_CD
Second_JJ
interim_JJ
530_CD
546_CD
Third_NN
interim_JJ
527_CD
546_CD
Fourth_JJ
interim_JJ
754_CD
718_CD
2,346_CD
2,356_CD
2000_CD
m_NN
Glaxo_NN
Wellcome_NN
plc_NN
:_:
Interim_NN
538_CD
Second_JJ
interim_JJ
827_CD
Final_JJ
1,365_CD
SmithKline_NN
Beecham_NN
plc_NN
:_:
First_NN
interim_JJ
162_CD
Second_JJ
interim_JJ
162_CD
Third_JJ
interim_JJ
163_CD
Fourth_JJ
interim_JJ
245_CD
732_CD
2,097_CD
2002_CD
2001_CD
Dividends_NN
per_PIN
share_NN
p_NN
p_VPRT
GlaxoSmithKline_NN
plc_NN
:_:
First_NN
interim_JJ
9_CD
9_CD
Second_JJ
interim_JJ
9_CD
9_CD
Third_NN
interim_JJ
9_CD
9_CD
Fourth_JJ
interim_JJ
13_CD
12_CD
40_CD
39_CD
2000_CD
p_NN
Glaxo_NN
Wellcome_NN
plc_SYM
-_:
per_PIN
Glaxo_NN
Wellcome_NN
share_NN
:_:
Interim_NN
15_CD
Second_JJ
interim_JJ
23_CD
Final_JJ
38_CD
The_DT
equivalent_JJ
dividend_NN
per_PIN
GlaxoSmithKline_NN
share_NN
is_VPRT [BEMA]
the_DT
same_JJ
as_IN
the_DT
dividend_NN
per_PIN
Glaxo_NN
Wellcome_NN
share_NN
._.
SmithKline_NN
Beecham_NN
plc_NN
per_PIN
SmithKline_NN
Beecham_NN
share_NN
:_:
First_NN
interim_JJ
3.0_CD
Second_JJ
interim_JJ
3.0_CD
Third_JJ
interim_JJ
3.0_CD
Fourth_JJ
interim_JJ
4.5_CD
13.5_CD
SmithKline_NN
Beecham_NN
plc_NN
equivalent_JJ
dividend_NN
per_PIN
GlaxoSmithKline_NN
share_NN
:_:
First_NN
interim_JJ
6.59_CD
Second_JJ
interim_JJ
6.59_CD
Third_JJ
interim_JJ
6.59_CD
Fourth_JJ
interim_JJ
9.89_CD
29.66_CD
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
95_CD
15_CD
Goodwill_NN
Total_NN
m_VBD
Cost_NN
at_PIN
1st_CD
January_NN
2002_CD
210_CD
Exchange_NN
adjustments_NOMZ
17_CD
Additions_NOMZ
Note_VPRT [PRIV]
31_CD
23_CD
Cost_NN
at_PIN
31st_CD
December_NN
2002_CD
216_CD
Amortisation_NOMZ
at_PIN
1st_CD
January_NN
2002_CD
36_CD
Exchange_NN
adjustments_NOMZ
3_CD
Provision_NN
for_PIN
the_DT
year_NN
12_CD
Amortisation_NOMZ
at_PIN
31st_CD
December_NN
2002_CD
45_CD
Net_JJ
book_NN
value_NN
at_PIN
1st_CD
January_NN
2002_CD
174_CD
Net_JJ
book_NN
value_NN
at_PIN
31st_CD
December_NN
2002_CD
171_CD
Licences_NN
,_,
16_CD
Intangible_JJ
assets_NN
patents_NN
,_,
etc._FW
._.
Brands_NN
Total_NN
m_FW
m_FW
m_FW
Cost_NN
at_PIN
1st_CD
January_NN
2002_CD
597_CD
1,266_CD
1,863_CD
Exchange_NN
adjustments_NOMZ
27_CD
94_CD
121_CD
Additions_NOMZ
182_CD
182_CD
Acquisition_NOMZ
of_PIN
businesses_NOMZ
4_CD
4_CD
Assets_NN
written_VBN [PUBV] [WZPAST]
off_PIN
44_CD
10_CD
54_CD
Cost_NN
at_PIN
31st_CD
December_NN
2002_CD
712_CD
1,162_CD
1,874_CD
Amortisation_NOMZ
at_PIN
1st_CD
January_NN
2002 119 119_CD
Exchange_NN
adjustments_NOMZ
5_CD
5_CD
Provision_NN
for_PIN
the_DT
year_NN
60_CD
60_CD
Assets_NN
written_VBN [PUBV] [WZPAST]
off_PIN
12_CD
12_CD
Amortisation_NOMZ
at_PIN
31st_CD
December_NN
2002 162 162_CD
Impairment_NOMZ
at_PIN
1st_CD
January_NN
2002_CD
46_CD
25_CD
71_CD
Exchange_NN
adjustments_NOMZ
3_CD
3_CD
Impairment_NOMZ
loss_NN
4_CD
4_CD
Impairment_NOMZ
at_PIN
31st_CD
December_NN
2002_CD
53_CD
22_CD
75_CD
Net_JJ
book_NN
value_NN
at_PIN
1st_CD
January_NN
2002_CD
432_CD
1,241_CD
1,673_CD
Net_JJ
book_NN
value_NN
at_PIN
31st_CD
December_NN
2002_CD
497_CD
1,140_CD
1,637_CD
The_DT
licences_NN
and_PHC
patents_NN
acquired_VBN [WZPAST]
in_PIN
the_DT
year_NN
relate_VPRT
to_PIN
the_DT
acquisition_NOMZ
of_PIN
various_JJ
compound_NN
rights_NN
and_CC
other_JJ
research_NN
based_VBN
agreements_NOMZ
see_VPRT [PRIV]
Note_NN
26_CD
._.
Brands_NN
largely_RB
comprise_VPRT
a_DT
portfolio_NN
of_PIN
Sterling_GER
products_NN
such_JJ
as_IN
Panadol_NN
,_,
Solpadeine_NN
and_PHC
Hedex_NN
and_CC
the_DT
Block_NN
Drug_NN
products_NN
such_JJ
as_IN
Sensodyne_NN
,_,
Polident_NN
and_PHC
Poligrip_NN
._.
Each_QUAN
of_PIN
these_DEMP
is_VPRT [PASS]
considered_VBN [PRIV]
to_TO
have_VB
an_DT
indefinite_JJ
life_NN
given_VBN
the_DT
strength_NN
and_PHC
durability_NOMZ
of_PIN
the_DT
brand_NN
and_CC
the_DT
level_NN
of_PIN
marketing_GER
support_NN
._.
Accordingly_RB
,_,
they_TPP3
are_VPRT [PASS]
not_XX0
amortised_VBN
._.
The_DT
valuation_NOMZ
of_PIN
each_QUAN
Sterling_GER
brand_NN
is_VPRT [PASS]
reviewed_VBN
annually_RB
using_VBG
a_DT
10_CD
year_NN
cash_NN
ow_NN
forecast_NN
as_IN
this_DEMP
was_VBD [BEMA]
the_DT
basis_NN
for_PIN
the_DT
original_JJ
independent_JJ
assessment_NOMZ
when_RB
they_TPP3
were_VBD [PASS]
acquired_VBN
in_PIN
1994_CD
and_CC
a_DT
post-tax_JJ
discount_NN
rate_NN
of_PIN
eight_CD
per_PIN
cent_NN
._.
The_DT
valuation_NOMZ
of_PIN
each_QUAN
Block_NN
Drug_NN
brand_NN
is_VPRT [SPAU] [PASS]
also_RB
reviewed_VBN
annually_RB
using_VBG
a_DT
five_CD
year_NN
cash_NN
ow_NN
forecast_NN
and_CC
a_DT
post-tax_JJ
discount_NN
rate_NN
of_PIN
eight_CD
per_PIN
cent_NN
._.
96_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
Plant_NN
,_,
Land_NN
and_PHC
equipment_NOMZ
Computer_NN
Assets_NN
in_PIN
17_CD
Tangible_JJ
xed_JJ
assets_NN
buildings_GER
and_PHC
vehicles_NN
software_NN
construction_NOMZ
Total_JJ
m_NN
m_FW
m_FW
m_FW
m_FW
Cost_NN
at_PIN
1st_CD
January_NN
2002_CD
3,903_CD
6,821_CD
300_CD
1,212_CD
12,236_CD
Exchange_NN
adjustments_NOMZ
154_CD
207_CD
5_CD
48_CD
414_CD
Additions_NOMZ
68_CD
350_CD
36_CD
573_CD
1,027_CD
Acquisitions_NOMZ
57_CD
1_CD
13_CD
Disposals_NN
69_CD
387_CD
8_CD
15_CD
479_CD
Reclassications_NOMZ
557_CD
130_CD
9_CD
696_CD
Cost_NN
at_PIN
31st_CD
December_NN
2002_CD
4,310_CD
6,714_CD
332_CD
1,027_CD
12,383_CD
Depreciation_NOMZ
at_PIN
1st_CD
January_NN
2002_CD
1,011_CD
4,002_CD
95_CD
5,108_CD
Exchange_NN
adjustments_NOMZ
41_CD
129_CD
3_CD
173_CD
Provision_NN
for_PIN
the_DT
year_NN
155_CD
555_CD
54_CD
764_CD
Disposals_NN
9_CD
305_CD
5_CD
319_CD
Reclassications_NOMZ
142_CD
173_CD
31_CD
Depreciation_NOMZ
at_PIN
31st_CD
December_NN
2002_CD
1,258_CD
3,950_CD
172_CD
5,380_CD
Impairment_NOMZ
at_PIN
1st_CD
January_NN
2002 147 112_CD
24_CD
283_CD
Exchange_NN
12_CD
7_CD
19_CD
Impairment_NOMZ
loss_NN
29_CD
73_CD
102_CD
Disposals_NN
11_CD
1_CD
12_CD
Reclassications_NOMZ
5_CD
5_CD
Impairment_NOMZ
at_PIN
31st_CD
December_NN
2002 148 182_CD
24_CD
354_CD
Net_JJ
book_NN
value_NN
at_PIN
1st_CD
January_NN
2002_CD
2,745_CD
2,707_CD
205_CD
1,188_CD
6,845_CD
Net_JJ
book_NN
value_NN
at_PIN
31st_CD
December_NN
2002_CD
2,904_CD
2,582_CD
160_CD
1,003_CD
6,649_CD
The_DT
net_JJ
book_NN
value_NN
at_PIN
31st_CD
December_NN
2002_CD
of_PIN
the_DT
Groups_NN
land_NN
and_PHC
buildings_GER
comprises_VPRT
freehold_NN
properties_NN
2,699_CD
million_CD
at_PIN
1st_CD
January_NN
2002_CD
2,516_CD
million_CD
,_,
properties_NN
with_PIN
leases_NN
of_PIN
50_CD
years_NN
or_CC
more_EMPH
135_CD
million_CD
at_PIN
1st_CD
January_NN
2002_CD
157_CD
million_CD
and_CC
properties_NN
with_PIN
leases_NN
of_PIN
less_JJ
than_PIN
50_CD
years_NN
70_CD
million_CD
at_PIN
1st_CD
January_NN
2002_CD
72_CD
million_CD
._.
Included_VBN [PASTP]
in_PIN
plant_NN
,_,
equipment_NOMZ
and_PHC
vehicles_NN
at_PIN
31st_CD
December_NN
2002_CD
are_VPRT [PASS]
leased_VBN
assets_NN
with_PIN
a_DT
cost_NN
of_PIN
6_CD
million_CD
at_PIN
1st_CD
January_NN
2002_CD
23_CD
million_CD
,_,
accumulated_VBN
depreciation_NOMZ
of_PIN
4_CD
million_CD
at_PIN
1st_CD
January_NN
2002_CD
14_CD
million_CD
and_CC
a_DT
net_JJ
book_NN
value_NN
of_PIN
2_CD
million_CD
at_PIN
1st_CD
January_NN
2002_CD
9_CD
million_CD
._.
The_DT
impairment_NOMZ
loss_NN
principally_RB
relates_VPRT
to_PIN
reductions_NOMZ
in_PIN
forecast_NN
cash_NN
ows_VPRT
resulting_VBG
from_PIN
decisions_NN
to_TO
close_VB
manufacturing_GER
facilities_NOMZ
and_CC
has_VPRT [PEAS]
been_VBN [BYPA]
measured_VBN
by_PIN
reference_NN
to_PIN
value_NN
in_PIN
use_NN
,_,
typically_RB
using_VBG
a_DT
discount_NN
rate_NN
of_PIN
eight_CD
per_PIN
cent_NN
._.
Joint_NN
Associated_NN
Equity_NOMZ
Own_NN
18_CD
Fixed_JJ
asset_NN
investments_NOMZ
ventures_NN
undertakings_GER
investments_NOMZ
shares_NN
Total_JJ
m_NN
m_FW
m_FW
m_FW
m_FW [BEMA]
At_PIN
1st_CD
January_NN
2002 32 127 133_CD
2,936_CD
3,228_CD
Exchange_NN
adjustments_NOMZ
2_CD
15_CD
16_CD
33_CD
Additions_NOMZ
539_CD
44_CD
Charge_NN
for_PIN
the_DT
year_NN
51_CD
51_CD
Impairment_NOMZ
19_CD
19_CD
Transfers_NN
5_CD
8_CD
13_CD
Disposals_NN
4_CD
59_CD
63_CD
Retained_VBN
profit_NN
for_PIN
the_DT
year_NN
13_CD
47_CD
34_CD
Goodwill_NN
amortisation_NOMZ
6_CD
6_CD
At_PIN
31st_CD
December_NN
2002 17 153 125_CD
2,826_CD
3,121_CD
Investments_NOMZ
in_PIN
joint_JJ
ventures_NN
comprise_VPRT
19_CD
million_CD
share_NN
of_PIN
gross_JJ
assets_NN
2001_CD
33_CD
million_CD
and_CC
2_CD
million_CD
share_NN
of_PIN
gross_JJ
liabilities_NOMZ
2001_CD
1_CD
million_CD
._.
The_DT
principal_NN
associated_VBN
undertaking_GER
is_VPRT
Quest_NN
Diagnostics_NN
,_,
Inc._NN
a_DT
US_FPP1
clinical_JJ
laboratory_NN
business_NOMZ
listed_VBN [WZPAST]
on_PIN
the_DT
New_NN
York_NN
Stock_NN
Exchange_NN
._.
The_DT
investment_NOMZ
has_VPRT
a_DT
book_NN
value_NN
at_PIN
31st_CD
December_NN
2002_CD
of_PIN
129_CD
million_CD
2001_CD
98_CD
million_CD
and_CC
a_DT
market_NN
value_NN
of_PIN
782_CD
million_CD
2001_CD
1,094_CD
million_CD
._.
At_PIN
31st_CD
December_NN
2002_CD
,_,
the_DT
Group_NN
owned_VBD
23_CD
per_PIN
cent_NN
of_PIN
Quest_NN
2001_CD
23_CD
per_PIN
cent_NN
._.
This_DEMO
holding_GER
was_VBD [PASS]
reduced_VBN
to_PIN
21_CD
per_PIN
cent_NN
in_PIN
February_NN
2003_CD
following_VBG
Quests_NN
acquisition_NOMZ
of_PIN
Unilab_NN
Corporation_NOMZ
._.
The_DT
book_NN
value_NN
includes_VPRT
goodwill_NN
which_WDT [WHSUB]
is_VPRT
being_VBG [PASS]
amortised_VBN
over_IN
20_CD
years_NN
:_:
the_DT
amortisation_NOMZ
charge_NN
for_PIN
2002_CD
was_VBD [BEMA]
6_CD
million_CD
._.
The_DT
goodwill_NN
at_PIN
31st_CD
December_NN
2002_CD
amounts_NN
to_PIN
101_CD
million_CD
2001_CD
118_CD
million_CD
._.
Goodwill_NN
of_PIN
115_CD
million_CD
which_WDT
relates_VPRT
to_PIN
the_DT
continuing_VBG
Group_NN
interest_NN
in_PIN
Clinical_NN
Laboratories_NN
assets_NN
attributed_VBD
to_PIN
Quest_NN
,_,
remains_VPRT
eliminated_VBN
against_PIN
Group_NN
reserves_NN
._.
Equity_NOMZ
investments_NOMZ
comprise_VPRT
listed_VBN
investments_NOMZ
of_PIN
7_CD
million_CD
2001_CD
8_CD
million_CD
and_CC
unlisted_JJ
investments_NOMZ
of_PIN
118_CD
million_CD
2001_CD
125_CD
million_CD
._.
The_DT
market_NN
value_NN
of_PIN
listed_VBN
investments_NOMZ
was_VBD [BEMA]
11_CD
million_CD
2001_CD
8_CD
million_CD
._.
Investments_NOMZ
in_PIN
own_JJ
shares_NN
consist_VPRT
of_PIN
shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
Employee_NN
Share_NN
Ownership_NN
Trusts_NN
see_VPRT [PRIV]
Note_NN
34_CD
._.
The_DT
market_NN
value_NN
of_PIN
own_JJ
shares_NN
at_PIN
31st_CD
December_NN
2002_CD
was_VBD [BEMA]
2,161_CD
million_CD
2001_CD
3,229_CD
million_CD
._.
This_DEMO
valuation_NOMZ
shortfall_NN
is_VPRT [PASS]
not_XX0
considered_VBN [PRIV]
to_TO
represent_VB
a_DT
permanent_JJ
diminution_NOMZ
in_PIN
value_NN
in_PIN
the_DT
context_NN
of_PIN
the_DT
length_NN
of_PIN
the_DT
future_JJ
period_NN
over_IN
which_WDT
the_DT
related_JJ
share_NN
options_NOMZ
may_POMD
be_VB [PASS]
exercised_VBN
._.
Accordingly_RB
no_SYNE
provision_NN
has_VPRT [PEAS]
been_VBN [PASS]
made_VBN
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
97_CD
19_CD
Equity_NOMZ
investments_NOMZ
Total_JJ
m_NN [BEMA]
At_PIN
1st_CD
January_NN
2002_CD
185_CD
Exchange_NN
adjustments_NOMZ
4_CD
Additions_NOMZ
43_CD
Transfer_NN
from_PIN
xed_JJ
asset_NN
investments_NOMZ
6_CD
Impairment_NOMZ
55_CD
Disposals_NN
14_CD
At_PIN
31st_CD
December_NN
2002_CD
161_CD
Equity_NOMZ
investments_NOMZ
include_VPRT
listed_VBN
investments_NOMZ
of_PIN
125_CD
million_CD
2001_CD
185_CD
million_CD
._.
The_DT
market_NN
value_NN
of_PIN
listed_VBN
investments_NOMZ
was_VBD [BEMA]
232_CD
million_CD
2001_CD
531_CD
million_CD
._.
20_CD
Stocks_NN
2002_CD
2001_CD
m_NN
m_NN
Raw_NN
materials_NN
and_PHC
consumables_NN
508_CD
565_CD
Work_NN
in_PIN
progress_NN
673_CD
808_CD
Finished_VBN
goods_NN
899_CD
717_CD
2,080_CD
2,090_CD
21_CD
Debtors_NN
2001_CD
2002_CD
restated_VBN
m_NN
m_NN
Amounts_NN
due_JJ
within_PIN
one_CD
year_NN
Trade_NN
debtors_NN
3,515_CD
3,628_CD
Other_JJ
debtors_NN
569_CD
575_CD
Prepaid_JJ
pension_NN
contributions_NOMZ
257_CD
11_CD
Other_JJ
prepayments_NOMZ
and_CC
accrued_VBN
income_NN
178_CD
177_CD
Amounts_NN
due_JJ
after_IN
one_CD
year_NN
Other_JJ
debtors_NN
294_CD
320_CD
Prepayments_NOMZ
and_CC
accrued_VBN
income_NN
14_CD
9_CD
Deferred_VBN
taxation_NOMZ
Note_NN
12_CD
1,373_CD
1,297_CD
6,200_CD
6,017_CD
Debtors_NN
include_VPRT
trading_GER
balances_NN
of_PIN
nil_NN
2001_CD
2_CD
million_CD
due_JJ
from_PIN
joint_JJ
ventures_NN
and_CC
associated_VBN
undertakings_GER
._.
22_CD
Other_JJ
creditors_NN
2002_CD
2001_CD
m_NN
m_NN
Amounts_NN
due_JJ
within_PIN
one_CD
year_NN
Trade_NN
creditors_NN
715_CD
760_CD
Taxation_NOMZ
Note_NN
12_CD
1,449_CD
1,672_CD
Social_NN
security_NOMZ
87_CD
123_CD
Other_JJ
creditors_NN
429_CD
345_CD
Accruals_NN
and_CC
deferred_JJ
income_NN
3,285_CD
3,142_CD
Dividends_NN
payable_JJ
1,292_CD
1,264_CD
7,257_CD
7,306_CD
Amounts_NN
due_JJ
after_IN
one_CD
year_NN
Other_JJ
creditors_NN
113_CD
58_CD
Accruals_NN
and_CC
deferred_JJ
income_NN
93 132 206 190_CD
Accruals_NN
include_VPRT
obligations_NOMZ
for_PIN
wages_NN
and_PHC
salaries_NN
of_PIN
557_CD
million_CD
2001_CD
617_CD
million_CD
._.
98_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
Pensions_NN
and_CC
other_JJ
Legal_JJ
23_CD
Provisions_NN
for_PIN
post-retirement_JJ
Manufacturing_GER
Merger_NN
and_CC
other_JJ
Deferred_NN
Other_JJ
liabilities_NOMZ
and_PHC
charges_NN
benets_NN
restructuring_VBG [WZPRES]
integration_NOMZ
disputes_NN
taxation_NOMZ
provisions_NN
Total_JJ
m_NN
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW [BEMA]
At_PIN
1st_CD
January_NN
2002_CD
as_IN
previously_TIME
reported_VBN [PUBV]
1,022_CD
126 240 227 195_CD
1,810_CD
Prior_RB
year_NN
adjustment_NOMZ
Note_VB [PRIV]
12 553 553_CD
At_PIN
1st_CD
January_NN
2002_CD
as_IN
restated_VBN
1,022_CD
126 240 227 553_CD
195_CD
2,363_CD
Exchange_NN
adjustments_NOMZ
69_CD
2_CD
8_CD
44_CD
12_CD
12_CD
123_CD
Charge_NN
for_PIN
the_DT
year_NN
198 32 379 304_CD
14_CD
4_CD
931_CD
Applied_NN
335_CD
52_CD
203_CD
72_CD
17_CD
679_CD
Reclassications_NOMZ
and_CC
other_JJ
movements_NOMZ
105_CD
1_CD
5_CD
92_CD
163_CD
13_CD
341_CD
At_PIN
31st_CD
December_NN
2002 921 103 403_CD
507 742 157_CD
2,833_CD
In_PIN
December_NN
2002_CD
,_,
the_DT
Group_NN
made_VBD
special_JJ
cash_NN
contributions_NOMZ
totalling_VBG [WZPRES]
320_CD
million_CD
into_PIN
the_DT
UK_NN
,_,
US_FPP1
and_CC
German_JJ
pension_NN
schemes_NN
._.
The_DT
contributions_NOMZ
relating_VBG [WZPRES]
to_PIN
the_DT
US_FPP1
and_CC
German_JJ
pension_NN
schemes_NN
are_VPRT [PASS]
included_VBN
within_PIN
the_DT
amounts_NN
applied_VBD
to_PIN
the_DT
provision_NN
above_PLACE
:_:
the_DT
contribution_NOMZ
relating_VBG [WZPRES]
to_PIN
the_DT
UK_NN
pension_NN
scheme_NN
has_VPRT [PEAS]
increased_VBN
the_DT
prepayment_NOMZ
amount_NN
shown_VBN [PRIV]
under_IN
debtors_NN
in_PIN
Note_NN
21_CD
._.
The_DT
Group_NN
has_VPRT [PEAS]
recognized_VBN [PRIV]
costs_NN
in_PIN
2002_CD
in_PIN
respect_NN
of_PIN
plans_NN
for_PIN
manufacturing_GER
and_CC
other_JJ
restructuring_GER
initiated_VBN [WZPAST]
in_PIN
1998_CD
,_,
1999_CD
and_CC
in_PIN
2001_CD
following_VBG
the_DT
merger_NN
of_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
and_PHC
acquisition_NOMZ
of_PIN
Block_NN
Drug_NN
._.
These_DEMO
plans_NN
are_VPRT
largely_RB
to_TO
be_VB [PASS]
completed_VBN
during_PIN
2003_CD
._.
Costs_NN
recognized_VBD [PRIV]
as_IN
a_DT
provision_NN
,_,
principally_RB
in_PIN
respect_NN
of_PIN
identied_JJ
severances_NN
at_PIN
sites_NN
where_RB
it_PIT
has_VPRT [PEAS]
been_VBN [PASS]
announced_VBN [PUBV] [THATD]
that_DEMP
manufacturing_VBG
activities_NOMZ
will_PRMD
cease_VB
,_,
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
incurred_VBN
mainly_RB
in_PIN
2003_CD
._.
Costs_NN
of_PIN
asset_NN
write-downs_NN
have_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
as_IN
an_DT
impairment_NOMZ
of_PIN
xed_JJ
assets_NN
._.
The_DT
Group_NN
has_VPRT [PEAS]
recognized_VBN [PRIV]
costs_NN
in_PIN
2001_CD
and_CC
2002_CD
in_PIN
respect_NN
of_PIN
plans_NN
for_PIN
the_DT
integration_NOMZ
of_PIN
the_DT
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
businesses_NOMZ
._.
Additional_JJ
costs_NN
will_PRMD
be_VB [PASS]
incurred_VBN
as_IN
implementation_NOMZ
of_PIN
the_DT
integration_NOMZ
following_VBG [WZPRES]
the_DT
merger_NN
continues_VPRT
._.
Costs_NN
recognized_VBD [PRIV]
as_IN
a_DT
provision_NN
in_PIN
respect_NN
of_PIN
identied_JJ
severances_NN
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
incurred_VBN
in_PIN
2003_CD
,_,
and_ANDC
in_PIN
respect_NN
of_PIN
the_DT
program_NN
to_TO
encourage_VB
staff_NN
to_TO
convert_VB
Glaxo_NN
Wellcome_NN
or_CC
SmithKline_NN
Beecham_NN
share_NN
options_NOMZ
into_PIN
GlaxoSmithKline_NN
share_NN
options_NOMZ
when_RB
employees_NN
exercise_VPRT
these_DEMO
options_NOMZ
._.
Provisions_NN
for_PIN
legal_JJ
and_PHC
other_JJ
disputes_NN
and_CC
other_JJ
matters_NN
include_VPRT
amounts_NN
relating_VBG [WZPRES]
to_PIN
US_FPP1
anti-trust_NN
,_,
product_NN
liability_NOMZ
,_,
contract_NN
terminations_NOMZ
,_,
self-insurance_NN
,_,
environmental_JJ
clean-up_JJ
and_CC
property_NN
rental_NN
._.
The_DT
companys_NN
Directors_NN
,_,
having_VBG [PEAS]
taken_VBN
legal_JJ
advice_NN
,_,
have_VPRT [PEAS]
established_VBN [PRIV]
provisions_NN
after_IN
taking_VBG
into_PIN
account_NN
insurance_NN
and_CC
other_JJ
agreements_NOMZ
and_CC
having_VBG
regard_NN
to_PIN
the_DT
relevant_JJ
facts_NN
and_PHC
circumstances_NN
of_PIN
each_QUAN
matter_NN
and_CC
in_PIN
accordance_NN
with_PIN
accounting_GER
requirements_NOMZ
._.
No_SYNE
provisions_NN
have_VPRT [PEAS]
been_VBN [PASS]
made_VBN
for_PIN
unasserted_JJ
claims_NN
._.
The_DT
ultimate_JJ
liability_NOMZ
for_PIN
such_JJ
matters_NN
may_POMD
vary_VB
from_PIN
the_DT
amounts_NN
provided_VBN
and_PHC
is_VPRT [BEMA]
dependent_PRED
upon_PIN
the_DT
outcome_NN
of_PIN
litigation_NOMZ
proceedings_GER
,_,
investigations_NOMZ
and_CC
possible_JJ
settlement_NOMZ
negotiations_NOMZ
._.
GlaxoSmithKline_NN
is_VPRT [PASS]
involved_VBN
in_PIN
a_DT
number_NN
of_PIN
legal_JJ
and_PHC
other_JJ
disputes_NN
including_VBG [WZPRES]
notication_NOMZ
of_PIN
possible_JJ
claims_NN
where_RB
,_,
because_CAUS
of_PIN
the_DT
early_TIME
stage_NN
of_PIN
the_DT
matter_NN
,_,
no_SYNE
reliable_JJ
estimate_NN
of_PIN
the_DT
outcome_NN
can_POMD
be_VB [PASS]
made_VBN
._.
Accordingly_RB
no_SYNE
provision_NN
has_VPRT [PEAS]
been_VBN [PASS]
recorded_VBN
for_PIN
these_DEMO
matters_NN
or_CC
any_QUAN
unasserted_JJ
claims_NN
._.
It_PIT
is_VPRT [BEMA]
in_PIN
the_DT
nature_NN
of_PIN
the_DT
Groups_NN
business_NOMZ
that_TOBJ
a_DT
number_NN
of_PIN
these_DEMO
matters_NN
may_POMD
be_VB [BEMA]
the_DT
subject_NN
of_PIN
negotiation_NOMZ
and_PHC
litigation_NOMZ
over_IN
several_QUAN
years_NN
._.
The_DT
largest_JJ
individual_JJ
amounts_NN
provided_VBN [WZPAST]
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
settled_VBN
within_PIN
two_CD
years_NN
._.
For_PIN
a_DT
discussion_NN
of_PIN
litigation_NOMZ
issues_NN
,_,
refer_VPRT
to_PIN
Legal_NN
proceedings_GER
in_PIN
Note_NN
30_CD
._.
24_CD
Contingent_JJ
liabilities_NOMZ
Contingent_JJ
liabilities_NOMZ
,_,
comprising_VBG
guarantees_NN
,_,
discounted_VBD
bills_NN
and_CC
other_JJ
items_NN
arising_VBG [WZPRES]
in_PIN
the_DT
normal_JJ
course_NN
of_PIN
business_NOMZ
,_,
amounted_VBD
at_PIN
31st_CD
December_NN
2002_CD
to_PIN
138_CD
million_CD
2001_CD
90_CD
million_CD
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
99_CD
25_CD
Net_JJ
debt_NN
2002_CD
2001_CD
m_NN
m_NN
Liquid_NN
investments_NOMZ
1,256_CD
1,415_CD
Cash_NN
at_PIN
bank_NN
1,052_CD
716_CD
2,308_CD
2,131_CD
Loans_NN
and_PHC
overdrafts_NN
due_JJ
within_PIN
one_CD
year_NN
:_:
Bank_NN
loans_NN
and_PHC
overdrafts_NN
263_CD
307_CD
Commercial_JJ
paper_NN
1,284_CD
1,269_CD
Eurobonds_NN
and_CC
Medium-Term_JJ
notes_NN
542_CD
Obligations_NOMZ
under_IN
finance_NN
leases_NN
1_CD
2_CD
Other_JJ
loans_NN
3_CD
4_CD
1,551_CD
2,124_CD
Loans_NN
due_JJ
after_IN
one_CD
year_NN
:_:
Bank_NN
loans_NN
3_CD
11_CD
Eurobonds_NN
,_,
Medium-Term_JJ
notes_NN
and_CC
private_JJ
nancing_GER
3,054_CD
2,059_CD
Loan_NN
Stock_NN
14_CD
16_CD
Obligations_NOMZ
under_IN
finance_NN
leases_NN
12_CD
12_CD
Other_JJ
loans_NN
9_CD
10_CD
3,092_CD
2,108_CD
Net_JJ
debt_NN
2,335_CD
2,101_CD
At_PIN
the_DT
balance_NN
sheet_NN
date_NN
the_DT
Groups_NN
liquid_JJ
investments_NOMZ
had_VBD
an_DT
aggregate_JJ
market_NN
value_NN
of_PIN
1,264_CD
million_CD
2001_CD
1,418_CD
million_CD
._.
Loans_NN
and_PHC
overdrafts_NN
due_JJ
within_PIN
one_CD
year_NN
Commercial_JJ
paper_NN
comprises_VPRT
a_DT
US$_$
10_CD
billion_CD
program_NN
,_,
of_PIN
which_WDT [PIRE]
1,284_CD
million_CD
was_VBD [BEMA]
in_PIN
issue_NN
at_PIN
31st_CD
December_NN
2002_CD
at_PIN
31st_CD
December_NN
2001_CD
1,269_CD
million_CD
,_,
backed_VBD
up_RP
by_PIN
committed_JJ
facilities_NOMZ
of_PIN
364_CD
days_NN
duration_NOMZ
of_PIN
872_CD
million_CD
,_,
renewable_JJ
annually_RB
,_,
and_ANDC
liquid_JJ
investments_NOMZ
of_PIN
787_CD
million_CD
._.
The_DT
weighted_JJ
average_JJ
interest_NN
rate_NN
on_PIN
commercial_JJ
paper_NN
borrowings_GER
at_PIN
31st_CD
December_NN
2002_CD
was_VBD [BEMA]
1.3_CD
per_PIN
cent_NN
._.
Loans_NN
due_JJ
after_IN
one_CD
year_NN
In_PIN
2002_CD
,_,
a_DT
500_CD
million_CD
,_,
4.875_CD
per_PIN
cent_NN
coupon_NN
bond_NN
and_CC
two_CD
,_,
US_FPP1
dollar_NN
denominated_VBD
,_,
oating_VBG
rate_NN
bonds_NN
totalling_VBG [WZPRES]
$_$
495_CD
million_CD
were_VBD [PASS]
issued_VBN
under_IN
the_DT
European_JJ
Medium_NN
Term_NN
Note_NN
program_NN
._.
The_DT
Group_NN
also_RB
raised_VBD
$_$
500_CD
million_CD
of_PIN
oating_NN
rate_NN
debt_NN
through_PIN
a_DT
private_JJ
nancing_GER
arrangement_NOMZ
._.
This_DEMP
may_POMD
be_VB [BYPA]
redeemed_VBN
by_PIN
the_DT
Group_NN
at_PIN
any_QUAN
time_NN
and_CC
,_,
in_CONJ
particular_NULL
,_,
in_PIN
the_DT
event_NN
of_PIN
any_QUAN
accelerating_VBG
event_NN
that_TSUB
would_PRMD
increase_VB
the_DT
cost_NN
of_PIN
funding_GER
for_PIN
the_DT
Group_NN
._.
Loans_NN
due_JJ
after_IN
one_CD
year_NN
are_VPRT [BEMA]
repayable_PRED
over_IN
various_JJ
periods_NN
as_IN
follows_VPRT
:_:
2002_CD
2001_CD
m_NN
m_NN [BEMA]
Between_PIN
one_CD
and_CC
two_CD
years_NN
423_CD
11_CD
Between_PIN
two_CD
and_CC
three_CD
years_NN
563_CD
116_CD
Between_PIN
three_CD
and_CC
four_CD
years_NN
311_CD
140_CD
Between_PIN
four_CD
and_CC
five_CD
years_NN
2_CD
843_CD
After_IN
five_CD
years_NN
1,793_CD
998_CD
3,092_CD
2,108_CD
The_DT
loans_NN
repayable_JJ
after_IN
five_CD
years_NN
carry_VPRT
interest_NN
at_PIN
effective_JJ
rates_NN
between_PIN
4.9_CD
per_PIN
cent_NN
and_CC
5.3_CD
per_PIN
cent_NN
._.
The_DT
repayment_NOMZ
dates_NN
range_VPRT
from_PIN
2008_CD
to_PIN
2033_CD
._.
100_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
25_CD
Net_JJ
debt_NN
continued_VBD
Secured_JJ
loans_NN
Loans_NN
amounting_VBG [WZPRES]
to_PIN
13_CD
million_CD
2001_CD
13_CD
million_CD
are_VPRT [BYPA]
secured_VBN
by_PIN
charges_NN
on_PIN
xed_VBN
and_CC
current_JJ
assets_NN
._.
2002_CD
2001_CD
Finance_NN
lease_NN
obligations_NOMZ
m_VPRT
m_FW [BEMA]
Rental_JJ
payments_NOMZ
due_JJ
within_PIN
one_CD
year_NN
1_CD
2_CD
Rental_JJ
payments_NOMZ
due_JJ
between_PIN
one_CD
and_CC
two_CD
years_NN
2_CD
2_CD
Rental_JJ
payments_NOMZ
due_JJ
between_PIN
two_CD
and_CC
three_CD
years_NN
1_CD
1_CD
Rental_JJ
payments_NOMZ
due_JJ
between_PIN
three_CD
and_CC
four_CD
years_NN
1_CD
1_CD
Rental_JJ
payments_NOMZ
due_JJ
between_PIN
four_CD
and_CC
five_CD
years_NN
1_CD
1_CD
Rental_JJ
payments_NOMZ
due_JJ
after_IN
five_CD
years_NN
7_CD
7_CD
Total_JJ
finance_NN
lease_NN
obligations_NOMZ
13_CD
14_CD
Financial_NN
instruments_NOMZ
Further_JJ
information_NOMZ
is_VPRT [PASS]
given_VBN
in_PIN
Note_NN
32_CD
._.
26_CD
Commitments_NOMZ
2002_CD
2001_CD
Capital_NN
commitments_NOMZ
m_VPRT
m_FW [PASS]
Contracted_VBN
for_PIN
but_CC
not_XX0
provided_VBN
in_PIN
the_DT
financial_JJ
statements_NOMZ
Intangible_NN
xed_VBD
assets_NN
1,410_CD
1,103_CD
Tangible_JJ
xed_JJ
assets_NN
382_CD
298_CD
1,792_CD
1,401_CD
A_DT
number_NN
of_PIN
commitments_NOMZ
were_VBD [PASS]
made_VBN
in_PIN
2002_CD
under_IN
licensing_GER
and_CC
other_JJ
agreements_NOMZ
,_,
principally_RB
with_PIN
elbion_NN
AG_NN
,_,
Adolor_NN
Corporation_NOMZ
,_,
Theravance_NN
,_,
Inc._NN
and_PHC
Unigene_NN
Laboratories_NN
,_,
Inc._NN
._.
Payments_NOMZ
become_VPRT
due_JJ
if_COND
future_JJ
milestones_NN
are_VPRT [PASS]
achieved_VBN
._.
As_IN
some_QUAN
of_PIN
these_DEMO
agreements_NOMZ
relate_VPRT
to_PIN
compounds_NN
in_PIN
the_DT
early_TIME
stages_NN
of_PIN
development_NOMZ
,_,
milestone_NN
payments_NOMZ
will_PRMD
continue_VB
for_PIN
a_DT
number_NN
of_PIN
years_NN
if_COND
the_DT
compounds_NN
move_VPRT [SUAV]
successfully_RB
through_PIN
the_DT
development_NOMZ
process_NN
._.
Generally_RB
the_DT
closer_RB
the_DT
product_NN
is_VPRT
to_TO
marketing_VBG
approval_NN
the_DT
greater_JJ
the_DT
possibility_NOMZ
of_PIN
success_NN
._.
The_DT
Group_NN
also_RB
has_VPRT
other_JJ
commitments_NOMZ
of_PIN
162_CD
million_CD
relating_VBG
to_PIN
other_JJ
payments_NOMZ
to_TO
be_VB [PASS]
made_VBN
under_IN
licences_NN
and_CC
other_JJ
alliances_NN
,_,
principally_RB
to_PIN
Exelixis_NN
Inc._NN
2002_CD
2001_CD
Commitments_NOMZ
under_IN
operating_VBG
leases_NN
to_TO
pay_VB
rentals_NN
for_PIN
the_DT
next_JJ
year_NN
m_FW
m_FW
Operating_GER
leases_NN
on_PIN
land_NN
and_PHC
buildings_GER
which_WDT [WHSUB]
expire_VPRT
:_:
In_PIN
one_CD
year_NN
or_CC
less_JJ
10_CD
5_CD
Between_PIN
one_CD
and_CC
five_CD
years_NN
47_CD
18_CD
After_IN
five_CD
years_NN
56_CD
51_CD
113_CD
74_CD
Operating_GER
leases_NN
on_PIN
plant_NN
,_,
equipment_NOMZ
and_PHC
vehicles_NN
which_WDT [WHSUB]
expire_VPRT
:_:
In_PIN
one_CD
year_NN
or_CC
less_JJ
7_CD
4_CD
Between_PIN
one_CD
and_CC
five_CD
years_NN
47_CD
27_CD
After_IN
five_CD
years_NN
1_CD
55_CD
31_CD
Commitments_NOMZ
under_IN
operating_VBG
leases_NN
to_TO
pay_VB
rentals_NN
in_PIN
future_JJ
years_NN
2003 168 105 2004_CD
97_CD
89_CD
2005_CD
80_CD
79_CD
2006_CD
59_CD
69_CD
2007_CD
49_CD
59_CD
2008_CD
and_CC
thereafter_RB
249 241 702 642_CD
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
101_CD
Share_NN
premium_NN
Ordinary_NN
Shares_NN
of_PIN
25p_JJ
each_QUAN
Redeemable_JJ
preference_NN
shares_NN
of_PIN
1_CD
each_QUAN
27_CD
Share_NN
capital_NN
and_PHC
share_NN
premium_NN
account_NN
account_NN
Number_NN
m_NN
Number_NN
m_FW
m_FW
Share_NN
capital_NN
authorised_VBN [WZPAST]
At_PIN
31st_CD
December_NN
2001_CD
10,000,000,000_CD
2,500_CD
At_PIN
31st_CD
December_NN
2002_CD
10,000,000,000_CD
2,500_CD
Share_NN
capital_NN
issued_VBN
and_CC
fully_AMP
paid_VBN
At_PIN
1st_CD
January_NN
2001_CD
50,000_CD
6,225,662,174_CD
1,556_CD
30_CD
Share_NN
capital_NN
redeemed_VBN [WZPAST]
at_PIN
par_JJ
50,000_CD
Share_NN
capital_NN
issued_VBN
under_IN
share_NN
option_NOMZ
schemes_NN
17,878,815_CD
4_CD
140_CD
Share_NN
capital_NN
purchased_VBN
and_PHC
canceled_VBN
70,575,000_CD
17_CD
At_PIN
31st_CD
December_NN
2001_CD
6,172,965,989_CD
1,543_CD
170_CD
Share_NN
capital_NN
issued_VBN
under_IN
share_NN
option_NOMZ
schemes_NN
7,049,394_CD
2_CD
54_CD
Share_NN
capital_NN
purchased_VBN
and_PHC
canceled_VBN
155,749,038_CD
39_CD
At_PIN
31st_CD
December_NN
2002_CD
6,024,266,345_CD
1,506_CD
224_CD
Number_NN
000_CD
Number_NN
of_PIN
shares_NN
issuable_JJ
under_IN
outstanding_JJ
options_NOMZ
Note_VPRT [PRIV]
34_CD
At_PIN
31st_CD
December_NN
2001_CD
155,078_CD
At_PIN
31st_CD
December_NN
2002_CD
217,953_CD
Number_NN
of_PIN
unissued_JJ
shares_NN
not_XX0
under_IN
option_NOMZ
At_PIN
31st_CD
December_NN
2001_CD
3,671,956_CD
At_PIN
31st_CD
December_NN
2002_CD
3,757,781_CD
The_DT
redeemable_JJ
preference_NN
shares_NN
were_VBD [BYPA]
redeemed_VBN
by_PIN
the_DT
company_NN
on_PIN
31st_CD
August_NN
2001_CD
._.
The_DT
nominal_JJ
amount_NN
of_PIN
these_DEMO
redeemable_JJ
preference_NN
shares_NN
was_VBD [PASS]
converted_VBN
into_PIN
200,000_CD
ordinary_JJ
shares_NN
of_PIN
25_CD
pence_NN
each_QUAN
resulting_VBG
in_PIN
authorised_JJ
share_NN
capital_NN
at_PIN
31st_CD
December_NN
2001_CD
of_PIN
10_CD
billion_CD
ordinary_JJ
shares_NN
of_PIN
25_CD
pence_NN
each_QUAN
._.
In_PIN
October_NN
2002_CD
,_,
GlaxoSmithKline_NN
commenced_VBD
a_DT
new_JJ
4_CD
billion_CD
share_NN
buy-back_JJ
program_NN
._.
This_DEMP
follows_VPRT
the_DT
completion_NOMZ
of_PIN
the_DT
4_CD
billion_CD
buy-back_NN
program_NN
announced_VBN [PUBV] [WZPAST]
in_PIN
2001_CD
._.
A_DT
total_NN
of_PIN
2,220_CD
million_CD
was_VBD [PASS]
spent_VBN
in_PIN
2002_CD
of_PIN
which_WDT [PIRE]
219_CD
million_CD
relates_VPRT
to_PIN
the_DT
new_JJ
buy-back_NN
program_NN
._.
The_DT
exact_JJ
amount_NN
and_PHC
timing_NN
of_PIN
future_JJ
purchases_NN
will_PRMD
be_VB [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
Group_NN
and_CC
is_VPRT [BEMA]
dependent_PRED
on_PIN
market_NN
conditions_NOMZ
and_CC
other_JJ
factors_NN
._.
In_PIN
the_DT
period_NN
1st_CD
January_NN
2003_CD
to_PIN
3rd_CD
March_NN
2003_CD
a_DT
further_JJ
9,350,000_CD
shares_NN
had_VBD [PEAS]
been_VBN [PASS]
purchased_VBN
and_PHC
canceled_VBN
at_PIN
a_DT
cost_NN
of_PIN
105_CD
million_CD
._.
For_PIN
details_NN
of_PIN
substantial_JJ
shareholdings_GER
refer_VPRT
to_PIN
Substantial_NN
shareholdings_GER
on_PIN
page_NN
155_CD
._.
28_CD
Non-equity_JJ
minority_NOMZ
interests_NN
SmithKline_NN
Beecham_NN
Holdings_GER
Corporation_NOMZ
SBH_NN
Corp_NN
,_,
a_DT
subsidiary_NN
incorporated_VBN [WZPAST]
in_PIN
Delaware_NN
,_,
USA_NN
,_,
has_VPRT
in_PIN
issue_NN
$_$
500_CD
million_CD
of_PIN
Flexible_NN
Auction_NOMZ
Market_NN
Preferred_NN
Stock_NN
Flex_NN
AMPS_NN
,_,
comprising_VBG [PRESP]
5,000_CD
shares_NN
of_PIN
$_$
100,000_CD
each_QUAN
,_,
issued_VBN [PASTP]
in_PIN
six_CD
series_NN
._.
The_DT
dividend_NN
on_PIN
half_NN
of_PIN
these_DEMO
shares_NN
was_VBD [PASS]
xed_VBN
on_PIN
issuance_NN
in_PIN
1996_CD
for_PIN
a_DT
seven_CD
year_NN
period_NN
._.
The_DT
dividend_NN
on_PIN
the_DT
other_JJ
half_NN
was_VBD [PASS]
xed_VBN
for_PIN
a_DT
five_CD
year_NN
period_NN
which_WDT [WHSUB]
ended_VBD
during_PIN
2001_CD
and_CC
now_TIME
varies_VPRT
,_,
predominately_RB
with_PIN
prevailing_VBG
interest_NN
rates_NN
,_,
and_ANDC
is_VPRT [PASS]
set_VBN
every_QUAN
seven_CD
weeks_NN
at_PIN
an_DT
auction_NOMZ
at_PIN
which_WDT [PIRE]
the_DT
shares_NN
are_VPRT [SPAU] [PASS]
also_RB
traded_VBN
._.
SBH_NN
Corp_NN
also_RB
has_VPRT
in_PIN
issue_NN
$_$
400_CD
million_CD
of_PIN
Auction_NOMZ
Rate_NN
Preference_NN
Stock_NN
ARPS_NN
,_,
comprising_VBG [PRESP]
4,000_CD
shares_NN
of_PIN
$_$
100,000_CD
each_QUAN
,_,
issued_VBN [PASTP]
in_PIN
five_CD
series_NN
,_,
the_DT
dividend_NN
on_PIN
which_WDT [PIRE]
also_RB
varies_VPRT
under_IN
conditions_NOMZ
similar_JJ
to_PIN
the_DT
Flex_NN
AMPS_NN
described_VBD
above_PLACE
._.
Together_RB
,_,
the_DT
ARPS_NN
and_CC
the_DT
Flex_NN
AMPS_NN
constitute_VPRT
the_DT
preference_NN
shares_NN
,_,
which_WDT [SERE]
represent_VPRT
the_DT
non-equity_JJ
minority_NOMZ
interest_NN
._.
SmithKline_NN
Beecham_NN
plc_NN
has_VPRT
,_,
in_PIN
certain_JJ
circumstances_NN
,_,
guaranteed_VBN [PUBV]
payment_NOMZ
of_PIN
dividends_NN
declared_VBD [PUBV]
on_PIN
the_DT
preference_NN
shares_NN
._.
SmithKline_NN
Beecham_NN
plc_NN
has_VPRT [SPAU] [PEAS]
also_RB
agreed_VBN [SUAV] [PUBV]
with_PIN
SBH_NN
Corp_NN
that_DEMO
in_PIN
certain_JJ
circumstances_NN
it_PIT
will_PRMD
provide_VB
support_NN
to_PIN
SBH_NN
Corp_NN
in_PIN
relation_NOMZ
to_PIN
the_DT
principal_NN
._.
However_CONJ
,_,
any_QUAN
guarantee_NN
or_CC
support_NN
is_VPRT [PASS]
limited_VBN
so_OSUB
that_NULL
in_PIN
no_SYNE
circumstances_NN
could_POMD
the_DT
holder_NN
of_PIN
preference_NN
shares_NN
be_VB [BEMA]
in_PIN
a_DT
more_EMPH
favourable_JJ
position_NOMZ
than_PIN
had_VBD [PEAS]
they_TPP3
been_VBN [BEMA]
a_DT
holder_NN
of_PIN
a_DT
preference_NN
share_NN
in_PIN
SmithKline_NN
Beecham_NN
plc._NN
._.
The_DT
preference_NN
shares_NN
represent_VPRT
a_DT
long-term_JJ
non-equity_JJ
minority_NOMZ
interest_NN
in_PIN
the_DT
Group_NN
balance_NN
sheet_NN
in_PIN
accordance_NN
with_PIN
FRS_NN
4_CD
Capital_NN
Instruments_NOMZ
and_PHC
UITF_NN
33_CD
Obligations_NOMZ
in_PIN
capital_NN
instruments_NOMZ
._.
102_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
profit_NN
and_CC
Other_JJ
loss_NN
account_NN
Total_JJ
29_CD
Reserves_NN
reserves_NN
restated_VBN
restated_VBN
m_FW
m_FW
m_FW [BEMA]
At_PIN
31st_CD
December_NN
1999_CD
1,701_CD
2,141_CD
3,842_CD
Goodwill_NN
written_VBN [PUBV] [WZPAST]
back_RB
22_CD
Exchange_NN
movements_NOMZ
23_CD
23_CD
UK_NN
tax_NN
on_PIN
exchange_NN
movements_NOMZ
16_CD
16_CD
Shares_NN
issued_VBD
148_CD
148_CD
profit_NN
attributable_JJ
to_PIN
shareholders_NN
4,106_CD
4,106_CD
Dividends_NN
2,097_CD
2,097_CD
Revaluation_NOMZ
of_PIN
goodwill_NN
due_JJ
to_TO
exchange_VB
10_CD
10_CD
At_PIN
31st_CD
December_NN
2000_CD
1,849_CD
4,155_CD
6,004_CD
Goodwill_NN
written_VBN [PUBV] [WZPAST]
back_RB
356_CD
356_CD
Exchange_NN
movements_NOMZ
151_CD
151_CD
Shares_NN
purchased_VBD
for_PIN
cancellation_NOMZ
17_CD
1,274_CD
1,257_CD
profit_NN
attributable_JJ
to_PIN
shareholders_NN
3,053_CD
3,053_CD
Dividends_NN
2,356_CD
2,356_CD
Revaluation_NOMZ
of_PIN
goodwill_NN
due_JJ
to_TO
exchange_VB
28_CD
28_CD
At_PIN
31st_CD
December_NN
2001_CD
1,866_CD
3,811_CD
5,677_CD
Exchange_NN
movements_NOMZ
154_CD
154_CD
UK_NN
tax_NN
on_PIN
exchange_NN
movements_NOMZ
67_CD
67_CD
Shares_NN
purchased_VBD
for_PIN
cancellation_NOMZ
39_CD
2,220_CD
2,181_CD
profit_NN
attributable_JJ
to_PIN
shareholders_NN
3,915_CD
3,915_CD
Dividends_NN
2,346_CD
2,346_CD
Unrealised_JJ
gains_NN
on_PIN
equity_NOMZ
investments_NOMZ
77_CD
At_PIN
31st_CD
December_NN
2002_CD
1,905_CD
2,946_CD
4,851_CD
Goodwill_NN
arising_VBG [WZPRES]
on_PIN
acquisitions_NOMZ
before_IN
1st_CD
January_NN
1998_CD
which_WDT
has_VPRT [PEAS]
been_VBN [PASS]
written_VBN [PUBV]
off_PIN
against_PIN
other_JJ
reserves_NN
amounts_NN
to_PIN
6,180_CD
million_CD
,_,
including_VBG
goodwill_NN
of_PIN
4,840_CD
million_CD
previously_TIME
held_VBN [PRIV]
as_IN
a_DT
goodwill_NN
reserve_NN
which_WDT [WHSUB]
was_VBD [PASS]
offset_VBN
against_PIN
other_JJ
reserves_NN
in_PIN
1998_CD
._.
The_DT
goodwill_NN
written_VBN [PUBV] [WZPAST]
back_RB
in_PIN
2001_CD
relates_VPRT
primarily_RB
to_PIN
the_DT
disposals_NN
of_PIN
Affymax_NN
and_PHC
part_NN
of_PIN
the_DT
Groups_NN
holding_VBG [PRIV] [WZPRES]
in_PIN
Quest_NN
Diagnostics_NN
,_,
Inc._NN
._.
Goodwill_NN
denominated_VBD
in_PIN
local_JJ
currencies_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
subject_PRED
to_PIN
revaluation_NOMZ
amounted_VBD
to_PIN
293_CD
million_CD
at_PIN
31st_CD
December_NN
2002_CD
._.
Goodwill_NN
on_PIN
acquisitions_NOMZ
after_IN
1st_CD
January_NN
1998_CD
has_VPRT [PEAS]
been_VBN [PASS]
capitalized_VBN
,_,
in_PIN
accordance_NN
with_PIN
the_DT
accounting_GER
policy_NN
set_VBN [WZPAST]
out_PIN
in_PIN
Note_NN
2_CD
._.
Exchange_NN
movements_NOMZ
taken_VBN [WZPAST]
to_PIN
reserves_NN
in_PIN
2002_CD
include_VPRT
losses_NN
of_PIN
1,251_CD
million_CD
2001_CD
losses_NN
114_CD
million_CD
,_,
2000_CD
losses_NN
84_CD
million_CD
on_PIN
foreign_JJ
currency_NN
loans_NN
less_RB
deposits_NN
,_,
gains_NN
of_PIN
1,097_CD
million_CD
2001_CD
losses_NN
9_CD
million_CD
,_,
2000_CD
gains_NN
71_CD
million_CD
on_PIN
the_DT
retranslation_NOMZ
of_PIN
net_JJ
assets_NN
and_PHC
nil_NN
2001_CD
losses_NN
28_CD
million_CD
,_,
2000_CD
losses_NN
10_CD
million_CD
on_PIN
goodwill_NN
eliminated_VBN [WZPAST]
against_PIN
reserves_NN
._.
The_DT
UK_NN
tax_NN
on_PIN
exchange_NN
movements_NOMZ
in_PIN
the_DT
year_NN
of_PIN
67_CD
million_CD
2001_CD
nil_NN
,_,
2000_CD
16_CD
million_CD
credit_NN
relates_VPRT
to_PIN
the_DT
UK_NN
taxable_JJ
element_NOMZ
of_PIN
the_DT
foreign_JJ
currency_NN
loans_NN
less_RB
deposits_NN
taken_VBN [WZPAST]
to_PIN
reserves_NN
._.
Exchange_NN
adjustments_NOMZ
debited_VBD
to_PIN
reserves_NN
cumulatively_RB
amount_VB
to_PIN
1,452_CD
million_CD
._.
Other_JJ
reserves_NN
include_VPRT
the_DT
merger_NN
reserve_NN
created_VBN [WZPAST]
on_PIN
the_DT
merger_NN
of_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
amounting_VBG [WZPRES]
to_PIN
1,561_CD
million_CD
at_PIN
31st_CD
December_NN
2002_CD
2001_CD
1,561_CD
million_CD
:_:
2000_CD
1,561_CD
million_CD
._.
Other_JJ
reserves_NN
also_RB
include_VPRT
the_DT
capital_NN
redemption_NOMZ
reserve_NN
created_VBN
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
share_NN
buy-back_JJ
program_NN
amounting_GER
to_PIN
56_CD
million_CD
at_PIN
31st_CD
December_NN
2002_CD
2001_CD
17_CD
million_CD
,_,
2000_CD
nil_NN
._.
Total_JJ
reserves_NN
amounted_VBD
to_PIN
4,851_CD
million_CD
at_PIN
31st_CD
December_NN
2002_CD
2001_CD
5,677_CD
million_CD
,_,
2000_CD
6,004_CD
million_CD
,_,
of_PIN
which_WDT [PIRE]
10,879_CD
million_CD
2001_CD
718_CD
million_CD
:_:
2000_CD
nil_NN
relates_VPRT
to_PIN
the_DT
company_NN
and_CC
76_CD
million_CD
2001_CD
61_CD
million_CD
,_,
2000_CD
28_CD
million_CD
relates_VPRT
to_PIN
joint_JJ
ventures_NN
and_CC
associated_VBN
undertakings_GER
._.
The_DT
profit_NN
of_PIN
GlaxoSmithKline_NN
plc_NN
for_PIN
the_DT
year_NN
was_VBD [BEMA]
10,598_CD
million_CD
2001_CD
4,331_CD
million_CD
,_,
6th_CD
December_NN
1999_CD
to_PIN
31st_CD
December_NN
2000_CD
nil_NN
,_,
which_WDT [SERE]
after_IN
dividends_NN
of_PIN
2,352_CD
million_CD
2001_CD
2,356_CD
million_CD
,_,
6th_CD
December_NN
1999_CD
to_PIN
31st_CD
December_NN
2000_CD
nil_NN
,_,
gave_VBD
a_DT
retained_VBN
profit_NN
of_PIN
8,246_CD
million_CD
2001_CD
1,975_CD
million_CD
,_,
6th_CD
December_NN
1999_CD
to_PIN
31st_CD
December_NN
2000_CD
nil_NN
._.
After_IN
the_DT
cost_NN
of_PIN
shares_NN
purchased_VBN [WZPAST]
for_PIN
cancellation_NOMZ
of_PIN
2,220_CD
million_CD
2001_CD
1,274_CD
million_CD
,_,
6th_CD
December_NN
1999_CD
to_PIN
31st_CD
December_NN
2000_CD
nil_NN
and_CC
an_DT
unrealised_JJ
profit_NN
on_PIN
capital_NN
reduction_NOMZ
by_PIN
subsidiary_NN
of_PIN
4,096_CD
million_CD
2001_CD
nil_NN
,_,
6th_JJ
December_NN
1999_CD
to_PIN
31st_CD
December_NN
2000_CD
nil_NN
,_,
the_DT
profit_NN
and_PHC
loss_NN
account_NN
reserve_NN
at_PIN
31st_CD
December_NN
2002_CD
stood_VBD
at_PIN
10,823_CD
million_CD
2001_CD
701_CD
million_CD
,_,
2000_CD
-_:
nil_NN
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
103_CD
30_CD
Legal_NN
proceedings_GER
Even_RB
if_COND
the_DT
FDA_NN
were_VBD
to_TO
approve_VB
the_DT
Pentech_NN
ANDA_NN
,_,
GlaxoSmithKline_NN
believes_VPRT [PRIV]
that_THVC
the_DT
Pentech_NN
capsule_NN
would_PRMD
not_XX0
be_VB [BEMA]
The_DT
Group_NN
is_VPRT [PASS]
involved_VBN
in_PIN
various_JJ
legal_JJ
and_PHC
administrative_JJ
substitutable_JJ
for_PIN
Paxil_NN
tablets_NN
._.
proceedings_GER
,_,
principally_RB
product_NN
liability_NOMZ
,_,
intellectual_JJ
property_NN
,_,
antitrust_JJ
,_,
and_ANDC
governmental_JJ
investigations_NOMZ
and_CC
related_JJ
private_JJ
In_PIN
October_NN
2000_CD
GlaxoSmithKline_NN
led_VBD
an_DT
action_NOMZ
against_PIN
Synthon_NN
litigation_NOMZ
._.
The_DT
most_EMPH
significant_JJ
of_PIN
these_DEMO
matters_NN
are_VPRT [PASS]
described_VBN
below_PLACE
._.
Pharmaceuticals_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Middle_NN
District_NN
of_PIN
North_NN
Carolina_NN
for_PIN
infringement_NOMZ
of_PIN
the_DT
Groups_NN
patents_NN
for_PIN
Intellectual_NN
property_NN
paroxetine_NN
hydrochloride_NN
and_CC
paroxetine_JJ
mesylate_NN
._.
Synthon_NN
had_VBD
In_PIN
the_DT
USA_NN
a_DT
number_NN
of_PIN
distributors_NN
of_PIN
generic_JJ
drugs_NN
have_VPRT [PEAS]
led_VBN
led_VBD
a_DT
505_CD
b_NN
2_CD
application_NOMZ
a_DT
paper_NN
NDA_NN
with_PIN
the_DT
FDA_NN
using_VBG [WZPRES]
applications_NOMZ
with_PIN
the_DT
FDA_NN
to_TO
market_VB
generic_JJ
versions_NN
of_PIN
paroxetine_JJ
mesylate_NN
,_,
a_DT
different_JJ
salt_NN
form_NN
of_PIN
paroxetine_NN
than_PIN
that_DEMO
Paxil_NN
Seroxat_NN
paroxetine_JJ
hydrochloride_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
in_PIN
used_VBN
in_PIN
the_DT
marketed_VBN
form_NN
of_PIN
Paxil_NN
._.
Even_RB
if_COND
the_DT
FDA_NN
approves_VPRT
the_DT
2006_CD
of_PIN
the_DT
Groups_NN
patent_NN
on_PIN
paroxetine_JJ
hydrochloride_NN
Synthon_NN
application_NOMZ
,_,
GlaxoSmithKline_NN
believes_VPRT [PRIV]
the_DT
Synthon_NN
hemihydrate_NN
._.
The_DT
distributors_NN
are_VPRT
looking_VBG
to_TO
bring_VB
to_PIN
market_NN
compound_NN
would_PRMD
not_XX0
be_VB [BEMA]
substitutable_PRED
for_PIN
Paxil_NN
._.
Brieng_NN
on_PIN
anhydrate_NN
or_CC
other_JJ
versions_NN
of_PIN
paroxetine_JJ
hydrochloride_NN
and_CC
in_PIN
one_CD
summary_NN
judgement_NOMZ
motions_NOMZ
led_VBN [WZPAST]
by_PIN
the_DT
parties_NN
has_VPRT [PEAS]
been_VBN
case_NN
paroxetine_NN
mesylate_NN
._.
The_DT
cases_NN
are_VPRT [BEMA]
complex_PRED
but_CC
the_DT
Group_NN
completed_VBD
and_CC
those_DEMO
motions_NOMZ
remain_VPRT
pending_VBG
._.
No_SYNE
trial_NN
date_NN
has_VPRT
believes_VPRT [PRIV]
that_THVC
the_DT
generic_JJ
anhydrate_NN
and_CC
other_JJ
versions_NN
infringe_VPRT
been_VBN [PASS]
set_VBN
._.
The_DT
Hatch-Waxman_NN
stay_VB
on_PIN
FDA_NN
approval_NN
of_PIN
the_DT
Synthon_NN
because_CAUS
they_TPP3
contain_VPRT
and_CC
or_CC
convert_VB
to_PIN
the_DT
hemihydrate_JJ
form_NN
application_NOMZ
expires_VPRT
in_PIN
April_NN
2003_CD
._.
and_ANDC
or_CC
infringe_VB
other_JJ
Group_NN
patents_NN
._.
In_PIN
response_NN
the_DT
Group_NN
has_VPRT [PEAS]
led_VBN
actions_NOMZ
against_PIN
all_QUAN
those_DEMO
distributors_NN
for_PIN
infringement_NOMZ
of_PIN
Following_VBG
the_DT
expiration_NOMZ
of_PIN
the_DT
data_NN
exclusivity_NOMZ
period_NN
in_PIN
Europe_NN
,_,
a_DT
various_JJ
of_PIN
the_DT
Groups_NN
patents_NN
._.
marketing_GER
authorisation_NOMZ
was_VBD [PASS]
issued_VBN
to_PIN
Synthon_NN
BV_NN
Genthon_NN
in_PIN
October_NN
2000_CD
by_PIN
regulatory_JJ
authorities_NOMZ
in_PIN
Denmark_NN
for_PIN
paroxetine_JJ
In_PIN
July_NN
1998_CD
GlaxoSmithKline_NN
led_VBD
an_DT
action_NOMZ
against_PIN
Apotex_NN
in_PIN
the_DT
mesylate_NN
,_,
a_DT
different_JJ
salt_NN
form_NN
of_PIN
paroxetine_NN
than_PIN
that_DEMP
used_VBN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Northern_NN
District_NN
of_PIN
Illinois_NN
for_PIN
infringement_NOMZ
marketed_VBN
form_NN
of_PIN
Seroxat_NN
Paxil_NN
._.
Marketing_GER
authorisations_NOMZ
have_VPRT
since_OSUB
of_PIN
the_DT
Groups_NN
patent_NN
for_PIN
paroxetine_JJ
hydrochloride_NN
hemihydrate_NN
._.
been_VBN [PASS]
granted_VBN [SUAV]
in_PIN
nine_CD
other_JJ
European_JJ
countries_NN
,_,
one_CD
further_JJ
national_JJ
Apotex_NN
had_VBD [PEAS]
led_VBN
an_DT
Abbreviated_NN
New_NN
Drug_NN
Application_NOMZ
ANDA_NN
approval_NN
and_CC
eight_CD
approvals_NN
under_IN
the_DT
Mutual_JJ
Recognition_NOMZ
process_NN
with_PIN
the_DT
FDA_NN
seeking_VBG [WZPRES]
approval_NN
to_TO
introduce_VB
a_DT
generic_JJ
form_NN
of_PIN
Paxil_NN
._.
based_VBN [PASTP]
on_PIN
the_DT
original_JJ
Danish_JJ
approval_NN
._.
Generic_JJ
products_NN
containing_VBG [WZPRES]
Following_VBG
a_DT
trial_NN
in_PIN
February_NN
2003_CD
the_DT
judge_NN
ruled_VBD [SUAV]
that_THVC
paroxetine_JJ
mesylate_NN
have_VPRT [PEAS]
been_VBN [PASS]
launched_VBN
in_PIN
Denmark_NN
,_,
Germany_NN
,_,
GlaxoSmithKlines_NN
patent_NN
is_VPRT [BEMA]
valid_PRED
but_CC
not_XX0
infringed_VBN
by_PIN
Apotexs_NN
The_NN
Netherlands_NN
,_,
Austria_NN
,_,
Ireland_NN
,_,
Sweden_NN
and_PHC
Italy_NN
,_,
although_CONC
the_DT
product_NN
._.
GlaxoSmithKline_NN
is_VPRT
appealing_VBG
the_DT
ruling_NN
of_PIN
nonproduct_NN
in_PIN
Austria_NN
and_PHC
Denmark_NN
has_VPRT [PEAS]
been_VBN [PASS]
withdrawn_VBN
following_VBG
the_DT
infringement_NOMZ
to_PIN
the_DT
US_FPP1
Court_NN
of_PIN
Appeals_NN
for_PIN
the_DT
Federal_NN
Circuit_NN
award_NN
of_PIN
patent_NN
interim_JJ
injunctions_NOMZ
._.
The_DT
Group_NN
has_VPRT [PEAS]
initiated_VBN
CAFC_NN
,_,
which_WDT [SERE]
hears_VPRT [PRIV]
all_QUAN
appeals_NN
from_PIN
US_FPP1
District_NN
Courts_NN
on_PIN
litigation_NOMZ
challenging_VBG [WZPRES]
the_DT
approval_NN
by_PIN
the_DT
Danish_JJ
Medicines_NN
Agency_NN
intellectual_JJ
property_NN
matters_NN
._.
on_PIN
grounds_NN
that_TOBJ
an_DT
authorisation_NOMZ
should_NEMD
not_XX0
have_VB [PEAS]
been_VBN [PASS]
granted_VBN [SUAV]
In_PIN
June_NN
1999_CD
GlaxoSmithKline_NN
led_VBD
an_DT
action_NOMZ
against_PIN
Geneva_NN
under_IN
the_DT
abridged_JJ
procedure_NN
as_IN
paroxetine_JJ
mesylate_NN
is_VPRT
not_XX0
Pharmaceuticals_NN
,_,
a_DT
subsidiary_NN
of_PIN
Novartis_NN
Pharmaceuticals_NN
,_,
in_PIN
the_DT
essentially_RB
similar_JJ
to_PIN
Seroxat_NN
._.
Marketing_GER
authorisations_NOMZ
have_VPRT
also_RB
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Eastern_NN
District_NN
of_PIN
Pennsylvania_NN
for_PIN
been_VBN [PASS]
issued_VBN
in_PIN
eleven_JJ
European_JJ
countries_NN
for_PIN
products_NN
containing_VBG [WZPRES]
infringement_NOMZ
of_PIN
the_DT
Groups_NN
patents_NN
for_PIN
paroxetine_JJ
hydrochloride_NN
paroxetine_NN
hydrochloride_NN
anhydrate_NN
,_,
another_DT
variant_NN
of_PIN
the_DT
Groups_NN
following_VBG [WZPRES]
notice_NN
of_PIN
Genevas_NN
ANDA_NN
ling_NN
._.
That_DEMO
case_NN
has_VPRT [PEAS]
been_VBN
product_NN
._.
Generic_JJ
products_NN
containing_VBG [WZPRES]
the_DT
anhydrate_NN
are_VPRT [BEMA]
now_TIME
on_PIN
the_DT
consolidated_JJ
with_PIN
similar_JJ
infringement_NOMZ
actions_NOMZ
against_PIN
other_JJ
market_NN
in_PIN
Germany_NN
,_,
Austria_NN
,_,
Denmark_NN
,_,
the_DT
Netherlands_NN
,_,
Spain_NN
,_,
generic_JJ
companies_NN
that_TSUB
subsequently_TIME
led_VBD
ANDAs_NN
._.
GlaxoSmithKline_NN
believes_VPRT [PRIV]
that_THVC
marketing_GER
of_PIN
infringement_NOMZ
actions_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
brought_VBN
based_VBN
on_PIN
patents_NN
issued_VBN [WZPAST]
either_RB
a_DT
paroxetine_JJ
hydrochloride_NN
anhydrate_JJ
product_NN
or_CC
a_DT
paroxetine_JJ
subsequent_JJ
to_PIN
the_DT
original_JJ
ling_NN
against_PIN
Apotex_NN
in_PIN
the_DT
Northern_NN
mesylate_NN
product_NN
by_PIN
third_JJ
parties_NN
in_PIN
European_JJ
countries_NN
infringes_VPRT
its_PIT
District_NN
of_PIN
Illinois_NN
._.
The_DT
Group_NN
also_RB
led_VBD
an_DT
action_NOMZ
against_PIN
Apotex_NN
patents_NN
and_CC
is_VPRT
litigating_VBG
its_PIT
position_NOMZ
in_PIN
actions_NOMZ
in_PIN
many_QUAN
European_JJ
and_CC
relating_VBG
to_PIN
those_DEMO
new_JJ
patents_NN
in_PIN
the_DT
Eastern_NN
District_NN
of_PIN
Pennsylvania_NN
._.
other_JJ
countries_NN
outside_PLACE
the_DT
USA_NN
._.
In_PIN
June_NN
2002_CD
the_DT
European_JJ
Patent_NN
In_PIN
December_NN
2002_CD
the_DT
judge_NN
granted_VBN [SUAV] [WZPAST]
in_PIN
part_NN
and_CC
denied_VBN [PUBV]
in_PIN
part_NN
Ofce_NN
Opposition_NOMZ
Division_NN
rejected_VBD
an_DT
opposition_NOMZ
led_VBN [WZPAST]
by_PIN
Synthon_NN
summary_NN
judgement_NOMZ
motions_NOMZ
led_VBN [WZPAST]
by_PIN
Apotex_NN
with_PIN
the_DT
result_NN
that_DEMO
against_PIN
the_DT
Groups_NN
European_JJ
patent_NN
covering_VBG [WZPRES]
a_DT
crystal_NN
form_NN
of_PIN
issues_NN
of_PIN
validity_NOMZ
and_PHC
infringement_NOMZ
of_PIN
three_CD
of_PIN
the_DT
four_CD
new_JJ
patents_NN
paroxetine_JJ
mesylate_NN
that_DEMP
is_VPRT [PASS]
used_VBN
in_PIN
Synthons_NN
product_NN
._.
That_DEMO
decision_NN
will_PRMD
move_VB [SUAV]
toward_PIN
trial_NN
._.
GlaxoSmithKline_NN
has_VPRT [PEAS]
petitioned_VBN
the_DT
District_NN
is_VPRT
under_IN
appeal_NN
._.
In_CONJ
contrast_NULL
,_,
following_VBG [PRESP]
an_DT
action_NOMZ
initiated_VBN [WZPAST]
by_PIN
Court_NN
to_TO
permit_VB
an_DT
interim_JJ
appeal_NN
to_PIN
the_DT
CAFC_NN
._.
The_DT
last_JJ
to_TO
expire_VB
Synthon_NN
,_,
a_DT
UK_NN
court_NN
revoked_VBD
the_DT
corresponding_JJ
UK_NN
patent_NN
relating_VBG [WZPRES]
Hatch-Waxman_NN
stay_VB
on_PIN
FDA_NN
approval_NN
of_PIN
the_DT
Apotex_NN
ANDA_NN
expires_VPRT
to_PIN
paroxetine_JJ
mesylate_NN
in_PIN
December_NN
2002_CD
._.
An_DT
appeal_NN
before_IN
the_DT
in_PIN
September_NN
2003_CD
._.
Court_NN
of_PIN
Appeal_NN
is_VPRT [PASS]
expected_VBN [PRIV]
to_PIN
commence_NN
in_PIN
May_POMD
2003_CD
._.
In_PIN
February_NN
2003_CD
the_DT
Dutch_JJ
court_NN
revoked_VBD
the_DT
corresponding_JJ
Dutch_JJ
In_PIN
February_NN
2003_CD
the_DT
CAFC_NN
heard_VBD [PRIV]
Apotexs_NN
appeal_NN
from_PIN
a_DT
decision_NN
patent_NN
which_WDT [WHOBJ]
decision_NN
will_PRMD [SPAU]
also_RB
be_VB [PASS]
appealed_VBN
._.
by_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
Columbia_NN
denying_VBG [PUBV] [WZPRES]
Apotexs_NN
request_NN
that_TOBJ
the_DT
FDA_NN
be_VB [PASS]
required_VBN [SUAV]
to_TO
delist_VB
certain_JJ
of_PIN
the_DT
In_PIN
response_NN
to_PIN
a_DT
challenge_NN
by_PIN
BASF_NN
to_PIN
the_DT
Groups_NN
UK_NN
patent_NN
for_PIN
Groups_NN
patents_NN
for_PIN
Paxil_NN
from_PIN
the_DT
Orange_NN
Book_NN
._.
The_DT
CAFC_NN
has_VPRT
not_XX0
paroxetine_JJ
hydrochloride_NN
anhydrate_NN
in_PIN
the_DT
UK_NN
High_NN
Court_NN
in_PIN
yet_RB
ruled_VBN [SUAV]
on_PIN
that_DEMO
matter_NN
._.
In_CONJ
addition_NULL
,_,
Apotex_NN
has_VPRT [PEAS]
applied_VBN
to_PIN
the_DT
July_NN
2002_CD
the_DT
Judge_NN
decided_VBD [SUAV] [PRIV]
that_THVC
the_DT
patent_NN
was_VBD [BEMA]
partly_DWNT
valid_PRED
and_CC
court_NN
in_PIN
the_DT
litigation_NOMZ
in_PIN
the_DT
Eastern_NN
District_NN
of_PIN
Pennsylvania_NN
for_PIN
an_DT
partly_DWNT
invalid_JJ
._.
The_DT
claims_NN
held_VBD [PRIV]
valid_JJ
were_VBD [PASS]
asserted_VBN [PUBV]
against_PIN
Apotex_NN
,_,
order_NN
that_TOBJ
GlaxoSmithKline_NN
delist_JJ
certain_JJ
patents_NN
._.
Neolab_NN
and_PHC
Waymade_NN
Healthcare_NN
and_CC
an_DT
interim_JJ
injunction_NOMZ
preventing_VBG [WZPRES]
sale_NN
of_PIN
their_TPP3
version_NN
of_PIN
the_DT
product_NN
was_VBD [PASS]
granted_VBN [SUAV]
in_PIN
In_PIN
March_NN
2000_CD
GlaxoSmithKline_NN
led_VBD
an_DT
action_NOMZ
against_PIN
Pentech_NN
November_NN
2002_CD
._.
The_DT
decision_NN
granting_VBG [SUAV] [THATD] [WZPRES]
the_DT
injunction_NOMZ
was_VBD [PASS]
afrmed_VBN
Pharmaceuticals_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Northern_NN
District_NN
of_PIN
on_PIN
appeal_NN
in_PIN
early_TIME
February_NN
2003_CD
._.
A_DT
full_JJ
trial_NN
relating_VBG [WZPRES]
to_PIN
both_DT
alleged_VBD [PUBV]
Illinois_NN
for_PIN
infringement_NOMZ
of_PIN
the_DT
Groups_NN
patents_NN
for_PIN
paroxetine_JJ
infringement_NOMZ
and_CC
alleged_VBD [PUBV] [THATD]
invalidity_NOMZ
will_PRMD
take_VB
place_NN
in_PIN
June_NN
2003_CD
._.
hydrochloride_NN
._.
Pentech_NN
led_VBD
an_DT
ANDA_NN
for_PIN
a_DT
capsule_NN
version_NN
of_PIN
Paxil_NN
,_,
asserting_VBG [PUBV]
that_THVC
its_PIT
compound_NN
and_PHC
presentation_NOMZ
do_VPRT
not_XX0
infringe_VB
the_DT
Groups_NN
patents_NN
or_CC
that_THVC
the_DT
patents_NN
are_VPRT [BEMA]
invalid_PRED
._.
104_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
30_CD
Legal_JJ
proceedings_GER
continued_VBD
The_DT
30-month_JJ
Hatch-Waxman_NN
stay_NN
on_PIN
final_JJ
FDA_NN
approval_NN
expires_VPRT
April_NN
2003_CD
but_CC
final_JJ
FDA_NN
approval_NN
may_POMD [SPAU]
also_RB
be_VB [PASS]
held_VBN [PRIV]
up_RP
in_PIN
view_NN
of_PIN
In_PIN
May_POMD
2001_CD
Geneva_NN
Pharmaceuticals_NN
commenced_VBD
an_DT
action_NOMZ
in_PIN
the_DT
rights_NN
to_PIN
a_DT
180_CD
day_NN
marketing_GER
exclusivity_NOMZ
that_TSUB
may_POMD
be_VB [BYPA]
held_VBN [PRIV]
by_PIN
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Eastern_NN
District_NN
of_PIN
Virginia_NN
over_IN
four_CD
Andrx_NN
._.
patents_NN
recently_TIME
issued_VBD
to_PIN
GlaxoSmithKline_NN
covering_VBG [WZPRES]
clavulanic_JJ
acid_NN
,_,
a_DT
key_JJ
ingredient_NN
in_PIN
Augmentin_NN
and_PHC
Timentin_NN
._.
Geneva_NN
asked_VBD [SUAV]
the_DT
The_NN
Group_NN
led_VBD
an_DT
action_NOMZ
for_PIN
infringement_NOMZ
of_PIN
its_PIT
patents_NN
for_PIN
court_NN
to_TO
declare_VB [PUBV]
the_DT
new_JJ
patents_NN
,_,
which_WDT [SERE]
expire_VPRT
in_PIN
2017_CD
and_CC
2018_CD
,_,
cefuroxime_NN
axetil_NN
,_,
the_DT
active_JJ
ingredient_NN
in_PIN
the_DT
Groups_NN
Ceftin_NN
antiinvalid_NN
._.
In_PIN
August_NN
2001_CD
Geneva_NN
extended_VBD
its_PIT
complaint_NN
to_TO
cover_VB
infective_JJ
product_NN
,_,
against_PIN
Ranbaxy_NN
Pharmaceuticals_NN
in_PIN
the_DT
US_FPP1
District_NN
three_CD
additional_JJ
patents_NN
which_WDT [WHSUB]
expired_VBD
in_PIN
2002_CD
._.
In_PIN
September_NN
2001_CD
Court_NN
for_PIN
New_NN
Jersey_NN
._.
A_DT
preliminary_JJ
injunction_NOMZ
was_VBD [PASS]
granted_VBN [SUAV]
in_PIN
Teva_NN
Pharmaceuticals_NN
led_VBD
a_DT
similar_JJ
action_NOMZ
challenging_VBG [WZPRES]
the_DT
four_CD
favor_NN
of_PIN
the_DT
Group_NN
but_CC
the_DT
CAFC_NN
subsequently_TIME
vacated_VBD
that_DEMO
recently_TIME
issued_VBN
patents_NN
and_CC
a_DT
patent_NN
expiring_VBG [WZPRES]
in_PIN
December_NN
2002_CD
injunction_NOMZ
and_CC
remanded_VBD
the_DT
case_NN
to_PIN
the_DT
District_NN
Court_NN
for_PIN
a_DT
full_JJ
that_THAC
cover_NN
Augmentin_NN
._.
In_PIN
December_NN
2001_CD
Ranbaxy_NN
Pharmaceuticals_NN
trial_NN
on_PIN
the_DT
merits_NN
._.
Thereafter_RB
Ranbaxy_NN
launched_VBD
its_PIT
generic_JJ
version_NN
led_VBD
a_DT
further_JJ
action_NOMZ
challenging_VBG [WZPRES]
the_DT
four_CD
patents_NN
expiring_VBG [WZPRES]
in_PIN
2017_CD
in_PIN
March_NN
2002_CD
._.
The_DT
trial_NN
is_VPRT [PASS]
scheduled_VBN
to_TO
begin_VB
8th_JJ
July_NN
2003_CD
._.
The_DT
Ranbaxy_NN
and_PHC
Teva_NN
actions_NOMZ
were_VBD [PASS]
consolidated_VBN
with_PIN
the_DT
patent_NN
as_IN
to_PIN
which_WDT [PIRE]
the_DT
Group_NN
claims_VPRT [PUBV] [THATD]
infringement_NOMZ
expires_VPRT
in_PIN
the_DT
Geneva_NN
case_NN
._.
At_PIN
December_NN
2001_CD
and_CC
March_NN
2002_CD
hearings_GER
on_PIN
May_POMD
2003_CD
,_,
the_DT
Group_NN
now_TIME
seeks_VPRT
monetary_JJ
damages_NN
based_VBN [WZPAST]
on_PIN
Tevas_NN
motions_NOMZ
for_PIN
summary_NN
judgement_NOMZ
the_DT
trial_NN
judge_NN
held_VBD [PRIV]
that_THVC
the_DT
Ranbaxys_NN
sales_NN
._.
The_DT
Group_NN
has_VPRT [PEAS]
led_VBN
a_DT
similar_JJ
action_NOMZ
against_PIN
Apotex_NN
,_,
Groups_NN
patents_NN
expiring_VBG [WZPRES]
in_PIN
2017_CD
and_CC
2018_CD
were_VBD [BEMA]
invalid_PRED
._.
At_PIN
the_DT
a_DT
second_JJ
distributor_NN
of_PIN
generic_JJ
pharmaceutical_JJ
products_NN
,_,
in_PIN
the_DT
US_FPP1
consolidated_JJ
trial_NN
in_PIN
May_POMD
2002_CD
,_,
the_DT
same_JJ
judge_NN
ruled_VBD [SUAV]
that_THVC
the_DT
District_NN
Court_NN
for_PIN
the_DT
Northern_NN
District_NN
of_PIN
Illinois_NN
._.
A_DT
preliminary_JJ
patents_NN
expiring_VBG [WZPRES]
in_PIN
2002_CD
were_VBD [BEMA]
invalid_PRED
._.
The_DT
FDA_NN
has_VPRT [PEAS]
granted_VBN [SUAV] [THATD]
injunction_NOMZ
was_VBD [PASS]
granted_VBN [SUAV]
in_PIN
favor_NN
of_PIN
the_DT
Group_NN
in_PIN
June_NN
2002_CD
._.
Apotex_NN
approval_NN
to_PIN
all_QUAN
three_CD
companies_NN
and_PHC
Lek_NN
Pharmaceuticals_NN
for_PIN
their_TPP3
subsequently_TIME
obtained_VBN
FDA_NN
approval_NN
for_PIN
their_TPP3
generic_JJ
product_NN
._.
The_DT
generic_JJ
products_NN
and_CC
all_QUAN
four_CD
are_VPRT [SPAU] [PASS]
now_TIME
marketed_VBN
in_PIN
the_DT
USA_NN
._.
The_DT
full_JJ
trial_NN
with_PIN
Apotex_NN
was_VBD [PASS]
concluded_VBN [PRIV]
in_PIN
January_NN
2003_CD
,_,
but_CC
as_RB
at_PIN
the_DT
Group_NN
continues_VPRT
to_TO
believe_VB [PRIV]
that_THVC
its_PIT
patents_NN
are_VPRT [BEMA]
valid_PRED
and_CC
appealed_VBD
date_NN
of_PIN
this_DEMO
report_NN
no_SYNE
decision_NN
had_VBD [PEAS]
been_VBN [PASS]
announced_VBN [PUBV]
._.
the_DT
District_NN
Court_NN
decisions_NN
to_PIN
the_DT
CAFC_NN
._.
The_DT
hearing_GER
on_PIN
the_DT
appeal_NN
In_PIN
August_NN
2001_CD
the_DT
Group_NN
commenced_VBD
an_DT
action_NOMZ
in_PIN
the_DT
US_FPP1
District_NN
was_VBD [PASS]
heard_VBN [PRIV]
on_PIN
5th_JJ
March_NN
2003_CD
but_CC
as_IN
of_PIN
the_DT
date_NN
of_PIN
this_DEMO
report_NN
the_DT
Court_NN
for_PIN
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
against_PIN
Reddy-Cheminor_NN
and_PHC
CAFC_NN
had_VBD [PEAS]
not_XX0
yet_RB
ruled_VBN [SUAV]
on_PIN
the_DT
appeal_NN
._.
Dr._NN
Reddys_NN
Laboratories_NN
,_,
alleging_VBG [PUBV]
infringement_NOMZ
of_PIN
three_CD
patents_NN
for_PIN
In_PIN
August_NN
2002_CD
the_DT
Group_NN
commenced_VBD
proceedings_GER
against_PIN
ondansetron_NN
,_,
the_DT
active_JJ
ingredient_NN
in_PIN
Zofran_NN
tablets_NN
._.
FDA_NN
approval_NN
Geneva_NN
Pharmaceuticals_NN
and_CC
its_PIT
parent_NN
Novartis_NN
AG_NN
,_,
Biochemie_NN
of_PIN
the_DT
ANDA_NN
led_VBN [WZPAST]
by_PIN
Reddy_NN
is_VPRT [PASS]
stayed_VBN
until_IN
the_DT
earlier_TIME
of_PIN
January_NN
GmbH_NN
and_PHC
Biochemie_NN
SpA_NN
before_IN
the_DT
US_FPP1
International_NN
Trade_NN
2004_CD
or_CC
resolution_NOMZ
of_PIN
the_DT
patent_NN
infringement_NOMZ
litigation_NOMZ
._.
In_PIN
March_NN
Commission_NN
and_CC
in_PIN
Colorado_NN
state_NN
court_NN
,_,
alleging_VBG [PUBV]
that_THVC
the_DT
2002_CD
the_DT
Group_NN
led_VBD
a_DT
similar_JJ
action_NOMZ
against_PIN
Teva_NN
,_,
which_WDT [SERE]
alleged_VBD [PUBV]
manufacture_NN
and_PHC
sale_NN
in_PIN
the_DT
USA_NN
of_PIN
Genevas_NN
generic_JJ
Augmentin_NN
invalidity_NOMZ
or_CC
non-infringement_NOMZ
of_PIN
two_CD
method_NN
of_PIN
use_NN
patents_NN
but_CC
product_NN
using_VBG [WZPRES]
a_DT
production_NOMZ
strain_NN
stolen_VBN [WZPAST]
earlier_TIME
from_PIN
not_XX0
the_DT
compound_NN
patent_NN
expiring_VBG [WZPRES]
in_PIN
2005_CD
,_,
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
GlaxoSmithKline_NN
constitutes_VPRT
misappropriation_NOMZ
of_PIN
the_DT
Groups_NN
trade_NN
for_PIN
the_DT
District_NN
of_PIN
Delaware_NN
._.
A_DT
trial_NN
date_NN
of_PIN
19th_JJ
November_NN
2003_CD
secrets_NN
and_CC
unfair_JJ
competition_NOMZ
._.
Both_DT
proceedings_GER
seek_VPRT
to_TO
prevent_VB
has_VPRT [PEAS]
been_VBN [PASS]
set_VBN
for_PIN
the_DT
Teva_NN
case_NN
._.
A_DT
third_JJ
ondansetron_NN
case_NN
,_,
involving_VBG [PRESP]
the_DT
importation_NOMZ
and_PHC
sale_NN
in_PIN
the_DT
USA_NN
of_PIN
generic_JJ
Augmentin_NN
orally_RB
disintegrating_VBG
Zofran_NN
tablets_NN
,_,
was_VBD [PASS]
commenced_VBN
in_PIN
February_NN
containing_VBG [WZPRES]
clavulanate_JJ
made_VBN
using_VBG
the_DT
stolen_VBN
GlaxoSmithKline_NN
2003_CD
against_PIN
Kali_NN
Laboratories_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
production_NOMZ
strain_NN
:_:
the_DT
Colorado_NN
action_NOMZ
seeks_VPRT
damages_NN
as_RB
well_RB
._.
Similar_JJ
state_NN
court_NN
actions_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
initiated_VBN
against_PIN
Teva_NN
,_,
Lek_NN
In_PIN
August_NN
2002_CD
the_DT
Group_NN
commenced_VBD
an_DT
action_NOMZ
in_PIN
the_DT
US_FPP1
District_NN
and_PHC
Ranbaxy_NN
._.
Court_NN
for_PIN
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
against_PIN
Teva_NN
,_,
alleging_VBG [PUBV] [PRESP]
Five_CD
distributors_NN
of_PIN
generic_JJ
pharmaceutical_JJ
products_NN
have_VPRT [PEAS]
led_VBN
infringement_NOMZ
of_PIN
the_DT
Groups_NN
compound_VPRT
patent_NN
for_PIN
lamotrigine_NN
,_,
the_DT
ANDAs_NN
for_PIN
sustained_VBN
release_NN
bupropion_NN
hydrochloride_NN
tablets_NN
active_JJ
ingredient_NN
in_PIN
Lamictal_JJ
oral_JJ
tablets_NN
._.
That_DEMO
patent_NN
expires_VPRT
in_PIN
July_NN
Wellbutrin_NN
SR_NN
and_PHC
Zyban_NN
in_PIN
the_DT
USA_NN
,_,
accompanied_VBN [PASTP]
in_PIN
each_QUAN
case_NN
2008_CD
._.
The_DT
defendant_NN
has_VPRT [PEAS]
led_VBN
an_DT
ANDA_NN
with_PIN
the_DT
FDA_NN
with_PIN
a_DT
with_PIN
a_DT
certication_NOMZ
of_PIN
invalidity_NOMZ
of_PIN
the_DT
Groups_NN
patents_NN
._.
The_DT
Group_NN
certication_NOMZ
of_PIN
invalidity_NOMZ
of_PIN
the_DT
Groups_NN
patent_NN
._.
FDA_NN
approval_NN
of_PIN
has_VPRT [PEAS]
brought_VBN
suit_NN
for_PIN
patent_NN
infringement_NOMZ
against_PIN
each_QUAN
of_PIN
the_DT
ling_NN
that_TOBJ
ANDA_NN
is_VPRT [PASS]
stayed_VBN
until_IN
the_DT
earlier_TIME
of_PIN
January_NN
2005_CD
or_CC
resolution_NOMZ
parties_NN
._.
The_DT
Group_NN
led_VBD
suit_NN
against_PIN
Andrx_NN
Pharmaceuticals_NN
,_,
the_DT
first_JJ
of_PIN
the_DT
patent_NN
infringement_NOMZ
litigation_NOMZ
._.
The_DT
case_NN
is_VPRT [BEMA]
in_PIN
its_PIT
early_TIME
stages_NN
._.
to_TO
le_FW
an_DT
ANDA_NN
,_,
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Southern_NN
District_NN
of_PIN
In_PIN
October_NN
2002_CD
Pzer_NN
Inc._NN
led_VBD
an_DT
action_NOMZ
against_PIN
Bayer_NN
AG_NN
and_PHC
Florida_NN
._.
In_PIN
February_NN
2002_CD
the_DT
District_NN
Court_NN
Judge_NN
granted_VBD [SUAV]
Andrxs_NN
GlaxoSmithKline_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
summary_NN
judgement_NOMZ
motion_NOMZ
and_CC
ruled_VBD [SUAV]
that_THVC
its_PIT
product_NN
does_VPRT
not_XX0
Delaware_NN
,_,
alleging_VBG [PUBV]
that_THVC
the_DT
manufacture_NN
and_PHC
sale_NN
of_PIN
Levitra_NN
infringe_VPRT
the_DT
Groups_NN
patents_NN
._.
The_DT
Group_NN
has_VPRT [PEAS]
appealed_VBN
that_DEMO
decision_NN
vardenal_NN
would_PRMD
infringe_VB
a_DT
patent_NN
newly_RB
issued_VBN
to_PIN
Pzer_NN
and_CC
to_PIN
the_DT
CAFC_NN
._.
The_DT
oral_JJ
argument_NOMZ
on_PIN
the_DT
appeal_NN
was_VBD [PASS]
held_VBN [PRIV]
in_PIN
asking_VBG [SUAV]
that_THVC
Bayer_NN
and_PHC
GlaxoSmithKline_NN
be_VB [SPAU] [PASS]
permanently_RB
enjoined_VBN [SUAV]
._.
December_NN
2002_CD
but_CC
as_IN
of_PIN
the_DT
date_NN
of_PIN
this_DEMO
report_NN
the_DT
CAFC_NN
has_VPRT
not_XX0
The_DT
case_NN
is_VPRT [BEMA]
in_PIN
its_PIT
early_TIME
stages_NN
._.
Actions_NOMZ
have_VPRT [SPAU] [PEAS]
also_RB
been_VBN [PASS]
led_VBN
against_PIN
Watson_NN
Pharmaceuticals_NN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Southern_NN
District_NN
of_PIN
In_PIN
January_NN
2003_CD
Cipla_NN
and_PHC
Neolab_NN
led_VBD
an_DT
action_NOMZ
in_PIN
the_DT
UK_NN
High_NN
Ohio_NN
,_,
Eon_NN
Labs_NN
Manufacturing_GER
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Court_NN
,_,
seeking_VBG
revocation_NOMZ
of_PIN
one_CD
of_PIN
the_DT
Groups_NN
patents_NN
relating_VBG [WZPRES]
to_PIN
Southern_NN
District_NN
of_PIN
New_NN
York_NN
,_,
Impax_NN
Laboratories_NN
in_PIN
the_DT
US_FPP1
District_NN
the_DT
asthma_NN
treatment_NOMZ
Seretide_NN
Advair_NN
._.
This_DEMO
patent_NN
,_,
set_VBN
to_TO
expire_VB
in_PIN
Court_NN
for_PIN
the_DT
Northern_NN
District_NN
of_PIN
California_NN
and_PHC
Excel_NN
2013_CD
,_,
including_VBG
supplementary_JJ
protection_NOMZ
certicate_NN
protection_NOMZ
,_,
Pharmaceuticals_NN
in_PIN
both_DT
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
New_NN
relates_VPRT
to_PIN
the_DT
combination_NOMZ
of_PIN
the_DT
active_JJ
ingredients_NN
,_,
salmeterol_NN
Jersey_NN
and_CC
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Eastern_NN
District_NN
of_PIN
Virginia_NN
._.
and_ANDC
uticasone_JJ
propionate_NN
,_,
on_PIN
which_WDT [PIRE]
separate_JJ
patents_NN
exist_VPRT
which_WDT
The_DT
Watson_NN
case_NN
has_VPRT [PEAS]
been_VBN [PASS]
settled_VBN
._.
Judges_NN
granted_VBD [SUAV] [THATD]
summary_NN
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
challenged_VBN
,_,
providing_VBG
patent_NN
protection_NOMZ
in_PIN
the_DT
UK_NN
judgement_NOMZ
of_PIN
non-infringement_NOMZ
in_PIN
the_DT
Impax_NN
and_PHC
Excel_NN
cases_NN
,_,
both_DT
until_IN
late_TIME
2005_CD
._.
Several_QUAN
other_JJ
UK_NN
Seretide_NN
patents_NN
,_,
for_CONJ
example_NULL
of_PIN
which_WDT [PIRE]
are_VPRT [BEMA]
on_PIN
appeal_NN
to_PIN
the_DT
CAFC_NN
._.
Summary_JJ
judgement_NOMZ
was_VBD [BEMA]
those_DEMP
relating_VBG
to_PIN
the_DT
Diskus_NN
device_NN
and_CC
the_DT
CFC-free_JJ
MDI_NN
device_NN
denied_VBD [PUBV]
to_PIN
Eon_NN
._.
On_PIN
Eons_NN
motion_NOMZ
for_PIN
reconsideration_NOMZ
,_,
the_DT
judge_NN
which_WDT [WHSUB]
expire_VPRT
in_PIN
2011_CD
and_CC
2012_CD
respectively_RB
,_,
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
confirmed_VBN [PUBV]
denial_NN
of_PIN
the_DT
summary_NN
judgement_NOMZ
._.
No_SYNE
trial_NN
date_NN
has_VPRT [SPAU] [PEAS]
yet_RB
challenged_VBN
._.
There_EX
has_VPRT [PEAS]
been_VBN
no_SYNE
challenge_NN
to_PIN
the_DT
Groups_NN
patents_NN
been_VBN [PASS]
set_VBN
in_PIN
the_DT
Eon_NN
case_NN
._.
At_PIN
this_DEMO
point_NN
Eon_NN
is_VPRT [BEMA]
the_DT
only_DWNT
distributor_NN
relating_VBG [WZPRES]
to_PIN
Seretide_NN
Advair_NN
in_PIN
the_DT
USA_NN
or_CC
in_PIN
other_JJ
countries_NN
._.
with_PIN
tentative_JJ
FDA_NN
approval_NN
for_PIN
its_PIT
generic_JJ
version_NN
of_PIN
the_DT
product_NN
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
105_CD
30_CD
Legal_NN
proceedings_GER
continued_VBD
Following_VBG
a_DT
report_NN
from_PIN
the_DT
Yale_NN
Haemorrhagic_NN
Stroke_NN
Project_NN
that_TSUB
found_VBD [PRIV]
a_DT
suggestion_NOMZ
of_PIN
an_DT
association_NOMZ
between_PIN
first_JJ
use_NN
of_PIN
In_PIN
February_NN
2003_CD
the_DT
Group_NN
received_VBD
a_DT
paragraph_NN
iv_NN
notication_NOMZ
of_PIN
phenylpropanolamine_NN
PPA_NN
decongestant_JJ
and_PHC
hemorrhagic_JJ
non-infringement_NOMZ
of_PIN
a_DT
patent_NN
relating_VBG [WZPRES]
to_TO
lm_VB
coating_GER
for_PIN
Imitrex_NN
stroke_NN
,_,
the_DT
Group_NN
and_CC
most_EMPH
other_JJ
manufacturers_NN
voluntarily_RB
sumatriptan_VPRT
in_PIN
connection_NOMZ
with_PIN
an_DT
ANDA_NN
ling_NN
by_PIN
Ranbaxy_NN
with_PIN
withdrew_VBD
consumer_NN
healthcare_NN
products_NN
in_PIN
which_WDT [PIRE]
PPA_NN
was_VBD [BEMA]
an_DT
active_JJ
respect_NN
to_PIN
Imitrex_NN
._.
The_DT
paragraph_NN
iv_NN
notication_NOMZ
does_VPRT
not_XX0
extend_VB
to_PIN
ingredient_NN
._.
Since_OSUB
the_DT
PPA_NN
product_NN
withdrawal_NN
the_DT
Group_NN
has_VPRT [PEAS]
been_VBN [BEMA]
the_DT
basic_JJ
US_FPP1
patents_NN
for_PIN
the_DT
product_NN
which_WDT [WHSUB]
expire_VPRT
in_PIN
2006_CD
and_CC
named_VBN
as_IN
a_DT
defendant_NN
in_PIN
numerous_JJ
personal_JJ
injury_NN
and_PHC
class_NN
action_NOMZ
2008_CD
._.
lawsuits_NN
led_VBD
in_PIN
state_NN
and_CC
federal_JJ
courts_NN
alleging_VBG [PUBV] [WZPRES]
personal_JJ
injury_NN
or_CC
In_PIN
February_NN
2003_CD
the_DT
FDA_NN
website_NN
posted_VBD
receipt_NN
by_PIN
the_DT
agency_NN
of_PIN
increased_VBN
risk_NN
of_PIN
injury_NN
from_PIN
use_NN
of_PIN
products_NN
containing_VBG [WZPRES]
PPA_NN
and_CC
an_DT
ANDA_NN
ling_NN
with_PIN
respect_NN
to_PIN
Valtrex_NN
._.
As_IN
of_PIN
the_DT
date_NN
of_PIN
this_DEMO
report_NN
unfair_JJ
and_PHC
deceptive_JJ
business_NOMZ
practices_NN
._.
Plaintiffs_NN
seek_VPRT
remedies_NN
the_DT
Group_NN
has_VPRT [PEAS]
not_XX0
yet_RB
received_VBN
notice_NN
of_PIN
a_DT
paragraph_NN
iv_NN
notication_NOMZ
including_VBG [WZPRES]
compensatory_JJ
and_PHC
punitive_JJ
damages_NN
and_PHC
refunds_NN
._.
The_DT
of_PIN
invalidity_NOMZ
and_CC
or_CC
non-infringement_JJ
with_PIN
respect_NN
to_PIN
that_DEMO
product_NN
._.
federal_JJ
cases_NN
have_VPRT [PEAS]
been_VBN [PASS]
consolidated_VBN
in_PIN
a_DT
multidistrict_JJ
litigation_NOMZ
The_DT
Groups_NN
US_FPP1
patent_NN
on_PIN
the_DT
active_JJ
ingredient_NN
in_PIN
Valtrex_NN
proceeding_GER
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
Washington_NN
._.
The_DT
judge_NN
responsible_JJ
for_PIN
those_DEMO
proceedings_GER
initially_TIME
denied_VBD [PUBV]
class_NN
certication_NOMZ
and_CC
struck_VBD
all_QUAN
class_NN
allegations_NOMZ
in_PIN
the_DT
federal_JJ
personal_JJ
Product_NN
liability_NOMZ
injury_NN
and_PHC
consumer_NN
refund_NN
class_NN
actions_NOMZ
but_CC
granted_VBN [SUAV] [THATD]
plaintiffs_NN
leave_VPRT
In_PIN
1997_CD
the_DT
FDA_NN
became_VBD
aware_JJ
of_PIN
reports_NN
of_PIN
cardiac_JJ
valvular_JJ
to_TO
le_FW
a_DT
renewed_JJ
motion_NOMZ
to_TO
certify_VB [PUBV]
a_DT
consumer_NN
refund_NN
class_NN
problems_NN
in_PIN
individuals_NN
for_PIN
whom_WP [PIRE]
fenuramine_VPRT
or_CC
dexfenuramine_VPRT
consisting_VBG
of_PIN
persons_NN
possessing_VBG [WZPRES]
PPA-containing_JJ
products_NN
at_PIN
the_DT
alone_JJ
or_CC
in_PIN
combination_NOMZ
of_PIN
phentermine_NN
was_VBD [PASS]
prescribed_VBN
as_IN
part_NN
of_PIN
time_NN
of_PIN
an_DT
FDA_NN
advisory_NN
in_PIN
November_NN
2000_CD
._.
Subsequently_TIME
,_,
the_DT
a_DT
regimen_NN
of_PIN
weight_NN
reduction_NOMZ
and_CC
requested_VBD [SUAV] [THATD]
the_DT
voluntary_JJ
judge_NN
denied_VBD [PUBV] [THATD]
that_DEMP
renewed_VBN
motion_NOMZ
._.
The_DT
lawsuits_NN
are_VPRT [BEMA]
in_PIN
their_TPP3
early_TIME
withdrawal_NN
of_PIN
fenuramine_NN
and_PHC
dexfenuramine_NN
from_PIN
the_DT
market_NN
._.
stages_NN
and_CC
there_EX
has_VPRT [PEAS]
been_VBN
no_SYNE
final_JJ
determination_NOMZ
as_IN
to_PIN
whether_IN
any_QUAN
The_DT
reports_NN
of_PIN
cardiac_JJ
valvular_JJ
problems_NN
and_CC
the_DT
subsequent_JJ
of_PIN
the_DT
lawsuits_NN
led_VBD
in_PIN
state_NN
courts_NN
will_PRMD
be_VB [PASS]
permitted_VBN
to_TO
proceed_VB
as_IN
withdrawal_NN
of_PIN
those_DEMO
products_NN
from_PIN
the_DT
market_NN
spawned_VBD
numerous_JJ
class_NN
actions_NOMZ
._.
Class_NN
certication_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
denied_VBN [PUBV]
in_PIN
California_NN
state_NN
product_NN
liability_NOMZ
lawsuits_NN
led_VBD
against_PIN
the_DT
manufacturers_NN
and_PHC
court_NN
and_CC
is_VPRT [BEMA]
on_PIN
appeal_NN
:_:
a_DT
motion_NOMZ
for_PIN
class_NN
certication_NOMZ
is_VPRT
still_RB
distributors_NN
of_PIN
fenuramine_NN
,_,
dexfenuramine_NN
and_PHC
phentermine_NN
._.
pending_VBG [PRESP]
in_PIN
Pennsylvania_NN
state_NN
court_NN
._.
As_IN
one_CD
of_PIN
a_DT
number_NN
of_PIN
manufacturers_NN
of_PIN
phentermine_NN
,_,
the_DT
Group_NN
In_PIN
August_NN
2001_CD
Bayer_NN
AG_NN
withdrew_VBD
Baycol_NN
cerivastatin_NN
sodium_NN
is_VPRT [BEMA]
a_DT
defendant_NN
in_PIN
thousands_NN
of_PIN
lawsuits_NN
in_PIN
various_JJ
state_NN
and_CC
federal_JJ
worldwide_NN
in_PIN
light_NN
of_PIN
reports_NN
of_PIN
adverse_JJ
events_NN
,_,
including_VBG
deaths_NN
,_,
district_NN
courts_NN
in_PIN
the_DT
USA_NN
,_,
many_QUAN
of_PIN
which_WDT [PIRE]
have_VPRT [PEAS]
been_VBN [PASS]
led_VBN
as_IN
class_NN
involving_VBG [WZPRES]
rhabdomyolosis_NN
._.
GlaxoSmithKline_NN
had_VBD [PEAS]
participated_VBN
in_PIN
the_DT
actions_NOMZ
._.
Most_EMPH
of_PIN
the_DT
lawsuits_NN
seek_VPRT
relief_NN
including_VBG [WZPRES]
some_QUAN
combination_NOMZ
marketing_GER
of_PIN
Baycol_NN
in_PIN
the_DT
USA_NN
pursuant_JJ
to_PIN
a_DT
co-promotion_NOMZ
of_PIN
compensatory_JJ
and_PHC
punitive_JJ
damages_NN
,_,
medical_JJ
monitoring_GER
and_PHC
agreement_NOMZ
with_PIN
Bayer_NN
which_WDT [WHSUB]
was_VBD [BEMA]
the_DT
license_NN
holder_NN
and_PHC
refunds_NN
for_PIN
purchases_NN
of_PIN
drugs_NN
._.
In_PIN
1997_CD
the_DT
Judicial_NN
Panel_NN
on_PIN
manufacturer_NN
of_PIN
the_DT
product_NN
._.
Following_VBG [PRESP]
the_DT
withdrawal_NN
,_,
Bayer_NN
and_PHC
Multidistrict_NN
Litigation_NOMZ
issued_VBD
an_DT
order_NN
consolidating_VBG [WZPRES]
and_PHC
transferring_VBG
GlaxoSmithKline_NN
have_VPRT [PEAS]
been_VBN [PASS]
named_VBN
as_IN
defendants_NN
in_PIN
thousands_NN
of_PIN
all_QUAN
federal_JJ
actions_NOMZ
to_PIN
the_DT
District_NN
Court_NN
for_PIN
the_DT
Eastern_NN
District_NN
of_PIN
lawsuits_NN
led_VBN [WZPAST]
in_PIN
state_NN
and_CC
federal_JJ
courts_NN
in_PIN
the_DT
USA_NN
on_PIN
behalf_NN
of_PIN
Pennsylvania_NN
._.
That_DEMO
court_NN
approved_VBD
a_DT
global_JJ
settlement_NOMZ
proposed_VBN [SUAV] [WZPAST]
by_PIN
both_DT
individuals_NN
and_CC
putative_JJ
classes_NN
of_PIN
former_JJ
Baycol_NN
users_NN
._.
A_DT
defendant_NN
Wyeth_NN
,_,
which_WDT [SERE]
sold_VBD
fenuramine_NN
and_PHC
dexfenuramine_NN
._.
number_NN
of_PIN
the_DT
suits_NN
allege_VPRT [PUBV]
that_THVC
the_DT
plaintiffs_NN
have_VPRT [PEAS]
suffered_VBN
personal_JJ
The_DT
settlement_NOMZ
,_,
subsequently_TIME
confirmed_VBN [PUBV]
by_PIN
the_DT
Third_NN
Circuit_NN
Court_NN
injuries_NN
,_,
including_VBG
rhabdomyolosis_NN
,_,
from_PIN
the_DT
use_NN
of_PIN
Baycol_NN
._.
Others_NN
of_PIN
Appeals_NN
,_,
does_VPRT
not_XX0
include_VB
any_QUAN
of_PIN
the_DT
phentermine_NN
defendants_NN
,_,
claim_VPRT [PUBV]
that_THVC
persons_NN
who_WP [WHSUB]
took_VBD
Baycol_NN
,_,
although_CONC
not_XX0
injured_VBN
,_,
may_POMD
be_VB
including_VBG
the_DT
Group_NN
._.
Individual_JJ
plaintiffs_NN
may_POMD
elect_VB
to_TO
opt_VB
out_PIN
of_PIN
the_DT
at_PIN
risk_NN
of_PIN
future_JJ
injury_NN
or_CC
may_POMD
have_VB [PEAS]
suffered_VBN
economic_JJ
damages_NN
class_NN
settlement_NOMZ
and_CC
pursue_VB
their_TPP3
claims_NN
individually_RB
._.
Wyeth_NN
from_PIN
purchasing_VBG
and_PHC
using_VBG
Baycol_NN
._.
Plaintiffs_NN
seek_VPRT
remedies_NN
including_VBG [WZPRES]
continues_VPRT
to_TO
settle_VB
individual_JJ
state_NN
court_NN
cases_NN
before_IN
trial_NN
and_CC
the_DT
compensatory_JJ
,_,
punitive_JJ
and_PHC
statutory_JJ
damages_NN
and_PHC
creation_NOMZ
of_PIN
Group_NN
continues_VPRT
to_TO
be_VB [PASS]
dismissed_VBN
from_PIN
lawsuits_NN
as_IN
they_TPP3
are_VPRT [PASS]
settled_VBN
funds_NN
for_PIN
medical_JJ
monitoring_GER
._.
GlaxoSmithKline_NN
and_PHC
Bayer_NN
by_PIN
Wyeth_NN
._.
Corporation_NOMZ
,_,
the_DT
principal_JJ
US_FPP1
subsidiary_NN
of_PIN
Bayer_NN
AG_NN
,_,
have_VPRT [PEAS]
signed_VBN
GlaxoSmithKline_NN
has_VPRT [PEAS]
received_VBN
purported_JJ
class_NN
action_NOMZ
lawsuits_NN
led_VBD
an_DT
allocation_NOMZ
agreement_NOMZ
under_IN
which_WDT
Bayer_NN
Corporation_NOMZ
has_VPRT [PEAS]
agreed_VBN [SUAV] [PUBV]
in_PIN
state_NN
and_CC
federal_JJ
courts_NN
in_PIN
the_DT
USA_NN
alleging_VBG [PUBV] [WZPRES]
that_THVC
paroxetine_NN
to_TO
pay_VB
95_CD
per_PIN
cent_NN
of_PIN
all_QUAN
settlements_NOMZ
and_CC
compensatory_JJ
damages_NN
the_DT
active_JJ
ingredient_NN
in_PIN
Paxil_NN
is_VPRT [BEMA]
addictive_PRED
and_CC
causes_VPRT
dependency_NN
judgements_NOMZ
with_PIN
each_QUAN
party_NN
retaining_VBG [WZPRES]
responsibility_NOMZ
for_PIN
its_PIT
own_JJ
and_CC
withdrawal_NN
reactions_NOMZ
._.
Plaintiffs_NN
seek_VPRT
remedies_NN
including_VBG [WZPRES]
attorneys_NN
fees_NN
and_CC
any_QUAN
punitive_JJ
damages_NN
._.
The_DT
federal_JJ
cases_NN
have_VPRT
compensatory_JJ
,_,
punitive_JJ
and_PHC
statutory_JJ
damages_NN
and_CC
the_DT
cost_NN
of_PIN
a_DT
been_VBN [PASS]
consolidated_VBN
in_PIN
a_DT
multidistrict_JJ
litigation_NOMZ
proceeding_GER
in_PIN
the_DT
US_FPP1
fund_NN
for_PIN
medical_JJ
monitoring_GER
._.
In_PIN
January_NN
2003_CD
a_DT
federal_JJ
district_NN
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
Minnesota_NN
._.
Most_EMPH
of_PIN
the_DT
lawsuits_NN
are_VPRT
court_NN
judge_NN
in_PIN
California_NN
denied_VBD [PUBV]
class_NN
action_NOMZ
certication_NOMZ
although_CONC
in_PIN
their_TPP3
early_TIME
stages_NN
and_CC
there_EX
has_VPRT [PEAS]
been_VBN
no_SYNE
determination_NOMZ
as_IN
to_TO
permitting_VBG
counsel_NN
for_PIN
the_DT
plaintiffs_NN
to_PIN
le_DT
one_CD
more_EMPH
motion_NOMZ
for_PIN
whether_IN
any_QUAN
of_PIN
the_DT
lawsuits_NN
to_PIN
which_WDT [PIRE]
the_DT
Group_NN
is_VPRT [BEMA]
a_DT
party_NN
will_PRMD
be_VB
certication_NOMZ
._.
Most_EMPH
of_PIN
the_DT
remaining_VBG
lawsuits_NN
are_VPRT [BEMA]
in_PIN
their_TPP3
early_TIME
permitted_VBN
to_TO
proceed_VB
as_IN
class_NN
actions_NOMZ
._.
stages_NN
and_CC
there_EX
has_VPRT [PEAS]
been_VBN
no_SYNE
determination_NOMZ
as_IN
to_PIN
whether_IN
any_QUAN
of_PIN
GlaxoSmithKline_NN
,_,
along_IN
with_PIN
a_DT
number_NN
of_PIN
other_JJ
pharmaceutical_JJ
the_DT
lawsuits_NN
pending_VBG [WZPRES]
in_PIN
state_NN
or_CC
federal_JJ
courts_NN
elsewhere_RB
will_PRMD
be_VB
companies_NN
,_,
has_VPRT [PEAS]
been_VBN [PASS]
named_VBN
as_IN
a_DT
defendant_NN
in_PIN
a_DT
number_NN
of_PIN
permitted_VBN
to_TO
proceed_VB
as_IN
class_NN
actions_NOMZ
._.
purported_JJ
class_NN
action_NOMZ
and_CC
numerous_JJ
individual_JJ
personal_JJ
injury_NN
In_PIN
the_DT
last_JJ
decade_NN
there_RB
has_VPRT [PEAS]
been_VBN
litigation_NOMZ
against_PIN
the_DT
lawsuits_NN
in_PIN
state_NN
and_CC
federal_JJ
district_NN
courts_NN
in_PIN
the_DT
USA_NN
alleging_VBG [PUBV] [WZPRES]
that_THVC
manufacturers_NN
of_PIN
Prozac_NN
and_CC
other_JJ
sustained_VBN
serotonin_NN
reuptake_NN
thimerosal_NN
,_,
a_DT
preservative_JJ
used_VBN
in_PIN
vaccines_NN
,_,
causes_VPRT
inhibitor_NN
SSRI_NN
products_NN
such_JJ
as_IN
Paxil_NN
for_PIN
homicidal_JJ
or_CC
suicidal_JJ
neurodevelopmental_JJ
disorders_NN
and_CC
other_JJ
injuries_NN
._.
Plaintiffs_NN
seek_VPRT
behavior_NN
exhibited_VBN [WZPAST]
by_PIN
users_NN
of_PIN
their_TPP3
products_NN
._.
The_DT
Group_NN
has_VPRT
remedies_NN
including_VBG [WZPRES]
compensatory_JJ
,_,
punitive_JJ
and_PHC
statutory_JJ
damages_NN
received_VBD
some_QUAN
such_JJ
claims_NN
and_PHC
lawsuits_NN
with_PIN
respect_NN
to_PIN
Paxil_NN
._.
and_ANDC
the_DT
cost_NN
of_PIN
a_DT
fund_NN
for_PIN
medical_JJ
monitoring_GER
and_PHC
research_NN
._.
The_DT
None_INPR
of_PIN
these_DEMP
are_VPRT
or_CC
purport_VPRT
to_TO
be_VB
class_NN
actions_NOMZ
._.
lawsuits_NN
are_VPRT [BEMA]
in_PIN
their_TPP3
very_AMP
early_TIME
stages_NN
and_CC
there_EX
has_VPRT [PEAS]
been_VBN
no_SYNE
determination_NOMZ
as_IN
to_PIN
whether_IN
any_QUAN
of_PIN
the_DT
purported_JJ
class_NN
actions_NOMZ
will_PRMD
be_VB [PASS]
permitted_VBN
to_TO
proceed_VB
as_IN
class_NN
actions_NOMZ
._.
106_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
30_CD
Legal_JJ
proceedings_GER
continued_VBD
Antitrust_NN
In_PIN
November_NN
2000_CD
the_DT
US_FPP1
Federal_NN
Trade_NN
Commission_NN
FTC_NN
staff_NN
Following_VBG [WZPRES]
the_DT
voluntary_JJ
withdrawal_NN
of_PIN
Lotronex_NN
in_PIN
the_DT
USA_NN
in_PIN
advised_VBD
the_DT
Group_NN
that_TOBJ
the_DT
staff_NN
was_VBD
conducting_VBG
a_DT
non-public_JJ
November_NN
2000_CD
a_DT
number_NN
of_PIN
lawsuits_NN
have_VPRT [PEAS]
been_VBN [PASS]
led_VBN
against_PIN
the_DT
investigation_NOMZ
to_TO
determine_VB [SUAV] [PRIV]
whether_IN [WHCL]
the_DT
Group_NN
was_VBD
violating_VBG
Group_NN
in_PIN
state_NN
and_CC
federal_JJ
district_NN
courts_NN
,_,
including_VBG
individual_JJ
Section_NOMZ
5_CD
of_PIN
the_DT
Federal_NN
Trade_NN
Commission_NN
Act_NN
by_PIN
monopolizing_VBG
personal_JJ
injury_NN
actions_NOMZ
and_CC
purported_JJ
class_NN
actions_NOMZ
asserting_VBG [PUBV] [WZPRES]
or_CC
attempting_VBG
to_TO
monopolize_VB
the_DT
market_NN
for_PIN
paroxetine_JJ
product_NN
liability_NOMZ
and_PHC
consumer_NN
fraud_NN
claims_NN
._.
Plaintiffs_NN
seek_VPRT
remedies_NN
hydrochloride_RB
by_PIN
preventing_VBG
generic_JJ
competition_NOMZ
to_PIN
Paxil_NN
and_CC
including_VBG
compensatory_JJ
,_,
punitive_JJ
and_PHC
statutory_JJ
damages_NN
._.
A_DT
requested_VBD [SUAV]
the_DT
Group_NN
to_TO
submit_VB [PUBV]
certain_JJ
information_NOMZ
in_PIN
connection_NOMZ
number_NN
of_PIN
claims_NN
have_VPRT [PEAS]
been_VBN [PASS]
settled_VBN
._.
Most_EMPH
of_PIN
the_DT
remaining_VBG
actions_NOMZ
with_PIN
that_DEMO
investigation_NOMZ
._.
The_DT
Group_NN
has_VPRT [PEAS]
cooperated_VBN
with_PIN
the_DT
staffs_NN
are_VPRT [BEMA]
at_PIN
their_TPP3
early_TIME
stages_NN
although_CONC
tentative_JJ
trial_NN
dates_NN
for_PIN
some_QUAN
investigation_NOMZ
._.
cases_NN
have_VPRT [PEAS]
been_VBN [PASS]
set_VBN
for_PIN
early_TIME
2003_CD
._.
Following_VBG
public_JJ
reference_NN
to_PIN
the_DT
FTC_NN
investigation_NOMZ
regarding_VBG [WZPRES]
Paxil_NN
,_,
Government_NOMZ
investigations_NOMZ
purported_JJ
consumer_NN
class_NN
actions_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
led_VBN
in_PIN
the_DT
US_FPP1
District_NN
GlaxoSmithKline_NN
has_VPRT [PEAS]
received_VBN
subpoenas_NN
from_PIN
the_DT
US_FPP1
Attorneys_NN
Court_NN
for_PIN
the_DT
Eastern_NN
District_NN
of_PIN
Pennsylvania_NN
on_PIN
behalf_NN
of_PIN
putative_JJ
ofce_NN
in_PIN
Boston_NN
,_,
Massachusetts_NN
,_,
requesting_VBG [SUAV]
production_NOMZ
of_PIN
classes_NN
of_PIN
indirect_JJ
purchasers_NN
,_,
including_VBG
consumers_NN
and_CC
third_JJ
party_NN
documents_NOMZ
for_PIN
the_DT
period_NN
from_PIN
1991_CD
to_PIN
the_DT
present_JJ
relating_VBG
to_PIN
any_QUAN
payers_NN
._.
The_DT
plaintiffs_NN
claim_VPRT [PUBV]
that_THVC
the_DT
Group_NN
has_VPRT [PEAS]
monopolised_VBN
a_DT
repackaging_VBG
,_,
relabelling_VBG
or_CC
private_JJ
label_NN
arrangements_NOMZ
that_DEMO
market_NN
for_PIN
Paxil_NN
by_PIN
bringing_VBG
allegedly_RB
sham_JJ
patent_NN
litigation_NOMZ
and_PHC
GlaxoSmithKline_NN
has_VPRT [PEAS]
had_VBN
or_CC
discussed_VBN
with_PIN
third-party_JJ
customers_NN
allegedly_RB
abusing_VBG
the_DT
regulatory_JJ
procedures_NN
for_PIN
the_DT
listing_GER
of_PIN
during_PIN
such_JJ
period_NN
._.
At_PIN
issue_NN
is_VPRT
whether_IN
the_DT
prices_NN
charged_VBD
to_PIN
such_JJ
patents_NN
in_PIN
the_DT
FDA_NN
Orange_NN
Book_NN
._.
Treble_NN
damages_NN
are_VPRT [PASS]
sought_VBN
for_PIN
third_JJ
parties_NN
for_PIN
GlaxoSmithKline_NN
products_NN
must_NEMD
be_VB [PASS]
counted_VBN
for_PIN
alleged_JJ
overcharges_NN
owing_VBG [WZPRES]
from_PIN
the_DT
conduct_NN
._.
The_DT
cases_NN
are_VPRT [BEMA]
at_PIN
an_DT
Medicaid_NN
best_JJ
price_NN
purposes_NN
._.
The_DT
Group_NN
has_VPRT [SPAU] [PEAS]
also_RB
received_VBN
letters_NN
early_TIME
stage_NN
with_PIN
no_SYNE
determination_NOMZ
as_IN
to_PIN
whether_IN
they_TPP3
will_PRMD
be_VB [BEMA]
from_PIN
the_DT
Centers_NN
for_PIN
Medicare_NN
&_CC
Medicaid_NN
Services_NN
CMS_NN
stating_VBG [PUBV] [WZPRES]
permitted_VBN
to_TO
proceed_VB
as_IN
class_NN
actions_NOMZ
._.
CMSs_NN
position_VPRT
that_DEMO
certain_JJ
of_PIN
those_DEMO
prices_NN
should_NEMD
have_VB [PEAS]
been_VBN [BEMA]
Through_PIN
the_DT
US_FPP1
pharmaceutical_JJ
businesses_NOMZ
of_PIN
both_DT
SmithKline_NN
included_VBD
in_PIN
Medicaid_NN
best_JJ
price_NN
and_CC
requesting_VBG [SUAV]
that_THVC
Beecham_NN
and_PHC
Glaxo_NN
Wellcome_NN
,_,
the_DT
Group_NN
is_VPRT
party_NN
to_PIN
a_DT
number_NN
of_PIN
GlaxoSmithKline_NN
retroactively_RB
adjust_VPRT
its_PIT
best_JJ
price_NN
reports_NN
for_PIN
antitrust_JJ
suits_NN
,_,
certain_JJ
of_PIN
which_WDT [PIRE]
have_VPRT [PEAS]
been_VBN [PASS]
certied_VBN
as_IN
class_NN
actions_NOMZ
,_,
quarters_NN
prior_RB
to_PIN
July_NN
2000_CD
to_TO
include_VB
those_DEMO
prices_NN
._.
The_DT
Group_NN
is_VPRT [BYPA]
instituted_VBN
by_PIN
most_EMPH
of_PIN
the_DT
nations_NOMZ
retail_JJ
pharmacies_NN
and_PHC
consumers_NN
involved_VBN [WZPAST]
in_PIN
discussions_NN
with_PIN
the_DT
US_FPP1
Attorneys_NN
ofce_NN
to_TO
resolve_VB [SUAV]
in_PIN
several_QUAN
states_NN
,_,
alleging_VBG [PUBV]
conspiracies_NN
in_PIN
restraint_NN
of_PIN
trade_NN
and_CC
these_DEMO
issues_NN
._.
challenging_VBG [PRESP]
the_DT
pricing_GER
practices_NN
of_PIN
the_DT
Group_NN
._.
A_DT
significant_JJ
GlaxoSmithKline_NN
has_VPRT [PEAS]
been_VBN
responding_VBG
to_PIN
subpoenas_NN
from_PIN
the_DT
number_NN
of_PIN
other_JJ
pharmaceutical_JJ
companies_NN
and_PHC
wholesalers_NN
have_VPRT
Ofce_NN
of_PIN
the_DT
Inspector_NN
General_NN
of_PIN
the_DT
US_FPP1
Department_NOMZ
of_PIN
Health_NN
also_RB
been_VBN [PASS]
sued_VBN
in_PIN
the_DT
same_JJ
or_CC
similar_JJ
litigation_NOMZ
._.
These_DEMO
actions_NOMZ
,_,
and_ANDC
Human_NN
Services_NN
,_,
the_DT
US_FPP1
Department_NOMZ
of_PIN
Justice_NN
and_CC
the_DT
states_NN
except_PIN
for_PIN
several_QUAN
actions_NOMZ
brought_VBN [WZPAST]
in_PIN
state_NN
courts_NN
,_,
were_VBD [BEMA]
of_PIN
Texas_NN
and_PHC
California_NN
in_PIN
connection_NOMZ
with_PIN
allegations_NOMZ
that_TSUB
consolidated_VBD
for_PIN
pre-trial_JJ
purposes_NN
in_PIN
the_DT
District_NN
Court_NN
for_PIN
the_DT
pharmaceutical_JJ
companies_NN
,_,
including_VBG
GlaxoSmithKline_NN
,_,
have_VPRT
Northern_JJ
District_NN
of_PIN
Illinois_NN
._.
The_DT
federal_JJ
class_NN
action_NOMZ
component_NN
,_,
violated_VBD
federal_JJ
fraud_NN
and_PHC
abuse_NN
laws_NN
such_JJ
as_IN
the_DT
Federal_NN
False_NN
which_WDT [WHSUB]
includes_VPRT
pharmacies_NN
representing_VBG [WZPRES]
approximately_RB
two-thirds_NN
Claims_NN
Act_NN
and_CC
,_,
with_PIN
respect_NN
to_PIN
Texas_NN
and_PHC
California_NN
,_,
comparable_JJ
of_PIN
total_JJ
US_FPP1
retail_JJ
sales_NN
volume_NN
,_,
was_VBD [BYPA]
settled_VBN
by_PIN
both_DT
Glaxo_NN
Wellcome_NN
state_NN
laws_NN
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
way_NN
certain_JJ
drugs_NN
are_VPRT [PASS]
priced_VBN
and_CC
the_DT
and_CC
SmithKline_NN
Beecham_NN
in_PIN
1996_CD
._.
Since_OSUB
that_DEMO
time_NN
,_,
the_DT
Group_NN
has_VPRT
way_NN
the_DT
Medicare_NN
and_PHC
Medicaid_NN
programs_NN
reimburse_VPRT
for_PIN
those_DEMP
entered_VBN
into_PIN
other_JJ
settlements_NOMZ
on_PIN
satisfactory_JJ
terms_NN
._.
In_PIN
2002_CD
,_,
the_DT
Nevada_NN
and_PHC
Montana_NN
state_NN
attorneys_NN
general_JJ
has_VPRT [PEAS]
not_XX0
engaged_VBN
in_PIN
any_QUAN
conspiracy_NN
and_CC
no_SYNE
admission_NN
of_PIN
each_QUAN
led_VBD
a_DT
civil_JJ
lawsuit_NN
in_PIN
state_NN
court_NN
against_PIN
GlaxoSmithKline_NN
wrongdoing_GER
was_VBD [PASS]
made_VBN
nor_SYNE
included_VBN
in_PIN
the_DT
final_JJ
agreements_NOMZ
._.
and_ANDC
several_QUAN
other_JJ
drug_NN
companies_NN
._.
The_DT
actions_NOMZ
claim_VPRT [PUBV]
-_:
on_PIN
behalf_NN
In_PIN
August_NN
2001_CD
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
of_PIN
the_DT
states_NN
as_IN
payers_NN
and_CC
on_PIN
behalf_NN
of_PIN
in-state_JJ
patients_NN
as_IN
Massachusetts_NN
ruled_VBD [SUAV]
the_DT
Groups_NN
patent_NN
for_PIN
nabumetone_NN
Relafen_NN
consumers_NN
-_:
damages_NN
and_PHC
restitution_NOMZ
based_VBN [WZPAST]
on_PIN
defendants_NN
invalid_JJ
for_PIN
anticipatory_JJ
art_NN
and_CC
unenforceable_JJ
on_PIN
the_DT
grounds_NN
of_PIN
pricing_GER
for_PIN
an_DT
undefined_JJ
set_NN
of_PIN
pharmaceutical_JJ
products_NN
._.
The_DT
Group_NN
led_VBD
an_DT
appeal_NN
from_PIN
that_DEMO
decision_NN
In_PIN
the_DT
first_JJ
quarter_NN
of_PIN
2003_CD
,_,
the_DT
County_NN
of_PIN
Suffolk_NN
,_,
New_NN
York_NN
,_,
in_PIN
November_NN
2001_CD
._.
In_PIN
August_NN
2002_CD
the_DT
CAFC_NN
issued_VBD
a_DT
decision_NN
led_VBD
an_DT
action_NOMZ
in_PIN
federal_JJ
court_NN
that_TSUB
also_RB
asserts_VPRT [PUBV]
claims_NN
against_PIN
afrming_VBG
the_DT
District_NN
Courts_NN
judgement_NOMZ
of_PIN
invalidity_NOMZ
but_CC
declining_VBG
GlaxoSmithKline_NN
and_PHC
others_NN
relating_VBG [WZPRES]
to_PIN
the_DT
reported_VBN [PUBV]
average_NN
to_TO
rule_VB [SUAV]
on_PIN
the_DT
judgement_NOMZ
of_PIN
inequitable_JJ
conduct_NN
._.
Following_VBG [PRESP]
the_DT
wholesale_JJ
price_NN
of_PIN
certain_JJ
drugs_NN
covered_VBN [WZPAST]
by_PIN
the_DT
states_NN
Medicaid_NN
District_NN
Court_NN
decision_NN
,_,
antitrust_JJ
claims_NN
alleging_VBG [PUBV] [WZPRES]
competitive_JJ
injury_NN
program_NN
._.
The_DT
New_NN
York_NN
state_NN
attorney_NN
general_JJ
led_VBD
a_DT
similar_JJ
and_CC
overcharges_NN
have_VPRT [PEAS]
been_VBN [BYPA]
led_VBN
by_PIN
Teva_NN
,_,
a_DT
generic_JJ
manufacturer_NN
complaint_NN
in_PIN
New_NN
York_NN
state_NN
court_NN
._.
In_CONJ
addition_NULL
,_,
private_JJ
payer_NN
class_NN
of_PIN
nabumetone_NN
,_,
by_PIN
purported_JJ
classes_NN
of_PIN
direct_JJ
purchasers_NN
and_PHC
action_NOMZ
lawsuits_NN
have_VPRT [PEAS]
been_VBN [PASS]
led_VBN
against_PIN
GlaxoSmithKline_NN
in_PIN
several_QUAN
payers_NN
and_CC
by_PIN
individual_JJ
groups_NN
of_PIN
purported_JJ
direct_JJ
purchasers_NN
._.
federal_JJ
district_NN
and_PHC
state_NN
courts_NN
._.
A_DT
number_NN
of_PIN
the_DT
federal_JJ
cases_NN
The_DT
plaintiffs_NN
claims_NN
are_VPRT [PASS]
based_VBN
on_PIN
allegations_NOMZ
of_PIN
fraudulent_JJ
have_VPRT [PEAS]
been_VBN [PASS]
consolidated_VBN
in_PIN
a_DT
multidistrict_JJ
litigation_NOMZ
proceeding_GER
in_PIN
procurement_NOMZ
of_PIN
a_DT
patent_NN
,_,
wrongful_JJ
listing_GER
of_PIN
the_DT
patent_NN
in_PIN
the_DT
FDA_NN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
Massachusetts_NN
._.
Most_EMPH
of_PIN
the_DT
Orange_NN
Book_NN
and_PHC
prosecution_NOMZ
of_PIN
sham_NN
patent_NN
infringement_NOMZ
civil_JJ
suits_NN
led_VBN [WZPAST]
by_PIN
state_NN
attorneys_NN
general_JJ
and_CC
class_NN
action_NOMZ
plaintiffs_NN
litigation_NOMZ
._.
Those_DEMO
cases_NN
,_,
which_WDT [SERE]
were_VBD [SPAU] [PASS]
originally_TIME
led_VBN
in_PIN
the_DT
US_FPP1
District_NN
have_VPRT [PEAS]
been_VBN [PASS]
removed_VBN
to_PIN
federal_JJ
court_NN
._.
Some_QUAN
of_PIN
the_DT
removed_VBN
cases_NN
,_,
Courts_NN
for_PIN
the_DT
District_NN
of_PIN
Massachusetts_NN
and_CC
the_DT
Eastern_NN
District_NN
of_PIN
including_VBG
the_DT
Nevada_NN
and_PHC
Montana_NN
cases_NN
,_,
have_VPRT [PEAS]
been_VBN [BEMA]
consolidated_JJ
Pennsylvania_NN
,_,
are_VPRT [BEMA]
now_TIME
all_QUAN
pending_VBG
in_PIN
the_DT
District_NN
of_PIN
Massachusetts_NN
into_PIN
the_DT
District_NN
of_PIN
Massachusetts_NN
proceedings_GER
and_PHC
steps_NN
have_VPRT [PEAS]
been_VBN
and_PHC
are_VPRT [BEMA]
in_PIN
their_TPP3
early_TIME
stages_NN
._.
There_EX
has_VPRT [PEAS]
been_VBN
no_SYNE
determination_NOMZ
as_IN
taken_VBN
to_TO
consolidate_VB
the_DT
other_JJ
removed_VBN
cases_NN
there_RB
too_RB
._.
Nevada_NN
,_,
to_PIN
whether_IN
the_DT
putative_JJ
class_NN
actions_NOMZ
will_PRMD
be_VB [PASS]
permitted_VBN
to_TO
proceed_VB
Montana_NN
and_CC
some_QUAN
of_PIN
the_DT
private_JJ
class_NN
action_NOMZ
plaintiffs_NN
who_WP [WHOBJ]
as_IN
class_NN
actions_NOMZ
._.
originally_TIME
led_VBN
in_PIN
state_NN
court_NN
are_VPRT
seeking_VBG
to_TO
have_VB
their_TPP3
cases_NN
remanded_VBD
to_PIN
their_TPP3
respective_JJ
state_NN
courts_NN
._.
All_QUAN
the_DT
actions_NOMZ
are_VPRT [BEMA]
in_PIN
their_TPP3
early_TIME
stages_NN
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
107_CD
30_CD
Legal_NN
proceedings_GER
continued_VBD
These_DEMO
proceedings_GER
seek_VPRT
to_TO
require_VB [SUAV]
the_DT
operators_NN
of_PIN
hazardous_JJ
waste_NN
facilities_NOMZ
,_,
transporters_NN
of_PIN
waste_NN
to_PIN
the_DT
sites_NN
and_PHC
generators_NN
of_PIN
In_PIN
2002_CD
,_,
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Eastern_NN
District_NN
of_PIN
Virginia_NN
hazardous_JJ
waste_NN
disposed_VBD
of_PIN
at_PIN
the_DT
sites_NN
to_TO
clean_VB
up_RP
the_DT
sites_NN
or_CC
to_TO
found_VBN [PRIV] [THATD]
various_JJ
patents_NN
covering_VBG [WZPRES]
Augmentin_NN
invalid_JJ
._.
The_DT
Group_NN
has_VPRT
reimburse_VB
the_DT
government_NOMZ
for_PIN
cleanup_NN
costs_NN
._.
In_PIN
most_EMPH
instances_NN
,_,
led_VBD
an_DT
appeal_NN
from_PIN
that_DEMO
decision_NN
,_,
which_WDT [SERE]
is_VPRT [SPAU]
still_RB
pending_VBG
before_IN
the_DT
GlaxoSmithKline_NN
is_VPRT [PASS]
involved_VBN
as_IN
an_DT
alleged_JJ
generator_NN
of_PIN
hazardous_JJ
CAFC_NN
._.
Immediately_TIME
following_VBG
the_DT
adverse_JJ
trial_NN
court_NN
decision_NN
,_,
waste_NN
although_CONC
there_EX
are_VPRT
a_DT
few_QUAN
sites_NN
where_RB
GlaxoSmithKline_NN
is_VPRT [BEMA]
purported_JJ
antitrust_JJ
class_NN
actions_NOMZ
were_VBD [PASS]
led_VBN
on_PIN
behalf_NN
of_PIN
consumers_NN
involved_VBN
as_IN
a_DT
current_JJ
or_CC
former_JJ
operator_NN
of_PIN
the_DT
facility_NOMZ
._.
Although_CONC
and_CC
third_JJ
party_NN
payers_NN
in_PIN
various_JJ
federal_JJ
courts_NN
,_,
which_WDT [SERE]
have_VPRT
now_TIME
all_QUAN
Superfund_NN
provides_VPRT
that_DEMO
the_DT
defendants_NN
are_VPRT
jointly_RB
and_PHC
severally_RB
been_VBN [PASS]
transferred_VBN
or_CC
consolidated_VBN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
liable_JJ
for_PIN
cleanup_NN
costs_NN
,_,
these_DEMO
proceedings_GER
are_VPRT [SPAU] [PASS]
frequently_RB
resolved_VBN [SUAV]
Eastern_NN
District_NN
of_PIN
Virginia_NN
._.
Plaintiffs_NN
allege_VPRT [PUBV]
that_THVC
the_DT
Group_NN
on_PIN
the_DT
basis_NN
of_PIN
the_DT
nature_NN
and_PHC
quantity_NOMZ
of_PIN
waste_NN
disposed_VBN [WZPAST]
of_PIN
at_PIN
the_DT
knowingly_RB
obtained_VBN
invalid_JJ
patents_NN
and_CC
engaged_VBN
in_PIN
other_JJ
site_NN
by_PIN
the_DT
generator_NN
._.
GlaxoSmithKlines_NN
proportionate_VPRT
liability_NOMZ
for_PIN
anticompetitive_JJ
conduct_NN
to_TO
prevent_VB
entry_NN
of_PIN
generic_JJ
products_NN
in_PIN
cleanup_NN
costs_NN
has_VPRT [PEAS]
been_VBN [SPAU] [PASS]
substantially_RB
determined_VBN [SUAV] [PRIV]
for_PIN
about_RB
20_CD
of_PIN
violation_NOMZ
of_PIN
the_DT
monopolization_NOMZ
section_NOMZ
of_PIN
the_DT
US_FPP1
antitrust_JJ
laws_NN
._.
the_DT
sites_NN
referred_VBD
to_PIN
above_PLACE
._.
Plaintiffs_NN
seek_VPRT
declaratory_JJ
and_PHC
injunctive_JJ
relief_NN
as_RB
well_RB
as_IN
treble_JJ
damages_NN
for_PIN
the_DT
alleged_JJ
overcharges_NN
._.
There_EX
has_VPRT [PEAS]
been_VBN
no_SYNE
GlaxoSmithKlines_NN
potential_JJ
liability_NOMZ
varies_VPRT
greatly_AMP
from_PIN
site_NN
to_PIN
site_NN
._.
determination_NOMZ
as_IN
to_PIN
whether_IN
the_DT
putative_JJ
class_NN
actions_NOMZ
,_,
which_WDT [SERE]
are_VPRT
While_OSUB
the_DT
cost_NN
of_PIN
investigation_NOMZ
,_,
study_NN
and_PHC
remediation_NOMZ
at_PIN
such_JJ
sites_NN
in_PIN
their_TPP3
early_TIME
stages_NN
,_,
will_PRMD
be_VB [PASS]
permitted_VBN
to_TO
proceed_VB
as_IN
class_NN
actions_NOMZ
._.
could_POMD
,_,
over_IN
time_NN
,_,
be_VB [BEMA]
substantial_PRED
,_,
GlaxoSmithKline_NN
routinely_RB
accrues_VPRT
Separately_NN
,_,
the_DT
Group_NN
is_VPRT
prosecuting_VBG
patent_NN
infringement_NOMZ
suits_NN
amounts_VPRT
related_VBN
to_PIN
its_PIT
share_NN
of_PIN
liability_NOMZ
for_PIN
such_JJ
matters_NN
._.
against_PIN
four_CD
companies_NN
that_TSUB
have_VPRT [PEAS]
led_VBN
ANDAs_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
sell_VB
generic_JJ
bupropion_NN
Wellbutrin_NN
SR_NN
Zyban_NN
in_PIN
the_DT
US_FPP1
._.
In_PIN
three_CD
Tax_NN
matters_NN
of_PIN
those_DEMO
cases_NN
,_,
summary_NN
judgement_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
entered_VBN
against_PIN
the_DT
Pending_GER
tax_NN
matters_NN
are_VPRT [PASS]
described_VBN
in_PIN
Note_NN
12_CD
._.
Following_VBG [PRESP]
these_DEMO
adverse_JJ
rulings_GER
in_PIN
the_DT
patent_NN
litigation_NOMZ
,_,
a_DT
purported_JJ
class_NN
action_NOMZ
on_PIN
behalf_NN
of_PIN
purchasers_NN
and_CC
third_JJ
party_NN
payers_NN
was_VBD [PASS]
led_VBN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Eastern_NN
District_NN
of_PIN
Pennsylvania_NN
,_,
alleging_VBG [PUBV]
that_THVC
the_DT
Group_NN
engaged_VBD
in_PIN
anticompetitive_JJ
conduct_NN
,_,
including_VBG
prosecution_NOMZ
of_PIN
sham_NN
patent_NN
infringement_NOMZ
litigation_NOMZ
,_,
to_TO
prevent_VB
entry_NN
of_PIN
generic_JJ
products_NN
._.
Plaintiffs_NN
seek_VPRT
declaratory_JJ
and_PHC
injunctive_JJ
relief_NN
,_,
as_RB
well_RB
as_IN
treble_JJ
damages_NN
for_PIN
the_DT
alleged_JJ
overcharges_NN
._.
Commercial_JJ
matters_NN
Otsuka_NN
Pharmaceutical_NN
Co._NN
._.
Ltd._NN
initiated_VBD
arbitration_NOMZ
proceedings_GER
in_PIN
December_NN
2001_CD
concerning_VBG
the_DT
Groups_NN
unilateral_JJ
withdrawal_NN
of_PIN
grepaoxacin_NN
Raxar_NN
Vaxar_NN
in_PIN
October_NN
1999_CD
for_PIN
safety_NN
reasons_NN
._.
Otsuka_FW
alleges_VPRT [PUBV]
that_THVC
the_DT
product_NN
withdrawal_NN
and_CC
simultaneous_JJ
public_JJ
announcement_NOMZ
constituted_VBD
material_NN
breaches_NN
of_PIN
the_DT
license_NN
and_PHC
supply_NN
agreements_NOMZ
._.
The_DT
Group_NN
believes_VPRT [PRIV]
the_DT
underlying_JJ
product_NN
withdrawal_NN
was_VBD [BEMA]
consistent_PRED
with_PIN
the_DT
terms_NN
of_PIN
the_DT
agreements_NOMZ
and_CC
that_DEMO
valid_JJ
defences_NN
exist_VPRT
to_PIN
the_DT
claims_NN
._.
A_DT
UK_NN
arbitration_NOMZ
panel_NN
has_VPRT [PEAS]
been_VBN [PASS]
selected_VBN
and_PHC
met_VBN
._.
The_DT
hearing_GER
to_TO
determine_VB [SUAV] [PRIV]
liability_NOMZ
,_,
if_COND
any_QUAN
,_,
is_VPRT [PASS]
scheduled_VBN
for_PIN
December_NN
2003_CD
._.
SmithKline_NN
Beecham_NN
Clinical_NN
Laboratories_NN
indemnities_VPRT
In_PIN
connection_NOMZ
with_PIN
the_DT
sale_NN
of_PIN
SmithKline_NN
Beecham_NN
Clinical_NN
Laboratories_NN
SBCL_NN
to_PIN
Quest_NN
Diagnostics_NN
,_,
Inc._NN
the_DT
Group_NN
has_VPRT [PEAS]
agreed_VBN [SUAV] [PUBV]
to_TO
indemnify_VB
Quest_NN
Diagnostics_NN
,_,
on_PIN
an_DT
after-tax_JJ
basis_NN
,_,
with_PIN
respect_NN
to_PIN
certain_JJ
liabilities_NOMZ
arising_VBG [WZPRES]
from_PIN
the_DT
conduct_NN
of_PIN
the_DT
SBCL_NN
business_NOMZ
prior_RB
to_PIN
closing_GER
,_,
including_VBG
governmental_JJ
and_PHC
private_JJ
claims_NN
arising_VBG [WZPRES]
from_PIN
the_DT
US_FPP1
governments_NOMZ
investigation_NOMZ
into_PIN
SBCLs_NN
billing_GER
and_PHC
marketing_GER
practices_NN
._.
Environmental_NN
matters_VPRT
GlaxoSmithKline_NN
has_VPRT [PEAS]
been_VBN [PASS]
notied_VBN
of_PIN
its_PIT
potential_JJ
responsibility_NOMZ
relating_VBG [WZPRES]
to_PIN
past_JJ
operations_NOMZ
and_CC
its_PIT
past_JJ
waste_NN
disposal_NN
practices_NN
at_PIN
certain_JJ
sites_NN
,_,
primarily_RB
in_PIN
the_DT
USA_NN
._.
Some_QUAN
of_PIN
these_DEMO
matters_NN
are_VPRT [BEMA]
the_DT
subject_NN
of_PIN
litigation_NOMZ
,_,
including_VBG
proceedings_GER
initiated_VBN [WZPAST]
by_PIN
the_DT
US_FPP1
federal_JJ
or_CC
state_NN
governments_NOMZ
for_PIN
waste_NN
disposal_NN
site_NN
remediation_NOMZ
costs_NN
and_PHC
tort_NN
actions_NOMZ
brought_VBN [WZPAST]
by_PIN
private_JJ
parties_NN
._.
GlaxoSmithKline_NN
has_VPRT [PEAS]
been_VBN [PASS]
advised_VBN
that_DEMO
it_PIT
may_POMD
be_VB [BEMA]
a_DT
responsible_JJ
party_NN
at_PIN
approximately_RB
27_CD
sites_NN
,_,
of_PIN
which_WDT [PIRE]
11_CD
appear_VPRT [SMP]
on_PIN
the_DT
National_NN
Priority_NOMZ
List_NN
created_VBN [WZPAST]
by_PIN
the_DT
Comprehensive_NN
Environmental_NN
Response_NN
Compensation_NOMZ
and_PHC
Liability_NOMZ
Act_NN
Superfund_NN
._.
108_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
31_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
Details_NN
of_PIN
the_DT
acquisition_NOMZ
and_PHC
disposal_NN
of_PIN
subsidiary_NN
and_CC
associated_VBN
undertakings_GER
and_CC
joint_JJ
ventures_NN
are_VPRT [PASS]
given_VBN
below_PLACE
._.
2002_CD
Book_NN
Fair_NN
value_NN
Net_JJ
assets_NN
Goodwill_NN
Cost_NN
of_PIN
values_NN
adjustments_NOMZ
acquired_VBD
capitalized_JJ
acquisition_NOMZ
Acquisitions_NOMZ
m_VPRT
m_FW
m_FW
m_FW
m_FW
Iter_NN
Sterilyo_NN
7_CD
4_CD
3_CD
21_CD
18_CD
Human_NN
Kft_NN
10_CD
10_CD
1_CD
11_CD
Other_JJ
11_CD
3_CD
4_CD
7_CD
23_CD
30_CD
Iter_NN
Sterilyo_NN
During_PIN
2002_CD
the_DT
Group_NN
acquired_VBD
Iter-Sterilyo_NN
Group_NN
for_PIN
an_DT
initial_JJ
cash_NN
consideration_NOMZ
of_PIN
9_CD
million_CD
._.
A_DT
further_JJ
payment_NOMZ
will_PRMD
be_VB [BEMA]
payable_PRED
during_PIN
2003_CD
,_,
up_RB
to_PIN
a_DT
maximum_NN
of_PIN
9_CD
million_CD
,_,
depending_VBG [PRESP]
on_PIN
the_DT
financial_JJ
performance_NN
of_PIN
the_DT
acquired_VBN
company_NN
during_PIN
2002_CD
._.
The_DT
net_JJ
assets_NN
of_PIN
Iter-Sterilyo_NN
have_VPRT [PEAS]
been_VBN [PASS]
incorporated_VBN
in_PIN
the_DT
financial_JJ
statements_NOMZ
at_PIN
their_TPP3
provisional_JJ
fair_JJ
values_NN
._.
Human_JJ
Kft_NN
During_PIN
2002_CD
the_DT
Group_NN
acquired_VBD
the_DT
vaccine_NN
related_VBN
assets_NN
of_PIN
Human_JJ
Kft_NN
,_,
a_DT
manufacturing_GER
business_NOMZ
located_VBN [WZPAST]
in_PIN
Hungary_NN
,_,
for_PIN
a_DT
cash_NN
consideration_NOMZ
of_PIN
11_CD
million_CD
._.
Disposals_NN
SB_NN
Clinical_NN
Laboratories_NN
A_DT
cash_NN
refund_NN
of_PIN
6_CD
million_CD
was_VBD [PASS]
received_VBN
during_PIN
2002_CD
in_PIN
respect_NN
of_PIN
indemnified_JJ
liabilities_NOMZ
arising_VBG [WZPRES]
from_PIN
the_DT
SB_NN
Clinical_NN
Laboratories_NN
disposal_NN
which_WDT [WHSUB]
occurred_VBD
in_PIN
1999_CD
._.
The_DT
refund_NN
is_VPRT
as_CONJ
a_NULL
result_NULL
of_PIN
a_DT
successful_JJ
case_NN
in_PIN
the_DT
US_FPP1
Court_NN
of_PIN
Appeal_NN
._.
SB_NN
Clinical_NN
Iter_NN
-_:
Human_JJ
Laboratories_NN
Sterilyo_NN
Kft_NN
Other_JJ
Total_NN
Cash_NN
ows_VPRT
m_FW
m_FW
m_FW
m_FW
m_FW
Cash_NN
consideration_NOMZ
paid_VBD
911_CD
6_CD
26_CD
Cash_NN
acquired_VBD
Net_JJ
cash_NN
payment_NOMZ
on_PIN
acquisitions_NOMZ
911_CD
6_CD
26_CD
Net_JJ
cash_NN
proceeds_NN
from_PIN
disposals_NN
6_CD
6_CD
2001_CD
Book_NN
Fair_NN
value_NN
Net_JJ
assets_NN
Goodwill_NN
Cost_NN
of_PIN
values_NN
adjustments_NOMZ
acquired_VBD
capitalized_JJ
acquisition_NOMZ
Acquisitions_NOMZ
m_VPRT
m_FW
m_FW
m_FW
m_FW
Block_NN
Drug_NN
491 352 843 843_CD
Shionogi_NN
joint_JJ
venture_NN
31_CD
31_CD
31_CD
Other_JJ
13_CD
8_CD
5_CD
13 18 535 344_CD
879_CD
13_CD
892_CD
Block_NN
Drug_NN
Company_NN
Inc._NN
._.
In_PIN
January_NN
2001_CD
,_,
the_DT
Group_NN
acquired_VBD
Block_NN
Drug_NN
for_PIN
cash_NN
consideration_NOMZ
of_PIN
843_CD
million_CD
which_WDT
represented_VBD
the_DT
fair_JJ
value_NN
of_PIN
the_DT
assets_NN
acquired_VBN
._.
Shionogi_NN
joint_JJ
venture_NN
During_PIN
2001_CD
the_DT
Group_NN
established_VBD [PRIV]
a_DT
joint_JJ
venture_NN
with_PIN
Shionogi_NN
to_TO
develop_VB
and_PHC
commercialise_VB
a_DT
number_NN
of_PIN
compounds_NN
contributed_VBN [WZPAST]
by_PIN
both_DT
parties_NN
._.
The_DT
Group_NN
acquired_VBD
50_CD
per_PIN
cent_NN
of_PIN
the_DT
equity_NOMZ
share_NN
capital_NN
for_PIN
a_DT
cash_NN
consideration_NOMZ
of_PIN
31_CD
million_CD
,_,
and_ANDC
has_VPRT [PEAS]
committed_VBN
to_TO
make_VB
further_JJ
contributions_NOMZ
if_COND
certain_JJ
development_NOMZ
milestones_NN
are_VPRT [PASS]
achieved_VBN
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
109_CD
31_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
continued_VBD
Disposals_NN
Quest_NN
Diagnostics_NN
,_,
Inc._NN
._.
In_PIN
May_POMD
2001_CD
the_DT
Group_NN
disposed_VBD
of_PIN
1.5_CD
million_CD
shares_NN
from_PIN
its_PIT
investment_NOMZ
in_PIN
Quest_NN
Diagnostics_NN
,_,
Inc._NN
for_PIN
cash_NN
proceeds_NN
of_PIN
124_CD
million_CD
,_,
reducing_VBG [PRESP]
the_DT
Groups_NN
holding_VBG [PRIV] [WZPRES]
at_PIN
31st_CD
December_NN
2001_CD
to_PIN
23_CD
per_PIN
cent_NN
._.
After_IN
recognizing_VBG [PRIV]
a_DT
charge_NN
for_PIN
goodwill_NN
previously_TIME
written_VBN [PUBV]
off_PIN
to_PIN
reserves_NN
of_PIN
17_CD
million_CD
a_DT
profit_NN
of_PIN
96_CD
million_CD
was_VBD [PASS]
recognized_VBN [PRIV]
._.
Affymax_NN
During_PIN
2001_CD
the_DT
Group_NN
completed_VBD
the_DT
sale_NN
of_PIN
the_DT
Affymax_NN
business_NOMZ
to_PIN
Affymax_NN
Inc._NN
a_DT
new_JJ
holding_VBG [PRIV]
company_NN
,_,
for_PIN
2.3_CD
million_CD
non-voting_JJ
preference_NN
shares_NN
in_PIN
Affymax_NN
Inc._NN
representing_VBG [WZPRES]
a_DT
value_NN
of_PIN
$_$
19.6_CD
million_CD
13.6_CD
million_CD
._.
After_IN
recognizing_VBG [PRIV]
a_DT
charge_NN
for_PIN
goodwill_NN
previously_TIME
written_VBN [PUBV]
off_PIN
to_PIN
reserves_NN
of_PIN
299_CD
million_CD
a_DT
loss_NN
of_PIN
301_CD
million_CD
was_VBD [PASS]
made_VBN
._.
Disposal_NN
costs_NN
of_PIN
5_CD
million_CD
were_VBD [PASS]
incurred_VBN
in_PIN
completing_VBG
the_DT
sale_NN
._.
Tagamet_NN
In_PIN
February_NN
2001_CD
the_DT
Group_NN
sold_VBD
Tagamet_NN
in_PIN
Japan_NN
to_PIN
Sumitomo_NN
Pharmaceutical_NN
Co._NN
._.
Ltd._NN
for_PIN
a_DT
cash_NN
consideration_NOMZ
of_PIN
71_CD
million_CD
._.
After_IN
recognizing_VBG [PRIV]
a_DT
charge_NN
for_PIN
goodwill_NN
previously_TIME
written_VBN [PUBV]
off_PIN
to_PIN
reserves_NN
of_PIN
72_CD
million_CD
a_DT
loss_NN
of_PIN
1_CD
million_CD
was_VBD [PASS]
recognized_VBN [PRIV]
._.
Quest_NN
Diagnostics_NN
Affymax_NN
Tagamet_NN
Block_NN
Drug_NN
Shionogi_NN
Other_JJ
Total_NN
Cash_NN
ows_VPRT
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
Cash_NN
consideration_NOMZ
paid_VBD
843_CD
31_CD
18_CD
892_CD
Cash_NN
acquired_VBN
45_CD
45_CD
Net_JJ
cash_NN
payment_NOMZ
on_PIN
acquisitions_NOMZ
798_CD
31_CD
18_CD
847_CD
Net_JJ
cash_NN
proceeds_NN
from_PIN
disposals_NN
124_CD
5_CD
71 190 2000_CD
Book_NN
Fair_NN
value_NN
Net_JJ
assets_NN
Goodwill_NN
Cost_NN
of_PIN
values_NN
adjustments_NOMZ
acquired_VBD
capitalized_JJ
acquisition_NOMZ
Acquisitions_NOMZ
m_VPRT
m_FW
m_FW
m_FW
m_FW
GlaxoSmithKline_NN
Pharmaceuticals_NN
SA_NN
7_CD
71623_CD
Acquisition_NOMZ
of_PIN
other_JJ
minority_NOMZ
interests_NN
2_CD
2_CD
2_CD
9_CD
91625_CD
GlaxoSmithKline_NN
Pharmaceuticals_NN
SA_NN
During_PIN
2000_CD
the_DT
Group_NN
acquired_VBD
a_DT
further_JJ
8.7_CD
per_PIN
cent_NN
of_PIN
GlaxoSmithKline_NN
Pharmaceuticals_NN
SA_NN
formerly_TIME
Polfa_NN
Poznan_NN
SA_NN
in_PIN
Poland_NN
for_PIN
a_DT
cash_NN
consideration_NOMZ
of_PIN
23_CD
million_CD
._.
Goodwill_NN
of_PIN
16_CD
million_CD
was_VBD [PASS]
capitalized_VBN
and_PHC
is_VPRT
being_VBG [PASS]
amortised_VBN
in_PIN
line_NN
with_PIN
the_DT
initial_JJ
acquisition_NOMZ
in_PIN
1998_CD
._.
In_PIN
May_POMD
2000_CD
the_DT
Group_NN
sold_VBD
two_CD
million_CD
shares_NN
in_PIN
Affymetrix_NN
,_,
Inc._NN
for_PIN
cash_NN
proceeds_NN
of_PIN
155_CD
million_CD
,_,
realizing_VBG [PRIV] [PRESP]
a_DT
profit_NN
of_PIN
144_CD
million_CD
._.
SB_NN
Clinical_NN
Laboratories_NN
A_DT
final_JJ
cash_NN
settlement_NOMZ
of_PIN
US$_$
95_CD
million_CD
62_CD
million_CD
was_VBD [PASS]
paid_VBN
in_PIN
October_NN
2000_CD
to_TO
complete_VB
the_DT
sale_NN
of_PIN
SB_NN
Clinical_NN
Laboratories_NN
._.
SB_NN
Clinical_NN
GlaxoSmithKline_NN
Laboratories_NN
Affymetrix_NN
Pharmaceuticals_NN
SA_NN
Other_JJ
Total_NN
Cash_NN
ows_VPRT
m_FW
m_FW
m_FW
m_FW
m_FW
Cash_NN
consideration_NOMZ
paid_VBD
23_CD
2_CD
25_CD
Cash_NN
acquired_VBD
Net_JJ
cash_NN
payment_NOMZ
on_PIN
acquisitions_NOMZ
23_CD
2_CD
25_CD
Net_JJ
cash_NN
proceeds_NN
from_PIN
disposals_NN
62_CD
155_CD
93_CD
110_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
32_CD
Financial_NN
instruments_NOMZ
and_CC
related_VBN
disclosures_NN
Fair_NN
value_NN
of_PIN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
The_DT
table_NN
on_PIN
page_NN
111_CD
presents_VPRT
the_DT
carrying_VBG
amounts_NN
under_IN
UK_NN
Policies_NN
GAAP_NN
and_CC
the_DT
fair_JJ
values_NN
of_PIN
the_DT
Groups_NN
financial_JJ
assets_NN
and_PHC
Discussion_NN
of_PIN
the_DT
Groups_NN
objectives_NN
and_PHC
policies_NN
for_PIN
the_DT
liabilities_NOMZ
at_PIN
31st_CD
December_NN
2002_CD
and_CC
31st_CD
December_NN
2001_CD
._.
management_NOMZ
of_PIN
financial_JJ
instruments_NOMZ
and_CC
associated_VBN
risks_NN
is_VPRT
Debtors_NN
and_PHC
creditors_NN
due_JJ
within_PIN
one_CD
year_NN
have_VPRT [PEAS]
been_VBN [PASS]
excluded_VBN
._.
included_VBN
under_IN
Treasury_NN
Policies_NN
in_PIN
the_DT
Operating_GER
and_CC
financial_JJ
review_NN
and_PHC
prospects_NN
on_PIN
page_NN
62_CD
._.
The_DT
fair_JJ
values_NN
of_PIN
the_DT
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
are_VPRT [PASS]
included_VBN
at_PIN
the_DT
amount_NN
at_PIN
which_WDT [PIRE]
the_DT
instrument_NOMZ
could_POMD
be_VB [PASS]
exchanged_VBN
in_PIN
a_DT
Investments_NOMZ
current_JJ
transaction_NOMZ
between_PIN
willing_JJ
parties_NN
,_,
other_JJ
than_PIN
in_PIN
a_DT
forced_VBN
The_DT
Group_NN
holds_VPRT [PRIV]
a_DT
number_NN
of_PIN
equity_NOMZ
investments_NOMZ
,_,
frequently_RB
in_PIN
or_CC
liquidation_NOMZ
sale_NN
._.
The_DT
following_VBG
methods_NN
and_PHC
assumptions_NOMZ
were_VBD
entities_NOMZ
where_RB
the_DT
Group_NN
has_VPRT [PEAS]
entered_VBN
into_PIN
research_NN
collaborations_NOMZ
._.
used_VBN
to_TO
estimate_VB [PRIV]
the_DT
fair_JJ
values_NN
:_:
The_DT
Group_NN
seeks_VPRT
to_TO
realize_VB [PRIV]
the_DT
value_NN
in_PIN
these_DEMO
investments_NOMZ
,_,
which_WDT [SERE]
Equity_NOMZ
investments_NOMZ
market_NN
value_NN
based_VBN [WZPAST]
on_PIN
quoted_VBN
market_NN
in_PIN
part_NN
the_DT
research_NN
collaboration_NOMZ
helps_VPRT
to_TO
create_VB
,_,
and_ANDC
therefore_CONJ
prices_NN
in_PIN
the_DT
case_NN
of_PIN
listed_VBN
investments_NOMZ
:_:
market_NN
value_NN
by_PIN
certain_JJ
of_PIN
these_DEMO
investments_NOMZ
are_VPRT [PASS]
regarded_VBN
as_IN
available_JJ
for_PIN
sale_NN
and_PHC
reference_NN
to_TO
quoted_VBN
prices_NN
for_PIN
similar_JJ
companies_NN
or_CC
recent_JJ
are_VPRT [PASS]
accounted_VBN
for_PIN
as_IN
current_JJ
asset_NN
investments_NOMZ
._.
For_PIN
the_DT
purposes_NN
nancing_VBG [WZPRES]
information_NOMZ
in_PIN
the_DT
case_NN
of_PIN
material_NN
unlisted_JJ
of_PIN
US_FPP1
GAAP_NN
all_QUAN
the_DT
current_JJ
asset_NN
investments_NOMZ
are_VPRT [PASS]
classied_VBN
as_IN
investments_NOMZ
available_JJ
for_PIN
sale_NN
._.
Cash_NN
at_PIN
bank_NN
approximates_VPRT
to_PIN
the_DT
carrying_VBG
amount_NN
In_PIN
2002_CD
,_,
GlaxoSmithKline_NN
hedged_VBD
part_NN
of_PIN
the_DT
equity_NOMZ
value_NN
of_PIN
its_PIT
Liquid_NN
investments_NOMZ
based_VBN [WZPAST]
on_PIN
quoted_VBN
market_NN
prices_NN
for_PIN
similar_JJ
holdings_GER
in_PIN
its_PIT
largest_JJ
equity_NOMZ
investment_NOMZ
,_,
Quest_NN
Diagnostics_NN
,_,
Inc._NN
companies_NN
or_CC
recent_JJ
nancing_GER
information_NOMZ
in_PIN
the_DT
case_NN
of_PIN
through_PIN
a_DT
series_NN
of_PIN
variable_JJ
sale_NN
forward_RB
contracts_NN
._.
These_DEMO
contracts_NN
marketable_JJ
securities_NOMZ
:_:
approximates_VPRT
to_PIN
the_DT
carrying_VBG
amount_NN
the_DT
equity_NOMZ
collar_NN
are_VPRT [PASS]
structured_VBN
in_PIN
five_CD
series_NN
,_,
each_QUAN
over_IN
one_CD
in_PIN
the_DT
case_NN
of_PIN
time_NN
deposits_NN
because_CAUS
of_PIN
their_TPP3
short_JJ
maturity_NOMZ
million_CD
Quest_NN
shares_NN
and_CC
mature_VB
between_PIN
2006_CD
and_CC
2008_CD
._.
Short-term_JJ
loans_NN
and_PHC
overdrafts_NN
approximates_VPRT
to_PIN
the_DT
carrying_VBG
amount_NN
because_CAUS
of_PIN
the_DT
short_JJ
maturity_NOMZ
of_PIN
these_DEMO
instruments_NOMZ
The_DT
Group_NN
has_VPRT
liquid_JJ
investments_NOMZ
,_,
representing_VBG
funds_NN
surplus_NN
to_PIN
Medium-term_JJ
loans_NN
market_NN
value_NN
based_VBN [WZPAST]
on_PIN
quoted_VBN
market_NN
immediate_JJ
operating_GER
requirements_NOMZ
,_,
which_WDT [SERE]
are_VPRT [PASS]
accounted_VBN
for_PIN
as_IN
prices_NN
in_PIN
the_DT
case_NN
of_PIN
the_DT
Eurobonds_NN
and_CC
other_JJ
xed_JJ
rate_NN
current_JJ
asset_NN
investments_NOMZ
._.
For_PIN
the_DT
purposes_NN
of_PIN
US_FPP1
GAAP_NN
the_DT
borrowings_GER
:_:
approximates_VPRT
to_PIN
the_DT
carrying_VBG
amount_NN
in_PIN
the_DT
case_NN
investments_NOMZ
are_VPRT [PASS]
classied_VBN
as_IN
available_JJ
for_PIN
sale_NN
._.
The_DT
proceeds_NN
from_PIN
of_PIN
oating_NN
rate_NN
bank_NN
loans_NN
and_CC
other_JJ
loans_NN
sale_NN
of_PIN
investments_NOMZ
classied_VBD
as_IN
available_JJ
for_PIN
sale_NN
under_IN
US_FPP1
GAAP_NN
Forward_RB
exchange_NN
contracts_NN
based_VBN [WZPAST]
on_PIN
market_NN
prices_NN
and_CC
in_PIN
the_DT
year_NN
ended_VBD
31st_CD
December_NN
2002_CD
were_VBD [BEMA]
162_CD
million_CD
._.
The_DT
exchange_NN
rates_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
proceeds_NN
include_VPRT
the_DT
roll-over_NN
of_PIN
liquid_JJ
funds_NN
on_PIN
short-term_JJ
deposit_NN
._.
Currency_NN
swaps_NN
based_VBN [WZPAST]
on_PIN
market_NN
valuations_NOMZ
at_PIN
the_DT
balance_NN
The_DT
gross_JJ
gains_NN
and_PHC
losses_NN
reected_VBD
in_PIN
the_DT
consolidated_JJ
profit_NN
and_PHC
sheet_NN
date_NN
loss_NN
account_NN
in_PIN
respect_NN
of_PIN
investments_NOMZ
classied_VBD
as_IN
available_JJ
for_PIN
sale_NN
Equity_NOMZ
collar_NN
-_:
fair_JJ
value_NN
is_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
based_VBN
on_PIN
an_DT
option_NOMZ
under_IN
US_FPP1
GAAP_NN
were_VBD [BEMA]
44_CD
million_CD
and_CC
1_CD
million_CD
,_,
respectively_RB
._.
pricing_GER
model_NN
Interest_NN
rate_NN
instruments_NOMZ
based_VBN [WZPAST]
on_PIN
market_NN
valuations_NOMZ
at_PIN
the_DT
Foreign_JJ
exchange_NN
risk_NN
management_NOMZ
balance_NN
sheet_NN
date_NN
The_DT
Group_NN
has_VPRT [PEAS]
entered_VBN
into_PIN
forward_RB
foreign_JJ
exchange_NN
contracts_NN
Debtors_NN
and_PHC
creditors_NN
approximates_VPRT
to_PIN
the_DT
carrying_VBG
amount_NN
in_PIN
order_NN
to_TO
swap_VB
liquid_JJ
assets_NN
and_PHC
borrowings_GER
into_PIN
the_DT
currencies_NN
Provisions_NN
approximates_VPRT
to_PIN
the_DT
carrying_VBG
amount_NN
required_VBN [SUAV] [WZPAST]
for_PIN
Group_NN
purposes_NN
._.
At_PIN
31st_CD
December_NN
2002_CD
the_DT
Group_NN
Auction_NOMZ
rate_NN
preference_NN
stock_NN
-_:
approximates_VPRT
to_PIN
the_DT
carrying_GER
had_VBD
outstanding_JJ
contracts_NN
to_TO
sell_VB
or_CC
purchase_VB
foreign_JJ
currency_NN
amount_NN
in_PIN
the_DT
case_NN
of_PIN
oating_NN
rate_NN
instruments_NOMZ
having_VBG [WZPRES]
a_DT
total_JJ
notional_JJ
principal_NN
amount_NN
of_PIN
1,937_CD
million_CD
Flexible_JJ
auction_NOMZ
market_NN
preferred_VBN [SUAV]
stock_NN
-_:
based_VBN [PASTP]
on_PIN
market_NN
2001_CD
7,312_CD
million_CD
._.
The_DT
majority_NOMZ
of_PIN
contracts_NN
are_VPRT [BEMA]
for_PIN
periods_NN
valuations_NOMZ
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
At_PIN
the_DT
end_NN
of_PIN
the_DT
year_NN
the_DT
Group_NN
had_VBD
a_DT
number_NN
of_PIN
currency_NN
swaps_NN
Fair_NN
value_NN
of_PIN
investments_NOMZ
in_PIN
own_JJ
shares_NN
in_PIN
place_NN
in_PIN
respect_NN
of_PIN
medium-term_JJ
debt_NN
instruments_NOMZ
._.
The_DT
Group_NN
had_VBD
at_PIN
31st_CD
December_NN
2002_CD
investments_NOMZ
in_PIN
own_JJ
shares_NN
of_PIN
2,826_CD
million_CD
2001_CD
2,936_CD
million_CD
with_PIN
a_DT
fair_JJ
value_NN
of_PIN
Borrowings_GER
denominated_VBN [WZPAST]
in_PIN [STPR]
,_,
or_CC
swapped_VBD
into_PIN [STPR]
,_,
foreign_JJ
currencies_NN
2,161_CD
million_CD
2001_CD
3,229_CD
million_CD
._.
The_DT
difference_NN
between_PIN
which_WDT [PIRE]
match_NN
investments_NOMZ
in_PIN
overseas_PLACE
Group_NN
assets_NN
are_VPRT [PASS]
treated_VBN
as_IN
the_DT
carrying_VBG
amount_NN
and_CC
the_DT
fair_JJ
value_NN
represents_VPRT
an_DT
unrealised_JJ
a_DT
hedge_NN
against_PIN
the_DT
relevant_JJ
net_JJ
assets_NN
and_PHC
exchange_NN
gains_NN
or_CC
loss_NN
of_PIN
665_CD
million_CD
._.
This_DEMO
valuation_NOMZ
shortfall_NN
is_VPRT [PASS]
not_XX0
considered_VBN [PRIV]
to_PIN
losses_NN
are_VPRT [PASS]
recorded_VBN
in_PIN
reserves_NN
._.
represent_VB
a_DT
permanent_JJ
diminution_NOMZ
in_PIN
value_NN
in_PIN
the_DT
context_NN
of_PIN
the_DT
length_NN
of_PIN
the_DT
future_JJ
period_NN
over_IN
which_WDT
the_DT
related_JJ
share_NN
options_NOMZ
Interest_NN
rate_NN
risk_NN
management_NOMZ
may_POMD
be_VB [PASS]
exercised_VBN
._.
These_DEMO
To_TO
manage_VB
the_DT
xed_VBN
oating_NN
interest_NN
rate_NN
prole_NN
of_PIN
debt_NN
,_,
the_DT
Group_NN
investments_NOMZ
are_VPRT [PASS]
excluded_VBN
from_PIN
financial_JJ
instrument_NOMZ
disclosure_NN
._.
The_DT
had_VBD
several_QUAN
interest_NN
rate_NN
swaps_NN
outstanding_JJ
with_PIN
commercial_JJ
banks_NN
fair_JJ
value_NN
is_VPRT [BEMA]
the_DT
market_NN
value_NN
based_VBN [WZPAST]
on_PIN
quoted_VBN
market_NN
price_NN
._.
The_DT
shares_NN
represent_VPRT
purchases_NN
by_PIN
Employee_NN
Share_NN
Ownership_NN
Concentrations_NOMZ
of_PIN
credit_NN
risk_NN
and_PHC
credit_NN
exposures_NN
of_PIN
Trusts_NN
to_TO
satisfy_VB
future_JJ
exercises_NN
of_PIN
options_NOMZ
and_PHC
awards_NN
under_IN
financial_JJ
instruments_NOMZ
employee_NN
incentive_NN
schemes_NN
._.
The_DT
purchases_NN
are_VPRT [PASS]
matched_VBN
against_PIN
The_DT
Group_NN
does_VPRT
not_XX0
believe_VB [PRIV] [THATD]
it_PIT
is_VPRT [PASS]
exposed_VBN
to_PIN
major_JJ
concentrations_NOMZ
options_NOMZ
at_PIN
pre-determined_JJ
exercise_NN
prices_NN
and_CC
the_DT
gain_NN
or_CC
loss_NN
to_PIN
of_PIN
credit_NN
risk_NN
._.
The_DT
Group_NN
is_VPRT [PASS]
exposed_VBN
to_PIN
credit-related_JJ
losses_NN
in_PIN
the_DT
be_VB [PASS]
recognized_VBN [PRIV]
is_VPRT [PASS]
measured_VBN
against_PIN
exercise_NN
price_NN
rather_RB
than_PIN
event_NN
of_PIN
non-performance_JJ
by_PIN
counterparties_NN
to_PIN
financial_JJ
market_NN
value_NN
._.
instruments_NOMZ
,_,
but_CC
does_VPRT
not_XX0
expect_VB [PRIV]
any_QUAN
counterparties_NN
to_TO
fail_VB
to_TO
meet_VB
their_TPP3
obligations_NOMZ
._.
The_DT
Group_NN
applies_VPRT
Board-approved_JJ
limits_NN
to_PIN
the_DT
amount_NN
of_PIN
credit_NN
exposure_NN
to_PIN
any_QUAN
one_CD
counterparty_NN
and_CC
employs_VPRT
strict_JJ
minimum_NN
credit_NN
worthiness_NOMZ
criteria_NN
as_IN
to_PIN
the_DT
choice_NN
of_PIN
counterparty_NN
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
111_CD
32_CD
Financial_NN
instruments_NOMZ
and_CC
related_VBN
disclosures_NN
continued_VBD
Classication_NOMZ
and_CC
fair_JJ
values_NN
of_PIN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
The_DT
following_JJ
table_NN
sets_VPRT
out_PIN
the_DT
classication_NOMZ
of_PIN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
and_CC
provides_VPRT
a_DT
reconciliation_NOMZ
to_PIN
Group_NN
net_JJ
debt_NN
in_PIN
Note_NN
25_CD
._.
Short-term_JJ
debtors_NN
and_PHC
creditors_NN
have_VPRT [PEAS]
been_VBN [PASS]
excluded_VBN
from_PIN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
._.
Provisions_NN
have_VPRT [PEAS]
been_VBN [PASS]
included_VBN
where_RB
there_EX
is_VPRT
a_DT
contractual_JJ
obligation_NOMZ
to_TO
settle_VB
in_PIN
cash_NN
._.
2002_CD
2001_CD
Carrying_VBG
Fair_NN
Carrying_VBG [WZPRES]
Fair_NN
amount_NN
value_NN
amount_NN
value_NN
m_NN
m_FW
m_FW
m_FW [BEMA]
Net_JJ
debt_NN
Liquid_NN
investments_NOMZ
1,256_CD
1,264_CD
1,415_CD
1,418_CD
Cash_NN
at_PIN
bank_NN
1,052_CD
1,052_CD
716_CD
716_CD
Current_JJ
asset_NN
financial_JJ
instruments_NOMZ
2,308_CD
2,316_CD
2,131_CD
2,134_CD
Sterling_GER
notes_NN
and_PHC
bonds_NN
1,472_CD
1,559_CD
1,471_CD
1,534_CD
1,472_CD
1,559_CD
1,471_CD
1,534_CD
US_FPP1
dollar_NN
notes_NN
,_,
bonds_NN
and_CC
private_JJ
nancing_GER
978_CD
1,018_CD
729_CD
752_CD
Notes_NN
and_PHC
bonds_NN
swapped_VBD
into_PIN
US_FPP1
dollars_NN
498_CD
507_CD
61_CD
53_CD
Currency_NN
swaps_NN
21_CD
8_CD
Interest_NN
rate_NN
swaps_NN
7_CD
1,476_CD
1,497_CD
790_CD
813_CD
Notes_NN
and_PHC
bonds_NN
swapped_VBD
into_PIN
Yen_NN
106 114 340 346_CD
Currency_NN
swaps_NN
6_CD
18 106 108 340_CD
328_CD
Other_JJ
medium-term_JJ
borrowings_GER
38_CD
38_CD
49_CD
49_CD
Other_JJ
short-term_JJ
loans_NN
and_PHC
overdrafts_NN
1,551_CD
1,551_CD
1,582_CD
1,582_CD
Total_JJ
borrowings_GER
4,643_CD
4,753_CD
4,232_CD
4,306_CD
Interest_NN
rate_NN
swaps_NN
1_CD
10_CD
Total_JJ
net_JJ
debt_NN
2,335_CD
2,438_CD
2,101_CD
2,162_CD
Fixed_VBN
asset_NN
equity_NOMZ
investments_NOMZ
125 129 133 133_CD
Current_JJ
asset_NN
equity_NOMZ
investments_NOMZ
161 232 185 531_CD
Other_JJ
debtors_NN
due_JJ
after_IN
1_CD
year_NN
308 308 329 329_CD
Other_JJ
creditors_NN
due_JJ
after_IN
1_CD
year_NN
206 206 110 110_CD
Provisions_NN
224 224 105 105_CD
Other_JJ
foreign_JJ
exchange_NN
derivatives_NN
133_CD
133_CD
6_CD
1_CD
Equity_NOMZ
collar_NN
78_CD
Auction_NOMZ
rate_NN
preference_NN
stock_NN
248 248 276 276_CD
Flexible_NN
auction_NOMZ
market_NN
preferred_VBN [SUAV]
stock_NN
311 316 345 355_CD
Total_JJ
non-equity_JJ
minority_NOMZ
interests_NN
559 564 621 631_CD
Total_JJ
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
2,597_CD
2,552_CD
2,296_CD
2,014_CD
Total_JJ
financial_JJ
assets_NN
3,035_CD
3,196_CD
2,778_CD
3,138_CD
Total_JJ
financial_JJ
liabilities_NOMZ
5,632_CD
5,748_CD
5,074_CD
5,152_CD
Where_RB
appropriate_JJ
currency_NN
and_PHC
interest_NN
rate_NN
swaps_NN
have_VPRT [PEAS]
been_VBN [PASS]
presented_VBN
alongside_PLACE
the_DT
underlying_VBG
principal_NN
instrument_NOMZ
._.
The_DT
carrying_VBG
amounts_NN
of_PIN
these_DEMO
instruments_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
adjusted_VBN
for_PIN
the_DT
effect_NN
of_PIN
the_DT
currency_NN
and_PHC
interest_NN
rate_NN
swaps_NN
acting_VBG [WZPRES]
as_IN
hedges_NN
._.
The_DT
difference_NN
between_PIN
the_DT
carrying_VBG
amount_NN
and_CC
the_DT
fair_JJ
value_NN
of_PIN
equity_NOMZ
xed_VBD
and_CC
current_JJ
assets_NN
and_CC
liquid_JJ
investments_NOMZ
represents_VPRT
gross_JJ
unrealised_JJ
gains_NN
of_PIN
75_CD
million_CD
and_CC
8_CD
million_CD
,_,
respectively_RB
._.
112_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
32_CD
Financial_NN
instruments_NOMZ
and_CC
related_VBN
disclosures_NN
continued_VBD
Currency_NN
and_PHC
interest_NN
rate_NN
risk_NN
prole_NN
of_PIN
financial_JJ
liabilities_NOMZ
Financial_JJ
liabilities_NOMZ
,_,
after_IN
taking_VBG
account_NN
of_PIN
currency_NN
and_PHC
interest_NN
rate_NN
swaps_NN
,_,
are_VPRT [PASS]
analyzed_VBN
below_PLACE
._.
Total_JJ
financial_JJ
liabilities_NOMZ
comprise_VPRT
total_JJ
borrowings_GER
of_PIN
4,643_CD
million_CD
2001_CD
4,232_CD
million_CD
,_,
other_JJ
creditors_NN
due_RB
after_IN
one_CD
year_NN
of_PIN
206_CD
million_CD
2001_CD
110_CD
million_CD
,_,
provisions_NN
of_PIN
224_CD
million_CD
2001_CD
105_CD
million_CD
and_CC
non-equity_JJ
minority_NOMZ
interest_NN
preference_NN
shares_NN
of_PIN
559_CD
million_CD
2001_CD
621_CD
million_CD
but_CC
exclude_VB
foreign_JJ
exchange_NN
derivatives_NN
of_PIN
nil_NN
2001_CD
6_CD
million_CD
._.
Creditors_NN
due_JJ
within_PIN
one_CD
year_NN
have_VPRT [PEAS]
been_VBN [PASS]
excluded_VBN
._.
The_DT
benchmark_JJ
rate_NN
for_PIN
determining_VBG [SUAV] [PRIV]
interest_NN
payments_NOMZ
for_PIN
all_QUAN
oating_NN
rate_NN
financial_JJ
liabilities_NOMZ
in_PIN
the_DT
tables_NN
below_PLACE
is_VPRT
LIBOR_NN
._.
Fixed_JJ
rate_NN
Non-interest_JJ
bearing_GER
Weighted_NN
Weighted_NN
average_JJ
average_JJ
Weighted_JJ
interest_NN
years_NN
for_PIN
Floating_VBG
average_JJ
At_PIN
31st_CD
December_NN
2002_CD
rate_NN
which_WDT [WHOBJ]
rate_NN
rate_NN
years_NN
to_PIN
Total_JJ
Currency_NN
m_CD
%_NN
is_VPRT [PASS]
xed_VBN
m_FW
m_FW
maturity_NOMZ
m_NN
US_FPP1
dollars_NN
471_CD
2.6_CD
0.7_CD
2,974_CD
325_CD
7.8_CD
3,770_CD
Sterling_GER
1,472_CD
6.4_CD
21.5_CD
4_CD
64_CD
1.6_CD
1,540_CD
Euro_NN
64_CD
13_CD
1.3_CD
77_CD
Japanese_JJ
Yen_NN
144_CD
0.7_CD
1.2_CD
144_CD
Other_JJ
currencies_NN
73_CD
28_CD
3.6_CD
101_CD
2,087_CD
4.2_CD
9.8_CD
3,115_CD
430_CD
6.4_CD
5,632_CD
Fixed_VBN
rate_NN
Non-interest_JJ
bearing_GER
Weighted_NN
Weighted_NN
average_JJ
average_JJ
Weighted_JJ
interest_NN
years_NN
for_PIN
Floating_VBG
average_JJ
At_PIN
31st_CD
December_NN
2001_CD
rate_NN
which_WDT [WHOBJ]
rate_NN
rate_NN
years_NN
to_PIN
Total_JJ
Currency_NN
m_CD
%_NN
is_VPRT [PASS]
xed_VBN
m_FW
m_FW
maturity_NOMZ
m_NN
US_FPP1
dollars_NN
516_CD
6.1_CD
3.2_CD
2,291_CD
131_CD
1.2_CD
2,938_CD
Sterling_GER
1,471_CD
6.5_CD
22.5_CD
45_CD
25_CD
1.3_CD
1,541_CD
Euro_NN
4_CD
7.9_CD
1.0_CD
45_CD
19_CD
0.4_CD
68_CD
Japanese_JJ
Yen_NN
340_CD
0.5_CD
1.4_CD
3_CD
1_CD
15.0_CD
344_CD
Other_JJ
currencies_NN
134_CD
43_CD
0.2_CD
177_CD
2,331_CD
5.5_CD
15.1_CD
2,518_CD
219_CD
1.0_CD
5,068_CD
Currency_NN
and_PHC
interest_NN
rate_NN
risk_NN
prole_NN
of_PIN
financial_JJ
assets_NN
Total_JJ
financial_JJ
assets_NN
comprise_VPRT
xed_JJ
asset_NN
equity_NOMZ
investments_NOMZ
of_PIN
125_CD
million_CD
2001_CD
133_CD
million_CD
,_,
current_JJ
asset_NN
equity_NOMZ
investments_NOMZ
of_PIN
161_CD
million_CD
2001_CD
185_CD
million_CD
,_,
liquid_JJ
investments_NOMZ
of_PIN
1,256_CD
million_CD
2001_CD
1,415_CD
million_CD
,_,
cash_NN
at_PIN
bank_NN
of_PIN
1,052_CD
million_CD
2001_CD
716_CD
million_CD
,_,
and_ANDC
debtors_NN
due_RB
after_IN
one_CD
year_NN
of_PIN
308_CD
million_CD
2001_CD
329_CD
million_CD
but_CC
exclude_VB
foreign_JJ
exchange_NN
derivatives_NN
of_PIN
133_CD
million_CD
2001_CD
nil_NN
._.
The_DT
benchmark_JJ
rate_NN
for_PIN
determining_VBG [SUAV] [PRIV]
interest_NN
receipts_NN
for_PIN
all_QUAN
oating_NN
rate_NN
assets_NN
in_PIN
the_DT
table_NN
below_PLACE
is_VPRT
LIBOR_NN
._.
Fixed_VBN
Floating_VBG
Non-interest_JJ
At_PIN
31st_CD
December_NN
2002_CD
rate_NN
rate_NN
bearing_VBG [WZPRES]
Total_JJ
Currency_NN
m_NN
m_FW
m_FW
m_FW [BEMA]
US_FPP1
dollars_NN
365_CD
1,275_CD
290_CD
1,930_CD
Sterling_GER
20_CD
123_CD
28_CD
171_CD
Euro_NN
41_CD
299_CD
22_CD
362_CD
Japanese_JJ
Yen_NN
72_CD
24_CD
33_CD
Other_JJ
currencies_NN
23_CD
323 60 406 456_CD
2,022_CD
424_CD
2,902_CD
Fixed_NN
Floating_VBG [WZPRES]
Non-interest_JJ
At_PIN
31st_CD
December_NN
2001_CD
rate_NN
rate_NN
bearing_VBG [WZPRES]
Total_JJ
Currency_NN
m_NN
m_FW
m_FW
m_FW [BEMA]
US_FPP1
dollars_NN
404_CD
1,050_CD
406_CD
1,860_CD
Sterling_GER
18_CD
17_CD
66_CD
101_CD
Euro_NN
60_CD
168_CD
96_CD
324_CD
Japanese_JJ
Yen_NN
7141940_CD
Other_JJ
currencies_NN
173_CD
254 26 453 662_CD
1,503_CD
613_CD
2,778_CD
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
113_CD
32_CD
Financial_NN
instruments_NOMZ
and_CC
related_VBN
disclosures_NN
continued_VBD
Currency_NN
exposure_NN
of_PIN
net_JJ
monetary_JJ
assets_NN
liabilities_NOMZ
The_DT
Groups_NN
currency_NN
exposures_NN
that_TSUB
give_VPRT
rise_VB
to_PIN
net_JJ
currency_NN
gains_NN
and_PHC
losses_NN
that_TSUB
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
arise_VB
principally_RB
in_PIN
companies_NN
with_PIN
sterling_GER
functional_JJ
currency_NN
._.
Monetary_NN
assets_NN
and_PHC
liabilities_NOMZ
denominated_VBN [WZPAST]
in_PIN
overseas_PLACE
functional_JJ
currency_NN
,_,
and_ANDC
borrowings_GER
designated_VBN
as_IN
a_DT
hedge_NN
against_PIN
overseas_PLACE
net_JJ
assets_NN
,_,
are_VPRT [PASS]
excluded_VBN
from_PIN
the_DT
table_NN
below_PLACE
._.
At_PIN
31st_CD
December_NN
2002_CD
Functional_JJ
currency_NN
of_PIN
Group_NN
operation_NOMZ
Net_JJ
monetary_JJ
assets_NN
liabilities_NOMZ
Sterling_GER
US$_$
Euro_NN
Yen_NN
Other_JJ
Total_NN
held_VBD [PRIV]
in_PIN
non-functional_JJ
currency_NN
m_NN
m_FW
m_FW
m_FW
m_FW
m_FW
Sterling_GER
144_CD
14_CD
18_CD
48_CD
188_CD
US_FPP1
dollars_NN
708_CD
54_CD
1_CD
63_CD
718_CD
Euro_NN
184_CD
6_CD
11_CD
167_CD
Japanese_JJ
Yen_NN
10_CD
2_CD
12_CD
Other_JJ
354_CD
10_CD
1_CD
1_CD
364 868 160_CD
43_CD
16_CD
122_CD
1,091_CD
At_PIN
31st_CD
December_NN
2001_CD
Functional_JJ
currency_NN
of_PIN
Group_NN
operation_NOMZ
Net_JJ
monetary_JJ
assets_NN
liabilities_NOMZ
Sterling_GER
US$_$
Euro_NN
Yen_NN
Other_JJ
Total_NN
held_VBD [PRIV]
in_PIN
non-functional_JJ
currency_NN
m_NN
m_FW
m_FW
m_FW
m_FW
m_FW
Sterling_GER
80_CD
5_CD
1_CD
10_CD
86_CD
US_FPP1
dollars_NN
329_CD
85_CD
63_CD
477_CD
Euro_NN
147_CD
7_CD
1_CD
153_CD
Japanese_JJ
Yen_NN
13_CD
2_CD
11_CD
Other_JJ
88_CD
3_CD
1_CD
92_CD
577_CD
70_CD
89_CD
1_CD
52_CD
647_CD
Non-equity_JJ
Finance_NN
minority_NOMZ
Total_JJ
Total_JJ
Debt_NN
leases_NN
interests_NN
Other_JJ
2002_CD
2001_CD
Maturity_NOMZ
of_PIN
financial_JJ
liabilities_NOMZ
m_VPRT
m_FW
m_FW
m_FW
m_FW
m_FW [BEMA]
Within_PIN
one_CD
year_NN
or_CC
on_PIN
demand_NN
1,550_CD
1_CD
559_CD
90_CD
2,201_CD
2,602_CD
Between_PIN
one_CD
and_CC
two_CD
years_NN
421_CD
2_CD
91 514 268_CD
Between_PIN
two_CD
and_CC
five_CD
years_NN
873_CD
3_CD
121_CD
996_CD
1,183_CD
After_IN
five_CD
years_NN
1,786_CD
7_CD
128_CD
1,921_CD
1,015_CD
4,630_CD
13 559 430_CD
5,632_CD
5,068_CD
2002_CD
Gains_NN
Losses_NN
Net_JJ
Hedges_NN
m_FW
m_FW
m_FW [BEMA]
Unrecognised_JJ
gains_NN
and_PHC
losses_NN
at_PIN
the_DT
beginning_GER
of_PIN
the_DT
year_NN
56_CD
29_CD
27_CD
Gains_NN
and_PHC
losses_NN
arising_VBG [WZPRES]
in_PIN
previous_JJ
years_NN
and_CC
recognized_VBN [PRIV]
in_PIN
the_DT
year_NN
51_CD
25_CD
26_CD
Gains_NN
and_PHC
losses_NN
arising_VBG [WZPRES]
before_IN
the_DT
beginning_GER
of_PIN
the_DT
year_NN
and_CC
still_RB
unrecognised_JJ
at_PIN
the_DT
end_NN
of_PIN
the_DT
year_NN
5_CD
4_CD
1_CD
Unrecognised_JJ
gains_NN
and_PHC
losses_NN
arising_VBG [WZPRES]
in_PIN
the_DT
year_NN
107_CD
3_CD
110_CD
Total_JJ
unrecognised_JJ
gains_NN
and_PHC
losses_NN
at_PIN
the_DT
end_NN
of_PIN
the_DT
year_NN
112_CD
1_CD
111_CD
Expected_VBN [PRIV]
to_TO
be_VB [PASS]
recognized_VBN [PRIV]
within_PIN
one_CD
year_NN
Expected_VBN [PRIV]
to_TO
be_VB [PASS]
recognized_VBN [PRIV]
after_IN
one_CD
year_NN
112_CD
1_CD
111_CD
Total_JJ
unrecognised_JJ
gains_NN
and_PHC
losses_NN
at_PIN
the_DT
end_NN
of_PIN
the_DT
year_NN
112_CD
1_CD
111_CD
The_DT
unrecognised_JJ
gains_NN
and_PHC
losses_NN
above_PLACE
represent_VPRT
the_DT
difference_NN
between_PIN
the_DT
carrying_VBG
amount_NN
and_CC
the_DT
fair_JJ
value_NN
of_PIN
the_DT
currency_NN
swaps_NN
,_,
interest_NN
rate_NN
swaps_NN
,_,
equity_NOMZ
collar_NN
and_CC
other_JJ
foreign_JJ
exchange_NN
derivatives_NN
._.
Committed_VBN
facilities_NOMZ
The_DT
Group_NN
has_VPRT [PEAS]
committed_VBN
facilities_NOMZ
to_TO
back_VB
up_RP
the_DT
commercial_JJ
paper_NN
program_NN
of_PIN
872_CD
million_CD
2001_CD
968_CD
million_CD
of_PIN
364_CD
days_NN
duration_NOMZ
renewable_JJ
annually_RB
._.
At_PIN
31st_CD
December_NN
2002_CD
,_,
undrawn_JJ
committed_JJ
facilities_NOMZ
totalled_VBD
1,404_CD
million_CD
._.
114_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
33_CD
Employee_NN
costs_NN
2002 2001 2000_CD
m_FW
m_FW
m_FW
Wages_NN
and_PHC
salaries_NN
3,876_CD
3,664_CD
3,578_CD
Social_NN
security_NOMZ
costs_NN
385 344 383_CD
Pension_NN
and_CC
other_JJ
post-retirement_JJ
costs_NN
299 228 244_CD
Cost_NN
of_PIN
share-based_JJ
incentive_NN
plans_NN
135 147 197_CD
Severance_NN
costs_NN
arising_VBG [WZPRES]
from_PIN
integration_NOMZ
and_PHC
restructuring_GER
activities_NOMZ
228_CD
245_CD
82_CD
Pension_NN
and_CC
other_JJ
post-retirement_JJ
costs_NN
arising_VBG [WZPRES]
from_PIN
integration_NOMZ
17_CD
58_CD
3_CD
4,940_CD
4,686_CD
4,487_CD
The_DT
Group_NN
provides_VPRT
benets_NN
to_PIN
employees_NN
,_,
commensurate_JJ
with_PIN
local_JJ
practice_NN
in_PIN
individual_JJ
countries_NN
,_,
including_VBG
,_,
in_PIN
some_QUAN
markets_NN
,_,
healthcare_NN
insurance_NN
,_,
subsidised_VBN
car_NN
schemes_NN
and_CC
personal_JJ
life_NN
assurance_NN
._.
Information_NOMZ
on_PIN
Directors_NN
remuneration_NOMZ
is_VPRT [PASS]
given_VBN
in_PIN
the_DT
Remuneration_NOMZ
Report_NN
on_PIN
pages_NN
39_CD
to_PIN
50_CD
._.
2002 2001 2000_CD
The_DT
average_JJ
number_NN
of_PIN
persons_NN
employed_VBN [WZPAST]
by_PIN
the_DT
Group_NN
including_VBG [WZPRES]
Directors_NN
during_PIN
the_DT
year_NN
Number_NN
Number_NN
Number_NN
Manufacturing_GER
36,548_CD
37,154_CD
36,177_CD
Selling_GER
,_,
general_JJ
and_CC
administration_NOMZ
54,810_CD
55,655_CD
55,365_CD
Research_NN
and_PHC
development_NOMZ
14,808_CD
15,090_CD
16,659_CD
106,166_CD
107,899_CD
108,201_CD
The_DT
average_JJ
number_NN
of_PIN
Group_NN
employees_NN
excludes_VPRT
temporary_JJ
and_CC
contract_NN
staff_NN
._.
The_DT
numbers_NN
of_PIN
Group_NN
employees_NN
at_PIN
the_DT
end_NN
of_PIN
each_QUAN
financial_JJ
year_NN
are_VPRT [PASS]
given_VBN
in_PIN
the_DT
Financial_NN
record_NN
page_NN
150_CD
._.
2002 2001 2000_CD
Pension_NN
and_CC
other_JJ
post-retirement_JJ
costs_NN
m_VPRT
m_FW
m_FW
UK_NN
pension_NN
schemes_NN
60_CD
16_CD
16_CD
US_FPP1
pension_NN
schemes_NN
86_CD
70_CD
68_CD
Other_JJ
overseas_PLACE
pensions_NN
schemes_NN
52_CD
57_CD
105_CD
Unfunded_JJ
post-retirement_NOMZ
healthcare_NN
schemes_NN
61_CD
57_CD
48_CD
Post-employment_NOMZ
costs_NN
40_CD
28_CD
7_CD
299 228 244_CD
Analysed_NN
as_IN
:_:
Funded_VBN
dened_VBN
benefit_NN
hybrid_NN
schemes_NN
134_CD
107_CD
82_CD
Unfunded_JJ
dened_VBN
benefit_NN
schemes_NN
34_CD
13_CD
10_CD
Dened_VBN
contribution_NOMZ
schemes_NN
30_CD
23_CD
97_CD
Unfunded_JJ
post-retirement_NOMZ
healthcare_NN
schemes_NN
61_CD
57_CD
48_CD
Post-employment_NOMZ
costs_NN
40_CD
28_CD
7_CD
299 228 244_CD
Pension_NN
and_CC
other_JJ
post-retirement_JJ
costs_NN
arising_VBG [WZPRES]
from_PIN
integration_NOMZ
17_CD
58_CD
3_CD
Included_VBN
within_PIN
the_DT
UK_NN
pension_NN
costs_NN
above_PLACE
is_VPRT [BEMA]
an_DT
exceptional_JJ
charge_NN
of_PIN
42_CD
million_CD
relating_VBG
to_PIN
pension_NN
augmentation_NOMZ
on_PIN
redundancies_NN
arising_VBG [WZPRES]
from_PIN
the_DT
manufacturing_GER
restructuring_GER
plans_NN
in_PIN
the_DT
UK_NN
._.
Pensions_NN
Group_NN
undertakings_GER
operate_VPRT
pension_NN
arrangements_NOMZ
which_WDT [WHSUB]
cover_VPRT
the_DT
Groups_NN
material_NN
obligations_NOMZ
to_TO
provide_VB
pensions_NN
to_PIN
retired_JJ
employees_NN
._.
These_DEMO
arrangements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
developed_VBN
in_PIN
accordance_NN
with_PIN
local_JJ
practices_NN
in_PIN
the_DT
countries_NN
concerned_VBN
._.
Pension_NN
benets_NN
can_POMD
be_VB [BYPA]
provided_VBN
by_PIN
State_NN
schemes_NN
:_:
by_PIN
dened_VBN
contribution_NOMZ
schemes_NN
,_,
whereby_OSUB
retirement_NOMZ
benets_NN
are_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
value_NN
of_PIN
funds_NN
arising_VBG [WZPRES]
from_PIN
contributions_NOMZ
paid_VBN [WZPAST]
in_PIN
respect_NN
of_PIN
each_QUAN
employee_NN
,_,
or_CC
by_PIN
dened_JJ
benefit_NN
schemes_NN
,_,
whereby_OSUB
retirement_NOMZ
benets_NN
are_VPRT [PASS]
based_VBN
on_PIN
employee_NN
pensionable_JJ
remuneration_NOMZ
and_PHC
length_NN
of_PIN
service_NN
._.
Some_QUAN
dened_VBD
benefit_NN
schemes_NN
now_TIME
also_RB
include_VPRT
dened_VBN
contribution_NOMZ
sections_NOMZ
and_CC
are_VPRT [PASS]
described_VBN
as_IN
hybrid_JJ
schemes_NN
in_PIN
the_DT
table_NN
._.
In_PIN
the_DT
majority_NOMZ
of_PIN
cases_NN
the_DT
contributions_NOMZ
to_PIN
dened_JJ
benefit_NN
schemes_NN
are_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
in_PIN
accordance_NN
with_PIN
the_DT
advice_NN
of_PIN
independent_JJ
,_,
professionally_RB
qualied_VBD
actuaries_NN
._.
Formal_JJ
,_,
independent_JJ
,_,
actuarial_JJ
valuations_NOMZ
of_PIN
the_DT
Groups_NN
main_JJ
plans_NN
are_VPRT [PASS]
undertaken_VBN
regularly_RB
,_,
normally_RB
at_PIN
least_JJ
every_QUAN
three_CD
years_NN
._.
The_DT
assets_NN
of_PIN
funded_JJ
schemes_NN
are_VPRT [SPAU] [PASS]
generally_RB
held_VBN [PRIV]
in_PIN
separately_RB
administered_VBN
trusts_NN
or_CC
are_VPRT [PASS]
insured_VBN [PRIV]
._.
Pension_NN
costs_NN
for_PIN
accounting_GER
purposes_NN
have_VPRT [PEAS]
been_VBN [PASS]
assessed_VBN
in_PIN
accordance_NN
with_PIN
independent_JJ
actuarial_JJ
advice_NN
,_,
generally_RB
using_VBG
the_DT
projected_VBN
unit_NN
method_NN
and_CC
by_PIN
spreading_VBG
surpluses_NN
or_CC
deficits_NN
over_IN
the_DT
average_NN
expected_VBN [PRIV]
remaining_VBG
service_NN
lives_NN
of_PIN
the_DT
respective_JJ
memberships_NN
._.
In_PIN
certain_JJ
countries_NN
pension_NN
benets_NN
are_VPRT [PASS]
provided_VBN
on_PIN
an_DT
unfunded_JJ
basis_NN
,_,
some_QUAN
of_PIN
which_WDT [PIRE]
are_VPRT
under_IN
a_DT
scheme_NN
administered_VBN [WZPAST]
by_PIN
a_DT
trustee_NN
company_NN
._.
Where_RB
assets_NN
are_VPRT [PASS]
not_XX0
held_VBN [PRIV]
with_PIN
the_DT
specic_JJ
purpose_NN
of_PIN
matching_VBG
the_DT
liabilities_NOMZ
of_PIN
unfunded_JJ
schemes_NN
,_,
a_DT
provision_NN
is_VPRT [PASS]
included_VBN
within_PIN
provisions_NN
for_PIN
pensions_NN
and_CC
other_JJ
post-retirement_JJ
benets_NN
._.
The_DT
charge_NN
against_PIN
profits_NN
in_PIN
respect_NN
of_PIN
these_DEMO
benets_NN
is_VPRT [BEMA]
the_DT
aggregate_NN
of_PIN
the_DT
increase_NN
over_IN
the_DT
year_NN
in_PIN
the_DT
assessed_VBN
liabilities_NOMZ
for_PIN
members_NN
still_RB
in_PIN
service_NN
and_CC
the_DT
net_JJ
movement_NOMZ
in_PIN
provisions_NN
set_VBN
up_RP
for_PIN
pensions_NN
in_PIN
payment_NOMZ
._.
Liabilities_NOMZ
are_VPRT [SPAU] [PASS]
generally_RB
assessed_VBN
annually_RB
in_PIN
accordance_NN
with_PIN
the_DT
advice_NN
of_PIN
independent_JJ
actuaries_NN
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
115_CD
33_CD
Employee_NN
costs_NN
continued_VBD
Throughout_PIN
2002_CD
the_DT
pension_NN
arrangements_NOMZ
in_PIN
some_QUAN
of_PIN
the_DT
former_JJ
Glaxo_NN
Wellcome_NN
companies_NN
and_CC
former_JJ
SmithKline_NN
Beecham_NN
companies_NN
continued_VBD
to_TO
be_VB [PASS]
operated_VBN
separately_RB
._.
However_CONJ
in_PIN
some_QUAN
instances_NN
,_,
including_VBG [PRESP]
the_DT
USA_NN
,_,
the_DT
pension_NN
arrangements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
merged_VBN
._.
The_DT
following_VBG
information_NOMZ
deals_NN
with_PIN
each_QUAN
set_NN
of_PIN
arrangements_NOMZ
accordingly_RB
._.
The_DT
market_NN
value_NN
of_PIN
the_DT
assets_NN
of_PIN
the_DT
Groups_NN
funded_VBN
dened_VBD
benefit_NN
pension_NN
funds_NN
at_PIN
the_DT
dates_NN
of_PIN
the_DT
latest_JJ
actuarial_JJ
valuations_NOMZ
,_,
some_QUAN
of_PIN
which_WDT [PIRE]
date_NN
back_RB
to_PIN
1999_CD
,_,
was_VBD [BEMA]
6.5_CD
billion_CD
and_CC
the_DT
actuarial_JJ
value_NN
of_PIN
assets_NN
was_VBD [BEMA]
sufficient_PRED
to_TO
cover_VB
approximately_RB
113_CD
per_PIN
cent_NN
of_PIN
the_DT
benets_NN
that_TSUB
had_VBD [PEAS]
accrued_VBN
to_PIN
members_NN
after_IN
allowing_VBG [SUAV]
for_PIN
future_JJ
salary_NN
and_PHC
pension_NN
increases_NN
._.
The_DT
UK_NN
dened_VBD
benefit_NN
pension_NN
schemes_NN
account_VPRT
for_PIN
approximately_RB
70_CD
per_PIN
cent_NN
of_PIN
the_DT
Groups_NN
plans_NN
in_PIN
asset_NN
valuation_NOMZ
and_CC
projected_VBD
benefit_NN
terms_NN
and_CC
the_DT
US_FPP1
dened_VBD
benefit_NN
pension_NN
schemes_NN
account_VPRT
for_PIN
approximately_RB
25_CD
per_PIN
cent_NN
of_PIN
the_DT
Groups_NN
plans_NN
in_PIN
asset_NN
valuation_NOMZ
and_CC
projected_VBD
benefit_NN
terms_NN
._.
In_PIN
December_NN
2002_CD
,_,
the_DT
Group_NN
made_VBD
special_JJ
funding_GER
contributions_NOMZ
to_PIN
the_DT
UK_NN
,_,
US_FPP1
and_CC
German_JJ
pension_NN
schemes_NN
totalling_VBG [WZPRES]
320_CD
million_CD
._.
The_DT
company_NN
will_PRMD
review_VB
the_DT
pension_NN
position_NOMZ
annually_RB
and_CC
will_PRMD
make_VB
further_JJ
contributions_NOMZ
as_IN
appropriate_JJ
._.
Pension_NN
costs_NN
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [BEMA]
higher_PRED
in_PIN
2003_CD
than_PIN
in_PIN
2002_CD
as_IN
the_DT
new_JJ
actuarial_JJ
valuations_NOMZ
of_PIN
the_DT
UK_NN
and_PHC
US_FPP1
schemes_NN
become_VPRT
available_JJ
._.
UK_NN
In_PIN
the_DT
UK_NN
the_DT
dened_VBN
benefit_NN
pension_NN
schemes_NN
operated_VBD
for_PIN
the_DT
benefit_NN
of_PIN
former_JJ
Glaxo_NN
Wellcome_NN
employees_NN
and_CC
former_JJ
SmithKline_NN
Beecham_NN
employees_NN
remain_VPRT
separate_JJ
._.
These_DEMO
schemes_NN
were_VBD [PASS]
closed_VBN
to_PIN
new_JJ
entrants_NN
in_PIN
2001_CD
and_CC
subsequent_JJ
UK_NN
employees_NN
are_VPRT [PASS]
entitled_VBN
to_TO
join_VB
a_DT
dened_VBN
contribution_NOMZ
scheme_NN
._.
The_DT
relevant_JJ
assumptions_NOMZ
used_VBN [WZPAST]
in_PIN
calculating_VBG [PRIV]
the_DT
pension_NN
costs_NN
of_PIN
both_DT
the_DT
former_JJ
Glaxo_NN
Wellcome_NN
and_CC
former_JJ
SmithKline_NN
Beecham_NN
UK_NN
dened_VBD
benefit_NN
schemes_NN
for_PIN
accounting_GER
purposes_NN
are_VPRT
as_IN
follows_VPRT
:_:
2002_CD
2001_CD
%_NN
pa_CD
%_NN
pa_NN
Rate_NN
of_PIN
increase_NN
of_PIN
future_JJ
earnings_GER
4.0_CD
4.0_CD
Discount_NN
rate_NN
8.0_CD
8.0_CD
Expected_VBN [PRIV]
long-term_JJ
rate_NN
of_PIN
return_NN
on_PIN
investments_NOMZ
8.0_CD
8.0_CD
Expected_VBN [PRIV]
pension_NN
increases_NN
2.5_CD
2.5_CD
UK_NN
equity_NOMZ
dividend_NN
growth_NN
5.0_CD
5.0_CD
The_DT
regular_JJ
cost_NN
for_PIN
the_DT
Glaxo_NN
Wellcome_NN
pension_NN
arrangements_NOMZ
in_PIN
2002_CD
was_VBD [BEMA]
62_CD
million_CD
,_,
which_WDT [SERE]
became_VBD
a_DT
14_CD
million_CD
credit_NN
for_PIN
the_DT
financial_JJ
statements_NOMZ
,_,
after_IN
allowance_NN
was_VBD [PASS]
made_VBN
for_PIN
spreading_VBG
the_DT
surplus_NN
disclosed_VBD [PUBV]
as_IN
a_DT
level_NN
percentage_NN
of_PIN
salary_NN
over_IN
the_DT
expected_JJ
future_NN
working_VBG [WZPRES]
lifetime_NN
of_PIN
the_DT
existing_VBG
members_NN
some_QUAN
11_CD
years_NN
._.
The_DT
most_EMPH
recent_JJ
triennial_JJ
actuarial_JJ
valuations_NOMZ
of_PIN
the_DT
Glaxo_NN
Wellcome_NN
schemes_NN
for_PIN
funding_VBG
purposes_NN
were_VBD [PASS]
carried_VBN
out_PIN
as_IN
at_PIN
31st_CD
March_NN
2000_CD
._.
At_PIN
that_DEMO
date_NN
the_DT
assets_NN
of_PIN
the_DT
schemes_NN
represented_VBD
133_CD
per_PIN
cent_NN
of_PIN
the_DT
actuarial_JJ
value_NN
of_PIN
all_QUAN
benets_NN
accrued_VBN [WZPAST]
to_PIN
members_NN
after_IN
allowing_VBG [SUAV]
for_PIN
future_JJ
salary_NN
and_PHC
pension_NN
increases_NN
._.
The_DT
trustees_NN
of_PIN
the_DT
UK_NN
pension_NN
schemes_NN
agreed_VBD [SUAV] [PUBV]
,_,
at_PIN
the_DT
companys_NN
request_NN
,_,
to_TO
grant_VB [SUAV]
various_JJ
benefit_NN
improvements_NOMZ
,_,
which_WDT [SERE]
included_VBD
a_DT
five_CD
per_PIN
cent_NN
enhancement_NOMZ
in_PIN
the_DT
entitlement_NOMZ
of_PIN
all_QUAN
beneciaries_NN
._.
After_IN
allowance_NN
was_VBD [PASS]
made_VBN
for_PIN
these_DEMO
improvements_NOMZ
,_,
the_DT
funding_GER
level_NN
fell_VBD
to_PIN
123_CD
per_PIN
cent_NN
._.
Following_VBG [PRESP]
the_DT
valuations_NOMZ
,_,
normal_JJ
company_NN
contributions_NOMZ
to_PIN
the_DT
schemes_NN
remain_VPRT
suspended_VBN
at_PIN
least_JJ
until_IN
the_DT
next_JJ
formal_JJ
valuation_NOMZ
._.
The_DT
total_JJ
market_NN
value_NN
of_PIN
the_DT
assets_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
schemes_NN
at_PIN
31st_CD
March_NN
2000_CD
was_VBD [BEMA]
3,670_CD
million_CD
._.
The_DT
regular_JJ
cost_NN
for_PIN
the_DT
SmithKline_NN
Beecham_NN
schemes_NN
in_PIN
2002_CD
was_VBD [BEMA]
17_CD
million_CD
,_,
which_WDT [SERE]
increased_VBD
to_PIN
an_DT
accounting_GER
cost_NN
of_PIN
28_CD
million_CD
after_IN
allowance_NN
was_VBD [PASS]
made_VBN
for_PIN
the_DT
spreading_VBG
of_PIN
the_DT
deficit_NN
over_IN
the_DT
expected_JJ
future_NN
working_VBG [WZPRES]
lifetime_NN
of_PIN
current_JJ
employees_NN
in_PIN
the_DT
scheme_NN
some_QUAN
11_CD
years_NN
._.
The_DT
latest_JJ
valuation_NOMZ
was_VBD [PASS]
carried_VBN
out_PIN
at_PIN
31st_CD
December_NN
1999_CD
and_CC
at_PIN
that_DEMO
date_NN
the_DT
actuarial_JJ
value_NN
of_PIN
scheme_NN
assets_NN
represented_VBD
90_CD
per_PIN
cent_NN
of_PIN
the_DT
actuarial_JJ
value_NN
of_PIN
the_DT
accrued_JJ
service_NN
liabilities_NOMZ
based_VBN [WZPAST]
on_PIN
the_DT
2002_CD
assumptions_NOMZ
._.
The_DT
total_JJ
market_NN
value_NN
of_PIN
assets_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
scheme_NN
at_PIN
31st_CD
December_NN
1999_CD
was_VBD [BEMA]
1,077_CD
million_CD
._.
USA_NN
In_PIN
the_DT
USA_NN
the_DT
former_JJ
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
dened_VBD
benefit_NN
and_CC
hybrid_JJ
schemes_NN
were_VBD [PASS]
merged_VBN
during_PIN
2001_CD
._.
The_DT
relevant_JJ
assumptions_NOMZ
used_VBN [WZPAST]
in_PIN
calculating_VBG [PRIV]
the_DT
pension_NN
costs_NN
for_PIN
accounting_GER
purposes_NN
are_VPRT
as_IN
follows_VPRT
:_:
2002_CD
2001_CD
%_NN
pa_CD
%_NN
pa_NN
Rate_NN
of_PIN
increase_NN
of_PIN
future_JJ
earnings_GER
5.5_CD
5.5_CD
Discount_NN
rate_NN
9.5_CD
9.5_CD
Expected_VBN [PRIV]
long-term_JJ
rate_NN
of_PIN
return_NN
on_PIN
investments_NOMZ
9.5_CD
9.5_CD
Cash_NN
balance_NN
credit_NN
conversion_NN
rate_NN
6.5_CD
6.5_CD
US_FPP1
equity_NOMZ
dividend_NN
growth_NN
7.75_CD
7.75_CD
The_DT
regular_JJ
cost_NN
for_PIN
the_DT
US_FPP1
scheme_NN
in_PIN
2002_CD
was_VBD [BEMA]
64_CD
million_CD
,_,
which_WDT [SERE]
increased_VBD
to_PIN
an_DT
accounting_GER
cost_NN
of_PIN
77_CD
million_CD
after_IN
allowance_NN
was_VBD [PASS]
made_VBN
for_PIN
the_DT
spreading_VBG
of_PIN
the_DT
deficit_NN
over_IN
the_DT
expected_JJ
future_NN
working_VBG [WZPRES]
lifetime_NN
of_PIN
current_JJ
employees_NN
in_PIN
the_DT
scheme_NN
._.
The_DT
latest_JJ
valuation_NOMZ
was_VBD [PASS]
carried_VBN
out_PIN
at_PIN
1st_CD
January_NN
2002_CD
and_CC
at_PIN
that_DEMO
date_NN
the_DT
actuarial_JJ
value_NN
of_PIN
scheme_NN
assets_NN
represented_VBD
90_CD
per_PIN
cent_NN
of_PIN
the_DT
actuarial_JJ
value_NN
of_PIN
the_DT
accrued_JJ
service_NN
liabilities_NOMZ
._.
The_DT
total_JJ
market_NN
value_NN
of_PIN
assets_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
scheme_NN
at_PIN
1st_CD
January_NN
2002_CD
was_VBD [BEMA]
1,536_CD
million_CD
._.
116_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
33_CD
Employee_NN
costs_NN
continued_VBD
FRS_NN
17_CD
disclosures_NN
The_DT
Group_NN
continues_VPRT
to_TO
account_VB
for_PIN
pension_NN
arrangements_NOMZ
in_PIN
accordance_NN
with_PIN
SSAP_NN
24_CD
Accounting_GER
for_PIN
Pension_NN
Costs_NN
._.
Under_IN
the_DT
transitional_JJ
provisions_NN
of_PIN
FRS_NN
17_CD
Retirement_NOMZ
Benets_NN
certain_JJ
disclosures_NN
are_VPRT [PASS]
required_VBN [SUAV]
on_PIN
the_DT
basis_NN
of_PIN
the_DT
valuation_NOMZ
methodology_NN
adopted_VBN [WZPAST]
by_PIN
FRS_NN
17_CD
._.
For_PIN
dened_VBN
benefit_NN
schemes_NN
the_DT
fair_JJ
values_NN
of_PIN
pension_NN
scheme_NN
assets_NN
at_PIN
31st_CD
December_NN
2002_CD
are_VPRT [PASS]
compared_VBN
with_PIN
the_DT
future_JJ
pension_NN
liabilities_NOMZ
calculated_VBN [PRIV]
under_IN
the_DT
projected_VBN
unit_NN
method_NN
applying_VBG [WZPRES]
the_DT
following_VBG
assumptions_NOMZ
:_:
UK_NN
USA_NN
Rest_VPRT
of_PIN
World_NN
2002 2001 2002 2001_CD
2002_CD
2001_CD
%_NN
pa_CD
%_NN
pa_CD
%_NN
pa_CD
%_NN
pa_CD
%_NN
pa_CD
%_NN
pa_NN
Rate_NN
of_PIN
increase_NN
of_PIN
future_JJ
earnings_GER
3.75_CD
4.0_CD
5.5_CD
5.5_CD
3.0_CD
3.5_CD
Discount_NN
rate_NN
5.75_CD
6.0_CD
6.75_CD
7.25_CD
4.75_CD
4.75_CD
Expected_VBN [PRIV]
pension_NN
increases_NN
2.25_CD
2.5_CD
n_VBD
a_DT
n_NN
a_DT
1.5_CD
1.0_CD
Cash_NN
balance_NN
credit_NN
conversion_NN
rate_NN
n_VBD
a_DT
n_NN
a_DT
5.75_CD
6.25_CD
n_VBD
a_DT
n_NN
a_DT
Ination_NOMZ
rate_NN
2.25_CD
2.5_CD
2.25_CD
3.5_CD
1.5_CD
1.5_CD
The_DT
expected_VBN [PRIV]
long-term_JJ
rates_NN
of_PIN
return_NN
on_PIN
the_DT
assets_NN
and_CC
the_DT
fair_JJ
values_NN
of_PIN
the_DT
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
the_DT
UK_NN
and_PHC
US_FPP1
dened_VBD
benefit_NN
schemes_NN
,_,
together_RB
with_PIN
aggregated_JJ
data_NN
for_PIN
other_JJ
dened_VBN
benefit_NN
schemes_NN
in_PIN
the_DT
Group_NN
are_VPRT
as_IN
follows_VPRT
:_:
UK_NN
USA_NN
Rest_VPRT
of_PIN
World_NN
Group_NN
Average_JJ
At_PIN
31st_CD
December_NN
2002_CD
Expected_VBN [PRIV]
rate_NN
Fair_NN
Expected_VBN [PRIV]
rate_NN
Fair_NN
expected_VBN [PRIV]
rate_NN
Fair_NN
Fair_NN
of_PIN
return_NN
value_NN
of_PIN
return_NN
value_NN
of_PIN
return_NN
value_NN
value_NN
%_NN
m_CD
%_NN
m_CD
%_NN
m_NN
m_NN
Equities_NOMZ
8.25_CD
2,523_CD
9.25_CD
804_CD
6.75_CD
172_CD
3,499_CD
Property_NN
7.0_CD
53_CD
7.0_CD
5_CD
58_CD
Bonds_NN
4.5_CD
299_CD
6.25_CD
265_CD
4.5_CD
145_CD
709_CD
Other_JJ
assets_NN
4.0_CD
137_CD
1.5_CD
240_CD
1.75_CD
9_CD
386_CD
Fair_NN
value_NN
of_PIN
assets_NN
2,959_CD
1,362_CD
331_CD
4,652_CD
Present_JJ
value_NN
of_PIN
scheme_NN
liabilities_NOMZ
4,153_CD
1,782_CD
578_CD
6,513_CD
1,194_CD
420_CD
247_CD
1,861_CD
Value_NN
of_PIN
schemes_NN
in_PIN
surplus_NN
11_CD
11_CD
Deferred_JJ
tax_NN
liability_NOMZ
3_CD
3_CD
8_CD
8_CD
Value_NN
of_PIN
schemes_NN
in_PIN
deficit_NN
1,194_CD
420_CD
258_CD
1,872_CD
Deferred_JJ
tax_NN
asset_NN
358_CD
147 97 602 836_CD
273_CD
161_CD
1,270_CD
Group_NN
total_JJ
1,262_CD
Other_JJ
assets_NN
in_PIN
the_DT
UK_NN
and_PHC
US_FPP1
schemes_NN
include_VPRT
the_DT
special_JJ
contributions_NOMZ
paid_VBN [WZPAST]
in_PIN
December_NN
2002_CD
._.
These_DEMP
will_PRMD
be_VB [PASS]
allocated_VBN
to_PIN
equities_NOMZ
and_PHC
bonds_NN
in_PIN
2003_CD
._.
UK_NN
USA_NN
Rest_VPRT
of_PIN
World_NN
Group_NN
Average_JJ
At_PIN
31st_CD
December_NN
2001_CD
Expected_VBN [PRIV]
rate_NN
Fair_NN
Expected_VBN [PRIV]
rate_NN
Fair_NN
expected_VBN [PRIV]
rate_NN
Fair_NN
Fair_NN
of_PIN
return_NN
value_NN
of_PIN
return_NN
value_NN
of_PIN
return_NN
value_NN
value_NN
%_NN
m_CD
%_NN
m_CD
%_NN
mm_NN
Equities_NOMZ
8.5_CD
3,234_CD
9.5_CD
1,220_CD
7.25_CD
193_CD
4,647_CD
Property_NN
8.0_CD
54_CD
7.5_CD
3_CD
57_CD
Bonds_NN
5.0_CD
411_CD
7.0_CD
250_CD
5.0_CD
107_CD
768_CD
Other_JJ
assets_NN
4.5_CD
70_CD
5.0_CD
12_CD
3.25_CD
10_CD
92_CD
Fair_NN
value_NN
of_PIN
assets_NN
3,715_CD
1,536_CD
313_CD
5,564_CD
Present_JJ
value_NN
of_PIN
scheme_NN
liabilities_NOMZ
3,970_CD
1,781_CD
527_CD
6,278_CD
255 245 214 714_CD
Value_NN
of_PIN
schemes_NN
in_PIN
surplus_NN
42_CD
24_CD
66_CD
Deferred_JJ
tax_NN
liability_NOMZ
13_CD
7_CD
20_CD
29_CD
17_CD
46_CD
Value_NN
of_PIN
schemes_NN
in_PIN
deficit_NN
297 245 238 780_CD
Deferred_JJ
tax_NN
asset_NN
89_CD
93 95 277 208_CD
152 143 503_CD
Group_NN
total_JJ
457_CD
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
117_CD
33_CD
Employee_NN
costs_NN
continued_VBD
The_DT
UK_NN
dened_VBD
benefit_NN
schemes_NN
also_RB
have_VPRT [PEAS]
dened_VBN
contribution_NOMZ
sections_NOMZ
with_PIN
account_NN
balances_NN
totalling_VBG [WZPRES]
281_CD
million_CD
at_PIN
31st_CD
December_NN
2002 2001 263_CD
million_CD
._.
The_DT
dened_VBN
benefit_NN
sections_NOMZ
of_PIN
the_DT
UK_NN
schemes_NN
have_VPRT [PEAS]
been_VBN [PASS]
closed_VBN
to_PIN
new_JJ
members_NN
,_,
and_ANDC
under_IN
the_DT
projected_VBN
unit_NN
method_NN
of_PIN
valuing_VBG
the_DT
pension_NN
scheme_NN
liabilities_NOMZ
the_DT
current_JJ
service_NN
cost_NN
will_PRMD
increase_VB
as_IN
the_DT
members_NN
of_PIN
the_DT
schemes_NN
approach_VPRT
retirement_NOMZ
._.
The_DT
deficits_NN
under_IN
FRS_NN
17_CD
reect_NN
the_DT
different_JJ
bases_NN
for_PIN
valuing_VBG
assets_NN
and_PHC
liabilities_NOMZ
compared_VBN [WZPAST]
with_PIN
SSAP_NN
24_CD
,_,
including_VBG [PRESP]
the_DT
immediate_JJ
impact_NN
of_PIN
the_DT
fair_JJ
values_NN
of_PIN
assets_NN
at_PIN
31st_CD
December_NN
2002_CD
._.
The_DT
Group_NN
also_RB
operates_VPRT
a_DT
number_NN
of_PIN
unfunded_JJ
post-retirement_JJ
healthcare_NN
schemes_NN
,_,
the_DT
principal_NN
one_CD
of_PIN
which_WDT [PIRE]
is_VPRT [BEMA]
in_PIN
the_DT
USA_NN
._.
The_DT
liability_NOMZ
under_IN
FRS_NN
17_CD
for_PIN
the_DT
US_FPP1
scheme_NN
has_VPRT [PEAS]
been_VBN [PASS]
assessed_VBN
using_VBG
the_DT
same_JJ
assumptions_NOMZ
as_IN
for_PIN
the_DT
US_FPP1
pension_NN
scheme_NN
,_,
together_RB
with_PIN
the_DT
assumption_NOMZ
for_PIN
future_JJ
medical_JJ
ination_NOMZ
of_PIN
11_CD
per_PIN
cent_NN
,_,
reducing_VBG [PRESP]
by_PIN
one_CD
per_PIN
cent_NN
per_PIN
year_NN
to_PIN
five_CD
per_PIN
cent_NN
._.
On_PIN
this_DEMO
basis_NN
the_DT
liability_NOMZ
for_PIN
the_DT
US_FPP1
scheme_NN
has_VPRT [PEAS]
been_VBN [PASS]
assessed_VBN
at_PIN
766_CD
million_CD
2001_CD
787_CD
million_CD
,_,
which_WDT [SERE]
reduced_VBD
to_PIN
475_CD
million_CD
2001_CD
488_CD
million_CD
after_IN
taking_VBG
account_NN
of_PIN
deferred_JJ
tax_NN
._.
If_COND
the_DT
dened_VBN
benefit_NN
pension_NN
and_PHC
post-retirement_NOMZ
benefit_NN
schemes_NN
had_VBD [PEAS]
been_VBN [PASS]
accounted_VBN
for_PIN
under_IN
FRS_NN
17_CD
,_,
the_DT
following_JJ
amounts_NN
would_PRMD
have_VB [PEAS]
been_VBN [PASS]
recorded_VBN
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
and_PHC
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
for_PIN
the_DT
year_NN
ended_VBD
31st_CD
December_NN
2002_CD
._.
Post-retirement_NOMZ
Pensions_NN
benets_VPRT
UK_NN
USA_NN
Rest_VPRT
of_PIN
World_NN
Group_NN
Group_NN
m_FW
m_FW
m_FW
m_FW
m_FW [PASS]
Amounts_NN
charged_VBD
to_TO
operating_VBG
profit_NN
Current_JJ
service_NN
cost_NN
118_CD
74_CD
32_CD
224_CD
24_CD
Past_JJ
service_NN
cost_NN
28_CD
34_CD
62_CD
Curtailments_NOMZ
settlements_NOMZ
1_CD
1_CD
146_CD
108_CD
33_CD
287_CD
24_CD
Amounts_NN
credited_VBD
charged_VBN
to_PIN
net_JJ
interest_NN
Expected_VBN [PRIV]
return_NN
on_PIN
pension_NN
scheme_NN
assets_NN
293_CD
129_CD
14_CD
436_CD
Interest_NN
on_PIN
scheme_NN
liabilities_NOMZ
235_CD
129_CD
22_CD
386_CD
53_CD
58_CD
8_CD
50_CD
53_CD
Amounts_NN
recorded_VBN [WZPAST]
in_PIN
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
Actual_JJ
return_NN
less_RB
expected_JJ
return_NN
on_PIN
pension_NN
scheme_NN
assets_NN
1,024_CD
293_CD
56_CD
1,373_CD
Experience_NN
gains_NN
losses_NN
arising_VBG [WZPRES]
on_PIN
scheme_NN
liabilities_NOMZ
34_CD
3_CD
2_CD
33_CD
95_CD
Changes_NN
in_PIN
assumptions_NOMZ
relating_VBG [WZPRES]
to_PIN
present_JJ
value_NN
of_PIN
scheme_NN
liabilities_NOMZ
15_CD
57_CD
10_CD
62_CD
124_CD
1,005_CD
353_CD
44_CD
1,402_CD
29_CD
Movements_NOMZ
in_PIN
deficits_NN
during_PIN
the_DT
year_NN
deficits_NN
in_PIN
schemes_NN
at_PIN
1st_CD
January_NN
2002 255 245 214_CD
714_CD
854_CD
Exchange_NN
adjustments_NOMZ
37_CD
9_CD
28_CD
85_CD
Charged_VBN
to_TO
operating_VBG
profit_NN
146_CD
108_CD
33_CD
287_CD
24_CD
Employer_NN
contributions_NOMZ
154_CD
249_CD
61_CD
464_CD
41_CD
Other_JJ
finance_NN
income_NN
expense_NN
58_CD
8_CD
50_CD
53_CD
Actuarial_JJ
loss_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
1,005_CD
353_CD
44_CD
1,402_CD
29_CD
deficits_NN
in_PIN
schemes_NN
at_PIN
31st_CD
December_NN
2002_CD
1,194_CD
420_CD
247_CD
1,861_CD
834_CD
History_NN
of_PIN
experience_NN
gains_NN
and_PHC
losses_NN
Difference_NN
between_PIN
the_DT
expected_VBN [PRIV]
and_CC
actual_JJ
return_NN
on_PIN
scheme_NN
assets_NN
m_VPRT [BEMA]
1,024_CD
293_CD
56_CD
1,373_CD
Percentage_NN
of_PIN
scheme_NN
assets_NN
at_PIN
31st_CD
December_NN
2002_CD
35_CD
%_NN
22_CD
%_NN
17_CD
%_NN
30_CD
%_NN
Experience_NN
gains_NN
losses_NN
of_PIN
scheme_NN
liabilities_NOMZ
m_VPRT [BEMA]
34_CD
3_CD
2_CD
33_CD
95_CD
Percentage_NN
of_PIN
present_JJ
value_NN
of_PIN
scheme_NN
liabilities_NOMZ
at_PIN
31st_CD
December_NN
2002_CD
1_CD
%_NN
1_CD
%_NN
11_CD
%_NN
Total_JJ
amount_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
m_VPRT [BEMA]
1,005_CD
353_CD
44_CD
1,402_CD
29_CD
Percentage_NN
of_PIN
present_JJ
value_NN
of_PIN
scheme_NN
liabilities_NOMZ
at_PIN
31st_CD
December_NN
2002_CD
24_CD
%_NN
20_CD
%_NN
8_CD
%_NN
22_CD
%_NN
3_CD
%_NN
118_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
33_CD
Employee_NN
costs_NN
continued_VBD
If_COND
the_DT
FRS_NN
17_CD
valuation_NOMZ
basis_NN
had_VBD [PEAS]
been_VBN [PASS]
applied_VBN
in_PIN
the_DT
financial_JJ
statements_NOMZ
instead_CONJ
of_NULL
the_DT
SSAP_NN
24_CD
valuation_NOMZ
basis_NN
,_,
the_DT
effect_NN
on_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
reserve_NN
after_IN
taking_VBG
account_NN
of_PIN
deferred_JJ
tax_NN
would_PRMD
have_VB [PEAS]
been_VBN
as_IN
follows_VPRT
:_:
2001_CD
2002_CD
restated_VBN
m_FW
m_FW
m_FW
m_FW
profit_NN
and_PHC
loss_NN
account_NN
reserve_NN
per_PIN
balance_NN
sheet_NN
2,946_CD
3,811_CD
Pension_NN
liability_NOMZ
under_IN
FRS_NN
17_CD
1,262_CD
457_CD
Pension_NN
liability_NOMZ
under_IN
SSAP_NN
24_CD
per_PIN
balance_NN
sheet_NN
39_CD
185_CD
1,223_CD
272_CD
Post-retirement_NOMZ
healthcare_NN
schemes_NN
under_IN
FRS_NN
17 545 519_CD
Post-retirement_NOMZ
healthcare_NN
schemes_NN
provision_NN
per_PIN
balance_NN
sheet_NN
378 388 167 131_CD
profit_NN
and_PHC
loss_NN
account_NN
reserve_NN
including_VBG [WZPRES]
pension_NN
and_CC
post-retirement_JJ
healthcare_NN
liability_NOMZ
1,556_CD
3,408_CD
34_CD
Employee_NN
share_NN
schemes_NN
The_DT
company_NN
operates_VPRT
share_NN
option_NOMZ
schemes_NN
,_,
whereby_OSUB
options_NOMZ
are_VPRT [PASS]
granted_VBN [SUAV]
to_PIN
employees_NN
to_TO
acquire_VB
shares_NN
or_CC
ADSs_NN
in_PIN
GlaxoSmithKline_NN
plc_NN
at_PIN
the_DT
grant_NN
price_NN
,_,
and_ANDC
share_NN
award_NN
schemes_NN
,_,
whereby_OSUB
awards_NN
are_VPRT [PASS]
granted_VBN [SUAV]
to_PIN
employees_NN
to_TO
acquire_VB
shares_NN
or_CC
ADSs_NN
in_PIN
GlaxoSmithKline_NN
plc_NN
at_PIN
no_SYNE
cost_NN
,_,
subject_JJ
to_PIN
the_DT
achievement_NOMZ
of_PIN
performance_NN
targets_NN
._.
The_DT
details_NN
given_VBN
below_PLACE
relate_VPRT
to_PIN
schemes_NN
operated_VBN [WZPAST]
by_PIN
GlaxoSmithKline_NN
in_PIN
2002_CD
and_CC
2001_CD
and_CC
separately_RB
by_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
up_IN
to_PIN
the_DT
date_NN
of_PIN
the_DT
merger_NN
,_,
which_WDT [SERE]
became_VBD
schemes_NN
of_PIN
GlaxoSmithKline_NN
on_PIN
the_DT
merger_NN
._.
Each_QUAN
Glaxo_NN
Wellcome_NN
option_NOMZ
outstanding_JJ
at_PIN
the_DT
date_NN
of_PIN
the_DT
merger_NN
was_VBD [PASS]
converted_VBN
into_PIN
one_CD
GlaxoSmithKline_NN
option_NOMZ
._.
Each_QUAN
SmithKline_NN
Beecham_NN
share_NN
option_NOMZ
was_VBD [PASS]
converted_VBN
into_PIN
0.4552_CD
of_PIN
a_DT
GlaxoSmithKline_NN
share_NN
option_NOMZ
and_CC
each_QUAN
SmithKline_NN
Beecham_NN
ADS_NN
option_NOMZ
was_VBD [PASS]
converted_VBN
into_PIN
1.138_CD
GlaxoSmithKline_NN
ADS_NN
options_NOMZ
,_,
with_PIN
corresponding_JJ
adjustments_NOMZ
to_PIN
the_DT
grant_NN
price_NN
._.
GlaxoSmithKline_NN
share_NN
option_NOMZ
schemes_NN
The_DT
company_NN
operates_VPRT
share_NN
option_NOMZ
schemes_NN
and_CC
savings-related_JJ
share_NN
option_NOMZ
schemes_NN
._.
Grants_NN
under_IN
share_NN
option_NOMZ
schemes_NN
are_VPRT [BEMA]
normally_RB
exercisable_PRED
between_PIN
three_CD
and_CC
ten_CD
years_NN
from_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
Grants_NN
under_IN
savings-related_JJ
share_NN
option_NOMZ
schemes_NN
are_VPRT [BEMA]
normally_RB
exercisable_PRED
after_IN
three_CD
years_NN
saving_VBG [WZPRES]
._.
Options_NOMZ
under_IN
the_DT
share_NN
option_NOMZ
schemes_NN
are_VPRT [SPAU] [PASS]
normally_RB
granted_VBN [SUAV]
at_PIN
the_DT
market_NN
price_NN
ruling_NN
at_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
In_PIN
accordance_NN
with_PIN
UK_NN
practice_NN
,_,
the_DT
majority_NOMZ
of_PIN
options_NOMZ
under_IN
the_DT
savings-related_JJ
share_NN
option_NOMZ
schemes_NN
are_VPRT [PASS]
granted_VBN [SUAV]
at_PIN
a_DT
price_NN
20_CD
per_PIN
cent_NN
below_PLACE
the_DT
market_NN
price_NN
ruling_NN
at_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
Share_NN
option_NOMZ
Share_NN
option_NOMZ
Savings-related_JJ
Options_NOMZ
outstanding_JJ
schemes_NN
shares_NN
schemes_NN
ADSs_NN
share_NN
option_NOMZ
schemes_NN
at_PIN
31st_CD
December_NN
2002_CD
Weighted_NN
Weighted_NN
Weighted_NN
Number_NN
exercise_NN
Number_NN
exercise_NN
Number_NN
exercise_NN
000_CD
price_NN
000_CD
price_NN
000_CD
price_NN
At_PIN
27th_JJ
December_NN
2000_CD
:_:
Converted_VBN [PASTP]
from_PIN
GW_NN
options_NOMZ
106,748_CD
13.87_CD
8,397_CD
12.34_CD
Converted_VBN
from_PIN
SB_NN
options_NOMZ
35,122_CD
12.81_CD
37,962_CD
$_$
44.10_CD
Options_NOMZ
exercised_VBN
4,275_CD
11.18_CD
62_CD
11.17_CD
Options_NOMZ
canceled_VBN
59_CD
13.41_CD
At_PIN
31st_CD
December_NN
2000_CD
137,595_CD
13.68_CD
37,962_CD
$_$
44.10_CD
8,276_CD
12.34_CD
Options_NOMZ
granted_VBN [SUAV]
67,763_CD
17.98_CD
42,034_CD
$_$
51.82_CD
4,443_CD
14.12_CD
Options_NOMZ
exercised_VBN
21,332_CD
10.36_CD
4,705_CD
$_$
13.06_CD
3,075_CD
8.48_CD
Options_NOMZ
canceled_VBN
4,090_CD
14.68_CD
1,466_CD
$_$
52.40_CD
1,444_CD
15.90_CD
At_PIN
31st_CD
December_NN
2001_CD
179,936_CD
15.67_CD
73,825_CD
$_$
50.31_CD
8,200_CD
14.13_CD
Options_NOMZ
granted_VBN [SUAV]
33,454_CD
11.91_CD
22,991_CD
$_$
37.57_CD
9,793_CD
9.16_CD
Options_NOMZ
exercised_VBN
8,857_CD
10.55_CD
1,504_CD
$_$
21.75_CD
398_CD
14.04_CD
Options_NOMZ
canceled_VBN
7,061_CD
17.53_CD
4,435_CD
$_$
54.69_CD
4,607_CD
14.41_CD
At_PIN
31st_CD
December_NN
2002_CD
197,472_CD
15.20_CD
90,877_CD
$_$
47.34_CD
12,988_CD
10.29_CD
Range_NN
of_PIN
exercise_NN
prices_NN
3.61_CD
19.77_CD
$_$
11.68_CD
$_$
61.35_CD
9.16_CD
16.48_CD
In_PIN
order_NN
to_TO
encourage_VB
employees_NN
to_TO
convert_VB
options_NOMZ
,_,
excluding_VBG
savings-related_JJ
share_NN
options_NOMZ
,_,
held_VBN [PRIV]
over_IN
Glaxo_NN
Wellcome_NN
or_CC
SmithKline_NN
Beecham_NN
shares_NN
or_CC
ADSs_NN
into_PIN
those_DEMO
over_IN
GlaxoSmithKline_NN
shares_NN
or_CC
ADSs_NN
,_,
a_DT
program_NN
was_VBD [PASS]
established_VBN [PRIV]
to_TO
give_VB
an_DT
additional_JJ
cash_NN
benefit_NN
of_PIN
ten_NN
per_PIN
cent_NN
of_PIN
the_DT
exercise_NN
price_NN
of_PIN
the_DT
original_JJ
option_NOMZ
provided_VBD
that_DEMO
the_DT
employee_NN
does_VPRT
not_XX0
voluntarily_RB
leave_VB
the_DT
Group_NN
for_PIN
two_CD
years_NN
from_PIN
the_DT
date_NN
of_PIN
the_DT
merger_NN
and_CC
does_VPRT
not_XX0
exercise_VB
the_DT
option_NOMZ
before_IN
the_DT
earlier_TIME
of_PIN
six_CD
months_NN
from_PIN
the_DT
expiry_NN
date_NN
of_PIN
the_DT
original_JJ
option_NOMZ
and_CC
two_CD
years_NN
from_PIN
the_DT
date_NN
of_PIN
the_DT
merger_NN
._.
The_DT
cash_NN
benefit_NN
will_PRMD [SPAU]
also_RB
be_VB [PASS]
paid_VBN
if_COND
the_DT
options_NOMZ
expire_VPRT
unexercised_JJ
if_COND
the_DT
market_NN
price_NN
is_VPRT
below_PLACE
the_DT
exercise_NN
price_NN
on_PIN
the_DT
date_NN
of_PIN
expiry_NN
._.
There_EX
has_VPRT [PEAS]
been_VBN
no_SYNE
change_NN
in_PIN
the_DT
effective_JJ
exercise_NN
price_NN
of_PIN
any_QUAN
outstanding_JJ
options_NOMZ
during_PIN
the_DT
year_NN
._.
No_DT
further_RB
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
between_PIN
31st_CD
December_NN
2002_CD
and_CC
3rd_CD
March_NN
2003_CD
._.
Share_NN
option_NOMZ
Share_NN
option_NOMZ
Savings-related_JJ
Options_NOMZ
exercisable_JJ
schemes_NN
shares_NN
schemes_NN
ADSs_NN
share_NN
option_NOMZ
schemes_NN
Weighted_NN
Weighted_NN
Weighted_NN
Number_NN
exercise_NN
Number_NN
exercise_NN
Number_NN
exercise_NN
000_CD
price_NN
000_CD
price_NN
000_CD
price_NN
At_PIN
31st_CD
December_NN
2000_CD
106,805_CD
13.36_CD
37,962_CD
$_$
44.10_CD
2,358_CD
6.73_CD
At_PIN
31st_CD
December_NN
2001_CD
85,601_CD
14.10_CD
32,373_CD
$_$
48.36_CD
289_CD
14.29_CD
At_PIN
31st_CD
December_NN
2002_CD
72,611_CD
14.33_CD
27,129_CD
$_$
48.89_CD
2,227_CD
13.27_CD
GlaxoSmithKline_NN
share_NN
award_NN
schemes_NN
The_DT
Group_NN
operates_VPRT
a_DT
Performance_NN
Share_NN
Plan_NN
whereby_OSUB
awards_NN
are_VPRT [PASS]
granted_VBN [SUAV]
to_PIN
Directors_NN
and_CC
senior_JJ
staff_NN
at_PIN
no_SYNE
cost_NN
._.
The_DT
percentage_NN
of_PIN
each_QUAN
award_NN
that_TOBJ
vests_NN
is_VPRT [PASS]
based_VBN
upon_PIN
the_DT
performance_NN
of_PIN
the_DT
Group_NN
over_IN
a_DT
three_CD
year_NN
measurement_NOMZ
period_NN
._.
The_DT
performance_NN
conditions_NOMZ
consist_VPRT
of_PIN
two_CD
parts_NN
,_,
each_QUAN
of_PIN
which_WDT [PIRE]
applies_VPRT
to_PIN
50_CD
per_PIN
cent_NN
of_PIN
the_DT
award_NN
._.
The_DT
first_JJ
part_NN
of_PIN
the_DT
condition_NOMZ
compares_VPRT
GlaxoSmithKlines_NN
Total_NN
Shareholder_NN
Return_NN
TSR_NN
over_IN
the_DT
period_NN
with_PIN
the_DT
TSR_NN
of_PIN
companies_NN
in_PIN
the_DT
UK_NN
FTSE_NN
100_CD
Index_NN
over_IN
the_DT
same_JJ
period_NN
._.
The_DT
second_JJ
part_NN
of_PIN
the_DT
performance_NN
condition_NOMZ
compares_VPRT
GlaxoSmithKlines_NN
earnings_GER
per_PIN
share_NN
growth_NN
to_PIN
the_DT
increase_NN
in_PIN
the_DT
UK_NN
Retail_NN
Prices_NN
Index_NN
over_IN
the_DT
three_CD
year_NN
performance_NN
period_NN
._.
Shares_NN
ADSs_NN
Number_NN
of_PIN
shares_NN
and_PHC
ADSs_NN
issuable_JJ
Number_NN
000_CD
Number_NN
000_CD
At_PIN
27th_JJ
December_NN
2000_CD
Converted_VBN
from_PIN
Glaxo_NN
Wellcome_NN
awards_NN
2,111_CD
Converted_VBN
from_PIN
SmithKline_NN
Beecham_NN
awards_NN
1,623_CD
1,386_CD
Awards_NN
exercised_VBN
243_CD
At_PIN
31st_CD
December_NN
2000_CD
3,491_CD
1,386_CD
Awards_NN
granted_VBD [SUAV]
1,778_CD
1,042_CD
Awards_NN
exercised_VBN
2,016_CD
598_CD
Awards_NN
canceled_VBD
72_CD
70_CD
At_PIN
31st_CD
December_NN
2001_CD
3,181_CD
1,760_CD
Awards_NN
granted_VBD [SUAV]
863_CD
477_CD
Awards_NN
exercised_VBN
728_CD
197_CD
Awards_NN
canceled_VBD
152_CD
97_CD
At_PIN
31st_CD
December_NN
2002_CD
3,164_CD
1,943_CD
Of_PIN
the_DT
above_PLACE
awards_NN
29,000_CD
relating_VBG
to_PIN
shares_NN
and_PHC
nil_NN
relating_VBG [WZPRES]
to_PIN
ADSs_NN
were_VBD [BEMA]
exercisable_PRED
at_PIN
31st_CD
December_NN
2002_CD
._.
120_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
34_CD
Employee_NN
share_NN
schemes_NN
continued_VBD
SmithKline_NN
Beecham_NN
share_NN
option_NOMZ
schemes_NN
At_PIN
the_DT
date_NN
of_PIN
the_DT
merger_NN
,_,
all_QUAN
SmithKline_NN
Beecham_NN
share_NN
options_NOMZ
became_VBD
exercisable_JJ
._.
Shares_NN
ADSs_NN
Weighted_NN
Weighted_NN
exercise_NN
exercise_NN
Number_NN
of_PIN
shares_NN
and_PHC
ADSs_NN
issuable_JJ
under_IN
outstanding_JJ
options_NOMZ
Number_NN
000_CD
price_NN
Number_NN
000_CD
price_NN
At_PIN
31st_CD
December_NN
1999_CD
100,429_CD
5.47_CD
42,399_CD
$_$
45.59_CD
Options_NOMZ
granted_VBD [SUAV]
1,448_CD
8.28_CD
560_CD
$_$
67.00_CD
Options_NOMZ
exercised_VBN
20,951_CD
4.30_CD
8,055_CD
$_$
30.09_CD
Options_NOMZ
canceled_VBD
3,769_CD
5.71_CD
1,545_CD
$_$
35.16_CD
Converted_VBN
to_PIN
GlaxoSmithKline_NN
options_NOMZ
77,157_CD
5.83_CD
33,359_CD
$_$
50.18_CD
At_PIN
31st_CD
December_NN
2000_CD
SmithKline_NN
Beecham_NN
Mid-Term_NN
Incentive_NN
Plan_NN
SmithKline_NN
Beecham_NN
adopted_VBD
the_DT
Mid-Term_NN
Incentive_NN
Plan_NN
MTIP_NN
in_PIN
1996_CD
._.
Participations_NOMZ
in_PIN
the_DT
MTIP_NN
were_VBD [PASS]
granted_VBN [SUAV]
annually_RB
to_PIN
senior_JJ
staff_NN
in_PIN
SmithKline_NN
Beecham_NN
,_,
designating_VBG [PRESP]
a_DT
target_NN
number_NN
of_PIN
shares_NN
for_PIN
each_QUAN
participant_NN
based_VBN [WZPAST]
on_PIN
job_NN
grade_NN
._.
Following_VBG [PRESP]
a_DT
three-year_JJ
measurement_NOMZ
period_NN
,_,
the_DT
R&N_NN
Committee_NN
reviewed_VBD
SmithKline_NN
Beechams_NN
total_JJ
shareholder_NN
return_NN
relative_JJ
to_PIN
the_DT
other_JJ
companies_NN
comprising_VBG [WZPRES]
the_DT
FTSE_NN
100_CD
Index_NN
,_,
and_ANDC
made_VBD
a_DT
final_JJ
award_NN
of_PIN
a_DT
proportion_NOMZ
of_PIN
the_DT
target_NN
number_NN
of_PIN
shares_NN
,_,
up_RB
to_PIN
100_CD
per_PIN
cent_NN
,_,
depending_VBG [PRESP]
on_PIN
performance_NN
._.
The_DT
first_JJ
two_CD
measurement_NOMZ
periods_NN
ended_VBN [WZPAST]
on_PIN
31st_CD
December_NN
1998_CD
and_CC
1999_CD
and_CC
,_,
100_CD
per_PIN
cent_NN
and_CC
97_CD
per_PIN
cent_NN
,_,
respectively_RB
,_,
of_PIN
the_DT
target_NN
number_NN
of_PIN
shares_NN
was_VBD [PASS]
awarded_VBN
._.
Receipt_NN
of_PIN
the_DT
award_NN
could_POMD
be_VB [PASS]
deferred_VBN
,_,
in_PIN
which_WDT [PIRE]
case_NN
the_DT
shares_NN
remained_VBD
in_PIN
the_DT
MTIP_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
merger_NN
all_QUAN
outstanding_JJ
awards_NN
became_VBD
payable_JJ
at_PIN
100_CD
per_PIN
cent_NN
of_PIN
the_DT
target_NN
number_NN
of_PIN
shares_NN
at_PIN
the_DT
end_NN
of_PIN
each_QUAN
three-year_JJ
cycle_NN
._.
Shares_NN
ADSs_NN
Number_NN
of_PIN
shares_NN
issuable_JJ
under_IN
the_DT
Mid-Term_NN
Incentive_NN
Plan_NN
Number_NN
000_CD
Number_NN
000_CD
At_PIN
31st_CD
December_NN
1999_CD
4,836_CD
1,482_CD
Awards_NN
granted_VBD [SUAV]
124_CD
24_CD
Awards_NN
exercised_VBN
1,224_CD
259_CD
Awards_NN
canceled_VBD
170_CD
29_CD
Converted_VBN
to_PIN
GlaxoSmithKline_NN
awards_NN
3,566_CD
1,218_CD
At_PIN
31st_CD
December_NN
2000_CD
Glaxo_NN
Wellcome_NN
share_NN
option_NOMZ
schemes_NN
At_PIN
the_DT
date_NN
of_PIN
the_DT
merger_NN
,_,
all_QUAN
Glaxo_NN
Wellcome_NN
options_NOMZ
,_,
except_PIN
for_PIN
share_NN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
in_PIN
2000_CD
and_CC
savings-related_JJ
share_NN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
in_PIN
1998_CD
,_,
1999_CD
and_CC
2000_CD
,_,
became_VBD
exercisable_JJ
and_CC
performance_NN
conditions_NOMZ
,_,
where_RB
applicable_JJ
,_,
lapsed_VBD
._.
Savings-related_JJ
Share_NN
option_NOMZ
schemes_NN
share_NN
option_NOMZ
schemes_NN
Total_JJ
Weighted_NN
Weighted_NN
Weighted_NN
exercise_NN
exercise_NN
exercise_NN
Number_NN
of_PIN
shares_NN
issuable_JJ
under_IN
outstanding_JJ
options_NOMZ
Number_NN
000_CD
price_NN
Number_NN
000_CD
price_NN
Number_NN
000_CD
price_NN
At_PIN
31st_CD
December_NN
1999_CD
83,014_CD
12.74_CD
11,418_CD
9.18_CD
94,432_CD
12.31_CD
Options_NOMZ
granted_VBN [SUAV]
35,989_CD
14.81_CD
2,112_CD
16.48_CD
38,101_CD
14.91_CD
Options_NOMZ
exercised_VBN
7,956_CD
7.77_CD
4,801_CD
6.72_CD
12,757_CD
7.38_CD
Options_NOMZ
canceled_VBN
4,299_CD
12.53_CD
332_CD
11.36_CD
4,631_CD
12.44_CD
Converted_VBN
to_PIN
GlaxoSmithKline_NN
options_NOMZ
106,748_CD
13.87_CD
8,397_CD
12.34_CD
115,145_CD
13.76_CD
At_PIN
31st_CD
December_NN
2000_CD
Glaxo_NN
Wellcome_NN
share_NN
award_NN
schemes_NN
Glaxo_NN
Wellcome_NN
operated_VBD
a_DT
Long_JJ
Term_NN
Incentive_NN
Plan_NN
and_CC
,_,
between_PIN
1996_CD
and_CC
1998_CD
,_,
an_DT
Annual_JJ
Incentive_NN
Plan_NN
._.
The_DT
Long_NN
Term_NN
Incentive_NN
Plan_NN
granted_VBD [SUAV]
awards_NN
over_IN
shares_NN
to_PIN
Directors_NN
and_CC
senior_JJ
staff_NN
at_PIN
a_DT
nominal_JJ
cost_NN
._.
The_DT
percentage_NN
of_PIN
each_QUAN
award_NN
that_TSUB
vested_VBD
was_VBD [PASS]
based_VBN
on_PIN
the_DT
performance_NN
of_PIN
Glaxo_NN
Wellcome_NN
over_IN
a_DT
three-year_JJ
period_NN
._.
The_DT
Annual_JJ
Incentive_NN
Plan_NN
was_VBD [BEMA]
a_DT
performance_NN
bonus_NN
consisting_VBG [WZPRES]
of_PIN
a_DT
basic_JJ
award_NN
of_PIN
shares_NN
and_CC
a_DT
matching_JJ
award_NN
with_PIN
a_DT
three-year_JJ
retention_NOMZ
period_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
merger_NN
the_DT
awards_NN
under_IN
the_DT
Long_NN
Term_NN
Incentive_NN
Plan_NN
became_VBD
payable_JJ
in_PIN
full_JJ
and_CC
the_DT
retention_NOMZ
period_NN
of_PIN
the_DT
Annual_JJ
Incentive_NN
Plan_NN
lapsed_VBD
._.
Number_NN
of_PIN
shares_NN
issuable_JJ
under_IN
share_NN
award_NN
schemes_NN
Number_NN
000_CD
At_PIN
31st_CD
December_NN
1999_CD
2,364_CD
Awards_NN
granted_VBN [SUAV] [THATD]
826_CD
Awards_NN
exercised_VBN
790_CD
Awards_NN
canceled_VBD
289_CD
Converted_VBN
to_PIN
GlaxoSmithKline_NN
awards_NN
2,111_CD
At_PIN
31st_CD
December_NN
2000_CD
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
121_CD
34_CD
Employee_NN
share_NN
schemes_NN
continued_VBD
Employee_NN
Share_NN
Ownership_NN
Trusts_NN
The_NN
Group_NN
sponsors_VPRT
Employee_NN
Share_NN
Ownership_NN
Trusts_NN
to_TO
acquire_VB
and_PHC
hold_VB [PRIV]
shares_NN
in_PIN
GlaxoSmithKline_NN
plc_NN
to_TO
satisfy_VB
awards_NN
made_VBN
under_IN
employee_NN
incentive_NN
plans_NN
and_PHC
options_NOMZ
granted_VBN [SUAV]
under_IN
employee_NN
share_NN
option_NOMZ
schemes_NN
._.
The_DT
trustees_NN
of_PIN
the_DT
Employee_NN
Share_NN
Ownership_NN
Trusts_NN
purchase_NN
shares_NN
on_PIN
the_DT
open_JJ
market_NN
with_PIN
finance_NN
provided_VBN [WZPAST]
by_PIN
the_DT
Group_NN
by_PIN
way_NN
of_PIN
loan_NN
or_CC
contributions_NOMZ
._.
The_DT
expected_VBN [PRIV]
cost_NN
of_PIN
the_DT
obligations_NOMZ
to_TO
deliver_VB
shares_NN
under_IN
the_DT
schemes_NN
are_VPRT [SPAU] [PASS]
normally_RB
spread_VBN
over_IN
the_DT
periods_NN
of_PIN
service_NN
in_PIN
respect_NN
of_PIN
which_WDT [PIRE]
the_DT
awards_NN
and_PHC
options_NOMZ
are_VPRT [PASS]
granted_VBN [SUAV]
._.
An_DT
accelerated_JJ
charge_NN
was_VBD [PASS]
made_VBN
in_PIN
2000_CD
in_PIN
respect_NN
of_PIN
the_DT
outstanding_JJ
cost_NN
of_PIN
providing_VBG
shares_NN
for_PIN
awards_NN
and_PHC
options_NOMZ
which_WDT [WHSUB]
became_VBD
exercisable_JJ
solely_RB
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
merger_NN
._.
Shares_NN
held_VBD [PRIV]
for_PIN
share_NN
award_NN
schemes_NN
2002_CD
2001_CD
Number_NN
of_PIN
shares_NN
000_CD
7,055_CD
6,701_CD
m_NN
m_NN [BEMA]
Nominal_JJ
value_NN
2_CD
2_CD
Cost_NN
less_JJ
provision_NN
75_CD
58_CD
Market_NN
value_NN
84_CD
115_CD
Shares_NN
held_VBN [PRIV] [WZPAST]
for_PIN
share_NN
option_NOMZ
schemes_NN
2002_CD
2001_CD
Number_NN
of_PIN
shares_NN
000_CD
174,256_CD
180,708_CD
m_NN
m_NN [BEMA]
Nominal_JJ
value_NN
44_CD
45_CD
Cost_NN
less_JJ
provision_NN
2,751_CD
2,878_CD
Market_NN
value_NN
2,077_CD
3,114_CD
The_DT
Trusts_NN
also_RB
acquire_VB
and_PHC
hold_VB [PRIV]
shares_NN
to_TO
meet_VB
notional_JJ
dividends_NN
re-invested_VBD
on_PIN
deferred_VBN
awards_NN
under_IN
the_DT
SmithKline_NN
Beecham_NN
Mid-Term_NN
Incentive_NN
Plan_NN
._.
The_DT
trustees_NN
have_VPRT [PEAS]
waived_VBN
their_TPP3
rights_NN
to_PIN
dividends_NN
on_PIN
the_DT
shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
Employee_NN
Share_NN
Ownership_NN
Trusts_NN
._.
Option_NOMZ
pricing_GER
For_PIN
the_DT
purposes_NN
of_PIN
valuing_VBG
options_NOMZ
to_TO
arrive_VB
at_PIN
the_DT
stock-based_JJ
compensation_NOMZ
adjustment_NOMZ
in_PIN
the_DT
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
in_PIN
Note_NN
37_CD
,_,
the_DT
Black-Scholes_NN
option_NOMZ
pricing_GER
model_NN
has_VPRT [PEAS]
been_VBN [PASS]
used_VBN
._.
The_DT
assumptions_NOMZ
used_VBN [WZPAST]
in_PIN
the_DT
model_NN
for_PIN
2002_CD
and_CC
2001_CD
are_VPRT
as_IN
follows_VPRT
:_:
2002_CD
2001_CD
Risk-free_JJ
interest_NN
rate_NN
4.2_CD
%_NN
5.4_CD
%_NN
4.5_CD
%_NN
5.0_CD
%_NN
Dividend_NN
yield_NN
1.9_CD
%_NN
1.8_CD
%_NN
1.9_CD
%_NN
Volatility_NOMZ
33_CD
%_NN
33_CD
%_NN
Expected_VBN [PRIV]
lives_NN
of_PIN
options_NOMZ
granted_VBN [SUAV]
under_IN
:_:
Share_NN
option_NOMZ
schemes_NN
5_CD
years_NN
5_CD
years_NN
Savings_GER
related_VBN
share_NN
option_NOMZ
schemes_NN
3_CD
years_NN
3_CD
years_NN
35_CD
Related_VBN
party_NN
transactions_NOMZ
GlaxoSmithKline_NN
held_VBD [PRIV]
a_DT
23_CD
per_PIN
cent_NN
interest_NN
in_PIN
Quest_NN
Diagnostics_NN
Inc._NN
throughout_PIN
2002_CD
._.
In_PIN
December_NN
2002_CD
GlaxoSmithKline_NN
and_PHC
Quest_NN
amended_VBD
the_DT
terms_NN
of_PIN
their_TPP3
Global_JJ
Trials_NN
Agreement_NOMZ
,_,
which_WDT [SERE]
is_VPRT [BEMA]
a_DT
long-term_JJ
contractual_JJ
relationship_NN
under_IN
which_WDT
Quest_NN
is_VPRT [BEMA]
the_DT
primary_JJ
provider_NN
of_PIN
clinical_JJ
laboratory_NN
testing_GER
to_TO
support_VB
the_DT
Groups_NN
clinical_JJ
trials_NN
testing_GER
requirements_NOMZ
worldwide_VPRT
._.
In_PIN
February_NN
2002_CD
,_,
Mr_NN
Ingram_NN
,_,
then_RB
a_DT
member_NN
of_PIN
the_DT
CET_NN
,_,
purchased_VBD
a_DT
portion_NOMZ
of_PIN
land_NN
being_VBG [WZPRES]
part_NN
of_PIN
a_DT
residential_JJ
property_NN
owned_VBN [WZPAST]
by_PIN
the_DT
Group_NN
that_TSUB
was_VBD [BEMA]
adjacent_PRED
to_PIN
Mr_NN
Ingrams_NN
own_JJ
residence_NN
._.
The_DT
total_JJ
sale_NN
price_NN
was_VBD
$_$
16,500_CD
based_VBN
on_PIN
an_DT
independent_JJ
valuation_NOMZ
of_PIN
the_DT
land_NN
._.
The_DT
Group_NN
subsequently_TIME
determined_VBD [SUAV] [PRIV]
that_THVC
retention_NOMZ
of_PIN
the_DT
residential_JJ
property_NN
no_RB
longer_RB
served_VBD
its_PIT
business_NOMZ
needs_NN
and_CC
listed_VBN
the_DT
property_NN
for_PIN
sale_NN
._.
An_DT
independent_JJ
valuation_NOMZ
of_PIN
the_DT
property_NN
on_PIN
3rd_CD
June_NN
2002_CD
valued_VBN
it_PIT
at_PIN
$_$
1,050,000_CD
and_CC
the_DT
property_NN
was_VBD [PASS]
offered_VBN
for_PIN
sale_NN
through_PIN
an_DT
estate_NN
agent_NN
._.
Mr_NN
Ingram_NN
made_VBD
the_DT
highest_JJ
offer_NN
for_PIN
the_DT
property_NN
and_CC
purchased_VBD
it_PIT
from_PIN
the_DT
Group_NN
for_PIN
total_JJ
consideration_NOMZ
of_PIN
$_$
1,070,000_CD
._.
36_CD
GlaxoSmithKline_NN
plc_NN
investment_NOMZ
in_PIN
subsidiary_NN
companies_NN
During_PIN
2002_CD
,_,
GlaxoSmithKline_NN
plc_NN
initiated_VBD
an_DT
internal_JJ
reorganisation_NOMZ
,_,
as_CONJ
a_NULL
result_NULL
of_PIN
which_WDT [PIRE]
the_DT
company_NN
acquired_VBD
direct_JJ
investments_NOMZ
in_PIN
subsidiary_NN
companies_NN
which_WDT [WHSUB]
had_VBD [SPAU] [PEAS]
previously_TIME
been_VBN [PASS]
held_VBN [PRIV]
as_IN
indirect_JJ
investments_NOMZ
._.
122_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
37_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
Summary_NN
of_PIN
material_NN
differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
GAAP_NN
The_NN
Financial_NN
statements_NOMZ
,_,
analyses_NN
and_PHC
reconciliations_NOMZ
presented_VBN [WZPAST]
in_PIN
Capitalised_JJ
interest_NN
this_DEMO
Note_NN
represent_VPRT
the_DT
financial_JJ
information_NOMZ
which_WDT [WHSUB]
would_PRMD
be_VB
Under_IN
UK_NN
GAAP_NN
,_,
the_DT
Group_NN
does_VPRT
not_XX0
capitalize_VB
interest_NN
._.
US_FPP1
GAAP_NN
required_VBN [SUAV]
if_COND
US_FPP1
Generally_RB
Accepted_JJ
Accounting_GER
Principles_NN
US_FPP1
GAAP_NN
requires_VPRT [SUAV] [THATD]
interest_NN
incurred_VBN
as_IN
part_NN
of_PIN
the_DT
cost_NN
of_PIN
constructing_VBG
xed_VBN
had_VBD [PEAS]
been_VBN [PASS]
applied_VBN
instead_CONJ
of_NULL
UK_NN
GAAP_NN
._.
assets_NN
to_TO
be_VB [PASS]
capitalized_VBN
and_PHC
amortised_VBN
over_IN
the_DT
life_NN
of_PIN
the_DT
asset_NN
._.
The_DT
most_EMPH
significant_JJ
difference_NN
between_PIN
US_FPP1
and_PHC
UK_NN
GAAP_NN
is_VPRT
that_DEMP
,_,
Computer_NN
software_NN
under_IN
UK_NN
GAAP_NN
,_,
the_DT
combination_NOMZ
of_PIN
Glaxo_NN
Wellcome_NN
plc_NN
and_CC
Under_IN
UK_NN
GAAP_NN
,_,
the_DT
Group_NN
capitalises_VPRT
costs_NN
incurred_VBN [WZPAST]
in_PIN
acquiring_VBG
SmithKline_NN
Beecham_NN
plc_NN
has_VPRT [PEAS]
been_VBN [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
merger_NN
and_CC
developing_VBG
computer_NN
software_NN
for_PIN
internal_JJ
use_NN
where_RB
the_DT
pooling_VBG
of_PIN
interest_NN
while_OSUB
under_IN
US_FPP1
GAAP_NN
this_DEMO
transaction_NOMZ
is_VPRT
software_NN
supports_VPRT
a_DT
significant_JJ
business_NOMZ
system_NN
and_CC
the_DT
accounted_VBN
for_PIN
as_IN
a_DT
purchase_NN
business_NOMZ
combination_NOMZ
with_PIN
Glaxo_NN
expenditure_NN
leads_VPRT
to_PIN
the_DT
creation_NOMZ
of_PIN
a_DT
durable_JJ
asset_NN
._.
For_PIN
US_FPP1
GAAP_NN
,_,
Wellcome_NN
acquiring_VBG [WZPRES]
SmithKline_NN
Beecham_NN
._.
the_DT
Group_NN
applies_VPRT
SOP_NN
98-1_CD
Accounting_GER
for_PIN
the_DT
Costs_NN
of_PIN
Computer_NN
Software_NN
Developed_VBD
or_CC
Obtained_VBN
for_PIN
Internal_NN
Use_NN
which_WDT [WHOBJ]
GlaxoSmithKline_NN
plc_NN
was_VBD [PASS]
formed_VBN
to_TO
give_VB
effect_NN
to_PIN
a_DT
Scheme_NN
of_PIN
restricts_VPRT
the_DT
categories_NN
of_PIN
costs_NN
which_WDT [WHSUB]
can_POMD
be_VB [PASS]
capitalized_VBN
._.
Arrangement_NOMZ
for_PIN
the_DT
merger_NN
of_PIN
Glaxo_NN
Wellcome_NN
plc_NN
and_PHC
SmithKline_NN
Beecham_NN
plc_NN
effective_JJ
on_PIN
27th_JJ
December_NN
2000_CD
._.
GlaxoSmithKline_NN
plc_NN
Goodwill_NN
and_CC
intangible_JJ
xed_JJ
assets_NN
acquired_VBD
the_DT
whole_NN
of_PIN
the_DT
issued_VBN
share_NN
capital_NN
of_PIN
Glaxo_NN
Wellcome_NN
plc_NN
Under_IN
UK_NN
GAAP_NN
,_,
goodwill_NN
arising_VBG [WZPRES]
on_PIN
acquisitions_NOMZ
before_IN
1998_CD
,_,
and_ANDC
SmithKline_NN
Beecham_NN
plc_NN
in_PIN
exchange_NN
for_PIN
shares_NN
in_PIN
accounted_VBN
for_PIN
under_IN
the_DT
purchase_NN
method_NN
,_,
has_VPRT [PEAS]
been_VBN [PASS]
eliminated_VBN
GlaxoSmithKline_NN
plc._NN
._.
Upon_PIN
completion_NOMZ
of_PIN
the_DT
merger_NN
the_DT
former_JJ
against_PIN
shareholders_NN
funds_NN
._.
Additionally_RB
,_,
UK_NN
GAAP_NN
requires_VPRT [SUAV]
that_THVC
shareholders_NN
of_PIN
Glaxo_NN
Wellcome_NN
held_VBD [PRIV]
approximately_RB
58.75_CD
per_PIN
cent_NN
on_PIN
subsequent_JJ
disposal_NN
or_CC
closure_NN
of_PIN
a_DT
business_NOMZ
,_,
any_QUAN
goodwill_NN
and_CC
the_DT
former_JJ
shareholders_NN
of_PIN
SmithKline_NN
Beecham_NN
held_VBD [PRIV]
previously_TIME
taken_VBN
directly_RB
to_PIN
shareholders_NN
funds_NN
is_VPRT [SPAU] [PASS]
then_RB
charged_VBN
approximately_RB
41.25_CD
per_PIN
cent_NN
of_PIN
the_DT
issued_VBN
share_NN
capital_NN
of_PIN
against_PIN
income_NN
._.
Beginning_VBG [PRESP]
in_PIN
1998_CD
,_,
the_DT
Group_NN
changed_VBD
its_PIT
GlaxoSmithKline_NN
plc._NN
._.
accounting_GER
policy_NN
for_PIN
goodwill_NN
and_CC
intangible_JJ
assets_NN
under_IN
UK_NN
GAAP_NN
in_PIN
respect_NN
of_PIN
acquisitions_NOMZ
from_PIN
1998_CD
._.
Under_IN
UK_NN
GAAP_NN
,_,
As_IN
the_DT
combination_NOMZ
of_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
goodwill_NN
arising_VBG [WZPRES]
on_PIN
acquisitions_NOMZ
from_PIN
1998_CD
is_VPRT [PASS]
capitalized_VBN
and_PHC
was_VBD [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
merger_NN
under_IN
UK_NN
GAAP_NN
,_,
the_DT
financial_JJ
amortised_VBN
over_IN
a_DT
period_NN
not_XX0
exceeding_VBG
20_CD
years_NN
._.
statements_NOMZ
of_PIN
GlaxoSmithKline_NN
under_IN
UK_NN
GAAP_NN
represent_VPRT
the_DT
combined_VBN
Financial_NN
statements_NOMZ
of_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Under_IN
US_FPP1
GAAP_NN
,_,
goodwill_NN
arising_VBG [WZPRES]
on_PIN
acquisitions_NOMZ
prior_RB
to_PIN
Beecham_NN
on_PIN
a_DT
historical_JJ
basis_NN
for_PIN
2000_CD
._.
30_CD
June_NN
2001_CD
was_VBD [PASS]
capitalized_VBN
and_PHC
amortised_VBN
over_IN
a_DT
period_NN
not_XX0
exceeding_VBG
40_CD
years_NN
._.
In_PIN
July_NN
2001_CD
,_,
the_DT
FASB_NN
issued_VBD
SFAS_NN
142_CD
Under_IN
US_FPP1
GAAP_NN
,_,
this_DEMO
business_NOMZ
combination_NOMZ
did_VBD
not_XX0
qualify_VB
for_PIN
Goodwill_NN
and_CC
Other_JJ
Intangible_NN
Assets_NN
._.
SFAS_NN
142_CD
requires_VPRT [SUAV] [THATD]
that_DEMP
pooling_VBG
of_PIN
interests_NN
accounting_VBG [WZPRES]
and_CC
Glaxo_NN
Wellcome_NN
was_VBD
goodwill_NN
no_RB
longer_RB
be_VB [PASS]
amortised_VBN
over_IN
its_PIT
estimated_VBN [PRIV]
useful_JJ
life_NN
._.
The_DT
determined_VBN [SUAV] [PRIV]
to_TO
be_VB [BEMA]
the_DT
accounting_GER
acquirer_NN
in_PIN
a_DT
purchase_NN
acquisition_NOMZ
Group_NN
must_NEMD [SPAU]
instead_CONJ
identify_VB
and_PHC
value_VB
its_PIT
reporting_VBG [PUBV]
units_NN
for_PIN
the_DT
dated_JJ
27th_JJ
December_NN
2000_CD
._.
Under_IN
US_FPP1
GAAP_NN
the_DT
financial_JJ
purpose_NN
of_PIN
assessing_VBG
,_,
at_PIN
least_JJ
annually_RB
,_,
potential_JJ
impairment_NOMZ
of_PIN
statements_NOMZ
of_PIN
GlaxoSmithKline_NN
prior_RB
to_PIN
the_DT
merger_NN
are_VPRT
therefore_CONJ
goodwill_NN
allocated_VBN [WZPAST]
to_PIN
each_QUAN
reporting_VBG [PUBV]
unit_NN
._.
Additionally_RB
,_,
the_DT
Group_NN
those_DEMO
of_PIN
Glaxo_NN
Wellcome_NN
._.
reassesses_VPRT
the_DT
useful_JJ
lives_NN
of_PIN
existing_VBG
recognized_VBN [PRIV]
intangible_JJ
assets_NN
._.
In_PIN
view_NN
of_PIN
the_DT
proximity_NOMZ
of_PIN
the_DT
merger_NN
date_NN
to_PIN
the_DT
financial_JJ
year_NN
end_NN
Intangible_JJ
assets_NN
deemed_VBD [PRIV]
to_TO
have_VB
indefinite_JJ
lives_NN
are_VPRT
no_RB
longer_RB
date_NN
,_,
and_ANDC
the_DT
relative_JJ
insignicance_NN
of_PIN
any_QUAN
business_NOMZ
activity_NOMZ
between_PIN
amortised_JJ
,_,
instead_CONJ
they_TPP3
are_VPRT [PASS]
tested_VBN
annually_RB
for_PIN
potential_JJ
27th_JJ
December_NN
2000_CD
and_CC
31st_CD
December_NN
2000_CD
,_,
the_DT
accounting_GER
impairment_NOMZ
._.
Separate_JJ
intangible_JJ
assets_NN
with_PIN
nite_JJ
lives_NN
continue_VPRT
to_PIN
date_NN
of_PIN
the_DT
acquisition_NOMZ
was_VBD [BEMA]
for_PIN
practical_JJ
purposes_NN
taken_VBN [WZPAST]
as_RB
be_VB [PASS]
amortised_VBN
over_IN
their_TPP3
useful_JJ
lives_NN
._.
The_DT
Group_NN
adopted_VBD
SFAS_NN
142_CD
as_IN
of_PIN
1st_CD
January_NN
2002_CD
._.
The_DT
The_DT
reconciliation_NOMZ
of_PIN
the_DT
consolidated_JJ
income_NN
statements_NOMZ
and_CC
the_DT
implementation_NOMZ
of_PIN
SFAS_NN
142_CD
resulted_VBD
in_PIN
no_SYNE
impairment_NOMZ
of_PIN
the_DT
consolidated_JJ
statements_NOMZ
of_PIN
comprehensive_JJ
income_NN
and_PHC
changes_NN
in_PIN
Groups_NN
goodwill_NN
and_CC
an_DT
initial_JJ
impairment_NOMZ
of_PIN
173_CD
million_CD
shareholder_NN
equity_NOMZ
for_PIN
the_DT
year_NN
ended_VBD
31st_CD
December_NN
2002_CD
127_CD
million_CD
net_NN
of_PIN
tax_NN
on_PIN
indefinite-lived_JJ
assets_NN
._.
This_DEMP
is_VPRT [PASS]
shown_VBN [PRIV]
as_IN
correspondingly_RB
reect_VB
the_DT
purchase_NN
method_NN
of_PIN
accounting_GER
for_PIN
a_DT
cumulative_JJ
effect_NN
of_PIN
an_DT
accounting_GER
change_NN
._.
the_DT
acquisition_NOMZ
of_PIN
SmithKline_NN
Beecham_NN
by_PIN
Glaxo_NN
Wellcome_NN
._.
The_DT
Under_IN
UK_NN
GAAP_NN
,_,
costs_VPRT
to_TO
be_VB [PASS]
incurred_VBN
in_PIN
integrating_VBG
and_CC
income_NN
statement_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
presented_VBN
in_PIN
a_DT
US_FPP1
GAAP_NN
format_NN
and_CC
restructuring_VBG
the_DT
Wellcome_NN
,_,
SmithKline_NN
Beecham_NN
and_PHC
Block_NN
Drug_NN
therefore_CONJ
certain_JJ
exceptional_JJ
items_NN
under_IN
UK_NN
GAAP_NN
being_VBG [WZPRES]
product_NN
businesses_NOMZ
following_VBG [WZPRES]
the_DT
acquisitions_NOMZ
in_PIN
1995_CD
,_,
2000_CD
and_CC
2001_CD
divestments_NOMZ
,_,
merger_NN
integration_NOMZ
costs_NN
and_CC
,_,
in_CONJ
addition_NULL
,_,
the_DT
write-off_PIN
respectively_RB
were_VBD [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
post_NN
of_PIN
in-process_JJ
research_NN
and_PHC
development_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
classied_VBN
within_PIN
acquisition_NOMZ
._.
Under_IN
US_FPP1
GAAP_NN
,_,
certain_JJ
of_PIN
such_JJ
costs_NN
are_VPRT [PASS]
considered_VBN [PRIV]
operating_GER
profit_NN
._.
in_PIN
the_DT
allocation_NOMZ
of_PIN
purchase_NN
consideration_NOMZ
thereby_RB
affecting_VBG
the_DT
A_DT
consolidated_JJ
balance_NN
sheet_NN
and_CC
a_DT
consolidated_JJ
statement_NOMZ
of_PIN
cash_NN
goodwill_NN
arising_VBG [WZPRES]
on_PIN
acquisition_NOMZ
._.
ows_NN
under_IN
US_FPP1
GAAP_NN
and_CC
in_PIN
US_FPP1
GAAP_NN
format_NN
are_VPRT [SPAU] [PASS]
also_RB
presented_VBN
._.
Under_IN
UK_NN
GAAP_NN
certain_JJ
intangible_JJ
assets_NN
related_VBN
to_TO
specic_VB
These_DEMO
Financial_NN
statements_NOMZ
reect_VPRT
both_DT
the_DT
purchase_NN
method_NN
of_PIN
compounds_NN
or_CC
products_NN
which_WDT [WHSUB]
are_VPRT [PASS]
purchased_VBN
from_PIN
a_DT
third_JJ
party_NN
accounting_GER
for_PIN
the_DT
combination_NOMZ
of_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
and_CC
are_VPRT [PASS]
developed_VBN
for_PIN
commercial_JJ
applications_NOMZ
are_VPRT [PASS]
capitalized_VBN
._.
Beecham_NN
and_CC
also_RB
other_JJ
material_NN
adjustments_NOMZ
which_WDT [WHSUB]
would_PRMD
be_VB
Under_IN
US_FPP1
GAAP_NN
,_,
payments_NOMZ
made_VBD
for_PIN
these_DEMO
compounds_NN
or_CC
products_NN
required_VBN [SUAV]
if_COND
US_FPP1
GAAP_NN
had_VBD [PEAS]
been_VBN [PASS]
applied_VBN
instead_CONJ
of_NULL
UK_NN
GAAP_NN
for_PIN
which_WDT [PIRE]
are_VPRT [BEMA]
still_RB
in_PIN
development_NOMZ
and_CC
have_VPRT [PEAS]
not_XX0
yet_RB
received_VBN
regulatory_JJ
the_DT
periods_NN
presented_VBN
._.
A_DT
summary_NN
of_PIN
the_DT
purchase_NN
accounting_GER
approval_NN
are_VPRT [PASS]
charged_VBN
directly_RB
to_PIN
profit_NN
and_PHC
loss_NN
until_IN
such_JJ
time_NN
that_TOBJ
adjustments_NOMZ
and_CC
of_PIN
other_JJ
US_FPP1
GAAP_NN
adjustments_NOMZ
is_VPRT [PASS]
provided_VBN
in_PIN
the_DT
they_TPP3
receive_VPRT
regulatory_JJ
approval_NN
._.
reconciliations_NOMZ
of_PIN
profit_NN
attributable_JJ
to_PIN
shareholders_NN
and_CC
of_PIN
equity_NOMZ
shareholders_NN
funds_NN
from_PIN
UK_NN
to_PIN
US_FPP1
GAAP_NN
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
123_CD
37_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
merger_NN
certain_JJ
of_PIN
the_DT
Groups_NN
options_NOMZ
vested_VBN [WZPAST]
immediately_TIME
requiring_VBG [SUAV]
the_DT
acceleration_NOMZ
of_PIN
compensation_NOMZ
expense_NN
._.
Merger_NN
transaction_NOMZ
costs_VPRT
The_DT
amount_NN
of_PIN
stock-based_JJ
compensation_NOMZ
expense_NN
related_VBN [WZPAST]
to_PIN
this_DEMO
Glaxo_NN
Wellcome_NN
incurred_VBD
total_JJ
merger-related_JJ
transaction_NOMZ
costs_NN
of_PIN
accelerated_VBN
vesting_GER
was_VBD [BEMA]
83_CD
million_CD
in_PIN
2000_CD
._.
The_DT
disclosures_NN
66_CD
million_CD
,_,
excluding_VBG
integration_NOMZ
and_PHC
restructuring_GER
costs_NN
._.
Under_IN
UK_NN
required_VBN [SUAV] [WZPAST]
by_PIN
SFAS_NN
123_CD
are_VPRT [PASS]
included_VBN
in_PIN
Note_NN
34_CD
._.
GAAP_NN
these_DEMO
merger_NN
transaction_NOMZ
costs_NN
were_VBD [PASS]
expensed_VBN
as_IN
incurred_VBN
during_PIN
2000_CD
._.
Under_IN
US_FPP1
GAAP_NN
,_,
direct_JJ
acquisition_NOMZ
costs_NN
of_PIN
the_DT
Additionally_RB
,_,
the_DT
Group_NN
is_VPRT [PASS]
entitled_VBN
to_TO
receive_VB
a_DT
tax_NN
deduction_NOMZ
for_PIN
the_DT
acquiring_VBG
company_NN
are_VPRT [PASS]
included_VBN
as_IN
a_DT
portion_NOMZ
of_PIN
the_DT
purchase_NN
amount_NN
treated_VBN
as_IN
compensation_NOMZ
under_IN
US_FPP1
tax_NN
rules_NN
for_PIN
employee_NN
consideration_NOMZ
._.
stock_NN
options_NOMZ
which_WDT [WHSUB]
have_VPRT [PEAS]
been_VBN [BYPA]
exercised_VBN
by_PIN
US_FPP1
employees_NN
during_PIN
the_DT
year_NN
._.
Under_IN
UK_NN
GAAP_NN
this_DEMP
is_VPRT [PASS]
treated_VBN
as_IN
a_DT
reduction_NOMZ
of_PIN
tax_NN
Restructuring_GER
costs_NN
expense_NN
whereas_OSUB
under_IN
US_FPP1
GAAP_NN
a_DT
portion_NOMZ
of_PIN
this_DEMO
amount_NN
is_VPRT [BEMA]
The_DT
requirements_NOMZ
for_PIN
recording_VBG
a_DT
provision_NN
for_PIN
restructuring_VBG
costs_NN
credited_VBN [WZPAST]
to_PIN
equity_NOMZ
._.
are_VPRT [BEMA]
different_PRED
in_PIN
certain_JJ
aspects_NN
under_IN
US_FPP1
GAAP_NN
than_PIN
under_IN
UK_NN
GAAP_NN
._.
Accordingly_RB
,_,
adjustments_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
made_VBN
to_TO
eliminate_VB
the_DT
Employee_NN
Share_NN
Ownership_NN
Trust_NN
ESOT_NN
UK_NN
GAAP_NN
provisions_NN
for_PIN
restructuring_VBG
costs_NN
that_TSUB
do_VPRT
not_XX0
meet_VB
US_FPP1
Under_IN
UK_NN
GAAP_NN
shares_NN
of_PIN
the_DT
Groups_NN
stock_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
ESOT_NN
GAAP_NN
requirements_NOMZ
._.
are_VPRT [PASS]
recorded_VBN
at_PIN
cost_NN
,_,
less_JJ
a_DT
provision_NN
representing_VBG [WZPRES]
the_DT
difference_NN
between_PIN
the_DT
cost_NN
and_CC
the_DT
option_NOMZ
exercise_NN
price_NN
,_,
and_ANDC
accounted_VBD
for_PIN
Marketable_JJ
securities_NOMZ
as_IN
xed_JJ
asset_NN
investments_NOMZ
._.
Projected_JJ
losses_NN
on_PIN
the_DT
exercise_NN
of_PIN
the_DT
Marketable_JJ
securities_NOMZ
consist_VPRT
primarily_RB
of_PIN
equity_NOMZ
securities_NOMZ
and_PHC
options_NOMZ
covered_VBN [WZPAST]
by_PIN
the_DT
shares_NN
are_VPRT [PASS]
recorded_VBN
through_PIN
the_DT
profit_NN
and_CC
certain_JJ
other_JJ
liquid_JJ
investments_NOMZ
._.
Under_IN
UK_NN
GAAP_NN
these_DEMO
securities_NOMZ
loss_NN
account_NN
over_IN
the_DT
life_NN
of_PIN
the_DT
options_NOMZ
._.
Under_IN
US_FPP1
GAAP_NN
shares_NN
of_PIN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
and_CC
net_JJ
realisable_JJ
value_NN
._.
Under_IN
US_FPP1
the_DT
Groups_NN
stock_NN
purchased_VBN [WZPAST]
by_PIN
the_DT
ESOT_NN
are_VPRT [PASS]
accounted_VBN
for_PIN
within_PIN
GAAP_NN
these_DEMO
securities_NOMZ
are_VPRT [BEMA]
available_PRED
for_PIN
sale_NN
under_IN
Statement_NOMZ
of_PIN
shareholders_NN
equity_NOMZ
at_PIN
cost_NN
._.
Gains_NN
or_CC
losses_NN
arising_VBG [WZPRES]
on_PIN
subsequent_JJ
Financial_NN
Accounting_GER
Standard_NN
No_NN
115_CD
SFAS_NN
115_CD
Accounting_GER
for_PIN
issuance_NN
of_PIN
the_DT
shares_NN
to_PIN
employees_NN
to_TO
satisfy_VB
share_NN
options_NOMZ
are_VPRT [BEMA]
certain_JJ
investments_NOMZ
in_PIN
debt_NN
and_PHC
equity_NOMZ
securities_NOMZ
and_CC
are_VPRT [PASS]
carried_VBN
at_PIN
recorded_VBN
as_IN
adjustments_NOMZ
to_PIN
shareholders_NN
equity_NOMZ
._.
fair_JJ
value_NN
,_,
with_PIN
the_DT
unrealised_JJ
gains_NN
and_PHC
losses_NN
,_,
net_NN
of_PIN
tax_NN
,_,
reported_VBD [PUBV]
as_IN
a_DT
separate_JJ
component_NN
of_PIN
shareholders_NN
equity_NOMZ
._.
Derivative_JJ
instruments_NOMZ
Statement_NOMZ
of_PIN
Financial_NN
Accounting_GER
Standard_NN
No._NN
._.
133_CD
,_,
Accounting_GER
Pensions_NN
and_CC
other_JJ
post-retirement_JJ
benets_NN
for_PIN
Derivative_JJ
Instruments_NOMZ
and_PHC
Hedging_GER
Activities_NOMZ
SFAS_NN
133_CD
as_IN
The_DT
key_JJ
differences_NN
between_PIN
UK_NN
SSAP_NN
24_CD
and_CC
US_FPP1
GAAP_NN
in_PIN
relation_NOMZ
amended_VBN [WZPAST]
by_PIN
SFAS_NN
137_CD
and_CC
SFAS_NN
138_CD
and_CC
as_IN
interpreted_VBN
by_PIN
the_DT
to_TO
dened_VBN
benefit_NN
pension_NN
plans_NN
are_VPRT
:_:
Derivatives_NN
Implementation_NOMZ
Group_NN
,_,
was_VBD [BYPA]
adopted_VBN
by_PIN
the_DT
Group_NN
with_PIN
under_IN
UK_NN
GAAP_NN
the_DT
effect_NN
of_PIN
variations_NOMZ
in_PIN
cost_NN
can_POMD
be_VB
effect_NN
from_PIN
1st_CD
January_NN
2001_CD
._.
SFAS_NN
133_CD
establishes_VPRT [PRIV]
accounting_GER
and_CC
accumulated_VBN
at_PIN
successive_JJ
valuations_NOMZ
and_CC
amortised_VBN
on_PIN
an_DT
reporting_GER
standards_NN
for_PIN
derivative_JJ
instruments_NOMZ
,_,
including_VBG
certain_JJ
aggregate_JJ
basis_NN
._.
Under_IN
US_FPP1
GAAP_NN
the_DT
amortisation_NOMZ
of_PIN
the_DT
derivative_JJ
instruments_NOMZ
embedded_VBN [WZPAST]
in_PIN
other_JJ
contracts_NN
collectively_RB
,_,
transition_NOMZ
asset_NN
and_CC
the_DT
costs_NN
of_PIN
past_JJ
service_NN
benefit_NN
referred_VBD
to_PIN
as_IN
derivatives_NN
and_CC
for_PIN
hedging_VBG
activities_NOMZ
._.
Under_IN
UK_NN
improvements_NOMZ
are_VPRT [SPAU] [PASS]
separately_RB
tracked_VBN
:_:
experience_NN
gains_NN
losses_NN
GAAP_NN
,_,
some_QUAN
derivative_JJ
instruments_NOMZ
used_VBN [WZPAST]
for_PIN
hedging_VBG
are_VPRT
not_XX0
are_VPRT [PASS]
dealt_VBN
with_PIN
on_PIN
an_DT
aggregate_JJ
basis_NN
but_CC
amortised_VBD
only_DWNT
if_COND
recognized_VBN [PRIV]
on_PIN
the_DT
balance_NN
sheet_NN
and_CC
the_DT
matching_JJ
principle_NN
is_VPRT
outside_PLACE
a_DT
10_CD
per_PIN
cent_NN
corridor_NN
._.
used_VBN
to_TO
match_VB
the_DT
gain_NN
or_CC
loss_NN
under_IN
these_DEMP
hedging_VBG
contracts_NN
to_PIN
the_DT
foreign_JJ
currency_NN
transaction_NOMZ
or_CC
profits_NN
to_PIN
which_WDT [PIRE]
they_TPP3
relate_VPRT
._.
UK_NN
GAAP_NN
allows_VPRT [SUAV]
measurements_NOMZ
of_PIN
plan_NN
assets_NN
and_PHC
liabilities_NOMZ
to_PIN
SFAS_NN
133_CD
requires_VPRT [SUAV]
that_THVC
an_DT
entity_NOMZ
recognize_VB [PRIV]
all_QUAN
derivatives_NN
as_IN
either_DT
be_VB [PASS]
based_VBN
on_PIN
the_DT
result_NN
of_PIN
the_DT
latest_JJ
actuarial_JJ
valuation_NOMZ
._.
US_FPP1
GAAP_NN
assets_NN
or_CC
liabilities_NOMZ
in_PIN
the_DT
consolidated_JJ
balance_NN
sheet_NN
and_PHC
measure_NN
requires_VPRT [SUAV]
measurement_NOMZ
of_PIN
plan_NN
assets_NN
and_PHC
liabilities_NOMZ
to_TO
be_VB [PASS]
made_VBN
those_DEMO
instruments_NOMZ
at_PIN
fair_JJ
value_NN
._.
Changes_NN
in_PIN
fair_JJ
value_NN
over_IN
the_DT
at_PIN
the_DT
date_NN
of_PIN
the_DT
Financial_NN
statements_NOMZ
or_CC
up_RB
to_PIN
three_CD
months_NN
period_NN
are_VPRT [PASS]
recorded_VBN
in_PIN
current_JJ
earnings_GER
unless_COND
hedge_JJ
accounting_GER
prior_RB
to_PIN
that_DEMO
date_NN
._.
The_DT
Group_NN
does_VPRT
not_XX0
designate_VB
any_QUAN
of_PIN
its_PIT
derivatives_NN
as_IN
The_DT
pension_NN
adjustment_NOMZ
also_RB
includes_VPRT
the_DT
impact_NN
of_PIN
changes_NN
in_PIN
qualifying_VBG
hedge_NN
instruments_NOMZ
under_IN
SFAS_NN
133_CD
._.
SFAS_NN
133_CD
prescribes_VPRT
minimum_JJ
pension_NN
liabilities_NOMZ
included_VBD
within_PIN
accumulated_VBN
other_JJ
requirements_NOMZ
for_PIN
designation_NOMZ
and_PHC
documentation_NOMZ
of_PIN
hedging_VBG
comprehensive_JJ
income_NN
._.
relationships_NN
and_CC
ongoing_JJ
assessments_NOMZ
of_PIN
effectiveness_NOMZ
in_PIN
order_NN
to_TO
qualify_VB
for_PIN
hedge_JJ
accounting_GER
._.
During_PIN
2002_CD
,_,
the_DT
Group_NN
decided_VBD [SUAV] [PRIV]
to_TO
align_VB
the_DT
measurement_NOMZ
date_NN
for_PIN
all_QUAN
of_PIN
its_PIT
pension_NN
plans_NN
to_PIN
31st_CD
December_NN
as_IN
certain_JJ
of_PIN
the_DT
The_NN
Group_NN
also_RB
evaluates_VPRT
contracts_NN
for_PIN
embedded_VBN
derivatives_NN
,_,
and_ANDC
Groups_NN
plans_NN
had_VBD
a_DT
measurement_NOMZ
date_NN
for_PIN
pension_NN
assets_NN
and_CC
considers_VPRT [PRIV]
whether_IN [WHCL]
any_QUAN
embedded_VBN
derivatives_NN
have_VPRT
to_TO
be_VB [PASS]
bifurcated_VBN
,_,
liabilities_NOMZ
of_PIN
30th_JJ
September_NN
._.
or_CC
separated_JJ
,_,
from_PIN
the_DT
host_NN
contracts_NN
in_PIN
accordance_NN
with_PIN
SFAS_NN
133_CD
requirements_NOMZ
._.
If_COND
embedded_VBN
derivatives_NN
exist_VPRT
and_PHC
are_VPRT
not_XX0
clearly_RB
and_CC
The_DT
impact_NN
,_,
reected_VBD
as_IN
a_DT
cumulative_JJ
effect_NN
of_PIN
an_DT
accounting_GER
closely_RB
related_VBN
to_PIN
the_DT
host_NN
contract_NN
,_,
they_TPP3
are_VPRT [PASS]
accounted_VBN
for_PIN
change_NN
,_,
was_VBD [BEMA]
a_DT
37_CD
million_CD
credit_NN
,_,
net_NN
of_PIN
tax_NN
,_,
to_PIN
income_NN
._.
separately_RB
from_PIN
the_DT
host_NN
contract_NN
as_IN
derivatives_NN
._.
The_DT
disclosures_NN
required_VBN [SUAV] [WZPAST]
by_PIN
SFAS_NN
132_CD
are_VPRT [PASS]
included_VBN
in_PIN
this_DEMO
Note_NN
._.
Gains_NN
and_PHC
losses_NN
related_VBN [WZPAST]
to_PIN
the_DT
fair_JJ
value_NN
adjustments_NOMZ
of_PIN
all_QUAN
derivative_JJ
instruments_NOMZ
are_VPRT [PASS]
classied_VBN
in_PIN
the_DT
consolidated_JJ
statement_NOMZ
Stock-based_JJ
compensation_NOMZ
of_PIN
income_NN
and_PHC
cash_NN
ows_NN
in_PIN
accordance_NN
with_PIN
the_DT
nature_NN
of_PIN
the_DT
Under_IN
UK_NN
GAAP_NN
share_NN
options_NOMZ
are_VPRT [PASS]
accounted_VBN
for_PIN
as_IN
equity_NOMZ
when_RB
derivative_NN
._.
exercised_VBN
,_,
valued_VBN [PASTP]
at_PIN
the_DT
issuance_NN
price_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
the_DT
Group_NN
applies_VPRT
SFAS_NN
123_CD
Accounting_GER
for_PIN
stock-based_JJ
compensation_NOMZ
and_CC
The_DT
fair_JJ
value_NN
and_PHC
book_NN
value_NN
of_PIN
derivative_JJ
instruments_NOMZ
in_PIN
respect_NN
related_VBN
accounting_GER
interpretations_NOMZ
in_PIN
accounting_GER
for_PIN
its_PIT
option_NOMZ
plans_NN
of_PIN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
as_IN
at_PIN
31st_CD
December_NN
2002_CD
is_VPRT
which_WDT
require_VPRT [SUAV]
options_NOMZ
to_TO
be_VB [BEMA]
fair_PRED
valued_VBN
at_PIN
their_TPP3
grant_NN
date_NN
and_CC
disclosed_VBN [PUBV]
in_PIN
the_DT
Classication_NOMZ
and_CC
fair_JJ
value_NN
of_PIN
financial_JJ
assets_NN
included_VBN [WZPAST]
in_PIN
profit_NN
and_PHC
loss_NN
over_IN
the_DT
vesting_JJ
period_NN
of_PIN
the_DT
options_NOMZ
._.
and_ANDC
liabilities_NOMZ
table_NN
in_PIN
Note_NN
32_CD
._.
124_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
37_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
Comprehensive_JJ
income_NN
statement_NOMZ
The_DT
requirement_NOMZ
of_PIN
SFAS_NN
130_CD
Reporting_GER
comprehensive_JJ
income_NN
to_PIN
Valuation_NOMZ
of_PIN
derivative_JJ
instruments_NOMZ
provide_VPRT
a_DT
comprehensive_JJ
income_NN
statement_NOMZ
is_VPRT [PASS]
met_VBN
under_IN
UK_NN
GAAP_NN
The_NN
fair_JJ
value_NN
of_PIN
derivative_JJ
instruments_NOMZ
is_VPRT [BEMA]
sensitive_PRED
to_PIN
movements_NOMZ
in_PIN
by_PIN
the_DT
Statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
pages_NN
76_CD
to_PIN
the_DT
underlying_VBG
market_NN
rates_NN
and_PHC
variables_NN
._.
A_DT
statement_NOMZ
of_PIN
comprehensive_JJ
income_NN
under_IN
US_FPP1
GAAP_NN
for_PIN
the_DT
fair_JJ
value_NN
of_PIN
derivative_JJ
instruments_NOMZ
on_PIN
a_DT
periodic_JJ
basis_NN
._.
Derivatives_NN
three_CD
years_NN
in_PIN
the_DT
period_NN
ending_VBG [WZPRES]
31st_CD
December_NN
2002_CD
is_VPRT [PASS]
presented_VBN
including_VBG
interest_NN
rate_NN
swaps_NN
and_CC
cross_JJ
currency_NN
swaps_NN
are_VPRT [PASS]
valued_VBN
on_PIN
pages_NN
126_CD
and_CC
127_CD
._.
Under_IN
US_FPP1
GAAP_NN
the_DT
statement_NOMZ
includes_VPRT
the_DT
using_VBG
standard_JJ
valuation_NOMZ
models_NN
,_,
counterparty_NN
valuations_NOMZ
,_,
or_CC
thirdnet_NN
impact_NN
of_PIN
gains_NN
and_PHC
losses_NN
on_PIN
equity_NOMZ
and_CC
liquid_JJ
investments_NOMZ
and_PHC
party_NN
valuations_NOMZ
._.
Standard_NN
valuation_NOMZ
models_NN
used_VBN [WZPAST]
by_PIN
the_DT
Group_NN
translation_NOMZ
adjustments_NOMZ
._.
consider_VB [PRIV]
relevant_JJ
discount_NN
rates_NN
,_,
the_DT
market_NN
yield_NN
curve_NN
on_PIN
the_DT
valuation_NOMZ
date_NN
,_,
forward_RB
currency_NN
exchange_NN
rates_NN
and_PHC
counterparty_NN
Recent_JJ
Financial_NN
Accounting_GER
Standards_NN
Board_NN
FASB_NN
risk_NN
._.
All_QUAN
significant_JJ
rates_NN
and_PHC
variables_NN
are_VPRT [PASS]
obtained_VBN
from_PIN
market_NN
pronouncements_NOMZ
sources_NN
._.
All_QUAN
valuations_NOMZ
are_VPRT [PASS]
based_VBN
on_PIN
the_DT
remaining_VBG
term_NN
to_PIN
maturity_NOMZ
In_PIN
June_NN
2001_CD
,_,
the_DT
FASB_NN
approved_VBD
SFAS_NN
143_CD
Accounting_GER
for_PIN
of_PIN
the_DT
instrument_NOMZ
._.
Foreign_JJ
exchange_NN
contracts_NN
are_VPRT [PASS]
valued_VBN
using_VBG
Obligations_NOMZ
Associated_NN
with_PIN
the_DT
Retirement_NOMZ
of_PIN
Long-Lived_NN
Assets_NN
forward_RB
rates_NN
observed_VBD [PRIV]
from_PIN
quoted_VBN
prices_NN
in_PIN
the_DT
relevant_JJ
markets_NN
which_WDT [WHSUB]
requires_VPRT [SUAV]
that_THVC
the_DT
fair_JJ
values_NN
of_PIN
the_DT
obligation_NOMZ
associated_VBN
when_RB
possible_JJ
._.
The_DT
Group_NN
assumes_VPRT [PRIV]
parties_NN
to_PIN
long-term_JJ
contracts_NN
with_PIN
the_DT
retirement_NOMZ
of_PIN
long-lived_JJ
assets_NN
be_VB [PASS]
capitalized_VBN
as_IN
part_NN
of_PIN
are_VPRT [BEMA]
economically_RB
viable_PRED
but_CC
reserves_NN
the_DT
right_NN
to_TO
exercise_VB
early_TIME
the_DT
cost_NN
._.
This_DEMP
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
be_VB [BYPA]
implemented_VBN
by_PIN
the_DT
Group_NN
with_PIN
termination_NOMZ
rights_NN
if_COND
economically_RB
beneficial_JJ
when_RB
such_JJ
rights_NN
exist_VPRT
effect_NN
from_PIN
1st_CD
January_NN
2003_CD
._.
The_DT
Group_NN
does_VPRT
not_XX0
believe_VB [PRIV]
the_DT
in_PIN
the_DT
contract_NN
._.
adoption_NOMZ
of_PIN
this_DEMO
standard_NN
will_PRMD
have_VB
a_DT
material_NN
impact_NN
on_PIN
its_PIT
results_NN
._.
Dividends_NN
Under_IN
UK_NN
GAAP_NN
,_,
dividends_NN
proposed_VBN [SUAV] [WZPAST]
are_VPRT [PASS]
provided_VBN
for_PIN
in_PIN
the_DT
year_NN
in_PIN
On_PIN
1st_CD
January_NN
2002_CD
,_,
SFAS_NN
144_CD
Accounting_GER
for_PIN
the_DT
Impairment_NOMZ
respect_NN
of_PIN
which_WDT [PIRE]
they_TPP3
are_VPRT [BYPA]
recommended_VBN [SUAV]
by_PIN
the_DT
Board_NN
of_PIN
Directors_NN
or_CC
Disposal_NN
of_PIN
Long-Lived_NN
Assets_NN
was_VBD [BYPA]
adopted_VBN
by_PIN
the_DT
Group_NN
._.
for_PIN
approval_NN
by_PIN
the_DT
shareholders_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
such_JJ
dividends_NN
SFAS_NN
144_CD
develops_VPRT
one_CD
accounting_GER
model_NN
for_PIN
long-lived_JJ
assets_NN
,_,
are_VPRT [PASS]
not_XX0
provided_VBN
for_PIN
until_IN
declared_VBN [PUBV]
by_PIN
the_DT
Board_NN
of_PIN
Directors_NN
._.
including_VBG
discontinued_VBN
operations_NOMZ
to_TO
be_VB [PASS]
disposed_VBN
of_PIN
by_PIN
sale_NN
._.
It_PIT
requires_VPRT [SUAV]
that_THVC
all_QUAN
long-lived_JJ
assets_NN
be_VB [PASS]
measured_VBN
at_PIN
the_DT
lower_JJ
of_PIN
Deferred_JJ
taxation_NOMZ
carrying_VBG [WZPRES]
amount_NN
or_CC
fair_JJ
value_NN
less_RB
cost_VBN
to_TO
sell_VB
whether_IN
reported_VBN [PUBV]
in_PIN
Under_IN
UK_NN
GAAP_NN
the_DT
Group_NN
has_VPRT [PEAS]
implemented_VBN
in_PIN
2002_CD
FRS_NN
19_CD
continuing_VBG
or_CC
discontinued_VBN
operations_NOMZ
._.
The_DT
adoption_NOMZ
of_PIN
SFAS_NN
144_CD
Deferred_NN
Tax_NN
._.
This_DEMP
requires_VPRT [SUAV]
deferred_JJ
tax_NN
to_TO
be_VB [PASS]
accounted_VBN
for_PIN
on_PIN
a_DT
has_VPRT [PEAS]
not_XX0
had_VBD
a_DT
material_NN
impact_NN
on_PIN
the_DT
Groups_NN
financial_JJ
full_JJ
provision_NN
basis_NN
,_,
similar_JJ
to_PIN
the_DT
requirement_NOMZ
for_PIN
US_FPP1
GAAP_NN
,_,
rather_CONJ
statements_NOMZ
._.
than_PIN
a_DT
partial_JJ
provision_NN
basis_NN
as_IN
in_PIN
2001_CD
and_CC
earlier_TIME
years_NN
._.
As_CONJ
a_NULL
consequence_NULL
the_DT
profit_NN
attributable_JJ
to_PIN
shareholders_NN
and_PHC
Equity_NOMZ
In_PIN
April_NN
2002_CD
,_,
SFAS_NN
145_CD
Rescission_NN
of_PIN
FASB_NN
Statements_NOMZ
no._NN
._.
4_CD
,_,
44_CD
shareholders_NN
funds_NN
under_IN
UK_NN
GAAP_NN
and_CC
the_DT
deferred_JJ
tax_NN
and_CC
64_CD
,_,
Amendment_NOMZ
of_PIN
FASB_NN
Statement_NOMZ
no._NN
._.
13_CD
and_CC
Technical_NN
adjustments_NOMZ
under_IN
US_FPP1
GAAP_NN
for_PIN
prior_RB
periods_NN
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
._.
The_DT
statement_NOMZ
updates_NN
,_,
claries_NN
and_CC
There_EX
is_VPRT
no_SYNE
impact_NN
to_PIN
Net_JJ
loss_NN
and_PHC
Shareholders_NN
equity_NOMZ
under_IN
US_FPP1
simplies_VPRT
existing_VBG
accounting_GER
standards_NN
._.
The_DT
Group_NN
does_VPRT
not_XX0
GAAP_NN
as_IN
previously_TIME
reported_VBN [PUBV]
._.
The_DT
adoption_NOMZ
of_PIN
FRS_NN
19_CD
has_VPRT
believe_VB [PRIV]
the_DT
adoption_NOMZ
of_PIN
this_DEMO
standard_NN
will_PRMD
have_VB
a_DT
material_NN
impact_NN
eliminated_VBN
most_EMPH
of_PIN
the_DT
differences_NN
for_PIN
deferred_JJ
tax_NN
that_DEMO
previously_TIME
on_PIN
its_PIT
results_NN
._.
existed_VBD
between_PIN
UK_NN
GAAP_NN
and_PHC
US_FPP1
GAAP_NN
._.
As_CONJ
a_NULL
result_NULL
,_,
the_DT
SFAS_NN
146_CD
Accounting_GER
for_PIN
Costs_NN
Associated_NN
with_PIN
Exit_NN
or_CC
Disposal_NN
adjustment_NOMZ
now_TIME
primarily_RB
relates_VPRT
to_PIN
the_DT
deferred_VBN
tax_NN
effect_NN
of_PIN
other_JJ
Activities_NOMZ
,_,
was_VBD [PASS]
issued_VBN
in_PIN
June_NN
2002_CD
._.
SFAS_NN
146_CD
requires_VPRT [SUAV]
companies_NN
US_FPP1
GAAP_NN
adjustments_NOMZ
._.
to_TO
recognize_VB [PRIV] [THATD]
costs_NN
associated_VBN [WZPAST]
with_PIN
exit_NN
or_CC
disposal_NN
activities_NOMZ
when_RB
they_TPP3
are_VPRT [PASS]
incurred_VBN
rather_RB
than_PIN
at_PIN
the_DT
date_NN
of_PIN
a_DT
commitment_NOMZ
to_PIN
an_DT
Exceptional_JJ
items_NN
exit_NN
or_CC
disposal_NN
plan_NN
and_CC
is_VPRT
to_TO
be_VB [PASS]
applied_VBN
prospectively_RB
to_PIN
exit_NN
or_CC
Items_NN
classied_VBD
as_IN
exceptional_JJ
under_IN
UK_NN
GAAP_NN
do_VPRT
not_XX0
meet_VB
the_DT
disposal_NN
activities_NOMZ
initiated_VBN
after_IN
31st_CD
December_NN
2002_CD
._.
The_DT
Group_NN
denition_NOMZ
of_PIN
extraordinary_JJ
under_IN
US_FPP1
GAAP_NN
and_CC
are_VPRT [SPAU]
therefore_CONJ
is_VPRT [SPAU]
currently_RB
assessing_VBG
the_DT
impact_NN
of_PIN
this_DEMO
standard_NN
._.
In_PIN
November_NN
2002_CD
,_,
the_DT
FASB_NN
published_VBD
Interpretation_NOMZ
no._NN
._.
45_CD
,_,
Consolidated_NN
statement_NOMZ
of_PIN
cash_NN
ows_VPRT
Guarantors_NN
Accounting_GER
and_PHC
Disclosures_NN
requirements_NOMZ
for_PIN
The_DT
US_FPP1
GAAP_NN
cash_NN
ow_NN
statement_NOMZ
reports_NN
changes_NN
in_PIN
cash_NN
and_PHC
Guarantees_NN
,_,
Including_VBG
Indirect_NN
Guarantees_NN
of_PIN
Indebtedness_NOMZ
of_PIN
cash_NN
equivalents_NN
,_,
which_WDT [SERE]
includes_VPRT
short-term_JJ
highly_AMP
liquid_JJ
Others_NN
FIN_NN
45_CD
._.
FIN_NN
45_CD
expands_VPRT
on_PIN
the_DT
accounting_GER
guidance_NN
of_PIN
investments_NOMZ
with_PIN
original_JJ
maturities_NOMZ
of_PIN
three_CD
months_NN
or_CC
less_JJ
._.
FIN_NN
45s_NN
provisions_NN
for_PIN
initial_JJ
recognition_NOMZ
and_CC
Only_DWNT
three_CD
categories_NN
of_PIN
cash_NN
ows_NN
are_VPRT [PASS]
reported_VBN [PUBV]
:_:
operating_VBG
measurement_NOMZ
should_NEMD
be_VB [PASS]
applied_VBN
to_PIN
guarantees_NN
issued_VBN
or_CC
modied_VBN
activities_NOMZ
including_VBG [WZPRES]
tax_NN
and_PHC
interest_NN
:_:
investing_VBG
activities_NOMZ
including_VBG [WZPRES]
after_IN
31st_CD
December_NN
2002_CD
._.
The_DT
disclosure_NN
requirements_NOMZ
are_VPRT [BEMA]
effective_JJ
capital_NN
expenditure_NN
,_,
acquisitions_NOMZ
and_PHC
disposals_NN
together_RB
with_PIN
for_PIN
financial_JJ
years_NN
ending_VBG [WZPRES]
after_IN
15th_JJ
December_NN
2002_CD
._.
The_DT
Group_NN
cash_NN
ows_VPRT
from_PIN
available_JJ
for_PIN
sale_NN
current_JJ
asset_NN
investments_NOMZ
:_:
does_VPRT
not_XX0
believe_VB [PRIV]
that_THVC
the_DT
adoption_NOMZ
of_PIN
FIN_NN
45_CD
will_PRMD
have_VB
a_DT
material_NN
and_PHC
nancing_GER
activities_NOMZ
including_VBG [WZPRES]
dividends_NN
paid_VBN
._.
A_DT
statement_NOMZ
impact_NN
on_PIN
its_PIT
results_NN
._.
of_PIN
cash_NN
ows_NN
is_VPRT [PASS]
presented_VBN
on_PIN
page_NN
128_CD
._.
In_PIN
January_NN
2003_CD
,_,
the_DT
FASB_NN
published_VBD
Interpretation_NOMZ
no._NN
._.
46_CD
Consolidation_NOMZ
of_PIN
Variable_JJ
Interest_NN
Entities_NOMZ
FIN_NN
46_CD
._.
Under_IN
FIN_NN
46_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
the_DT
primary_JJ
beneciary_NN
of_PIN
the_DT
entity_NOMZ
must_NEMD
consolidate_VB
certain_JJ
Under_IN
UK_NN
GAAP_NN
the_DT
cash_NN
balance_NN
includes_VPRT
only_DWNT
cash_NN
at_PIN
bank_NN
and_PHC
entities_NOMZ
known_VBN [PRIV]
as_IN
Variable_JJ
Interest_NN
Entities_NOMZ
._.
The_DT
measurement_NOMZ
other_JJ
cash_NN
balances_NN
._.
Under_IN
US_FPP1
GAAP_NN
cash_NN
and_PHC
cash_NN
equivalents_NN
principles_NN
will_PRMD
apply_VB
to_PIN
the_DT
Groups_NN
2003_CD
Financial_NN
statements_NOMZ
._.
The_DT
include_VPRT
cash_NN
at_PIN
bank_NN
and_CC
certain_JJ
liquid_JJ
investments_NOMZ
with_PIN
original_JJ
Group_NN
does_VPRT
not_XX0
believe_VB [PRIV]
that_THVC
the_DT
adoption_NOMZ
of_PIN
FIN_NN
46_CD
will_PRMD
have_VB
a_DT
maturities_NOMZ
of_PIN
three_CD
months_NN
or_CC
less_JJ
._.
material_NN
impact_NN
on_PIN
its_PIT
results_NN
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
125_CD
37_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
2002_CD
2001_CD
Consolidated_NN
balance_NN
sheet_NN
under_IN
US_FPP1
GAAP_NN
m_FW
m_FW
Assets_NN
Current_JJ
assets_NN
Cash_NN
and_PHC
cash_NN
equivalents_NN
1,082_CD
832_CD
Marketable_JJ
securities_NOMZ
1,466_CD
1,647_CD
Accounts_NN
and_CC
notes_VPRT [PRIV]
receivable_JJ
3,657_CD
3,647_CD
Inventories_NN
2,080_CD
2,090_CD
Prepaid_NN
expenses_NN
862_CD
744_CD
Deferred_JJ
income_NN
taxes_NN
1,133_CD
1,242_CD
Total_JJ
current_JJ
assets_NN
10,280_CD
10,202_CD
Goodwill_NN
18,160_CD
18,102_CD
Intangible_JJ
assets_NN
19,961_CD
24,223_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
6,864_CD
7,015_CD
Investments_NOMZ
in_PIN
afliates_NN
1,033_CD
1,038_CD
Other_JJ
assets_NN
1,055_CD
491_CD
Deferred_JJ
income_NN
taxes_NN
318_CD
270_CD
Total_JJ
assets_NN
57,671_CD
61,341_CD
Liabilities_NOMZ
and_PHC
Shareholders_NN
equity_NOMZ
Current_JJ
liabilities_NOMZ
Cash_NN
overdrafts_NN
193_CD
230_CD
Accounts_NN
payable_JJ
715_CD
760_CD
Short-term_JJ
borrowings_GER
and_PHC
capital_NN
lease_NN
obligations_NOMZ
1,358_CD
1,894_CD
Income_NN
taxes_NN
1,449_CD
1,672_CD
Dividends_NN
payable_JJ
538_CD
555_CD
Deferred_JJ
income_NN
taxes_NN
113_CD
113_CD
Other_JJ
accrued_VBN
liabilities_NOMZ
3,801_CD
3,601_CD
Total_JJ
current_JJ
liabilities_NOMZ
8,167_CD
8,825_CD
Long-term_JJ
borrowings_GER
and_PHC
capital_NN
lease_NN
obligations_NOMZ
3,092_CD
2,108_CD
Other_JJ
liabilities_NOMZ
4,197_CD
1,747_CD
Deferred_JJ
income_NN
taxes_NN
6,486_CD
7,692_CD
Total_JJ
liabilities_NOMZ
21,942_CD
20,372_CD
Minority_NOMZ
interest_NN
807_CD
862_CD
Contingent_JJ
liabilities_NOMZ
and_PHC
commitments_NOMZ
Notes_NN
24_CD
and_CC
26_CD
Shareholders_NN
equity_NOMZ
Common_JJ
stock_NN
,_,
0.25_CD
per_PIN
share_NN
par_JJ
value_NN
:_:
10,000,000,000_CD
shares_NN
authorised_VBN
:_:
6,024,266,345_CD
2002_CD
and_CC
6,172,965,989_CD
2001_CD
shares_NN
issued_VBN
1,506_CD
1,543_CD
Redeemable_JJ
preference_NN
shares_NN
,_,
1.00_CD
per_PIN
share_NN
par_JJ
value_NN
:_:
50,000_CD
shares_NN
authorised_VBN
,_,
nil_NN
2002_CD
and_CC
nil_NN
2001_CD
shares_NN
outstanding_JJ
Additional_JJ
paid-in_PIN
capital_NN
43,749_CD
45,532_CD
Retained_VBN
deficit_NN
and_CC
cumulative_JJ
other_JJ
comprehensive_JJ
loss_NN
7,266_CD
3,794_CD
Treasury_NN
stock_NN
3,067_CD
3,174_CD
Total_JJ
shareholders_NN
equity_NOMZ
34,922_CD
40,107_CD
Total_JJ
liabilities_NOMZ
and_PHC
shareholders_NN
equity_NOMZ
57,671_CD
61,341_CD
Certain_NN
items_NN
for_PIN
the_DT
year_NN
ended_VBD
31st_CD
December_NN
2001_CD
have_VPRT [PEAS]
been_VBN [PASS]
reclassied_VBN
for_PIN
comparative_JJ
purposes_NN
._.
126_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
37_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
2002_CD
GlaxoGlaxoSmithKline_NN
US_FPP1
GAAP_NN
SmithKline_NN
UK_NN
GAAP_NN
adjustments_NOMZ
US_FPP1
GAAP_NN
Reconciliation_NOMZ
of_PIN
consolidated_JJ
income_NN
statement_NOMZ
m_NN
m_FW
m_FW
Revenues_NN
21,212_CD
21,212_CD
Cost_NN
of_PIN
sales_NN
4,609_CD
13_CD
4,596_CD
Gross_NN
profit_NN
16,603_CD
13_CD
16,616_CD
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenditure_NN
8,041_CD
347_CD
8,388_CD
Research_NN
and_PHC
development_NOMZ
expenditure_NN
2,900_CD
85_CD
2,985_CD
Trading_GER
profit_NN
5,662_CD
419_CD
5,243_CD
Other_JJ
operating_GER
income_NN
expense_NN
111_CD
71_CD
40_CD
Amortisation_NOMZ
and_PHC
impairment_NOMZ
of_PIN
goodwill_NN
and_CC
intangible_JJ
assets_NN
4,195_CD
4,195_CD
Write-off_PIN
in-process_JJ
R&D_NN
acquired_VBD
Product_NN
divestments_VPRT
11_CD
7_CD
18_CD
Merger_NN
transaction_NOMZ
costs_NN
Operating_VBG [WZPRES]
profit_NN
5,562_CD
4,536_CD
1,026_CD
Share_NN
of_PIN
profits_NN
losses_NN
of_PIN
joint_JJ
ventures_NN
and_CC
associated_VBN
undertakings_GER
75_CD
6_CD
81_CD
profit_NN
loss_NN
on_PIN
disposal_NN
of_PIN
interest_NN
in_PIN
associate_JJ
Disposal_NN
of_PIN
businesses_NOMZ
10_CD
10_CD
profit_NN
before_IN
interest_NN
5,647_CD
4,530_CD
1,117_CD
Net_JJ
interest_NN
expense_NN
141_CD
51_CD
192_CD
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
5,506_CD
4,581_CD
925_CD
Taxation_NOMZ
1,461_CD
1,169_CD
292_CD
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
after_IN
taxation_NOMZ
4,045_CD
3,412_CD
633_CD
Minority_NOMZ
interests_NN
110_CD
110_CD
Preference_NN
share_NN
dividends_NN
20_CD
20_CD
Net_JJ
income_NN
loss_NN
before_IN
cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
3,915_CD
3,412_CD
503_CD
Cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
90_CD
90_CD
Net_JJ
income_NN
loss_NN
3,915_CD
3,502_CD
413_CD
Basic_JJ
and_PHC
diluted_JJ
net_JJ
income_NN
loss_NN
per_PIN
share_NN
before_IN
cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
under_IN
US_FPP1
GAAP_NN
pence_NN
8.5_CD
p_NN
Cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
per_PIN
share_NN
under_IN
US_FPP1
GAAP_NN
pence_NN
1.5_CD
p_NN
Basic_JJ
and_PHC
diluted_JJ
net_JJ
income_NN
loss_NN
per_PIN
share_NN
after_IN
cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
under_IN
US_FPP1
GAAP_NN
pence_NN
7.0_CD
p_NN
Basic_JJ
and_PHC
diluted_JJ
net_JJ
income_NN
loss_NN
per_PIN
ADS_NN
before_IN
cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
under_IN
US_FPP1
GAAP_NN
$_$
$_$
0.26_CD
Cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
per_PIN
ADS_NN
under_IN
US_FPP1
GAAP_NN
$_$
$_$
0.05_CD
Basic_JJ
and_PHC
diluted_JJ
net_JJ
income_NN
loss_NN
per_PIN
ADS_NN
after_IN
cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
under_IN
US_FPP1
GAAP_NN
$_$
$_$
0.21_CD
Consolidated_NN
statement_NOMZ
of_PIN
comprehensive_JJ
income_NN
and_CC
2002_CD
changes_NN
in_PIN
shareholders_NN
equity_NOMZ
under_IN
US_FPP1
GAAP_NN
m_NN
Shareholders_NN
equity_NOMZ
at_PIN
beginning_GER
of_PIN
year_NN
40,107_CD
Net_JJ
income_NN
loss_NN
413_CD
Exchange_NN
movements_NOMZ
on_PIN
overseas_PLACE
net_JJ
assets_NN
73_CD
Unrealised_JJ
loss_NN
gain_NN
on_PIN
equity_NOMZ
investments_NOMZ
,_,
net_NN
of_PIN
tax_NN
83_CD
Unrealised_NN
gain_NN
loss_NN
on_PIN
liquid_JJ
investments_NOMZ
,_,
net_NN
of_PIN
tax_NN
7_CD
Unrealised_NN
gain_NN
on_PIN
derivatives_NN
61_CD
Minimum_NN
pension_NN
liability_NOMZ
1,446_CD
Cumulative_JJ
effect_NN
of_PIN
change_NN
in_PIN
accounting_GER
principle_NN
Comprehensive_JJ
loss_NN
income_NN
1,121_CD
Dividends_NN
2,310_CD
Shares_NN
purchased_VBD
and_PHC
canceled_VBD
2,220_CD
Shares_NN
issued_VBN
56_CD
Employee_NN
Share_NN
Ownership_NN
Plan_NN
58_CD
Shares_NN
issued_VBN
to_TO
purchase_VB
SmithKline_NN
Beecham_NN
Other_JJ
352_CD
Shareholders_NN
equity_NOMZ
at_PIN
end_NN
of_PIN
year_NN
34,922_CD
Certain_NN
items_NN
for_PIN
the_DT
years_NN
ended_VBN
31st_CD
December_NN
2000_CD
and_CC
2001_CD
have_VPRT [PEAS]
been_VBN [PASS]
reclassied_VBN
for_PIN
comparative_JJ
purposes_NN
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
127 2001 2000_CD
Less_RB
SmithKline_NN
GlaxoGlaxoBeecham_NN
SmithKline_NN
US_FPP1
GAAP_NN
GlaxoSmithKline_NN
pre-acquisition_JJ
US_FPP1
GAAP_NN
GlaxoUK_NN
GAAP_NN
adjustments_NOMZ
SmithKline_NN
UK_NN
GAAP_NN
UK_NN
GAAP_NN
adjustments_NOMZ
SmithKline_NN
restated_VBN
restated_VBN
US_FPP1
GAAP_NN
restated_VBD
restated_VBN
restated_VBN
US_FPP1
GAAP_NN
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW [BEMA]
20,489_CD
20,489_CD
18,079_CD
8,520_CD
9,559_CD
4,733_CD
324_CD
5,057_CD
3,962_CD
1,802_CD
32_CD
2,192_CD
15,756_CD
324_CD
15,432_CD
14,117_CD
6,718_CD
32_CD
7,367_CD
8,408_CD
28_CD
8,436_CD
7,136_CD
3,578_CD
65_CD
3,623_CD
2,651_CD
140_CD
2,791_CD
2,526_CD
1,158_CD
28_CD
1,396_CD
4,697_CD
492_CD
4,205_CD
4,455_CD
1,982_CD
125_CD
2,348_CD
37_CD
75_CD
38_CD
274_CD
23_CD
251_CD
3,577_CD
3,577_CD
725_CD
725_CD
6,324_CD
6,324_CD
1,416_CD
1,422_CD
6_CD
121_CD
55_CD
66_CD
4,734_CD
4,144_CD
590_CD
6,024_CD
3,372_CD
7,108_CD
4,456_CD
71_CD
71_CD
57_CD
57_CD
96_CD
117 21 144 144_CD
296_CD
204_CD
92_CD
14_CD
14_CD
4,605_CD
4,057_CD
548_CD
6,211_CD
3,415_CD
7,108_CD
4,312_CD
88_CD
34_CD
54_CD
182_CD
95_CD
87_CD
4,517_CD
4,023_CD
494_CD
6,029_CD
3,320_CD
7,108_CD
4,399_CD
1,333_CD
827_CD
506_CD
1,747_CD
956_CD
17_CD
808_CD
3,184_CD
3,196_CD
12_CD
4,282_CD
2,364_CD
7,125_CD
5,207_CD
97_CD
97_CD
120_CD
99_CD
21_CD
34_CD
34_CD
56_CD
56_CD
3,053_CD
3,196_CD
143_CD
4,106_CD
2,209_CD
7,125_CD
5,228_CD
3,053_CD
3,196_CD
143_CD
4,106_CD
2,209_CD
7,125_CD
5,228_CD
2.4_CD
p_NN
145.6_CD
p_NN
2.4_CD
p_NN
145.6_CD
p_VPRT
$_$
0.07_CD
$_$
4.43_CD
$_$
0.07_CD
$_$
4.43_CD
2001_CD
2000_CD
m_NN
m_NN [BEMA]
44,995_CD
7,230_CD
143_CD
5,228_CD
107 88 381 356_CD
1_CD
1_CD
24_CD
5_CD
603_CD
4,783_CD
2,872_CD
1,334_CD
1,274_CD
144 121 501 472_CD
43,919_CD
218_CD
314_CD
40,107_CD
44,995_CD
128_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
37_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
2002 2001 2000_CD
Consolidated_NN
statement_NOMZ
of_PIN
cash_NN
ows_NN
under_IN
US_FPP1
GAAP_NN
m_FW
m_FW
m_FW
Cash_NN
ows_VPRT
from_PIN
operating_VBG
activities_NOMZ
Net_JJ
income_NN
loss_NN
413_CD
143_CD
5,228_CD
Adjustments_NOMZ
to_TO
reconcile_VB
net_JJ
income_NN
to_PIN
net_JJ
cash_NN
provided_VBN [WZPAST]
by_PIN
operating_VBG
activities_NOMZ
:_:
Depreciation_NOMZ
755 742 427_CD
Amortisation_NOMZ
of_PIN
intangible_JJ
assets_NN
1,781_CD
3,577_CD
735_CD
Write-off_PIN
in-process_JJ
R&D_NN
acquired_VBD
6,324_CD
Impairment_NOMZ
of_PIN
goodwill_NN
,_,
tangible_JJ
and_PHC
intangible_JJ
xed_JJ
assets_NN
2,829_CD
253_CD
47_CD
Gain_NN
loss_NN
on_PIN
sale_NN
of_PIN
xed_JJ
assets_NN
and_CC
other_JJ
productive_JJ
assets_NN
46_CD
99_CD
152_CD
Deferred_JJ
taxes_NN
1,216_CD
877_CD
28_CD
Stock_NN
compensation_NOMZ
331 162 254_CD
Tax_NN
benefit_NN
from_PIN
exercise_NN
of_PIN
stock_NN
options_NOMZ
13_CD
56_CD
9_CD
Income_NN
in_PIN
associate_JJ
75_CD
71_CD
Loss_NN
on_PIN
sale_NN
of_PIN
associate_NN
and_PHC
investment_NOMZ
5_CD
Derivatives_NN
8_CD
15_CD
Other_JJ
41_CD
93_CD
Changes_NN
in_PIN
operating_VBG
assets_NN
and_PHC
liabilities_NOMZ
,_,
net_NN
of_PIN
acquisitions_NOMZ
:_:
Increase_VB
decrease_NN
in_PIN
inventory_NN
2_CD
550_CD
21_CD
Increase_VPRT
in_PIN
trade_NN
and_CC
other_JJ
debtors_NN
72_CD
77_CD
281_CD
Increase_VPRT
in_PIN
trade_NN
and_CC
other_JJ
creditors_NN
426 368 444_CD
Increase_VPRT
decrease_NN
in_PIN
pension_NN
and_CC
other_JJ
provisions_NN
257_CD
80_CD
92_CD
Net_JJ
cash_NN
provided_VBN [WZPAST]
by_PIN
operating_VBG
activities_NOMZ
5,345_CD
4,606_CD
2,536_CD
Cash_NN
ows_VPRT
from_PIN
investing_VBG
activities_NOMZ
Acquisition_NOMZ
of_PIN
xed_JJ
assets_NN
1,080_CD
1,111_CD
416_CD
Acquisition_NOMZ
of_PIN
intangible_JJ
assets_NN
5_CD
80_CD
76_CD
Acquisition_NOMZ
of_PIN
SmithKline_NN
Beecham_NN
cash_NN
received_VBD
on_PIN
acquisition_NOMZ
1,129_CD
Acquisition_NOMZ
of_PIN
other_JJ
new_JJ
businesses_NOMZ
net_NN
of_PIN
cash_NN
acquired_VBN
17_CD
803_CD
24_CD
Proceeds_NN
from_PIN
disposition_NOMZ
of_PIN
xed_JJ
assets_NN
and_PHC
businesses_NOMZ
61_CD
211_CD
12_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
intangible_JJ
xed_JJ
assets_NN
6_CD
Increase_VPRT
decrease_NN
in_PIN
equity_NOMZ
investments_NOMZ
10_CD
92_CD
194_CD
Net_JJ
cash_NN
used_VBN [WZPAST]
in_PIN
provided_VBN
by_PIN
investing_VBG
activities_NOMZ
1,051_CD
1,685_CD
819_CD
Cash_NN
ows_VPRT
from_PIN
nancing_VBG
activities_NOMZ
Increase_VB
decrease_NN
in_PIN
liquid_JJ
investments_NOMZ
34_CD
1,006_CD
235_CD
Proceeds_NN
from_PIN
additional_JJ
borrowings_GER
1,094_CD
973_CD
Reduction_NOMZ
in_PIN
debt_NN
89_CD
112_CD
3_CD
Purchase_NN
of_PIN
treasury_NN
stock_NN
795_CD
471_CD
Dividends_NN
paid_VBD
2,432_CD
2,454_CD
1,334_CD
Net_JJ
repayment_NOMZ
of_PIN
short-term_JJ
loans_NN
408 718 193_CD
Net_JJ
repayment_NOMZ
of_PIN
increase_NN
in_PIN
cash_NN
overdrafts_NN
27_CD
38_CD
121_CD
Redemption_NOMZ
of_PIN
preference_NN
shares_NN
issued_VBN [WZPAST]
by_PIN
a_DT
subsidiary_NN
457_CD
Ordinary_NN
shares_NN
purchased_VBD
for_PIN
cancellation_NOMZ
2,220_CD
1,274_CD
Issue_NN
of_PIN
share_NN
capital_NN
114 338 121_CD
Other_JJ
28_CD
13_CD
Net_JJ
cash_NN
used_VBN [WZPAST]
in_PIN
nancing_VBG
activities_NOMZ
4,002_CD
3,483_CD
2,223_CD
Net_JJ
increase_NN
decrease_NN
in_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
292_CD
562_CD
1,132_CD
Exchange_NN
rate_NN
movements_NOMZ
42_CD
15_CD
1_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
at_PIN
beginning_GER
of_PIN
year_NN
832_CD
1,379_CD
246_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
at_PIN
end_NN
of_PIN
year_NN
1,082_CD
832_CD
1,379_CD
Supplemental_NN
cash_NN
ow_NN
information_NOMZ
Cash_NN
paid_VBN [WZPAST]
during_PIN
the_DT
year_NN
for_PIN
:_:
Interest_NN
215 196 235_CD
Income_NN
taxes_NN
1,633_CD
1,717_CD
635_CD
Non-cash_JJ
investing_GER
and_PHC
nancing_GER
activities_NOMZ
Under_IN
the_DT
purchase_NN
acquisition_NOMZ
dated_VBN
27th_JJ
December_NN
2000_CD
the_DT
Group_NN
acquired_VBD
all_QUAN
the_DT
outstanding_JJ
shares_NN
of_PIN
SmithKline_NN
Beecham_NN
in_PIN
exchange_NN
for_PIN
shares_NN
of_PIN
GlaxoSmithKline_NN
._.
In_PIN
conjunction_NOMZ
with_PIN
the_DT
acquisition_NOMZ
,_,
liabilities_NOMZ
were_VBD [PASS]
assumed_VBN [PRIV]
as_IN
follows_VPRT
:_:
Fair_NN
value_NN
of_PIN
assets_NN
acquired_VBN
57,158_CD
Fair_NN
value_NN
of_PIN
shares_NN
issued_VBN
43,919_CD
Fair_NN
value_NN
of_PIN
liabilities_NOMZ
assumed_VBD [PRIV]
13,239_CD
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
129_CD
37_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
The_DT
following_GER
is_VPRT [BEMA]
a_DT
summary_NN
of_PIN
the_DT
material_NN
adjustments_NOMZ
to_TO
profit_VB
and_CC
shareholders_NN
funds_NN
which_WDT [WHSUB]
would_PRMD
be_VB [PASS]
required_VBN [SUAV]
if_COND
US_FPP1
GAAP_NN
had_VBD [PEAS]
been_VBN [PASS]
applied_VBN
instead_CONJ
of_NULL
UK_NN
GAAP_NN
._.
These_DEMO
adjustments_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
reected_VBN
in_PIN
the_DT
income_NN
statements_NOMZ
and_PHC
balance_NN
sheets_NN
presented_VBN [WZPAST]
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
._.
2001 2000 2002_CD
restated_VBN
restated_JJ
profit_NN
m_NN
m_FW
m_FW
profit_NN
attributable_JJ
to_PIN
shareholders_NN
under_IN
UK_NN
GAAP_NN
3,915_CD
3,053_CD
4,106_CD
Less_RB
:_:
SmithKline_NN
Beechams_NN
pre-acquisition_JJ
profit_NN
attributable_JJ
to_PIN
shareholders_NN
under_IN
UK_NN
GAAP_NN
and_PHC
merger_NN
alignment_NOMZ
adjustments_NOMZ
2,237_CD
US_FPP1
GAAP_NN
adjustments_NOMZ
:_:
Write-off_PIN
of_PIN
SmithKline_NN
Beecham_NN
in-process_JJ
R&D_NN
acquired_VBD
6,324_CD
Capitalised_VBN
interest_NN
25_CD
18_CD
15_CD
Computer_NN
software_NN
20_CD
3_CD
13_CD
Purchased_VBN
intangibles_NN
86_CD
140_CD
Reversal_NN
amortisation_NOMZ
of_PIN
goodwill_NN
18_CD
1,261_CD
559_CD
Amortisation_NOMZ
and_PHC
impairment_NOMZ
of_PIN
intangible_JJ
assets_NN
4,184_CD
2,266_CD
166_CD
Recognition_NOMZ
of_PIN
cost_NN
of_PIN
sales_NN
on_PIN
fair_JJ
value_NN
step-up_NN
of_PIN
inventory_NN
298_CD
Disposal_NN
of_PIN
purchased_VBN
investment_NOMZ
117_CD
Product_NN
divestments_NOMZ
7_CD
Loss_NN
on_PIN
disposal_NN
of_PIN
subsidiary_NN
204_CD
Pensions_NN
and_CC
post-retirement_JJ
benets_NN
138_CD
12_CD
75_CD
Stock-based_JJ
compensation_NOMZ
331 162 254_CD
Provision_NN
against_PIN
ESOT_NN
shares_NN
51_CD
108_CD
26_CD
Derivative_JJ
instruments_NOMZ
8_CD
15_CD
Restructuring_GER
37_CD
182_CD
Tax_NN
benets_NN
on_PIN
exercise_NN
of_PIN
US_FPP1
stock_NN
options_NOMZ
13_CD
56_CD
9_CD
Merger_NN
transaction_NOMZ
costs_NN
66_CD
Deferred_JJ
taxation_NOMZ
1,182_CD
883_CD
20_CD
Impairment_NOMZ
of_PIN
equity_NOMZ
investments_NOMZ
8_CD
75_CD
Net_JJ
income_NN
loss_NN
under_IN
US_FPP1
GAAP_NN
before_IN
cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
503_CD
143_CD
5,228_CD
Cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
90_CD
Net_JJ
income_NN
loss_NN
after_IN
cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
413_CD
143_CD
5,228_CD
2001_CD
2002_CD
restated_VBN
Equity_NOMZ
shareholders_NN
funds_NN
m_VPRT
m_NN
Equity_NOMZ
shareholders_NN
funds_NN
under_IN
UK_NN
GAAP_NN
6,581_CD
7,390_CD
US_FPP1
GAAP_NN
adjustments_NOMZ
:_:
Tangible_JJ
xed_JJ
assets_NN
49_CD
44_CD
Investments_NOMZ
829_CD
879_CD
Product_NN
rights_NN
18,590_CD
22,927_CD
Capitalised_VBN
interest_NN
175_CD
155_CD
Computer_NN
software_NN
9_CD
29_CD
Goodwill_NN
17,989_CD
17,928_CD
Other_JJ
intangible_JJ
assets_NN
438_CD
377_CD
Unrealised_JJ
gains_NN
on_PIN
marketable_JJ
securities_NOMZ
113_CD
163_CD
Pensions_NN
and_CC
other_JJ
post-retirement_JJ
benets_NN
1,198_CD
299_CD
Employee_NN
Share_NN
Ownership_NN
Trust_NN
2,826_CD
2,936_CD
Restructuring_GER
costs_NN
6_CD
46_CD
Derivative_JJ
instruments_NOMZ
98_CD
29_CD
Dividends_NN
754_CD
718_CD
Deferred_JJ
taxation_NOMZ
5,779_CD
7,037_CD
Shareholders_NN
equity_NOMZ
under_IN
US_FPP1
GAAP_NN
34,922_CD
40,107_CD
Certain_NN
items_NN
for_PIN
the_DT
years_NN
ended_VBN
31st_CD
December_NN
2001_CD
and_CC
2000_CD
have_VPRT [PEAS]
been_VBN [PASS]
reclassied_VBN
for_PIN
comparative_JJ
purposes_NN
._.
During_PIN
2002_CD
,_,
FRS_NN
19_CD
Deferred_NN
Tax_NN
has_VPRT [PEAS]
been_VBN [BYPA]
implemented_VBN
by_PIN
the_DT
Group_NN
under_IN
UK_NN
GAAP_NN
._.
This_DEMO
FRS_NN
requires_VPRT [SUAV]
deferred_JJ
tax_NN
to_TO
be_VB [PASS]
accounted_VBN
for_PIN
on_PIN
a_DT
full_JJ
provision_NN
basis_NN
,_,
rather_CONJ
than_PIN
a_DT
partial_JJ
provision_NN
basis_NN
as_IN
in_PIN
2001_CD
and_CC
earlier_TIME
years_NN
._.
This_DEMO
change_NN
has_VPRT [PEAS]
been_VBN [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
prior_JJ
year_NN
adjustment_NOMZ
for_PIN
UK_NN
GAAP_NN
purposes_NN
and_CC
comparative_JJ
adjustments_NOMZ
to_TO
arrive_VB
at_PIN
US_FPP1
GAAP_NN
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
as_RB
necessary_JJ
._.
This_DEMO
change_NN
had_VBD
no_SYNE
impact_NN
on_PIN
US_FPP1
GAAP_NN
results_NN
._.
130_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
37_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
c_NN
The_DT
market_NN
value_NN
of_PIN
investments_NOMZ
was_VBD [PASS]
included_VBN
in_PIN
the_DT
book_NN
value_NN
of_PIN
SmithKline_NN
Beechams_NN
net_JJ
assets_NN
under_IN
US_FPP1
GAAP_NN
._.
The_DT
increase_NN
Acquisition_NOMZ
of_PIN
SmithKline_NN
Beecham_NN
in_PIN
investments_NOMZ
related_VBN [WZPAST]
to_PIN
increases_NN
in_PIN
the_DT
fair_JJ
market_NN
value_NN
of_PIN
Under_IN
US_FPP1
GAAP_NN
,_,
the_DT
Financial_NN
statements_NOMZ
of_PIN
GlaxoSmithKline_NN
prior_RB
to_PIN
non-marketable_JJ
securities_NOMZ
at_PIN
31st_CD
December_NN
2000_CD
._.
Included_VBD
the_DT
merger_NN
are_VPRT [BEMA]
those_DEMO
of_PIN
Glaxo_NN
Wellcome_NN
,_,
the_DT
US_FPP1
GAAP_NN
accounting_GER
in_PIN
this_DEMO
amount_NN
are_VPRT
increases_NN
to_PIN
equity_NOMZ
investments_NOMZ
._.
The_DT
acquisition_NOMZ
of_PIN
SmithKline_NN
Beecham_NN
is_VPRT [PASS]
accounted_VBN
for_PIN
investments_NOMZ
were_VBD [PASS]
measured_VBN
at_PIN
fair_JJ
value_NN
and_CC
any_QUAN
excess_NN
of_PIN
the_DT
under_IN
the_DT
purchase_NN
method_NN
as_IN
of_PIN
the_DT
date_NN
of_PIN
the_DT
merger_NN
,_,
fair_JJ
value_NN
over_IN
the_DT
underlying_VBG
tangible_JJ
assets_NN
and_PHC
liabilities_NOMZ
was_VBD [BEMA]
27th_JJ
December_NN
2000_CD
._.
recognized_VBN [PRIV]
as_IN
goodwill_NN
within_PIN
investments_NOMZ
._.
This_DEMO
goodwill_NN
is_VPRT [SPAU] [PASS]
no_RB
longer_RB
amortised_VBN
,_,
but_CC
reviewed_VBN
annually_RB
for_PIN
impairment_NOMZ
._.
Purchase_NN
accounting_GER
adjustments_NOMZ
In_PIN
order_NN
to_TO
determine_VB [SUAV] [PRIV]
the_DT
proper_JJ
allocation_NOMZ
of_PIN
purchase_NN
price_NN
d_SYM
The_DT
fair_JJ
value_NN
attributed_VBD
to_PIN
pension_NN
obligations_NOMZ
reected_VBD
the_DT
related_VBN
to_PIN
the_DT
acquired_VBN
assets_NN
of_PIN
SmithKline_NN
Beecham_NN
under_IN
US_FPP1
recognition_NOMZ
of_PIN
previously_TIME
unrecognised_JJ
actuarial_JJ
gains_NN
losses_NN
,_,
GAAP_NN
purchase_NN
accounting_GER
,_,
the_DT
cost_NN
of_PIN
acquisition_NOMZ
is_VPRT [PASS]
calculated_VBN [PRIV]
prior_RB
service_NN
costs_NN
and_PHC
transition_NOMZ
amounts_NN
._.
The_DT
amounts_NN
recognized_VBN [PRIV]
using_VBG
the_DT
market_NN
value_NN
of_PIN
the_DT
shares_NN
issued_VBN
,_,
the_DT
fair_JJ
value_NN
of_PIN
vested_JJ
were_VBD [PASS]
based_VBN
on_PIN
actuarial_JJ
assessments_NOMZ
at_PIN
the_DT
acquisition_NOMZ
date_NN
._.
options_NOMZ
exchanged_VBD
and_CC
direct_JJ
external_JJ
acquisition_NOMZ
costs_NN
and_CC
then_RB
e_SYM
The_DT
fair_JJ
value_NN
attributed_VBD
to_PIN
other_JJ
intangible_JJ
assets_NN
related_VBN
allocated_VBN
to_PIN
the_DT
fair_JJ
value_NN
of_PIN
net_JJ
assets_NN
acquired_VBN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
primarily_RB
to_PIN
managements_NOMZ
estimate_NN
of_PIN
the_DT
value_NN
of_PIN
product_NN
fair_JJ
value_NN
exercise_NN
,_,
increases_NN
in_PIN
the_DT
values_NN
of_PIN
SmithKline_NN
Beechams_NN
rights_NN
inclusive_NN
of_PIN
their_TPP3
respective_JJ
patents_NN
and_PHC
trade_NN
marks_NN
inventory_NN
,_,
tangible_JJ
xed_JJ
assets_NN
,_,
investments_NOMZ
and_PHC
pension_NN
obligations_NOMZ
on_PIN
existing_VBG
products_NN
and_CC
of_PIN
the_DT
assembled_VBN
workforce_NN
._.
The_DT
fair_JJ
were_VBD [PASS]
recognized_VBN [PRIV]
and_CC
fair_JJ
market_NN
values_NN
attributed_VBD
to_PIN
its_PIT
other_JJ
value_NN
of_PIN
the_DT
product_NN
rights_NN
was_VBD [PASS]
determined_VBN [SUAV] [PRIV]
based_VBN
on_PIN
a_DT
intangible_JJ
assets_NN
,_,
mainly_RB
product_NN
rights_NN
inclusive_NN
of_PIN
patents_NN
and_CC
discounted_JJ
net_JJ
future_NN
cash_NN
ow_NN
analysis_NN
of_PIN
SmithKline_NN
Beechams_NN
trade_NN
marks_NN
,_,
assembled_VBN
workforce_NN
and_CC
in-process_JJ
research_NN
and_CC
approved_VBD
product_NN
portfolio_NN
which_WDT [WHSUB]
included_VBD
all_QUAN
existing_VBG
approved_VBN
development_NOMZ
,_,
together_RB
with_PIN
appropriate_JJ
deferred_VBN
taxation_NOMZ
effects_NN
._.
products_NN
within_PIN
the_DT
pharmaceutical_JJ
therapeutic_JJ
areas_NN
and_CC
The_DT
difference_NN
between_PIN
the_DT
cost_NN
of_PIN
acquisition_NOMZ
and_CC
the_DT
fair_JJ
value_NN
consumer_NN
healthcare_NN
product_NN
portfolios_NN
._.
Any_QUAN
supplemental_JJ
of_PIN
the_DT
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
SmithKline_NN
Beecham_NN
has_VPRT [PEAS]
been_VBN
products_NN
in_PIN
the_DT
development_NOMZ
process_NN
which_WDT [WHSUB]
built_VBD
upon_PIN
existing_VBG
recorded_VBN
as_IN
goodwill_NN
._.
The_DT
amount_NN
allocated_VBN [WZPAST]
to_PIN
in-process_JJ
research_NN
chemical_NN
entities_NOMZ
within_PIN
existing_VBG
areas_NN
and_ANDC
which_WDT
were_VBD
not_XX0
and_CC
development_NOMZ
is_VPRT [PASS]
required_VBN [SUAV]
under_IN
US_FPP1
GAAP_NN
to_TO
be_VB [PASS]
expensed_VBN
subject_JJ
to_PIN
separate_JJ
US_FPP1
Food_NN
and_PHC
Drug_NN
Administration_NOMZ
approval_NN
immediately_TIME
in_PIN
the_DT
first_JJ
reporting_GER
period_NN
after_IN
the_DT
business_NOMZ
were_VBD [SPAU] [PASS]
also_RB
included_VBN
._.
Management_NOMZ
based_VBN
the_DT
estimates_NN
of_PIN
the_DT
combination_NOMZ
,_,
which_WDT [SERE]
for_PIN
GlaxoSmithKline_NN
was_VBD [BEMA]
the_DT
period_NN
ended_VBD
weighted_JJ
average_JJ
useful_JJ
life_NN
of_PIN
the_DT
product_NN
rights_NN
on_PIN
the_DT
future_JJ
31st_CD
December_NN
2000_CD
._.
Fair_NN
value_NN
adjustments_NOMZ
to_PIN
the_DT
recorded_JJ
period_NN
over_IN
which_WDT
the_DT
substantial_JJ
majority_NOMZ
of_PIN
the_DT
estimated_JJ
net_JJ
amount_NN
of_PIN
inventory_NN
were_VBD [PASS]
expensed_VBN
in_PIN
2001_CD
and_CC
additional_JJ
future_JJ
cash_NN
ow_NN
value_NN
was_VBD [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
realized_VBN [PRIV]
._.
The_DT
fair_JJ
value_NN
amortisation_NOMZ
and_PHC
depreciation_NOMZ
will_PRMD
be_VB [PASS]
recorded_VBN
in_PIN
respect_NN
of_PIN
the_DT
of_PIN
the_DT
assembled_VBN
workforce_NN
was_VBD [PASS]
reclassied_VBN
to_PIN
goodwill_NN
under_IN
fair_JJ
value_NN
adjustments_NOMZ
to_PIN
tangible_JJ
and_PHC
intangible_JJ
assets_NN
and_CC
the_DT
SFAS_NN
142_CD
in_PIN
2002_CD
and_CC
will_PRMD
be_VB [PASS]
reviewed_VBN
annually_RB
for_PIN
impairment_NOMZ
._.
resulting_VBG
goodwill_NN
over_IN
the_DT
periods_NN
of_PIN
their_TPP3
respective_JJ
economic_JJ
useful_JJ
lives_NN
._.
f_LS
The_DT
amount_NN
of_PIN
total_JJ
consideration_NOMZ
allocated_VBN [WZPAST]
to_PIN
SmithKline_NN
Beechams_NN
in-process_JJ
research_NN
and_PHC
development_NOMZ
projects_NN
IPR&D_NN
The_DT
adjustments_NOMZ
to_PIN
the_DT
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
SmithKline_NN
Beecham_NN
was_VBD [PASS]
estimated_VBN [PRIV]
using_VBG
current_JJ
estimates_NN
of_PIN
the_DT
status_NN
and_CC
to_TO
reect_VB
the_DT
fair_JJ
values_NN
and_PHC
allocation_NOMZ
of_PIN
the_DT
excess_JJ
purchase_NN
prospects_NN
of_PIN
its_PIT
R&D_NN
portfolio_NN
._.
The_DT
IPR&D_NN
included_VBD
only_DWNT
those_DEMO
consideration_NOMZ
over_IN
the_DT
fair_JJ
value_NN
of_PIN
net_JJ
assets_NN
acquired_VBN
,_,
based_VBN
identied_JJ
projects_NN
that_TSUB
had_VBD [PEAS]
advanced_VBN
to_PIN
a_DT
stage_NN
of_PIN
development_NOMZ
on_PIN
management_NOMZ
best_JJ
estimates_NN
of_PIN
fair_JJ
value_NN
,_,
are_VPRT [PASS]
summarised_VBN
in_PIN
where_RB
management_NOMZ
believed_VBD [PRIV]
reasonable_JJ
estimates_NN
of_PIN
projected_VBN
the_DT
table_NN
opposite_PIN
and_CC
discussed_VBN
below_PLACE
:_:
cash_NN
ows_NN
could_POMD
be_VB [PASS]
prepared_VBN
._.
This_DEMP
did_VBD
not_XX0
include_VB
basic_JJ
a_DT
The_DT
total_JJ
assumed_JJ
purchase_NN
consideration_NOMZ
was_VBD [PASS]
calculated_VBN [PRIV]
discovery_NN
and_CC
the_DT
portfolio_NN
of_PIN
gene_NN
patents_NN
._.
The_DT
reported_VBN [PUBV]
IPR&D_NN
by_PIN
multiplying_VBG
the_DT
number_NN
of_PIN
GlaxoSmithKline_NN
shares_NN
issued_VBN
value_NN
was_VBD [PASS]
not_XX0
intended_VBN [SUAV]
to_TO
reect_VB
the_DT
present_JJ
value_NN
of_PIN
all_QUAN
to_PIN
SmithKline_NN
Beechams_NN
shareholders_NN
for_PIN
all_QUAN
outstanding_JJ
development_NOMZ
activities_NOMZ
under_IN
way_NN
._.
The_DT
value_NN
allocated_VBN [WZPAST]
to_PIN
the_DT
SmithKline_NN
Beecham_NN
shares_NN
by_PIN
the_DT
average_JJ
fair_JJ
value_NN
of_PIN
Glaxo_NN
IPR&D_NN
was_VBD [PASS]
determined_VBN [SUAV] [PRIV]
utilising_VBG
a_DT
risk_NN
adjusted_VBN
income_NN
approach_NN
Wellcome_NN
securities_NOMZ
._.
The_DT
average_JJ
fair_JJ
value_NN
of_PIN
Glaxo_NN
Wellcome_NN
that_TSUB
included_VBD
earnings_GER
discounted_VBN [WZPAST]
by_PIN
the_DT
appropriate_JJ
cost_NN
of_PIN
securities_NOMZ
was_VBD [PASS]
calculated_VBN [PRIV]
over_IN
a_DT
period_NN
of_PIN
four_CD
days_NN
prior_JJ
capital_NN
for_PIN
the_DT
investment_NOMZ
._.
Estimates_NN
of_PIN
future_JJ
cash_NN
ows_NN
related_VBN
to_TO
and_CC
subsequent_JJ
to_PIN
the_DT
announcement_NOMZ
of_PIN
the_DT
merger_NN
on_PIN
to_PIN
individual_JJ
IPR&D_NN
projects_NN
were_VBD [PASS]
based_VBN
on_PIN
existing_VBG
estimates_NN
of_PIN
17th_JJ
January_NN
2000_CD
._.
The_DT
total_JJ
assumed_JJ
purchase_NN
consideration_NOMZ
revenues_NN
and_PHC
contribution_NOMZ
margin_NN
for_PIN
the_DT
project_NN
._.
also_RB
included_VBD
the_DT
fair_JJ
value_NN
of_PIN
SmithKline_NN
Beecham_NN
vested_JJ
g_NN
Additional_JJ
liabilities_NOMZ
related_VBN
to_TO
restructuring_VBG
costs_NN
directly_RB
linked_VBN
options_NOMZ
exchanged_VBD
for_PIN
vested_JJ
options_NOMZ
in_PIN
GlaxoSmithKline_NN
._.
to_PIN
plans_NN
that_TSUB
were_VBD [BEMA]
in_PIN
place_NN
at_PIN
the_DT
date_NN
of_PIN
the_DT
acquisition_NOMZ
._.
These_DEMO
The_DT
total_JJ
number_NN
of_PIN
SmithKline_NN
Beecham_NN
vested_JJ
options_NOMZ
was_VBD [PASS]
liabilities_NOMZ
reected_VBD
the_DT
costs_NN
to_TO
close_VB
certain_JJ
SmithKline_NN
Beecham_NN
multiplied_VBD
by_PIN
the_DT
respective_JJ
fair_JJ
value_NN
of_PIN
each_QUAN
of_PIN
the_DT
ordinary_JJ
manufacturing_GER
sites_NN
and_PHC
redundancy_NN
costs_NN
._.
The_DT
other_JJ
liabilities_NOMZ
shares_NN
and_PHC
ADR_NN
plans_VPRT
determined_VBN [SUAV] [PRIV]
at_PIN
17th_JJ
January_NN
2000_CD
._.
related_VBN [PASTP]
to_PIN
additional_JJ
deferred_VBN
tax_NN
liabilities_NOMZ
previously_TIME
not_XX0
b_NN
The_DT
increase_NN
in_PIN
fair_JJ
value_NN
of_PIN
inventory_NN
and_CC
xed_VBD
assets_NN
was_VBD [PASS]
recognized_VBN [PRIV]
._.
determined_VBN [SUAV] [PRIV]
based_VBN
on_PIN
the_DT
difference_NN
between_PIN
the_DT
carrying_VBG
h_NN
Deferred_JJ
taxes_NN
were_VBD [PASS]
computed_VBN
on_PIN
the_DT
excess_NN
of_PIN
fair_JJ
value_NN
over_IN
value_NN
and_CC
the_DT
market_NN
value_NN
of_PIN
these_DEMO
assets_NN
._.
The_DT
increase_NN
to_PIN
book_NN
value_NN
,_,
other_JJ
than_PIN
for_PIN
goodwill_NN
and_CC
in-process_JJ
research_NN
and_PHC
inventory_NN
was_VBD [PASS]
expensed_VBN
in_PIN
2001_CD
,_,
as_IN
all_QUAN
inventory_NN
was_VBD [PASS]
sold_VBN
._.
The_DT
development_NOMZ
,_,
using_VBG [PRESP]
the_DT
applicable_JJ
weighted_JJ
average_JJ
statutory_JJ
increase_NN
in_PIN
xed_JJ
assets_NN
was_VBD [PASS]
allocated_VBN
to_PIN
its_PIT
respective_JJ
category_NN
tax_NN
rates_NN
._.
and_ANDC
is_VPRT
being_VBG [PASS]
depreciated_VBN
over_IN
the_DT
remaining_VBG
useful_JJ
lives_NN
of_PIN
these_DEMO
assets_NN
._.
i_FPP1
Goodwill_NN
represents_VPRT
the_DT
remainder_NN
of_PIN
unallocated_JJ
purchase_NN
consideration_NOMZ
and_CC
now_TIME
includes_VPRT
the_DT
value_NN
originally_TIME
allocated_VBN
to_PIN
workforce_NN
._.
Goodwill_NN
is_VPRT [SPAU] [PASS]
no_RB
longer_RB
amortised_VBN
under_IN
SFAS_NN
142_CD
,_,
but_CC
rather_RB
reviewed_VBN
annually_RB
for_PIN
impairment_NOMZ
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
131_CD
37_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
Purchase_NN
accounting_GER
adjustments_NOMZ
m_VPRT [BEMA]
Total_PRED
assumed_VBD [PRIV]
purchase_NN
consideration_NOMZ
for_PIN
outstanding_JJ
shares_NN
a_DT
43,919_CD
Costs_NN
and_PHC
fees_NN
of_PIN
transaction_NOMZ
66_CD
Less_RB
:_:
Book_NN
value_NN
of_PIN
SmithKline_NN
Beecham_NN
net_JJ
assets_NN
US_FPP1
GAAP_NN
less_JJ
goodwill_NN
2,742_CD
Excess_NN
fair_JJ
value_NN
of_PIN
inventory_NN
b_NN
267_CD
Excess_NN
fair_JJ
value_NN
of_PIN
tangible_JJ
xed_JJ
assets_NN
b_NN
15_CD
Excess_NN
fair_JJ
value_NN
of_PIN
investments_NOMZ
c_NN
1,042_CD
Excess_NN
fair_JJ
value_NN
of_PIN
pension_NN
asset_NN
d_SYM
81_CD
Fair_NN
value_NN
attributed_VBD
to_PIN
other_JJ
intangible_JJ
assets_NN
e_LS
24,382_CD
Fair_NN
value_NN
attributed_VBD
to_PIN
workforce_NN
now_TIME
considered_VBN [PRIV]
goodwill_NN
e_SYM
483_CD
Fair_NN
value_NN
attributed_VBD
to_PIN
in-process_JJ
R&D_NN
projects_NN
f_LS
6,324_CD
Additional_JJ
liabilities_NOMZ
assumed_VBD [PRIV]
g_RB
110_CD
Deferred_JJ
tax_NN
liabilities_NOMZ
related_VBN
to_TO
purchase_VB
price_NN
adjustments_NOMZ
h_VPRT
7,669_CD
Goodwill_NN
i_FPP1
16,428_CD
132_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
37_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
The_DT
following_JJ
tables_NN
present_JJ
details_NN
of_PIN
the_DT
Groups_NN
total_VPRT
purchased_VBN
identiable_JJ
intangible_JJ
assets_NN
which_WDT [WHSUB]
are_VPRT [BEMA]
subject_PRED
to_PIN
amortisation_NOMZ
._.
Accumulated_VBN
31st_JJ
December_NN
2002_CD
Gross_NN
amortisation_NOMZ
Impairment_NOMZ
Net_NN
m_FW
m_FW
m_FW
m_FW
Product_NN
rights_NN
20,120_CD
3,693_CD
2,076_CD
14,351_CD
Brands_NN
1,151_CD
58_CD
1,093_CD
Total_JJ
21,271_CD
3,751_CD
2,076_CD
15,444_CD
Following_VBG
the_DT
launch_NN
in_PIN
the_DT
USA_NN
of_PIN
a_DT
generic_JJ
Augmentin_NN
product_NN
,_,
the_DT
carrying_VBG
value_NN
of_PIN
product_NN
rights_NN
relating_VBG [WZPRES]
to_PIN
Augmentin_NN
has_VPRT [PEAS]
been_VBN [PASS]
reviewed_VBN
and_CC
an_DT
impairment_NOMZ
of_PIN
1,667_CD
million_CD
recorded_VBN
._.
The_DT
carrying_VBG
values_NN
of_PIN
certain_JJ
other_JJ
product_NN
rights_NN
have_VPRT [SPAU] [PEAS]
also_RB
been_VBN [PASS]
reviewed_VBN
and_CC
an_DT
impairment_NOMZ
of_PIN
409_CD
million_CD
recorded_VBN
._.
Fair_NN
values_NN
were_VBD [PASS]
determined_VBN [SUAV] [PRIV]
using_VBG
a_DT
discounted_JJ
cash_NN
ow_NN
model_NN
._.
As_IN
discussed_VBN
in_PIN
Note_NN
30_CD
Legal_NN
proceedings_GER
,_,
a_DT
number_NN
of_PIN
distributors_NN
of_PIN
generic_JJ
drugs_NN
have_VPRT [PEAS]
led_VBN
applications_NOMZ
to_PIN
market_NN
generic_JJ
versions_NN
of_PIN
Paxil_NN
in_PIN
the_DT
USA_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
Groups_NN
patent_NN
._.
The_DT
carrying_VBG
value_NN
of_PIN
the_DT
Paxil_NN
product_NN
rights_NN
under_IN
US_FPP1
GAAP_NN
is_VPRT [BEMA]
3.6_CD
billion_CD
at_PIN
31st_CD
December_NN
2002_CD
._.
The_DT
Group_NN
will_PRMD
continue_VB
to_TO
keep_VB
the_DT
position_NOMZ
under_IN
review_NN
._.
Accumulated_VBN
31st_JJ
December_NN
2001_CD
Gross_NN
amortisation_NOMZ
Impairment_NOMZ
Net_NN
m_FW
m_FW
m_FW
m_FW
Product_NN
rights_NN
20,116_CD
1,865_CD
18,251_CD
Brands_NN
1,151_CD
29_CD
1,122_CD
Total_JJ
21,267_CD
1,894_CD
19,373_CD
The_DT
estimated_JJ
future_JJ
amortisation_NOMZ
expense_NN
for_PIN
the_DT
next_JJ
five_CD
years_NN
for_PIN
purchased_VBN
identiable_JJ
intangible_JJ
assets_NN
subject_JJ
to_PIN
amortisation_NOMZ
as_IN
of_PIN
31st_CD
December_NN
2002_CD
is_VPRT
as_IN
follows_VPRT
:_:
Year_NN
m_NN [BEMA]
2003_CD
1,636_CD
2004_CD
1,629_CD
2005_CD
1,629_CD
2006_CD
1,588_CD
2007_CD
1,574_CD
Total_JJ
8,056_CD
Carrying_VBG
amount_NN
of_PIN
identiable_JJ
intangible_JJ
assets_NN
which_WDT [WHSUB]
are_VPRT [BEMA]
not_XX0
subject_PRED
to_PIN
amortisation_NOMZ
2002_CD
2001_CD
m_NN
m_NN
Brands_NN
4,345_CD
4,850_CD
Following_VBG
the_DT
initial_JJ
implementation_NOMZ
of_PIN
SFAS_NN
142_CD
in_PIN
2002_CD
,_,
the_DT
carrying_VBG
values_NN
of_PIN
the_DT
brands_NN
determined_VBD [SUAV] [PRIV]
to_TO
have_VB
indefinite_JJ
lives_NN
were_VBD [PASS]
reviewed_VBN
and_CC
an_DT
impairment_NOMZ
of_PIN
173_CD
million_CD
127_CD
million_CD
net_NN
of_PIN
tax_NN
was_VBD [PASS]
recognized_VBN [PRIV]
._.
This_DEMP
is_VPRT [PASS]
recorded_VBN
as_IN
a_DT
cumulative_JJ
effect_NN
of_PIN
a_DT
change_NN
in_PIN
accounting_GER
principle_NN
._.
In_CONJ
addition_NULL
,_,
a_DT
332_CD
million_CD
charge_NN
was_VBD [PASS]
recognized_VBN [PRIV]
during_PIN
2002_CD
as_CONJ
a_NULL
result_NULL
of_PIN
changes_NN
in_PIN
market_NN
conditions_NOMZ
and_PHC
management_NOMZ
forecasts_NN
for_PIN
certain_JJ
brand_NN
intangibles_NN
._.
The_DT
following_JJ
table_NN
presents_VPRT
the_DT
changes_NN
in_PIN
goodwill_NN
allocated_VBN [WZPAST]
to_PIN
the_DT
Groups_NN
reportable_JJ
segments_NOMZ
during_PIN
2002_CD
._.
The_DT
carrying_VBG
value_NN
of_PIN
the_DT
assembled_VBN
workforce_NN
at_PIN
31st_CD
December_NN
2001_CD
,_,
net_NN
of_PIN
tax_NN
,_,
has_VPRT [PEAS]
been_VBN [PASS]
reclassied_VBN
into_PIN
opening_VBG
balance_NN
of_PIN
goodwill_NN
in_PIN
accordance_NN
with_PIN
SFAS_NN
142_CD
._.
At_PIN
31.12.01_CD
Acquired_VBN
Impairment_NOMZ
Exchange_NN
At_PIN
31.12.02_CD
m_FW
m_FW
m_FW
m_FW
m_FW
Pharmaceuticals_NN
15,670_CD
23_CD
14_CD
15,679_CD
Consumer_NN
Healthcare_NN
2,503_CD
22_CD
2,481_CD
Total_JJ
18,173_CD
23_CD
36_CD
18,160_CD
If_COND
the_DT
Group_NN
had_VBD [PEAS]
accounted_VBN
for_PIN
goodwill_NN
and_CC
identiable_JJ
intangible_JJ
assets_NN
that_TSUB
have_VPRT
indefinite_JJ
lives_NN
under_IN
SFAS_NN
142_CD
for_PIN
the_DT
years_NN
ended_VBN
31st_CD
December_NN
2000_CD
and_CC
2001_CD
,_,
the_DT
impact_NN
on_PIN
reported_VBN [PUBV]
US_FPP1
GAAP_NN
results_NN
would_PRMD
have_VB [PEAS]
been_VBN
as_IN
follows_VPRT
:_:
2001_CD
2000_CD
m_NN
m_NN [BEMA]
Net_JJ
income_NN
under_IN
US_FPP1
GAAP_NN
143_CD
5,228_CD
Amortisation_NOMZ
,_,
net_NN
of_PIN
tax_NN
:_:
Goodwill_NN
1,475_CD
570_CD
Brands_NN
124_CD
Adjusted_JJ
net_JJ
income_NN
under_IN
US_FPP1
GAAP_NN
1,456_CD
4,658_CD
Adjusted_VBN
basic_JJ
net_JJ
income_NN
per_PIN
share_NN
pence_NN
24.0_CD
129.7_CD
Adjusted_VBN
diluted_JJ
net_JJ
income_NN
per_PIN
share_NN
pence_NN
23.8_CD
129.7_CD
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
133_CD
37_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
Earnings_GER
per_PIN
share_NN
under_IN
US_FPP1
GAAP_NN
2002 2001 2000_CD
Weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
in_PIN
issue_NN
millions_NN
millions_NN
millions_NN
Basic_JJ
5,912_CD
6,064_CD
3,591_CD
Adjustments_NOMZ
:_:
Share_NN
options_NOMZ
22_CD
52_CD
35_CD
Diluted_NN
5,934_CD
6,116_CD
3,626_CD
Shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
Employee_NN
Share_NN
Ownership_NN
Trusts_NN
are_VPRT [PASS]
excluded_VBN
from_PIN
shares_NN
in_PIN
issue_NN
._.
Taxation_NOMZ
2001 2000 2002_CD
restated_VBN
restated_VBN
Total_JJ
tax_NN
expense_NN
m_NN
m_FW
m_FW
UK_NN
GAAP_NN
:_:
Current_JJ
tax_NN
expense_NN
1,432_CD
1,386_CD
808_CD
Deferred_JJ
tax_NN
expense_NN
29_CD
53_CD
17_CD
Total_JJ
tax_NN
expense_NN
1,461_CD
1,333_CD
791_CD
US_FPP1
GAAP_NN
:_:
Current_JJ
tax_NN
expense_NN
1,445_CD
1,442_CD
817_CD
Deferred_JJ
tax_NN
expense_NN
1,737_CD
936_CD
9_CD
Total_JJ
tax_NN
expense_NN
292 506 808_CD
Deferred_JJ
taxation_NOMZ
under_IN
US_FPP1
GAAP_NN
Classication_NOMZ
of_PIN
GlaxoSmithKlines_NN
deferred_VBD
taxation_NOMZ
liabilities_NOMZ
and_PHC
assets_NN
under_IN
US_FPP1
GAAP_NN
is_VPRT
as_IN
follows_VPRT
:_:
2002_CD
2001_CD
m_NN
m_NN
Liabilities_NOMZ
Stock_NN
valuation_NOMZ
adjustment_NOMZ
113_CD
113_CD
Current_JJ
deferred_VBN
taxation_NOMZ
liabilities_NOMZ
113_CD
113_CD
Accelerated_VBN
capital_NN
allowances_NN
710_CD
691_CD
Product_NN
rights_NN
5,620_CD
6,126_CD
Other_JJ
timing_NN
differences_NN
156_CD
1,030_CD
Total_JJ
deferred_VBN
taxation_NOMZ
liabilities_NOMZ
6,599_CD
7,960_CD
Assets_NN
Intra-Group_JJ
profit_NN
487_CD
375_CD
Other_JJ
timing_NN
differences_NN
646_CD
842_CD
Current_JJ
deferred_VBN
taxation_NOMZ
assets_NN
1,133_CD
1,217_CD
Asset_NN
disposal_NN
125_CD
161_CD
Pensions_NN
and_CC
other_JJ
post-retirement_JJ
benets_NN
111_CD
221_CD
Tax_NN
losses_NN
93_CD
97_CD
Manufacturing_GER
restructuring_GER
52_CD
71_CD
Legal_NN
and_CC
other_JJ
disputes_NN
124_CD
25_CD
Other_JJ
timing_NN
differences_NN
63_CD
42_CD
Total_JJ
deferred_VBN
taxation_NOMZ
assets_NN
1,451_CD
1,512_CD
Net_JJ
deferred_VBN
taxation_NOMZ
under_IN
US_FPP1
GAAP_NN
5,148_CD
6,448_CD
The_DT
difference_NN
between_PIN
the_DT
UK_NN
effective_JJ
taxation_NOMZ
rate_NN
and_CC
the_DT
US_FPP1
effective_JJ
taxation_NOMZ
rate_NN
is_VPRT [SPAU] [PASS]
primarily_RB
related_VBN
to_PIN
the_DT
fair_JJ
value_NN
adjustments_NOMZ
for_PIN
goodwill_NN
and_PHC
intangibles_NN
related_VBN [WZPAST]
to_PIN
the_DT
acquisitions_NOMZ
of_PIN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
._.
134_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
37_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
Segment_NOMZ
information_NOMZ
under_IN
US_FPP1
GAAP_NN
Under_IN
UK_NN
GAAP_NN
,_,
the_DT
segment_NOMZ
information_NOMZ
presented_VBN [WZPAST]
in_PIN
Note_NN
6_CD
includes_VPRT
results_NN
of_PIN
operations_NOMZ
and_CC
other_JJ
information_NOMZ
on_PIN
a_DT
historical_JJ
combined_VBN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
basis_NN
for_PIN
2002_CD
,_,
2001_CD
and_CC
2000_CD
._.
Under_IN
US_FPP1
GAAP_NN
,_,
the_DT
segment_NOMZ
information_NOMZ
for_PIN
results_NN
of_PIN
operations_NOMZ
for_PIN
2002_CD
and_CC
2001_CD
reect_VB
the_DT
merged_JJ
operations_NOMZ
of_PIN
GlaxoSmithKline_NN
,_,
while_OSUB
for_PIN
2000_CD
it_PIT
relates_VPRT
to_PIN
Glaxo_NN
Wellcome_NN
only_DWNT
as_IN
this_DEMO
period_NN
is_VPRT
,_,
for_PIN
practical_JJ
purposes_NN
,_,
regarded_VBN
as_IN
being_VBG [BEMA]
prior_RB
to_PIN
the_DT
acquisition_NOMZ
of_PIN
SmithKline_NN
Beecham_NN
._.
Glaxo_NN
Wellcome_NN
operated_VBD
in_PIN
only_DWNT
one_CD
segment_NOMZ
Pharmaceuticals_NN
._.
Segment_NOMZ
information_NOMZ
in_PIN
respect_NN
of_PIN
assets_NN
relates_VPRT
to_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
on_PIN
a_DT
consolidated_JJ
basis_NN
at_PIN
31st_CD
December_NN
2002_CD
and_CC
2001_CD
as_IN
the_DT
acquisition_NOMZ
of_PIN
SmithKline_NN
Beecham_NN
by_PIN
Glaxo_NN
Wellcome_NN
occurred_VBD
on_PIN
27th_JJ
December_NN
2000_CD
._.
2001 2000 2002_CD
restated_VBN
restated_VBN
Turnover_NN
by_PIN
location_NOMZ
of_PIN
customer_NN
m_NN
m_FW
m_FW
USA_NN
10,807_CD
10,087_CD
4,314_CD
Europe_NN
6,064_CD
5,855_CD
2,959_CD
International_NN
4,341_CD
4,547_CD
2,286_CD
External_NN
turnover_NN
21,212_CD
20,489_CD
9,559_CD
Turnover_NN
by_PIN
business_NOMZ
sector_NN
Pharmaceuticals_NN
17,995_CD
17,205_CD
9,559_CD
Consumer_NN
Healthcare_NN
3,217_CD
3,284_CD
External_NN
turnover_NN
21,212_CD
20,489_CD
9,559_CD
Operating_GER
profit_NN
loss_NN
by_PIN
business_NOMZ
sector_NN
Pharmaceuticals_NN
876_CD
565_CD
4,456_CD
Consumer_NN
Healthcare_NN
150_CD
25_CD
Operating_GER
profit_NN
loss_NN
1,026_CD
590_CD
4,456_CD
Turnover_NN
by_PIN
location_NOMZ
of_PIN
subsidiary_NN
undertaking_GER
USA_NN
11,096_CD
10,517_CD
4,494_CD
Europe_NN
10,423_CD
10,704_CD
5,375_CD
International_NN
6,824_CD
7,540_CD
3,370_CD
Gross_NN
turnover_NN
28,343_CD
28,761_CD
13,239_CD
USA_NN
168 327 176_CD
Europe_NN
3,873_CD
4,372_CD
2,271_CD
International_NN
3,090_CD
3,573_CD
1,233_CD
Inter-segment_NOMZ
turnover_NN
7,131_CD
8,272_CD
3,680_CD
USA_NN
10,928_CD
10,190_CD
4,318_CD
Europe_NN
6,550_CD
6,332_CD
3,104_CD
International_NN
3,734_CD
3,967_CD
2,137_CD
External_NN
turnover_NN
21,212_CD
20,489_CD
9,559_CD
profit_NN
before_IN
tax_NN
by_PIN
location_NOMZ
of_PIN
subsidiary_NN
undertaking_GER
USA_NN
418_CD
938_CD
2,850_CD
Europe_NN
795_CD
1,305_CD
670_CD
International_NN
187 223 936_CD
Operating_GER
profit_NN
loss_NN
1,026_CD
590_CD
4,456_CD
Share_NN
of_PIN
profits_NN
of_PIN
joint_JJ
ventures_NN
and_CC
associated_VBN
undertakings_GER
81_CD
71_CD
profit_NN
loss_NN
on_PIN
disposal_NN
of_PIN
businesses_NOMZ
and_CC
or_CC
interest_NN
in_PIN
associates_NN
10 113 144_CD
Net_JJ
interest_NN
expense_NN
192_CD
54_CD
87_CD
profit_NN
loss_NN
before_IN
taxation_NOMZ
925_CD
494_CD
4,399_CD
profit_NN
loss_NN
before_IN
taxation_NOMZ
925_CD
494_CD
4,399_CD
Taxation_NOMZ
292 506 808_CD
Minority_NOMZ
interests_NN
and_PHC
preference_NN
share_NN
dividends_NN
130_CD
131_CD
21_CD
Net_JJ
income_NN
loss_NN
before_IN
cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
503_CD
143_CD
5,228_CD
Cumulative_JJ
effect_NN
of_PIN
change_NN
in_PIN
accounting_GER
principle_NN
90_CD
Net_JJ
income_NN
loss_NN
413_CD
143_CD
5,228_CD
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
135_CD
37_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
2002_CD
2001_CD
Total_JJ
assets_NN
by_PIN
business_NOMZ
sector_NN
m_NN
m_NN
Pharmaceuticals_NN
46,706_CD
52,391_CD
Consumer_NN
Healthcare_NN
10,965_CD
8,950_CD
Total_JJ
assets_NN
57,671_CD
61,341_CD
Total_JJ
assets_NN
by_PIN
location_NOMZ
of_PIN
subsidiary_NN
undertaking_GER
USA_NN
22,727_CD
25,741_CD
Europe_NN
20,982_CD
20,865_CD
International_NN
11,414_CD
12,256_CD
Total_JJ
operating_VBG
assets_NN
55,123_CD
58,862_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
and_CC
marketable_JJ
securities_NOMZ
2,548_CD
2,479_CD
Total_JJ
assets_NN
57,671_CD
61,341_CD
2002_CD
2001_CD
Total_JJ
liabilities_NOMZ
by_PIN
business_NOMZ
sector_NN
m_NN
m_NN
Pharmaceuticals_NN
16,816_CD
15,757_CD
Consumer_NN
Healthcare_NN
5,126_CD
4,615_CD
Total_JJ
liabilities_NOMZ
21,942_CD
20,372_CD
Total_JJ
liabilities_NOMZ
by_PIN
location_NOMZ
of_PIN
subsidiary_NN
undertaking_GER
USA_NN
8,710_CD
7,971_CD
Europe_NN
9,351_CD
9,112_CD
International_NN
3,881_CD
3,289_CD
Total_JJ
liabilities_NOMZ
21,942_CD
20,372_CD
2002_CD
2001_CD
Plant_NN
,_,
Land_NN
and_PHC
equipment_NOMZ
Computer_NN
Assets_NN
in_PIN
buildings_GER
and_PHC
vehicles_NN
software_NN
construction_NOMZ
Total_JJ
Total_JJ
Tangible_JJ
xed_JJ
assets_NN
by_PIN
location_NOMZ
of_PIN
subsidiary_NN
undertaking_GER
m_NN
m_FW
m_FW
m_FW
m_FW
m_FW
USA_NN
691_CD
379_CD
29_CD
378_CD
1,477_CD
1,611_CD
Europe_NN
1,729_CD
1,833_CD
111_CD
649_CD
4,322_CD
4,210_CD
International_NN
533_CD
370_CD
11_CD
151_CD
1,065_CD
1,194_CD
Total_JJ
2,953_CD
2,582_CD
151_CD
1,178_CD
6,864_CD
7,015_CD
UK_NN
segment_NOMZ
Information_NOMZ
is_VPRT [PASS]
given_VBN
separately_RB
in_PIN
respect_NN
of_PIN
the_DT
UK_NN
,_,
which_WDT [SERE]
,_,
although_CONC
included_VBN
in_PIN
the_DT
Groups_NN
Europe_NN
market_NN
region_NN
,_,
is_VPRT [PASS]
considered_VBN [PRIV]
the_DT
Groups_NN
home_NN
segment_NOMZ
for_PIN
the_DT
purposes_NN
of_PIN
segmental_JJ
reporting_GER
._.
2002 2001 2000_CD
m_FW
m_FW
m_FW
Turnover_NN
by_PIN
location_NOMZ
of_PIN
customer_NN
1,366_CD
1,328_CD
474_CD
Gross_NN
turnover_NN
4,945_CD
5,388_CD
1,241_CD
Inter-segment_NOMZ
turnover_NN
3,230_CD
3,753_CD
562_CD
Turnover_NN
by_PIN
location_NOMZ
of_PIN
subsidiary_NN
1,715_CD
1,635_CD
679_CD
Operating_GER
profit_NN
373 321 370_CD
Total_JJ
assets_NN
8,253_CD
6,962_CD
136_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
37_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
Pensions_NN
under_IN
US_FPP1
GAAP_NN
The_NN
SFAS_NN
132_CD
disclosures_NN
for_PIN
the_DT
year_NN
ended_VBD
31st_CD
December_NN
2002_CD
and_CC
2001_CD
are_VPRT [PASS]
provided_VBN
in_PIN
relation_NOMZ
to_PIN
the_DT
employees_NN
of_PIN
GlaxoSmithKline_NN
._.
For_PIN
2000_CD
the_DT
income_NN
statement_NOMZ
disclosures_NN
are_VPRT [PASS]
provided_VBN
in_PIN
relation_NOMZ
to_PIN
the_DT
employees_NN
of_PIN
Glaxo_NN
Wellcome_NN
only_DWNT
._.
During_PIN
2002_CD
,_,
the_DT
Group_NN
decided_VBD [SUAV] [PRIV]
to_TO
align_VB
the_DT
measurement_NOMZ
date_NN
for_PIN
all_QUAN
of_PIN
its_PIT
pension_NN
plans_NN
._.
As_IN
certain_JJ
of_PIN
the_DT
Groups_NN
pension_NN
plans_NN
had_VBD
a_DT
measurement_NOMZ
date_NN
for_PIN
pension_NN
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
30th_JJ
September_NN
,_,
the_DT
Group_NN
elected_VBD
to_TO
change_VB
the_DT
measurement_NOMZ
date_NN
for_PIN
these_DEMO
plans_NN
from_PIN
30th_JJ
September_NN
to_TO
31st_VB
December_NN
._.
As_CONJ
a_NULL
result_NULL
,_,
included_VBD
in_PIN
2002_CD
net_JJ
loss_NN
is_VPRT [BEMA]
a_DT
49_CD
million_CD
credit_NN
to_PIN
income_NN
37_CD
million_CD
net_NN
of_PIN
tax_NN
,_,
treated_VBN
as_IN
the_DT
cumulative_JJ
effect_NN
of_PIN
change_NN
in_PIN
accounting_GER
principle_NN
._.
The_DT
average_JJ
number_NN
of_PIN
persons_NN
employed_VBN [WZPAST]
by_PIN
the_DT
Group_NN
2002 2001 2000_CD
including_VBG
Directors_NN
during_PIN
the_DT
year_NN
Number_NN
Number_NN
Number_NN
Manufacturing_GER
36,548_CD
37,154_CD
20,477_CD
Selling_GER
,_,
general_JJ
and_CC
administration_NOMZ
54,810_CD
55,655_CD
30,765_CD
Research_NN
and_PHC
development_NOMZ
14,808_CD
15,090_CD
9,659_CD
106,166_CD
107,899_CD
60,901_CD
2002 2001 2000_CD
Pension_NN
and_CC
other_JJ
post-retirement_JJ
costs_NN
m_VPRT
m_FW
m_FW
UK_NN
pension_NN
schemes_NN
103_CD
26_CD
6_CD
US_FPP1
pension_NN
schemes_NN
67_CD
70_CD
59_CD
Other_JJ
overseas_PLACE
pension_NN
schemes_NN
51_CD
70_CD
31_CD
Unfunded_JJ
post-retirement_NOMZ
healthcare_NN
schemes_NN
78_CD
57_CD
16_CD
Post-employment_NOMZ
costs_NN
40_CD
28_CD
7_CD
339 251 119_CD
Analysed_NN
as_IN
:_:
Funded_VBN
dened_VBN
benefit_NN
hybrid_NN
schemes_NN
149_CD
123_CD
57_CD
Unfunded_JJ
dened_VBN
benefit_NN
schemes_NN
48_CD
11_CD
10_CD
Dened_VBN
contribution_NOMZ
schemes_NN
24_CD
32_CD
29_CD
Unfunded_JJ
post-retirement_NOMZ
healthcare_NN
schemes_NN
78_CD
57_CD
16_CD
Post-employment_NOMZ
costs_NN
40_CD
28_CD
7_CD
339 251 119_CD
The_DT
disclosures_NN
below_PLACE
include_VPRT
the_DT
additional_JJ
information_NOMZ
required_VBN [SUAV] [WZPAST]
by_PIN
SFAS_NN
132_CD
._.
The_DT
pension_NN
costs_NN
of_PIN
the_DT
UK_NN
,_,
US_FPP1
and_CC
major_JJ
overseas_PLACE
dened_VBN
benefit_NN
pension_NN
plans_NN
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
in_PIN
the_DT
following_VBG
tables_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
._.
Pension_NN
costs_NN
in_PIN
2002_CD
of_PIN
12_CD
million_CD
,_,
2001_CD
17_CD
million_CD
,_,
2000_CD
35_CD
million_CD
in_PIN
respect_NN
of_PIN
minor_JJ
retirement_NOMZ
plans_NN
,_,
which_WDT [SERE]
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
recalculated_VBN
in_PIN
accordance_NN
with_PIN
the_DT
requirements_NOMZ
of_PIN
SFAS_NN
87_CD
,_,
have_VPRT [PEAS]
been_VBN [PASS]
excluded_VBN
._.
2002 2001 2000_CD
The_DT
net_JJ
periodic_JJ
pension_NN
cost_NN
income_NN
for_PIN
the_DT
major_JJ
retirement_NOMZ
plans_NN
comprised_VBN
:_:
m_VB
m_FW
m_FW
Service_NN
cost_NN
219 194 119_CD
Interest_NN
cost_NN
388 351 161_CD
Expected_VBN [PRIV]
return_NN
on_PIN
plan_NN
assets_NN
470 508 253_CD
Amortisation_NOMZ
of_PIN
prior_JJ
service_NN
cost_NN
20_CD
15_CD
16_CD
Amortisation_NOMZ
of_PIN
transition_NOMZ
obligation_NOMZ
6_CD
9_CD
12_CD
Recognised_VBN [PRIV]
net_JJ
actuarial_JJ
gain_NN
3_CD
57_CD
70_CD
Net_JJ
periodic_JJ
pension_NN
cost_NN
income_NN
under_IN
US_FPP1
GAAP_NN
154_CD
14_CD
39_CD
Termination_NOMZ
benets_NN
and_PHC
curtailment_NOMZ
costs_NN
56_CD
27_CD
Adjustment_NOMZ
for_PIN
change_NN
in_PIN
accounting_GER
principle_NN
62_CD
The_DT
major_JJ
assumptions_NOMZ
used_VBN [WZPAST]
in_PIN
computing_VBG
the_DT
above_PLACE
pension_NN
cost_NN
income_NN
were_VBD
:_:
%_NN
pa_CD
%_NN
pa_CD
%_NN
pa_NN
Rates_NN
of_PIN
future_JJ
pay_NN
increases_VPRT
4.25_CD
4.5_CD
4.6_CD
Discount_NN
rate_NN
6.0_CD
6.25_CD
6.5_CD
Expected_VBN [PRIV]
long-term_JJ
rates_NN
of_PIN
return_NN
on_PIN
plan_NN
assets_NN
7.75_CD
8.25_CD
7.0_CD
In_PIN
aggregate_JJ
,_,
average_JJ
international_JJ
plan_NN
assumptions_NOMZ
did_VBD
not_XX0
vary_VB
signicantly_RB
from_PIN
US_FPP1
assumptions_NOMZ
._.
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
137_CD
37_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
2002_CD
2001_CD
Change_NN
in_PIN
benefit_NN
obligation_NOMZ
m_NN
m_NN
benefit_NN
obligation_NOMZ
at_PIN
beginning_GER
of_PIN
year_NN
6,372_CD
5,560_CD
Adjustment_NOMZ
for_PIN
change_NN
in_PIN
accounting_GER
principle_NN
153_CD
Amendments_NOMZ
24_CD
32_CD
Service_NN
cost_NN
219_CD
194_CD
Interest_NN
cost_NN
388_CD
351_CD
Plan_NN
participants_NN
contributions_NOMZ
16_CD
30_CD
Actuarial_JJ
loss_NN
51_CD
114_CD
Benets_NN
paid_VBD
324_CD
260_CD
Acquisition_NOMZ
326_CD
Termination_NOMZ
benets_NN
and_PHC
curtailment_NOMZ
costs_NN
35_CD
2_CD
Exchange_NN
174_CD
23_CD
benefit_NN
obligation_NOMZ
at_PIN
end_NN
of_PIN
year_NN
6,760_CD
6,372_CD
benefit_NN
obligation_NOMZ
at_PIN
end_NN
of_PIN
year_NN
for_PIN
pension_NN
plans_NN
with_PIN
accumulated_VBN
benefit_NN
obligations_NOMZ
in_PIN
excess_NN
of_PIN
plan_NN
assets_NN
6,087_CD
2,995_CD
2002_CD
2001_CD
Change_NN
in_PIN
plan_NN
assets_NN
m_VPRT
m_NN
Fair_NN
value_NN
of_PIN
plan_NN
assets_NN
at_PIN
beginning_GER
of_PIN
year_NN
5,385_CD
6,452_CD
Adjustment_NOMZ
for_PIN
change_NN
in_PIN
accounting_GER
principle_NN
383_CD
Actual_JJ
return_NN
on_PIN
plan_NN
assets_NN
913_CD
1,106_CD
Employer_NN
contribution_NOMZ
457_CD
82_CD
Plan_NN
participants_NN
contributions_NOMZ
16_CD
30_CD
Benets_NN
paid_VBD
324_CD
260_CD
Acquisition_NOMZ
146_CD
Termination_NOMZ
benets_NN
and_PHC
curtailment_NOMZ
costs_NN
3_CD
Exchange_NN
146_CD
41_CD
Fair_NN
value_NN
of_PIN
plan_NN
assets_NN
at_PIN
end_NN
of_PIN
year_NN
4,855_CD
5,385_CD
Fair_NN
value_NN
of_PIN
plan_NN
assets_NN
at_PIN
end_NN
of_PIN
year_NN
for_PIN
pension_NN
plans_NN
with_PIN
accumulated_VBN
benefit_NN
obligations_NOMZ
in_PIN
excess_NN
of_PIN
plan_NN
assets_NN
4,741_CD
2,484_CD
Plan_NN
assets_NN
consist_VPRT
primarily_RB
of_PIN
investments_NOMZ
in_PIN
UK_NN
and_CC
overseas_PLACE
equities_NOMZ
,_,
xed_VBN
interest_NN
securities_NOMZ
,_,
securities_NOMZ
linked_VBN [WZPAST]
to_PIN
the_DT
UK_NN
Retail_NN
Price_NN
Index_NN
and_PHC
property_NN
._.
At_PIN
31st_CD
December_NN
2002_CD
UK_NN
equities_NOMZ
included_VBD
2.1_CD
million_CD
GlaxoSmithKline_NN
shares_NN
2001_CD
5.3_CD
million_CD
shares_NN
with_PIN
a_DT
market_NN
value_NN
of_PIN
25_CD
million_CD
2001_CD
91_CD
million_CD
._.
2002_CD
2001_CD
Funded_VBN
status_NN
m_NN [PASS]
m_NN [PASS]
Funded_VBN
status_NN
1,905_CD
987_CD
Unrecognised_JJ
net_JJ
actuarial_JJ
loss_NN
1,932_CD
724_CD
Unrecognised_JJ
prior_JJ
service_NN
cost_NN
145_CD
152_CD
Unrecognised_JJ
transition_NOMZ
obligation_NOMZ
29_CD
24_CD
Other_JJ
3_CD
Net_JJ
amount_NN
recognized_VBN [PRIV] [THATD]
201 84 2002 2001_CD
Amounts_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
the_DT
statement_NOMZ
of_PIN
financial_JJ
position_NOMZ
consist_VPRT
of_PIN
:_:
m_VB
m_FW
Prepaid_FW
benefit_NN
cost_NN
532_CD
353_CD
Accrued_VBN
pension_NN
liability_NOMZ
331_CD
437_CD
Additional_JJ
required_VBN [SUAV]
liability_NOMZ
1,618_CD
373_CD
Intangible_JJ
asset_NN
172_CD
36_CD
Accumulated_VBN
other_JJ
comprehensive_JJ
income_NN
1,446_CD
337_CD
Net_JJ
amount_NN
recognized_VBN [PRIV]
201_CD
84_CD
138_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
37_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
Post-retirement_JJ
healthcare_NN
under_IN
US_FPP1
GAAP_NN
The_NN
disclosures_NN
for_PIN
2002_CD
and_CC
2001_CD
are_VPRT [PASS]
provided_VBN
in_PIN
relation_NOMZ
to_PIN
the_DT
employees_NN
of_PIN
GlaxoSmithKline_NN
._.
2002 2001 2000_CD
Net_JJ
healthcare_NN
cost_NN
m_FW
m_FW
m_FW
Service_NN
cost_NN
23_CD
15_CD
5_CD
Interest_NN
cost_NN
53_CD
40_CD
13_CD
Amortisation_NOMZ
of_PIN
prior_JJ
service_NN
cost_NN
2_CD
3_CD
2_CD
Net_JJ
healthcare_NN
cost_NN
78_CD
52_CD
16_CD
The_DT
major_JJ
assumptions_NOMZ
used_VBN [WZPAST]
in_PIN
calculating_VBG [PRIV]
the_DT
net_JJ
healthcare_NN
cost_NN
were_VBD
:_:
%_NN
pa_CD
%_NN
pa_CD
%_NN
pa_NN
Rate_NN
of_PIN
future_JJ
healthcare_NN
ination_NOMZ
7.0_CD
to_PIN
5.0_CD
7.0_CD
to_PIN
5.0_CD
7.8_CD
to_PIN
4.9_CD
Discount_NN
rate_NN
6.75_CD
7.3_CD
7.2_CD
The_DT
rate_NN
of_PIN
future_JJ
healthcare_NN
ination_NOMZ
reects_VPRT
the_DT
fact_NN
that_TOBJ
the_DT
benets_NN
of_PIN
certain_JJ
groups_NN
of_PIN
participants_NN
are_VPRT [PASS]
capped_VBN
._.
2002_CD
2001_CD
Change_NN
in_PIN
benefit_NN
obligation_NOMZ
m_NN
m_NN
benefit_NN
obligation_NOMZ
at_PIN
beginning_GER
of_PIN
year_NN
788_CD
583_CD
Adjustment_NOMZ
for_PIN
change_NN
in_PIN
accounting_GER
principle_NN
13_CD
Amendments_NOMZ
1_CD
Service_NN
cost_NN
77_CD
15_CD
Interest_NN
cost_NN
53_CD
40_CD
Plan_NN
participants_NN
contributions_NOMZ
9_CD
2_CD
Actuarial_JJ
loss_NN
24_CD
202_CD
Benets_NN
paid_VBD
50_CD
31_CD
Acquisition_NOMZ
32_CD
Curtailments_NOMZ
2_CD
Exchange_NN
84_CD
12_CD
benefit_NN
obligation_NOMZ
at_PIN
end_NN
of_PIN
year_NN
830_CD
788_CD
Change_NN
in_PIN
plan_NN
assets_NN
Fair_NN
value_NN
of_PIN
plan_NN
assets_NN
at_PIN
beginning_GER
of_PIN
year_NN
Employer_NN
and_PHC
plan_NN
participants_NN
contributions_NOMZ
51_CD
31_CD
Benets_NN
paid_VBD
51_CD
31_CD
Fair_NN
value_NN
of_PIN
plan_NN
assets_NN
at_PIN
end_NN
of_PIN
year_NN
Funded_VBN
status_NN
Funded_VBN
status_NN
830_CD
788_CD
Unrecognised_JJ
net_JJ
actuarial_JJ
loss_NN
230_CD
216_CD
Unrecognised_JJ
prior_JJ
service_NN
cost_NN
17_CD
20_CD
Other_JJ
8_CD
Accrued_VBN
post-retirement_JJ
healthcare_NN
cost_NN
617_CD
584_CD
1_CD
%_NN
decrease_NN
1_CD
%_NN
increase_NN
The_DT
impact_NN
of_PIN
a_DT
1_CD
per_PIN
cent_NN
variation_NOMZ
in_PIN
the_DT
rate_NN
of_PIN
future_JJ
healthcare_NN
ination_NOMZ
would_PRMD
be_VB
:_:
m_VB
m_FW
Effect_NN
on_PIN
total_JJ
service_NN
and_PHC
interest_NN
cost_NN
9_CD
8_CD
Effect_NN
on_PIN
provision_NN
for_PIN
post-retirement_JJ
benets_NN
85_CD
71_CD
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
139_CD
38_CD
Principal_NN
Group_NN
companies_NN
The_DT
following_JJ
represent_VPRT
the_DT
principal_JJ
subsidiary_NN
and_CC
associated_VBN
undertakings_GER
of_PIN
the_DT
GlaxoSmithKline_NN
Group_NN
at_PIN
31st_CD
December_NN
2002_CD
._.
Details_NN
are_VPRT [PASS]
given_VBN
of_PIN
the_DT
principal_JJ
country_NN
of_PIN
operation_NOMZ
,_,
the_DT
location_NOMZ
of_PIN
the_DT
headquarters_NN
,_,
the_DT
business_NOMZ
segment_NOMZ
and_CC
the_DT
business_NOMZ
activities_NOMZ
._.
The_DT
equity_NOMZ
share_NN
capital_NN
of_PIN
these_DEMO
undertakings_GER
is_VPRT [SPAU] [BYPA]
wholly_RB
owned_VBN
by_PIN
the_DT
Group_NN
except_PIN
where_RB
its_PIT
percentage_NN
interest_NN
is_VPRT [PASS]
shown_VBN [PRIV]
otherwise_CONJ
._.
All_QUAN
companies_NN
are_VPRT [PASS]
incorporated_VBN
in_PIN
their_TPP3
principal_JJ
country_NN
of_PIN
operation_NOMZ
except_PIN
where_RB
stated_VBN [PUBV]
._.
Europe_NN
Location_NOMZ
Subsidiary_NN
undertaking_VBG [WZPRES]
Segment_NOMZ
Activity_NOMZ
%_NN
England_NN
Brentford_NN
GlaxoSmithKline_NN
Services_NN
Unlimited_NN
plc_NN
Ph_NN
,_,
CH_NN
s_VPRT
formerly_TIME
GlaxoSmithKline_NN
Services_NN
plc_NN
Brentford_NN
SmithKline_NN
Beecham_NN
plc_NN
Ph_NN
,_,
CH_NN
e_LS
h_FW
r_NN
d_SYM
m_FW
p_FW
Greenford_NN
Glaxo_NN
Group_NN
Ltd_NN
Ph_NN
h_VPRT
Brentford_NN
SmithKline_NN
Beecham_NN
Research_NN
Ltd_NN
Ph_NN
m_NN
Brentford_NN
SmithKline_NN
Beecham_NN
Investments_NOMZ
Ltd_NN
Ph_NN
,_,
CH_NN
f_LS
Brentford_NN
GlaxoSmithKline_NN
Research_NN
&_CC
Development_NOMZ
Ltd_NN
Ph_NN
r_NN
d_SYM
Brentford_NN
GlaxoSmithKline_NN
Export_NN
Ltd_NN
Ph_NN
e_SYM
Brentford_NN
GlaxoSmithKline_NN
UK_NN
Ltd_NN
Ph_NN
m_FW
p_FW
Greenford_NN
The_DT
Wellcome_NN
Foundation_NOMZ
Ltd_NN
Ph_NN
p_VPRT
Brentford_NN
Wellcome_NN
Limited_NN
Ph_NN
,_,
CH_NN
h_NN
Brentford_NN
SmithKline_NN
Beecham_NN
SWG_NN
Ltd_NN
CH_NN
e_LS
m_FW
Brentford_NN
Glaxo_NN
Operations_NOMZ
UK_NN
Ltd_NN
Ph_NN
p_VPRT
Brentford_NN
Glaxo_NN
Wellcome_NN
International_NN
BV_NN
Footnote_NN
iv_VB
Ph_NN
,_,
CH_NN
h_NN
Brentford_NN
Glaxo_NN
Wellcome_NN
Investments_NOMZ
BV_NN
Footnote_NN
iv_VB
Ph_NN
,_,
CH_NN
h_NN
Stockley_NN
Park_NN
Glaxo_NN
Wellcome_NN
UK_NN
Ltd_NN
Ph_NN
h_VPRT
m_FW
p_FW
Brentford_NN
Stafford-Miller_NN
Ltd_NN
CH_NN
m_FW
p_FW
Austria_NN
Vienna_NN
GlaxoSmithKline_NN
Pharma_NN
GmbH_NN
Ph_NN
m_NN
Belgium_NN
Genval_NN
GlaxoSmithKline_NN
SA_NN
formerly_TIME
GlaxoSmithKline_NN
Belgium_NN
SA_NN
Ph_NN
m_NN
Rixensart_NN
GlaxoSmithKline_NN
Biologicals_NN
SA_NN
Ph_NN
e_SYM
r_SYM
d_SYM
p_FW
Rixensart_NN
GlaxoSmithKline_NN
Biologicals_NN
Manufacturing_GER
SA_NN
Ph_NN
e_SYM
p_FW
Guernsey_NN
St._NN
Peter_NN
Port_NN
S._NN
B._NN
Insurance_NN
Ltd_NN
Ph_NN
,_,
CH_NN
i_FPP1
Denmark_NN
Ballerup_NN
GlaxoSmithKline_NN
Consumer_NN
Healthcare_NN
A_NN
S_NN
CH_NN
m_FW
formerly_TIME
SmithKline_NN
Beecham_NN
A_NN
S_NN
Brndby_NN
GlaxoSmithKline_NN
Pharma_NN
a_DT
s_PRP
Ph_NN
m_FW
Finland_NN
Espoo_NN
GlaxoSmithKline_NN
Oy_NN
Ph_NN
m_NN
France_NN
Marly_NN
le_FW
Roi_NN
GlaxoSmithKline_NN
Sante_NN
Grand_NN
Publique_NN
SAS_NN
CH_NN
m_FW
Marly_NN
le_FW
Roi_NN
Glaxo_NN
Wellcome_NN
Production_NOMZ
SAS_NN
Ph_NN
m_FW
p_FW
Germany_NN
Buehl_NN
GlaxoSmithKline_NN
Consumer_NN
Healthcare_NN
GmbH_NN
&_CC
Co_NN
KG_NN
CH_NN
m_FW
p_FW
Munich_NN
SmithKline_NN
Beecham_NN
GmbH_NN
Ph_NN
m_NN
Greece_NN
Athens_NN
GlaxoSmithKline_NN
AEBE_NN
formerly_TIME
Glaxo_NN
Wellcome_NN
AEBE_NN
Ph_NN
h_VPRT
m_FW
p_FW
Hungary_NN
Budapest_NN
GlaxoSmithKline_NN
Kft_NN
Ph_NN
,_,
CH_NN
m_NN
Italy_NN
Verona_NN
GlaxoSmithKline_NN
SpA_NN
Ph_NN
m_NN
p_NN
r_NN
d_SYM
Milan_NN
GlaxoSmithKline_NN
Consumer_NN
Healthcare_NN
SpA_NN
CH_NN
h_VPRT
m_FW
Luxembourg_NN
Mamer_NN
GlaxoSmithKline_NN
International_NN
Luxembourg_NN
SA_NN
Ph_NN
,_,
CH_NN
h_NN
Mamer_NN
GlaxoSmithKline_NN
Luxembourg_NN
SA_NN
Ph_NN
,_,
CH_NN
h_VBD
140_CD
GlaxoSmithKline_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
38_CD
Principal_NN
Group_NN
companies_NN
continued_VBD
Europe_NN
Location_NOMZ
Subsidiary_NN
undertaking_VBG [WZPRES]
Segment_NOMZ
Activity_NOMZ
%_NN
Netherlands_NN
Zeist_NN
GlaxoSmithKline_NN
BV_NN
Ph_NN
m_NN
Zeist_NN
GlaxoSmithKline_NN
Consumer_NN
Healthcare_NN
BV_NN
CH_NN
m_FW
Norway_NN
Oslo_NN
GlaxoSmithKline_NN
AS_NN
Ph_NN
m_NN
Poland_NN
Poznan_NN
GlaxoSmithKline_NN
Pharmaceuticals_NN
SA_NN
Ph_NN
m_NN
p_NN
97_CD
Warsaw_NN
GlaxoSmithKline_NN
Consumer_NN
Healthcare_NN
sp_NN
zoo_NN
CH_NN
m_NN
Portugal_NN
Lisbon_NN
Farmaceuticos_NN
Lda_NN
Ph_NN
m_NN
formerly_TIME
Instituto_NN
Luso-Farmaco_NN
Lda_NN
Republic_NN
of_PIN
Carrigaline_NN
SmithKline_NN
Beecham_NN
Cork_NN
Ltd_NN
Footnote_NN
i_FPP1
Ph_NN
p_FW
Ireland_NN
Carrigaline_NN
SmithKline_NN
Beecham_NN
Manufacturing_GER
Ltd_NN
Footnote_NN
i_FPP1
Ph_NN
p_FW
Spain_NN
Madrid_NN
Glaxo_NN
Wellcome_NN
,_,
SA_NN
Ph_NN
r_NN
m_FW
p_FW
Madrid_NN
SmithKline_NN
Beecham_NN
SA_NN
Ph_NN
m_NN
Sweden_NN
Mlndal_NN
GlaxoSmithKline_NN
AB_NN
Ph_NN
m_NN
Switzerland_NN
Muenchenbuchsee_NN
GlaxoSmithKline_NN
Investments_NOMZ
Switzerland_NN
GmbH_NN
Ph_NN
,_,
CH_NN
h_NN
Muenchenbuchsee_NN
GlaxoSmithKline_NN
International_NN
Switzerland_NN
GmbH_NN
Ph_NN
,_,
CH_NN
h_NN
Muenchenbuchsee_NN
Glaxo_NN
Wellcome_NN
International_NN
Footnote_NN
i_FPP1
,_,
v_VB
Ph_NN
,_,
CH_NN
h_NN
Muenchenbuchsee_NN
GlaxoSmithKline_NN
AG_NN
formerly_TIME
Glaxo_NN
Wellcome_NN
AG_NN
Ph_NN
m_NN
Zug_NN
Adechsa_NN
GmbH_NN
Ph_NN
e_SYM
Turkey_NN
Istanbul_NN
GlaxoSmithKline_NN
Ilaclari_NN
Sanayi_NN
five_CD
Ticaret_NN
AS_NN
Ph_NN
m_NN
p_NN
formerly_TIME
Glaxo_NN
Wellcome_NN
ISAS_NN
USA_NN
USA_NN
Philadelphia_NN
SmithKline_NN
Beecham_NN
Corporation_NOMZ
Ph_NN
,_,
CH_NN
e_LS
h_FW
r_NN
d_SYM
m_FW
p_FW
s_PRP
Pittsburgh_NN
GlaxoSmithKline_NN
Consumer_NN
Healthcare_NN
LP_NN
CH_NN
m_FW
p_FW
66_CD
Jersey_NN
City_NOMZ
Block_NN
Drug_NN
Company_NN
,_,
Inc_NN
CH_NN
h_VPRT
m_FW
p_FW
Wilmington_NN
GlaxoSmithKline_NN
Financial_NN
Inc_NN
Ph_NN
,_,
CH_NN
f_LS
Wilmington_NN
SmithKline_NN
Beecham_NN
Holdings_GER
Corporation_NOMZ
Ph_NN
,_,
CH_NN
h_NN
Wilmington_NN
GlaxoSmithKline_NN
Holdings_GER
Americas_NN
Inc_NN
Ph_NN
,_,
CH_NN
h_NN
Americas_NN
Bermuda_NN
Hamilton_NN
GlaxoSmithKline_NN
Insurance_NN
Ltd_NN
Ph_NN
,_,
CH_NN
i_FPP1
Canada_NN
Mississauga_NN
GlaxoSmithKline_NN
Inc_NN
Ph_NN
,_,
CH_NN
m_FW
p_FW
r_NN
Asia_NN
Pacic_NN
Australia_NN
Boronia_NN
Glaxo_NN
Wellcome_NN
Australia_NN
Ltd_NN
Ph_NN
m_FW
p_FW
Dandenong_NN
SmithKline_NN
Beecham_NN
Australia_NN
Pty_NN
Ltd_NN
Ph_NN
,_,
CH_NN
m_NN
China_NN
Hong_NN
Kong_NN
GlaxoSmithKline_NN
Limited_NN
formerly_TIME
Glaxo_NN
Wellcome_NN
China_NN
Ltd_NN
Ph_NN
m_NN
Tianjin_NN
Sino-American_NN
Tianjin_NN
Smith_NN
Kline_NN
&_CC
French_NN
Laboratories_NN
Ltd_NN
Ph_NN
m_NN [BEMA]
55_CD
India_NN
Mumbai_NN
GlaxoSmithKline_NN
Pharmaceuticals_NN
Ltd_NN
Footnote_NN
ii_FW
Ph_NN
m_FW
p_FW
49_CD
Nabha_NN
GlaxoSmithKline_NN
Consumer_NN
Healthcare_NN
Ltd_NN
formerly_TIME
SmithKline_NN
CH_NN
m_FW
p_FW
40_CD
Beecham_NN
Consumer_NN
Healthcare_NN
Ltd_NN
Footnote_NN
ii_FW
Malaysia_NN
Selangor_NN
GlaxoSmithKline_NN
Pharmaceutical_NN
Sdn_NN
Bhd_NN
Ph_NN
m_NN
Darul_NN
Ehsan_NN
New_NN
Zealand_NN
Auckland_NN
GlaxoSmithKline_NN
NZ_NN
Limited_NN
Ph_NN
,_,
CH_NN
m_NN
Pakistan_NN
Karachi_NN
Glaxo_NN
Wellcome_NN
Pakistan_NN
Ltd_NN
Ph_NN
,_,
CH_NN
m_FW
p_FW
79_CD
Philippines_NN
Manila_NN
Glaxo_NN
Wellcome_NN
Philippines_NN
Inc_NN
Ph_NN
m_NN
Singapore_NN
Singapore_NN
Glaxo_NN
Wellcome_NN
Manufacturing_GER
Pte_NN
Ltd_NN
Ph_NN
p_VPRT
Singapore_NN
GlaxoSmithKline_NN
Pte_NN
Ltd_NN
formerly_TIME
Glaxo_NN
Wellcome_NN
Asia_NN
Pacic_NN
Pte_NN
Ltd_NN
Ph_NN
m_NN
South_NN
Korea_NN
Seoul_NN
GlaxoSmithKline_NN
Korea_NN
Ph_NN
m_FW
p_FW
Taiwan_NN
Taipei_NN
Glaxo_NN
Wellcome_NN
Taiwan_NN
Ltd_NN
Ph_NN
m_NN
p_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
GlaxoSmithKline_NN
141_CD
38_CD
Principal_NN
Group_NN
companies_NN
continued_VBD
Japan_NN
Location_NOMZ
Subsidiary_NN
undertaking_VBG [WZPRES]
Segment_NOMZ
Activity_NOMZ
%_NN
Japan_NN
Tokyo_NN
GlaxoSmithKline_NN
KK_NN
Ph_NN
m_NN
p_NN
r_NN
85_CD
Kobe_NN
Block_NN
Drug_NN
Company_NN
Japan_NN
Inc_NN
CH_NN
m_FW
Latin_NN
America_NN
Argentina_NN
Buenos_NN
Aires_NN
GlaxoSmithKline_NN
Argentina_NN
SA_NN
Ph_NN
,_,
CH_NN
m_FW
p_FW
Brazil_NN
Rio_NN
fide_VBD
Janeiro_NN
GlaxoSmithKline_NN
Brasil_NN
Lda_NN
formerly_TIME
SmithKline_NN
Beecham_NN
Brasil_NN
Lda_NN
Ph_NN
,_,
CH_NN
m_FW
p_FW
Colombia_NN
Bogota_NN
GlaxoSmithKline_NN
Colombia_NN
SA_NN
Ph_NN
,_,
CH_NN
m_NN
Mexico_NN
Mexico_NN
City_NOMZ
GlaxoSmithKline_NN
Mexico_NN
,_,
SA_NN
fide_VBD
CV_NN
Ph_NN
,_,
CH_NN
m_FW
p_FW
formerly_TIME
Glaxo_NN
Wellcome_NN
Mexico_NN
,_,
SA_NN
fide_VBD
CV_NN
Puerto_NN
Rico_NN
San_NN
Juan_NN
GlaxoSmithKline_NN
Puerto_NN
Rico_NN
Inc_NN
Ph_NN
m_VBD
Hato_NN
Rey_NN
SB_NN
Pharmco_NN
Puerto_NN
Rico_NN
Inc_NN
Ph_NN
p_NN
Venezuela_NN
Caracas_NN
GlaxoSmithKline_NN
Venezuela_NN
CA_NN
formerly_TIME
Glaxo_NN
Wellcome_NN
CA_NN
Ph_NN
m_NN
p_NN
Middle_NN
East_NN
Africa_NN
Egypt_NN
Cairo_NN
Glaxo_NN
Wellcome_NN
Egypt_NN
SAE_NN
Ph_NN
m_FW
p_FW
90_CD
South_NN
Africa_NN
Midrand_NN
GlaxoSmithKline_NN
South_NN
Africa_NN
Pty_NN
Ph_NN
m_NN
p_NN
formerly_TIME
Glaxo_NN
Wellcome_NN
South_NN
Africa_NN
Pty_NN
Ltd_NN
Johannesburg_NN
SmithKline_NN
Beecham_NN
Consumer_NN
Healthcare_NN
Pty_NN
Ltd_NN
CH_NN
m_FW
p_FW
USA_NN
Location_NOMZ
Associated_NN
undertaking_VBG [WZPRES]
%_NN
USA_NN
Teterboro_NN
,_,
Quest_NN
Diagnostics_NN
,_,
Inc._NN
._.
Footnote_NN
iii_FW
23_CD
New_NN
Jersey_NN
Footnotes_NN
i_FPP1
Exempt_NN
from_PIN
the_DT
provisions_NN
of_PIN
Section_NOMZ
7_CD
of_PIN
the_DT
Companies_NN
Amendment_NOMZ
Act_NN
1986_CD
Ireland_NN
ii_FW
Consolidated_NN
as_IN
a_DT
subsidiary_NN
undertaking_GER
in_PIN
accordance_NN
with_PIN
Section_NOMZ
258_CD
4_CD
a_DT
of_PIN
the_DT
Companies_NN
Act_NN
on_PIN
the_DT
grounds_NN
of_PIN
significant_JJ
inuence_NN
iii_FW
This_DEMO
holding_GER
was_VBD [PASS]
reduced_VBN
to_PIN
21_CD
per_PIN
cent_NN
in_PIN
February_NN
2003_CD
,_,
following_VBG
Quests_NN
acquisition_NOMZ
of_PIN
Unilab_NN
Corporation_NOMZ
iv_NN
Incorporated_NN
in_PIN
the_DT
Netherlands_NN
v_NN
Incorporated_NN
in_PIN
the_DT
Republic_NN
of_PIN
Ireland_NN
._.
directly_RB
held_VBN [PRIV]
wholly_RB
owned_VBN
subsidiary_NN
of_PIN
GlaxoSmithKline_NN
plc._NN
._.
Business_NOMZ
segment_NOMZ
:_:
Ph_NN
Pharmaceuticals_NN
,_,
CH_NN
Consumer_NN
Healthcare_NN
Business_NOMZ
activity_NOMZ
:_:
d_LS
development_NOMZ
,_,
e_SYM
exporting_VBG
,_,
f_SYM
finance_NN
,_,
h_VPRT
holding_VBG [PRIV]
company_NN
,_,
i_FPP1
insurance_NN
,_,
m_NN
marketing_GER
,_,
p_NN
production_NOMZ
,_,
r_NN
research_NN
,_,
s_VPRT
service_NN
Full_NN
details_NN
of_PIN
all_QUAN
Group_NN
subsidiary_NN
and_CC
associated_VBN
undertakings_GER
will_PRMD
be_VB [PASS]
attached_VBN
to_PIN
the_DT
companys_NN
Annual_JJ
Return_NN
to_TO
be_VB [PASS]
led_VBN
with_PIN
the_DT
Registrar_NN
of_PIN
Companies_NN
._.
